_pmid,_doi,_publicationTitle,_year,_confidence,_toolType,resourceName,resourceType,rrid,synonyms,description,aiSummary,howToAcquire
PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,0.95,animal_model,129T2/SvEmsJ::C57Bl/6NTac Nf1+/+ and Nf1+/- mice,Animal Model,,,,,
PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,0.9,antibody,Anti-tyrosine hydroxylase (Rabbit polyclonal),Antibody,,,,,
PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,0.9,antibody,Anti-tyrosine hydroxylase (mouse monoclonal),Antibody,,,,,
PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,0.9,antibody,Anti-GFP (mouse polyclonal),Antibody,,,,,
PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,0.85,antibody,Alexa Fluor 488-conjugated donkey anti-chicken IgY F(ab')two fragment,Antibody,,,,,
PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,0.85,antibody,Alexa Fluor 647-conjugated donkey anti-mouse IgG Fab fragment,Antibody,,,,,
PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,0.95,genetic_reagent,pAAV-hSyn-dLight1.2,Genetic Reagent,,,,,
PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,0.9,genetic_reagent,pAAV-hSyn-hChR2(H134R)-EYFP,Genetic Reagent,,,,,
PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,0.9,genetic_reagent,AAV9-Th-PI-Cre-SV40,Genetic Reagent,,,,,
PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,0.9,genetic_reagent,pAAV-DJ-Ef1α-DO-eNpHR3.0-eYFP-WPRE-pA,Genetic Reagent,,,,,
PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,0.9,genetic_reagent,pAAV-DJ-Ef1α-DO-mCherry-WPRE-pA,Genetic Reagent,,,,,
PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,0.9,genetic_reagent,pAAV-ihSyn1-tTA-WPRE,Genetic Reagent,,,,,
PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,0.9,genetic_reagent,pAAV-Th-tTA-WPRE,Genetic Reagent,,,,,
PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,0.9,genetic_reagent,pAAV-TRE-mRuby-WPRE,Genetic Reagent,,,,,
PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,0.9,genetic_reagent,pAAV-TRE-mTurquoise-WPRE,Genetic Reagent,,,,,
PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,0.9,genetic_reagent,pAAV-Th-GFP-WPRE,Genetic Reagent,,,,,
PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,0.9,genetic_reagent,pUCmini-iCAP-PHP.eB,Genetic Reagent,,,,,
PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,0.8,computational_tool,Matlab,Computational Tool,,,,,
PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,0.8,computational_tool,GraphPad Prism 7,Computational Tool,,,,,
PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,0.85,computational_tool,ABET II Software for Operant Control,Computational Tool,,,,,
PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,0.9,computational_tool,Fiber Photometry Trace Processing,Computational Tool,,,,,
PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,0.95,genetic_reagent,dLight1,Genetic Reagent,,,,,
PMID:32642734,10.1093/noajnl/vdz026,Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1.,,0.85,genetic_reagent,Qiagen DNeasy Blood & Tissue kit,Genetic Reagent,,,,,
PMID:32642734,10.1093/noajnl/vdz026,Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1.,,0.9,genetic_reagent,SureSelectXT Human All Exon version 5,Genetic Reagent,,,,,
PMID:32642734,10.1093/noajnl/vdz026,Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1.,,0.95,computational_tool,Novoalign tool v3.02.06,Computational Tool,,,,,
PMID:32642734,10.1093/noajnl/vdz026,Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1.,,0.95,computational_tool,PICARD tools v2.4.1,Computational Tool,,,,,
PMID:32642734,10.1093/noajnl/vdz026,Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1.,,0.95,computational_tool,Genome Analysis Toolkit (GATK) v3.6-0,Computational Tool,,,,,
PMID:32642734,10.1093/noajnl/vdz026,Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1.,,0.95,computational_tool,Mutect v1.1.4,Computational Tool,,,,,
PMID:32642734,10.1093/noajnl/vdz026,Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1.,,0.9,computational_tool,CNVkit,Computational Tool,,,,,
PMID:32642734,10.1093/noajnl/vdz026,Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1.,,0.9,computational_tool,SciClone,Computational Tool,,,,,
PMID:32642734,10.1093/noajnl/vdz026,Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1.,,0.95,antibody,"TRIM23 antibody (ThermoFisher, PA5-34624)",Antibody,,,,,
PMID:32642734,10.1093/noajnl/vdz026,Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1.,,0.95,antibody,H3K27me3 antibody (C36B11),Antibody,,,,,
PMID:32642734,10.1093/noajnl/vdz026,Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1.,,0.9,antibody,Cleaved-caspase 3 antibody,Antibody,,,,,
PMID:32642734,10.1093/noajnl/vdz026,Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1.,,0.9,antibody,Ki67 antibody (790–4286),Antibody,,,,,
PMID:32642734,10.1093/noajnl/vdz026,Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1.,,0.95,animal_model,C57BL6/J Nf1+/−;Trp53+/− (NPcis),Animal Model,,,,,
PMID:32642734,10.1093/noajnl/vdz026,Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1.,,0.95,cell_line,NPcis cell line,Cell Line,,,,,
PMID:32642734,10.1093/noajnl/vdz026,Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1.,,0.9,genetic_reagent,shLacZ control,Genetic Reagent,,,,,
PMID:32642734,10.1093/noajnl/vdz026,Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1.,,0.95,genetic_reagent,shTrim23 (TRCN0000308323),Genetic Reagent,,,,,
PMID:32642734,10.1093/noajnl/vdz026,Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1.,,0.9,animal_model,B6N-Tyrc-Brd/BrdCrCrl mice,Animal Model,,,,,
PMID:32642734,10.1093/noajnl/vdz026,Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1.,,0.85,computational_tool,Simple Western system,Computational Tool,,,,,
PMID:32642734,10.1093/noajnl/vdz026,Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1.,,0.85,computational_tool,Incucyte FLR imaging system,Computational Tool,,,,,
PMID:41468561,10.1212/WNL.0000000000214480,NF1-Specific Growth Charts for Head Circumference Over the First 3 Years of Life.,,0.95,clinical_assessment_tool,Survey of Well-being of Young Children (SWYC),Clinical Assessment Tool,,,,,
PMID:41468561,10.1212/WNL.0000000000214480,NF1-Specific Growth Charts for Head Circumference Over the First 3 Years of Life.,,0.9,computational_tool,LMSz,Computational Tool,,,,,
PMID:41468561,10.1212/WNL.0000000000214480,NF1-Specific Growth Charts for Head Circumference Over the First 3 Years of Life.,,0.85,computational_tool,GAMLSS,Computational Tool,,,,,
PMID:41468561,10.1212/WNL.0000000000214480,NF1-Specific Growth Charts for Head Circumference Over the First 3 Years of Life.,,0.9,computational_tool,gamlssTools,Computational Tool,,,,,
PMID:41468561,10.1212/WNL.0000000000214480,NF1-Specific Growth Charts for Head Circumference Over the First 3 Years of Life.,,0.85,clinical_assessment_tool,Centers for Disease Control (CDC) growth charts,Clinical Assessment Tool,,,,,
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,0.95,animal_model,Nf1 c.5425 C > T ; Arg1809Cys-mutant mice,Animal Model,,,,,
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,0.9,animal_model,R681X Nf1-mutant mice,Animal Model,,,,,
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,0.95,animal_model,Nf1 flox/flox ; Hoxb7-Cre mice,Animal Model,,,,,
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,0.95,animal_model,Nf1 f/neo ; hGFAP-Cre mice,Animal Model,,,,,
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,0.9,animal_model,athymic nude mice,Animal Model,,,,,
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,0.9,cell_line,BJFF.6,Cell Line,,,,,
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,0.9,cell_line,Normal human Schwann cells (Sciencell),Cell Line,,,,,
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,0.95,genetic_reagent,sh NF1 1–3 lentiviral particles,Genetic Reagent,,,,,
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,0.9,genetic_reagent,Ad-CMV-Cre,Genetic Reagent,,,,,
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,0.95,genetic_reagent,sh COL1A2 lentiviral particles,Genetic Reagent,,,,,
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,0.9,antibody,GFAP,Antibody,,,,,
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,0.9,antibody,Iba1,Antibody,,,,,
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,0.9,antibody,Ki67,Antibody,,,,,
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,0.9,antibody,SOX10,Antibody,,,,,
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,0.9,antibody,Rbpms,Antibody,,,,,
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,0.9,antibody,Tuj-1,Antibody,,,,,
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,0.9,antibody,Peripherin,Antibody,,,,,
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,0.9,antibody,ISL1,Antibody,,,,,
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,0.85,computational_tool,AXION Biosystems 48-well MEA plates,Computational Tool,,,,,
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,0.95,computational_tool,AXION Biosystems integrated studio (AxIS) version 2.5.1,Computational Tool,,,,,
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,0.9,computational_tool,Offline sorter x64 version 4,Computational Tool,,,,,
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,0.9,computational_tool,ImageJ 1.53a,Computational Tool,,,,,
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,0.95,computational_tool,"Partek Flow software, version 10.0",Computational Tool,,,,,
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,0.95,computational_tool,STAR version 2.7.8a,Computational Tool,,,,,
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,0.8,computational_tool,GraphPad Prism,Computational Tool,,,,,
PMID:40299482,10.3390/biomedicines13040907,Sleep Disorders in Pediatric Patients Affected by Neurofibromatosis Type 1: Reports of a Questionnaire and an Apple Watch Sleep Assessment.,,0.85,clinical_assessment_tool,Apple Watch Ultra model 2,Clinical Assessment Tool,,,,,
PMID:40299482,10.3390/biomedicines13040907,Sleep Disorders in Pediatric Patients Affected by Neurofibromatosis Type 1: Reports of a Questionnaire and an Apple Watch Sleep Assessment.,,0.8,computational_tool,Sleep++,Computational Tool,,,,,
PMID:12057013,10.1186/1471-2164-3-13,Complex splicing pattern generates great diversity in human NF1 transcripts.,,0.85,genetic_reagent,TRIzol LS Reagent,Genetic Reagent,,,,,
PMID:12057013,10.1186/1471-2164-3-13,Complex splicing pattern generates great diversity in human NF1 transcripts.,,0.85,genetic_reagent,SuperScript II Reverse transcriptase,Genetic Reagent,,,,,
PMID:12057013,10.1186/1471-2164-3-13,Complex splicing pattern generates great diversity in human NF1 transcripts.,,0.9,genetic_reagent,pCR2.1-TOPO-vector,Genetic Reagent,,,,,
PMID:12057013,10.1186/1471-2164-3-13,Complex splicing pattern generates great diversity in human NF1 transcripts.,,0.85,cell_line,TOP-10F' cells,Cell Line,,,,,
PMID:12057013,10.1186/1471-2164-3-13,Complex splicing pattern generates great diversity in human NF1 transcripts.,,0.85,genetic_reagent,Thermo Sequenase fluorescent labelled primer cycle sequencing kit,Genetic Reagent,,,,,
PMID:12057013,10.1186/1471-2164-3-13,Complex splicing pattern generates great diversity in human NF1 transcripts.,,0.8,computational_tool,ALF-express automated DNA sequencer,Computational Tool,,,,,
PMID:12057013,10.1186/1471-2164-3-13,Complex splicing pattern generates great diversity in human NF1 transcripts.,,0.9,computational_tool,Splice Site Prediction by Neural Network (SSPNN),Computational Tool,,,,,
PMID:12057013,10.1186/1471-2164-3-13,Complex splicing pattern generates great diversity in human NF1 transcripts.,,0.95,computational_tool,mfold computer program version 3.0,Computational Tool,,,,,
PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,,0.85,animal_model,K14Cre,Animal Model,,,,,
PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,,0.85,animal_model,K14CreERT,Animal Model,,,,,
PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,,0.85,animal_model,TyrCreERT2,Animal Model,,,,,
PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,,0.85,animal_model,R26-rtTA,Animal Model,,,,,
PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,,0.85,animal_model,tetO-DTA,Animal Model,,,,,
PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,,0.85,animal_model,K14-Scf,Animal Model,,,,,
PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,,0.85,animal_model,Krox20Cre,Animal Model,,,,,
PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,,0.85,animal_model,DhhCre,Animal Model,,,,,
PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,,0.85,animal_model,PLPCreERT2,Animal Model,,,,,
PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,,0.85,animal_model,CMVCreERT,Animal Model,,,,,
PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,,0.85,animal_model,R26-LacZ,Animal Model,,,,,
PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,,0.85,animal_model,R26-YFP,Animal Model,,,,,
PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,,0.9,antibody,"P-cadherin antibody (R&D Systems, AF761)",Antibody,,,,,
PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,,0.9,antibody,DCT antibody (PEP8h),Antibody,,,,,
PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,,0.9,antibody,"K14 antibody (Thermo, clone LL002)",Antibody,,,,,
PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,,0.9,antibody,"LacZ antibody (Abcam, ab9361)",Antibody,,,,,
PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,,0.9,antibody,"GFP/YFP antibody (Aves, 1020)",Antibody,,,,,
PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,,0.9,antibody,"Krox20 antibody (Covance, PRB-236P)",Antibody,,,,,
PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,,0.9,antibody,"KIT antibody (Cell Signaling, 3074)",Antibody,,,,,
PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,,0.85,computational_tool,ImageJ,Computational Tool,,,,,
PMID:28465357,10.1101/gad.298703.117,Identification of hair shaft progenitors that create a niche for hair pigmentation.,,0.85,computational_tool,Prism7 (GraphPad),Computational Tool,,,,,
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,0.9,cell_line,MCF7,Cell Line,,,,,
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,0.95,animal_model,Nf1-IF rat model,Animal Model,,,,,
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,0.95,animal_model,Nf1-PS rat model,Animal Model,,,,,
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,0.95,animal_model,Nf1-IFPS rat model,Animal Model,,,,,
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,0.85,computational_tool,IncuCyte,Computational Tool,,,,,
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,0.9,computational_tool,Agilent Seahorse XF-96,Computational Tool,,,,,
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,0.9,computational_tool,STAR v2.7.8a,Computational Tool,,,,,
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,0.9,computational_tool,iDEP 9.1,Computational Tool,,,,,
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,0.9,computational_tool,Trim Galore v0.6.0,Computational Tool,,,,,
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,0.95,antibody,neurofibromin antibody (Bethyl A300-140A),Antibody,,,,,
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,0.95,antibody,neurofibromin antibody (Santa Cruz H12),Antibody,,,,,
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,0.95,antibody,neurofibromin antibody (iNF-07E),Antibody,,,,,
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,0.9,antibody,pERα S118 antibody,Antibody,,,,,
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,0.9,antibody,pERK T202/Y204 antibody,Antibody,,,,,
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,0.9,antibody,pAKT S473 antibody,Antibody,,,,,
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,0.9,antibody,β-tubulin antibody,Antibody,,,,,
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,0.85,genetic_reagent,CRISPR guides,Genetic Reagent,,,,,
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,0.9,advanced_cellular_model,Matrigel spheroids,Advanced Cellular Model,,,,,
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,0.9,computational_tool,LipidSearch v5.0,Computational Tool,,,,,
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,0.9,computational_tool,Compound Discoverer v3.2,Computational Tool,,,,,
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,0.9,computational_tool,SynergyFinder R package,Computational Tool,,,,,
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,0.9,computational_tool,CEAS R Package,Computational Tool,,,,,
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,0.9,computational_tool,FactoMineR R package,Computational Tool,,,,,
PMID:34930951,10.1038/s41536-021-00195-3,A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy.,,0.85,animal_model,Long Evans rats,Animal Model,,,,,
PMID:34930951,10.1038/s41536-021-00195-3,A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy.,,0.9,cell_line,human retinal ganglion cells (hRGC),Cell Line,,,,,
PMID:34930951,10.1038/s41536-021-00195-3,A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy.,,0.85,antibody,Brn3a-FITC,Antibody,,,,,
PMID:34930951,10.1038/s41536-021-00195-3,A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy.,,0.85,antibody,RBPMS-APC,Antibody,,,,,
PMID:34930951,10.1038/s41536-021-00195-3,A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy.,,0.85,antibody,Thy1.1-APC,Antibody,,,,,
PMID:34930951,10.1038/s41536-021-00195-3,A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy.,,0.85,antibody,Caspase9-FITC,Antibody,,,,,
PMID:34930951,10.1038/s41536-021-00195-3,A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy.,,0.85,antibody,Ki67-FITC,Antibody,,,,,
PMID:34930951,10.1038/s41536-021-00195-3,A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy.,,0.85,antibody,Cmyc-FITC,Antibody,,,,,
PMID:34930951,10.1038/s41536-021-00195-3,A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy.,,0.85,antibody,Oct4-APC,Antibody,,,,,
PMID:34930951,10.1038/s41536-021-00195-3,A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy.,,0.85,antibody,NeuN-APC,Antibody,,,,,
PMID:34930951,10.1038/s41536-021-00195-3,A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy.,,0.85,antibody,CD45-PE,Antibody,,,,,
PMID:34930951,10.1038/s41536-021-00195-3,A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy.,,0.85,antibody,IBA1-FITC,Antibody,,,,,
PMID:34930951,10.1038/s41536-021-00195-3,A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy.,,0.85,antibody,GFAP-PE,Antibody,,,,,
PMID:34930951,10.1038/s41536-021-00195-3,A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy.,,0.85,antibody,STEM121-FITC,Antibody,,,,,
PMID:34930951,10.1038/s41536-021-00195-3,A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy.,,0.9,computational_tool,ImageJ,Computational Tool,,,,,
PMID:34930951,10.1038/s41536-021-00195-3,A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy.,,0.85,computational_tool,MATLAB,Computational Tool,,,,,
PMID:34930951,10.1038/s41536-021-00195-3,A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy.,,0.85,computational_tool,MACSQuant flow cytometer,Computational Tool,,,,,
PMID:34930951,10.1038/s41536-021-00195-3,A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy.,,0.85,computational_tool,Leica SP8 confocal microscope,Computational Tool,,,,,
PMID:33963966,10.1007/s10803-021-05043-3,Cognitive and Electrophysiological Correlates of Working Memory Impairments in Neurofibromatosis Type 1.,,0.85,clinical_assessment_tool,National Institute of Health diagnostic criteria for NF1,Clinical Assessment Tool,,,,,
PMID:33963966,10.1007/s10803-021-05043-3,Cognitive and Electrophysiological Correlates of Working Memory Impairments in Neurofibromatosis Type 1.,,0.8,clinical_assessment_tool,P300 event-related potential,Clinical Assessment Tool,,,,,
PMID:33963966,10.1007/s10803-021-05043-3,Cognitive and Electrophysiological Correlates of Working Memory Impairments in Neurofibromatosis Type 1.,,0.75,clinical_assessment_tool,WM nback task,Clinical Assessment Tool,,,,,
PMID:33817379,10.1016/j.heliyon.2021.e06518,Clinical assessment of the use of topical liquid diclofenac following laser microporation of cutaneous neurofibromas in individuals with neurofibromatosis type 1.,,0.85,clinical_assessment_tool,P.L.E.A.S.E.® device,Clinical Assessment Tool,,,,,
PMID:33817379,10.1016/j.heliyon.2021.e06518,Clinical assessment of the use of topical liquid diclofenac following laser microporation of cutaneous neurofibromas in individuals with neurofibromatosis type 1.,,0.8,clinical_assessment_tool,Dermlite DL3,Clinical Assessment Tool,,,,,
PMID:33817379,10.1016/j.heliyon.2021.e06518,Clinical assessment of the use of topical liquid diclofenac following laser microporation of cutaneous neurofibromas in individuals with neurofibromatosis type 1.,,0.9,clinical_assessment_tool,NIH Consensus Development Conference NF1 diagnostic criteria,Clinical Assessment Tool,,,,,
PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,0.85,genetic_reagent,dispase grade II,Genetic Reagent,,,,,
PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,0.85,genetic_reagent,collagenase type I,Genetic Reagent,,,,,
PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,0.9,antibody,anti-HLA-DR Percp-cy5.5,Antibody,,,,,
PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,0.9,antibody,anti-CD33 APC,Antibody,,,,,
PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,0.9,antibody,anti-CD11b FITC,Antibody,,,,,
PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,0.85,computational_tool,FlowJo software,Computational Tool,,,,,
PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,0.8,genetic_reagent,Cell Counting Kit-8,Genetic Reagent,,,,,
PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,0.85,computational_tool,SpectraMax M5 microplate reader,Computational Tool,,,,,
PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,0.9,computational_tool,Orbitrap Fusion Lumos mass spectrometer,Computational Tool,,,,,
PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,0.9,antibody,CD9 antibody,Antibody,,,,,
PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,0.9,antibody,CD81 antibody,Antibody,,,,,
PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,0.9,antibody,TOMM20 antibody,Antibody,,,,,
PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,0.9,antibody,HSP90 antibody,Antibody,,,,,
PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,0.9,antibody,AKT antibody,Antibody,,,,,
PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,0.9,antibody,p-AKT antibody,Antibody,,,,,
PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,0.9,antibody,ERK antibody,Antibody,,,,,
PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,0.9,antibody,p-ERK antibody,Antibody,,,,,
PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,0.85,computational_tool,ImageJ software,Computational Tool,,,,,
PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,0.85,computational_tool,STRING database,Computational Tool,,,,,
PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,0.85,computational_tool,Cytoscape,Computational Tool,,,,,
PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,0.85,computational_tool,GraphPad Prism,Computational Tool,,,,,
PMID:41149489,10.3390/curroncol32100569,Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via HSP90.,,0.95,cell_line,Primary Schwannoma Cells,Cell Line,,,,,
PMID:20200958,10.1002/jbmr.42,Local low-dose lovastatin delivery improves the bone-healing defect caused by Nf1 loss of function in osteoblasts.,,0.9,animal_model,Nf1(ob) (-/-) conditional mouse model,Animal Model,,,,,
PMID:20200958,10.1002/jbmr.42,Local low-dose lovastatin delivery improves the bone-healing defect caused by Nf1 loss of function in osteoblasts.,,0.85,animal_model,2.3-kb α1(I) collagen-cre Nf1 flox/flox mice,Animal Model,,,,,
PMID:20200958,10.1002/jbmr.42,Local low-dose lovastatin delivery improves the bone-healing defect caused by Nf1 loss of function in osteoblasts.,,0.85,animal_model,Nf1 flox/flox mice,Animal Model,,,,,
PMID:20200958,10.1002/jbmr.42,Local low-dose lovastatin delivery improves the bone-healing defect caused by Nf1 loss of function in osteoblasts.,,0.8,computational_tool,Scanco µCT 40,Computational Tool,,,,,
PMID:20200958,10.1002/jbmr.42,Local low-dose lovastatin delivery improves the bone-healing defect caused by Nf1 loss of function in osteoblasts.,,0.75,computational_tool,Dynamight 8841,Computational Tool,,,,,
PMID:20200958,10.1002/jbmr.42,Local low-dose lovastatin delivery improves the bone-healing defect caused by Nf1 loss of function in osteoblasts.,,0.8,computational_tool,Bioquant Analysis System,Computational Tool,,,,,
PMID:20200958,10.1002/jbmr.42,Local low-dose lovastatin delivery improves the bone-healing defect caused by Nf1 loss of function in osteoblasts.,,0.9,genetic_reagent,Ad5-CMV-Cre,Genetic Reagent,,,,,
PMID:20200958,10.1002/jbmr.42,Local low-dose lovastatin delivery improves the bone-healing defect caused by Nf1 loss of function in osteoblasts.,,0.9,genetic_reagent,Ad5-CMV-eGFP,Genetic Reagent,,,,,
PMID:20200958,10.1002/jbmr.42,Local low-dose lovastatin delivery improves the bone-healing defect caused by Nf1 loss of function in osteoblasts.,,0.85,antibody,anti-total Erk1/2,Antibody,,,,,
PMID:20200958,10.1002/jbmr.42,Local low-dose lovastatin delivery improves the bone-healing defect caused by Nf1 loss of function in osteoblasts.,,0.85,antibody,anti-phospho Erk1/2,Antibody,,,,,
PMID:20200958,10.1002/jbmr.42,Local low-dose lovastatin delivery improves the bone-healing defect caused by Nf1 loss of function in osteoblasts.,,0.8,cell_line,Nf1 flox/flox calvaria osteoblasts,Cell Line,,,,,
PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,0.9,genetic_reagent,Addgene construct 70423,Genetic Reagent,,,,,
PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,0.85,genetic_reagent,pDonr255,Genetic Reagent,,,,,
PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,0.85,genetic_reagent,pDest-635,Genetic Reagent,,,,,
PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,0.85,genetic_reagent,pDest-636,Genetic Reagent,,,,,
PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,0.85,genetic_reagent,pDest-566,Genetic Reagent,,,,,
PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,0.9,cell_line,DH10Bac cells,Cell Line,,,,,
PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,0.9,cell_line,BL21(DE3),Cell Line,,,,,
PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,0.9,cell_line,Sf9 cells,Cell Line,,,,,
PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,0.9,cell_line,Tni-FNL cells,Cell Line,,,,,
PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,0.95,cell_line,NF1-null HEK293T cell line,Cell Line,,,,,
PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,0.9,cell_line,HEK293T,Cell Line,,,,,
PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,0.9,computational_tool,SEDFIT 16.1,Computational Tool,,,,,
PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,0.85,computational_tool,SEDNTERP,Computational Tool,,,,,
PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,0.9,computational_tool,SEDPHAT 14.0,Computational Tool,,,,,
PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,0.9,computational_tool,EMAN2 e2boxer,Computational Tool,,,,,
PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,0.9,computational_tool,Sphire,Computational Tool,,,,,
PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,0.85,computational_tool,Chimera,Computational Tool,,,,,
PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,0.85,computational_tool,Relion,Computational Tool,,,,,
PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,0.85,computational_tool,MantidPlot,Computational Tool,,,,,
PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,0.9,computational_tool,ATSAS,Computational Tool,,,,,
PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,0.85,computational_tool,DAMMIF,Computational Tool,,,,,
PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,0.85,computational_tool,EM2DAM,Computational Tool,,,,,
PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,0.85,computational_tool,MULCh,Computational Tool,,,,,
PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,0.9,antibody,"FLAG antibody (rabbit, 14793)",Antibody,,,,,
PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,0.9,antibody,"V5 antibody (rabbit, 13202)",Antibody,,,,,
PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,0.9,antibody,"HA antibody (rabbit, 3724)",Antibody,,,,,
PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,0.9,antibody,pEGFR antibody (Cell Signaling 3777),Antibody,,,,,
PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,0.9,antibody,vinculin antibody (Cell Signaling 19301),Antibody,,,,,
PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,0.9,antibody,KRAS antibody (Sigma/Novus Biologicals WH0003845M1/H0003845M1),Antibody,,,,,
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.9,animal_model,Myf5 Cre,Animal Model,,,,,
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.9,animal_model,Lbx1 Cre,Animal Model,,,,,
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.95,animal_model,Nf1 flox,Animal Model,,,,,
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.9,animal_model,Rosa26 mTmG,Animal Model,,,,,
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.95,antibody,goat anti-collagen IV (Millipore AB769),Antibody,,,,,
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.95,antibody,mouse anti-MyHC type 1 (DSHB BA-D5),Antibody,,,,,
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.95,antibody,mouse anti-MyHC type 2A (DSHB SC-71),Antibody,,,,,
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.95,antibody,rabbit anti-laminin (Sigma-Aldrich L9393),Antibody,,,,,
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.95,antibody,mouse anti-Pax7 (DSHB Pax7),Antibody,,,,,
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.95,antibody,mouse anti-myosin heavy chain (Sigma-Aldrich 05-716),Antibody,,,,,
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.95,antibody,anti-beta III tubulin antibody (Sigma-Aldrich AB9354),Antibody,,,,,
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.95,antibody,anti-perilipin A/B antibody (Sigma-Aldrich p1873),Antibody,,,,,
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.95,antibody,rabbit anti-PPARG (Cell Signaling Technology 2443),Antibody,,,,,
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.95,antibody,rabbit anti-phosphor (pThr172) AMPKa (Cell Signaling Technology 2535),Antibody,,,,,
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.95,antibody,rabbit anti-AMPKα (Cell Signaling Technology 2532),Antibody,,,,,
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.95,antibody,mouse anti-β-actin (Cell Signaling Technology 58169),Antibody,,,,,
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.95,antibody,mouse anti-β-tubulin (Sigma-Aldrich T8328),Antibody,,,,,
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.95,antibody,rabbit anti-phosphor (s235/236) S6 (Cell Signaling Technology 4858),Antibody,,,,,
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.95,antibody,mouse anti-MyHC type 2B (DSHB BF-F3),Antibody,,,,,
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.95,antibody,"rabbit anti-phosphor (Ser473) AKT (Cell Signaling, #9271)",Antibody,,,,,
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.95,antibody,"rabbit anti-phospho (Ser1101) IRS-1 (Cell Signaling, #2385)",Antibody,,,,,
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.95,antibody,"rabbit anti-phospho (Ser636/639) IRS-1 (Cell Signaling, #2388)",Antibody,,,,,
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.95,antibody,"anti-DIG-Fab antibody coupled to alkaline phosphatase (Roche, 11093274910)",Antibody,,,,,
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.9,computational_tool,STAR 2.4.2a,Computational Tool,,,,,
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.9,computational_tool,DESeq2,Computational Tool,,,,,
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.9,computational_tool,GSEA software 4.0.1,Computational Tool,,,,,
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.9,computational_tool,DAVID 6.8,Computational Tool,,,,,
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.9,computational_tool,MaxQuant (v1.5.3.30),Computational Tool,,,,,
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.85,computational_tool,ZEN imaging software,Computational Tool,,,,,
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.85,computational_tool,AxioVision 4.6 software,Computational Tool,,,,,
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.85,computational_tool,FUSION FX software,Computational Tool,,,,,
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.9,computational_tool,ImageJ,Computational Tool,,,,,
PMID:33078583,10.1002/jcsm.12632,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis.,,0.85,computational_tool,DatLab software,Computational Tool,,,,,
PMID:32369930,10.3390/genes11050499,Unmasking Intra-tumoral Heterogeneity and Clonal Evolution in NF1-MPNST.,,0.8,clinical_assessment_tool,Olympus BX-51 microscope,Clinical Assessment Tool,,,,,
PMID:32369930,10.3390/genes11050499,Unmasking Intra-tumoral Heterogeneity and Clonal Evolution in NF1-MPNST.,,0.8,clinical_assessment_tool,Olympus DP71 digital camera,Clinical Assessment Tool,,,,,
PMID:32369930,10.3390/genes11050499,Unmasking Intra-tumoral Heterogeneity and Clonal Evolution in NF1-MPNST.,,0.85,computational_tool,DP Controller software,Computational Tool,,,,,
PMID:32369930,10.3390/genes11050499,Unmasking Intra-tumoral Heterogeneity and Clonal Evolution in NF1-MPNST.,,0.9,computational_tool,CNVkit,Computational Tool,,,,,
PMID:32369930,10.3390/genes11050499,Unmasking Intra-tumoral Heterogeneity and Clonal Evolution in NF1-MPNST.,,0.9,computational_tool,Illumina HiSeq4000,Computational Tool,,,,,
PMID:32369930,10.3390/genes11050499,Unmasking Intra-tumoral Heterogeneity and Clonal Evolution in NF1-MPNST.,,0.85,genetic_reagent,IDT exome reagent,Genetic Reagent,,,,,
PMID:32369930,10.3390/genes11050499,Unmasking Intra-tumoral Heterogeneity and Clonal Evolution in NF1-MPNST.,,0.85,genetic_reagent,TrueSeq stranded total RNA library kit,Genetic Reagent,,,,,
PMID:32369930,10.3390/genes11050499,Unmasking Intra-tumoral Heterogeneity and Clonal Evolution in NF1-MPNST.,,0.9,computational_tool,BWA-MEM,Computational Tool,,,,,
PMID:32369930,10.3390/genes11050499,Unmasking Intra-tumoral Heterogeneity and Clonal Evolution in NF1-MPNST.,,0.9,computational_tool,manta,Computational Tool,,,,,
PMID:32369930,10.3390/genes11050499,Unmasking Intra-tumoral Heterogeneity and Clonal Evolution in NF1-MPNST.,,0.9,computational_tool,VarScan2,Computational Tool,,,,,
PMID:32369930,10.3390/genes11050499,Unmasking Intra-tumoral Heterogeneity and Clonal Evolution in NF1-MPNST.,,0.9,computational_tool,Strelka2,Computational Tool,,,,,
PMID:32369930,10.3390/genes11050499,Unmasking Intra-tumoral Heterogeneity and Clonal Evolution in NF1-MPNST.,,0.9,computational_tool,MuTect2,Computational Tool,,,,,
PMID:32369930,10.3390/genes11050499,Unmasking Intra-tumoral Heterogeneity and Clonal Evolution in NF1-MPNST.,,0.9,computational_tool,Pindel,Computational Tool,,,,,
PMID:32369930,10.3390/genes11050499,Unmasking Intra-tumoral Heterogeneity and Clonal Evolution in NF1-MPNST.,,0.9,computational_tool,VEP,Computational Tool,,,,,
PMID:32369930,10.3390/genes11050499,Unmasking Intra-tumoral Heterogeneity and Clonal Evolution in NF1-MPNST.,,0.9,computational_tool,GenVisR,Computational Tool,,,,,
PMID:32369930,10.3390/genes11050499,Unmasking Intra-tumoral Heterogeneity and Clonal Evolution in NF1-MPNST.,,0.9,computational_tool,COSMIC,Computational Tool,,,,,
PMID:32369930,10.3390/genes11050499,Unmasking Intra-tumoral Heterogeneity and Clonal Evolution in NF1-MPNST.,,0.9,computational_tool,ClinVar,Computational Tool,,,,,
PMID:32369930,10.3390/genes11050499,Unmasking Intra-tumoral Heterogeneity and Clonal Evolution in NF1-MPNST.,,0.9,computational_tool,SIFT,Computational Tool,,,,,
PMID:32369930,10.3390/genes11050499,Unmasking Intra-tumoral Heterogeneity and Clonal Evolution in NF1-MPNST.,,0.9,computational_tool,Polyphen,Computational Tool,,,,,
PMID:32369930,10.3390/genes11050499,Unmasking Intra-tumoral Heterogeneity and Clonal Evolution in NF1-MPNST.,,0.9,computational_tool,SciClone,Computational Tool,,,,,
PMID:32369930,10.3390/genes11050499,Unmasking Intra-tumoral Heterogeneity and Clonal Evolution in NF1-MPNST.,,0.9,computational_tool,ClonEvol,Computational Tool,,,,,
PMID:32369930,10.3390/genes11050499,Unmasking Intra-tumoral Heterogeneity and Clonal Evolution in NF1-MPNST.,,0.9,computational_tool,Partek Flow,Computational Tool,,,,,
PMID:32369930,10.3390/genes11050499,Unmasking Intra-tumoral Heterogeneity and Clonal Evolution in NF1-MPNST.,,0.9,computational_tool,edgeR,Computational Tool,,,,,
PMID:32369930,10.3390/genes11050499,Unmasking Intra-tumoral Heterogeneity and Clonal Evolution in NF1-MPNST.,,0.9,computational_tool,gplots,Computational Tool,,,,,
PMID:32369930,10.3390/genes11050499,Unmasking Intra-tumoral Heterogeneity and Clonal Evolution in NF1-MPNST.,,0.9,computational_tool,PantherDB,Computational Tool,,,,,
PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,,0.95,cell_line,S462TY,Cell Line,,,,,
PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,,0.9,cell_line,iSC,Cell Line,,,,,
PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,,0.85,cell_line,A549,Cell Line,,,,,
PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,,0.95,cell_line,ST88-14,Cell Line,,,,,
PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,,0.85,cell_line,MCF10A,Cell Line,,,,,
PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,,0.95,antibody,"pan-RAS antibody (BD Biosciences, product #610002)",Antibody,,,,,
PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,,0.95,antibody,"N-RAS antibody (Santa Cruz, product #sc-519)",Antibody,,,,,
PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,,0.95,antibody,"RAB5A antibody (Santa Cruz, product #sc-309)",Antibody,,,,,
PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,,0.95,antibody,"RAP1A antibody (Santa Cruz, product #1482)",Antibody,,,,,
PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,,0.95,antibody,"GAPDH antibody (Cell Signaling, product #2118)",Antibody,,,,,
PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,,0.95,antibody,"β-actin antibody (Sigma, product #A5441)",Antibody,,,,,
PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,,0.95,animal_model,NOD SCID mice (NOD.CB17-Prkdc/NCrCrl),Animal Model,,,,,
PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,,0.9,animal_model,Balb/c mice,Animal Model,,,,,
PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,,0.95,computational_tool,CompuSyn software Version 1.0,Computational Tool,,,,,
PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,,0.9,computational_tool,IBM SPSS Statistics software version 29.0.1.0,Computational Tool,,,,,
PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,,0.95,computational_tool,SPIN (Signal Processing in MR Version SVN Revision 1895),Computational Tool,,,,,
PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,genetic_reagent,TruSeq DNA PCR Free 350bp kit,Genetic Reagent,,,,,
PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.9,computational_tool,Illumina NovaSeq6000,Computational Tool,,,,,
PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,computational_tool,BWA-MEM,Computational Tool,,,,,
PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,computational_tool,GATK,Computational Tool,,,,,
PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,computational_tool,NGSCheckMate,Computational Tool,,,,,
PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,genetic_reagent,Covaris truXTRAC FFPE DNA kit,Genetic Reagent,,,,,
PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,genetic_reagent,Roche Kapa HyperPlus kit,Genetic Reagent,,,,,
PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,computational_tool,Strelka2,Computational Tool,,,,,
PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,computational_tool,VarDict,Computational Tool,,,,,
PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,computational_tool,Annovar,Computational Tool,,,,,
PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,computational_tool,BamSnap,Computational Tool,,,,,
PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,computational_tool,Manta,Computational Tool,,,,,
PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,computational_tool,LUMPY,Computational Tool,,,,,
PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,computational_tool,SvABA,Computational Tool,,,,,
PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,computational_tool,Delly,Computational Tool,,,,,
PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,computational_tool,mosdepth,Computational Tool,,,,,
PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,computational_tool,Mutect2,Computational Tool,,,,,
PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,computational_tool,MuSE,Computational Tool,,,,,
PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,computational_tool,dNdScv,Computational Tool,,,,,
PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,computational_tool,NMF,Computational Tool,,,,,
PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,computational_tool,MutationalPatterns,Computational Tool,,,,,
PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,computational_tool,MSIprofiler,Computational Tool,,,,,
PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,computational_tool,FACETS,Computational Tool,,,,,
PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,computational_tool,ascatNGS,Computational Tool,,,,,
PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,computational_tool,ASCAT,Computational Tool,,,,,
PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,computational_tool,sigProfilerExtractor,Computational Tool,,,,,
PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,computational_tool,sigProfilerSingleSample,Computational Tool,,,,,
PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,computational_tool,ShatterSeek,Computational Tool,,,,,
PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,computational_tool,STAR,Computational Tool,,,,,
PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,computational_tool,HTSeq,Computational Tool,,,,,
PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,computational_tool,DESeq2,Computational Tool,,,,,
PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,computational_tool,ARRIBA,Computational Tool,,,,,
PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,computational_tool,TopHat-fusion,Computational Tool,,,,,
PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,computational_tool,EricScript,Computational Tool,,,,,
PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,computational_tool,STAR-Fusion,Computational Tool,,,,,
PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,computational_tool,consensusTME,Computational Tool,,,,,
PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,genetic_reagent,HumanMethylationEPIC beadchip,Genetic Reagent,,,,,
PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,genetic_reagent,Zymo EZ DNA methylation Gold kit,Genetic Reagent,,,,,
PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,computational_tool,minfi,Computational Tool,,,,,
PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,computational_tool,ConsensusClusterPlus,Computational Tool,,,,,
PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,computational_tool,coca,Computational Tool,,,,,
PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,computational_tool,IchorCNA,Computational Tool,,,,,
PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,computational_tool,survival,Computational Tool,,,,,
PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,computational_tool,phangorn,Computational Tool,,,,,
PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,computational_tool,MesKit,Computational Tool,,,,,
PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,antibody,H3K27me3 antibody,Antibody,,,,,
PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,antibody,MYF-4 antibody,Antibody,,,,,
PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,antibody,S100 antibody,Antibody,,,,,
PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,antibody,Sox10 antibody,Antibody,,,,,
PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,antibody,HMB45 antibody,Antibody,,,,,
PMID:36598417,10.1158/2159-8290.CD-22-0786,Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA.,,0.85,antibody,Melan-A antibody,Antibody,,,,,
PMID:32781282,10.1016/j.trsl.2020.08.001,Nf1 heterozygous mice recapitulate the anthropometric and metabolic features of human neurofibromatosis type 1.,,0.95,animal_model,Nf1+/- mice,Animal Model,,,,,
PMID:32781282,10.1016/j.trsl.2020.08.001,Nf1 heterozygous mice recapitulate the anthropometric and metabolic features of human neurofibromatosis type 1.,,0.85,computational_tool,Bruker minispec LF90 TD‐NMR analyzer,Computational Tool,,,,,
PMID:32781282,10.1016/j.trsl.2020.08.001,Nf1 heterozygous mice recapitulate the anthropometric and metabolic features of human neurofibromatosis type 1.,,0.85,computational_tool,Comprehensive Lab Animal Monitoring System (CLAMS),Computational Tool,,,,,
PMID:32781282,10.1016/j.trsl.2020.08.001,Nf1 heterozygous mice recapitulate the anthropometric and metabolic features of human neurofibromatosis type 1.,,0.8,computational_tool,AlphaTrak 2,Computational Tool,,,,,
PMID:32781282,10.1016/j.trsl.2020.08.001,Nf1 heterozygous mice recapitulate the anthropometric and metabolic features of human neurofibromatosis type 1.,,0.8,computational_tool,A1C Now Diabetes Management HbA1C test kit,Computational Tool,,,,,
PMID:32781282,10.1016/j.trsl.2020.08.001,Nf1 heterozygous mice recapitulate the anthropometric and metabolic features of human neurofibromatosis type 1.,,0.8,computational_tool,LDX Cholestech cartridges,Computational Tool,,,,,
PMID:32781282,10.1016/j.trsl.2020.08.001,Nf1 heterozygous mice recapitulate the anthropometric and metabolic features of human neurofibromatosis type 1.,,0.8,computational_tool,Pro-diabetes multiplex assay,Computational Tool,,,,,
PMID:32781282,10.1016/j.trsl.2020.08.001,Nf1 heterozygous mice recapitulate the anthropometric and metabolic features of human neurofibromatosis type 1.,,0.85,computational_tool,Image Pro Plus,Computational Tool,,,,,
PMID:32781282,10.1016/j.trsl.2020.08.001,Nf1 heterozygous mice recapitulate the anthropometric and metabolic features of human neurofibromatosis type 1.,,0.9,computational_tool,GraphPad Prism version 6.0h,Computational Tool,,,,,
PMID:41545416,10.1038/s41540-026-00647-w,Asthma-mediated control of optic glioma growth via T cell-microglia interactions: A mathematical model.,,0.85,computational_tool,MATLAB,Computational Tool,,,,,
PMID:41545416,10.1038/s41540-026-00647-w,Asthma-mediated control of optic glioma growth via T cell-microglia interactions: A mathematical model.,,0.8,computational_tool,ode15s solver,Computational Tool,,,,,
PMID:25851896,10.3988/jcn.2015.11.2.172,Preclinical assessment of the anticancer drug response of plexiform neurofibroma tissue using primary cultures.,,0.85,advanced_cellular_model,primary cultures derived from plexiform neurofibromas,Advanced Cellular Model,,,,,
PMID:25851896,10.3988/jcn.2015.11.2.172,Preclinical assessment of the anticancer drug response of plexiform neurofibroma tissue using primary cultures.,,0.9,antibody,"rabbit anti-human S100 antibody (DAKO, Glostrup, Denmark)",Antibody,,,,,
PMID:25851896,10.3988/jcn.2015.11.2.172,Preclinical assessment of the anticancer drug response of plexiform neurofibroma tissue using primary cultures.,,0.85,antibody,"anti-human CD90 antibody (Dianova, Hamburg, Germany)",Antibody,,,,,
PMID:25851896,10.3988/jcn.2015.11.2.172,Preclinical assessment of the anticancer drug response of plexiform neurofibroma tissue using primary cultures.,,0.85,antibody,FITC-conjugated anti-rabbit antibody (DAKO),Antibody,,,,,
PMID:25851896,10.3988/jcn.2015.11.2.172,Preclinical assessment of the anticancer drug response of plexiform neurofibroma tissue using primary cultures.,,0.85,antibody,FITC-conjugated goat anti-mouse IgG (DAKO),Antibody,,,,,
PMID:25851896,10.3988/jcn.2015.11.2.172,Preclinical assessment of the anticancer drug response of plexiform neurofibroma tissue using primary cultures.,,0.9,computational_tool,"ImageJ software (version 1.48; National Institutes of Health, Behesda, MD, USA)",Computational Tool,,,,,
PMID:39110684,10.1371/journal.pone.0308207,Electrical stimulation of Schwann cells on electrospun hyaluronic acid carbon nanotube fibers.,,0.9,cell_line,ipNF 95.11b,Cell Line,,,,,
PMID:39110684,10.1371/journal.pone.0308207,Electrical stimulation of Schwann cells on electrospun hyaluronic acid carbon nanotube fibers.,,0.9,cell_line,ipn 02.8,Cell Line,,,,,
PMID:39110684,10.1371/journal.pone.0308207,Electrical stimulation of Schwann cells on electrospun hyaluronic acid carbon nanotube fibers.,,0.85,antibody,s-100b antibody (Sigma),Antibody,,,,,
PMID:39110684,10.1371/journal.pone.0308207,Electrical stimulation of Schwann cells on electrospun hyaluronic acid carbon nanotube fibers.,,0.85,antibody,"anti-rabbit IgG (Alexa Fluor 594, Invitrogen)",Antibody,,,,,
PMID:39110684,10.1371/journal.pone.0308207,Electrical stimulation of Schwann cells on electrospun hyaluronic acid carbon nanotube fibers.,,0.8,computational_tool,ImageJ (v1.53a),Computational Tool,,,,,
PMID:39110684,10.1371/journal.pone.0308207,Electrical stimulation of Schwann cells on electrospun hyaluronic acid carbon nanotube fibers.,,0.8,computational_tool,NIH ImageJ (version 1.53a),Computational Tool,,,,,
PMID:39110684,10.1371/journal.pone.0308207,Electrical stimulation of Schwann cells on electrospun hyaluronic acid carbon nanotube fibers.,,0.75,computational_tool,Thermo Scientific Multiskan GO,Computational Tool,,,,,
PMID:39110684,10.1371/journal.pone.0308207,Electrical stimulation of Schwann cells on electrospun hyaluronic acid carbon nanotube fibers.,,0.75,computational_tool,Rigol oscilloscope,Computational Tool,,,,,
PMID:39110684,10.1371/journal.pone.0308207,Electrical stimulation of Schwann cells on electrospun hyaluronic acid carbon nanotube fibers.,,0.75,computational_tool,Raspberry Pi Python script,Computational Tool,,,,,
PMID:18670322,10.1097/MLG.0b013e318177e20b,Vestibular schwannoma quantitative polymerase chain reaction expression of estrogen and progesterone receptors.,,0.85,genetic_reagent,Trizol reagent,Genetic Reagent,,,,,
PMID:18670322,10.1097/MLG.0b013e318177e20b,Vestibular schwannoma quantitative polymerase chain reaction expression of estrogen and progesterone receptors.,,0.8,genetic_reagent,oligo-dT columns,Genetic Reagent,,,,,
PMID:18670322,10.1097/MLG.0b013e318177e20b,Vestibular schwannoma quantitative polymerase chain reaction expression of estrogen and progesterone receptors.,,0.85,genetic_reagent,Gene AMP kit,Genetic Reagent,,,,,
PMID:18670322,10.1097/MLG.0b013e318177e20b,Vestibular schwannoma quantitative polymerase chain reaction expression of estrogen and progesterone receptors.,,0.9,computational_tool,DNA Engine Peltier Thermal cycler (PTC-200),Computational Tool,,,,,
PMID:18670322,10.1097/MLG.0b013e318177e20b,Vestibular schwannoma quantitative polymerase chain reaction expression of estrogen and progesterone receptors.,,0.85,genetic_reagent,Taqman Universal PCR Master Mix,Genetic Reagent,,,,,
PMID:18670322,10.1097/MLG.0b013e318177e20b,Vestibular schwannoma quantitative polymerase chain reaction expression of estrogen and progesterone receptors.,,0.9,genetic_reagent,Taqman Gene Expression Assays,Genetic Reagent,,,,,
PMID:18670322,10.1097/MLG.0b013e318177e20b,Vestibular schwannoma quantitative polymerase chain reaction expression of estrogen and progesterone receptors.,,0.95,computational_tool,"ABI Prism 7,000 Sequence Detection System",Computational Tool,,,,,
PMID:18670322,10.1097/MLG.0b013e318177e20b,Vestibular schwannoma quantitative polymerase chain reaction expression of estrogen and progesterone receptors.,,0.8,computational_tool,Microsoft Excel program designed for Q-PCR quantitation,Computational Tool,,,,,
PMID:39966622,10.1038/s41598-025-88589-x,The development of an artificial intelligence auto-segmentation tool for 3D volumetric analysis of vestibular schwannomas.,,0.95,computational_tool,Simpleware ScanIP,Computational Tool,,,,,
PMID:39966622,10.1038/s41598-025-88589-x,The development of an artificial intelligence auto-segmentation tool for 3D volumetric analysis of vestibular schwannomas.,,0.9,computational_tool,DPP V1.0,Computational Tool,,,,,
PMID:39966622,10.1038/s41598-025-88589-x,The development of an artificial intelligence auto-segmentation tool for 3D volumetric analysis of vestibular schwannomas.,,0.95,computational_tool,Simpleware,Computational Tool,,,,,
PMID:33507822,10.1200/JCO.20.02220,NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas.,,0.9,clinical_assessment_tool,Numerical Rating Scale-11,Clinical Assessment Tool,,,,,
PMID:33507822,10.1200/JCO.20.02220,NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas.,,0.9,clinical_assessment_tool,Brief Pain Inventory Pain Interference subscale,Clinical Assessment Tool,,,,,
PMID:33507822,10.1200/JCO.20.02220,NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas.,,0.95,clinical_assessment_tool,Pediatric Quality of Life Inventory NF1 module,Clinical Assessment Tool,,,,,
PMID:33507822,10.1200/JCO.20.02220,NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas.,,0.85,computational_tool,Phoenix WinNonlin (Version 8.1),Computational Tool,,,,,
PMID:33507822,10.1200/JCO.20.02220,NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas.,,0.85,computational_tool,NONMEM (version 7.2),Computational Tool,,,,,
PMID:33507822,10.1200/JCO.20.02220,NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas.,,0.8,computational_tool,Perl speaks NONMEM version 3.6.2,Computational Tool,,,,,
PMID:33507822,10.1200/JCO.20.02220,NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas.,,0.8,computational_tool,Pirana version 2.7.1,Computational Tool,,,,,
PMID:33507822,10.1200/JCO.20.02220,NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas.,,0.8,computational_tool,SAS version 9.4,Computational Tool,,,,,
PMID:38811427,10.1186/s41687-024-00732-w,Quality of life in individuals with neurofibromatosis type 1 associated cutaneous neurofibromas: validation of the Dutch cNF-Skindex.,,0.95,clinical_assessment_tool,cNF-Skindex,Clinical Assessment Tool,,,,,
PMID:38811427,10.1186/s41687-024-00732-w,Quality of life in individuals with neurofibromatosis type 1 associated cutaneous neurofibromas: validation of the Dutch cNF-Skindex.,,0.9,clinical_assessment_tool,EQ-5D-5L,Clinical Assessment Tool,,,,,
PMID:38811427,10.1186/s41687-024-00732-w,Quality of life in individuals with neurofibromatosis type 1 associated cutaneous neurofibromas: validation of the Dutch cNF-Skindex.,,0.9,clinical_assessment_tool,SF-36,Clinical Assessment Tool,,,,,
PMID:38811427,10.1186/s41687-024-00732-w,Quality of life in individuals with neurofibromatosis type 1 associated cutaneous neurofibromas: validation of the Dutch cNF-Skindex.,,0.85,computational_tool,Castor EDC,Computational Tool,,,,,
PMID:38811427,10.1186/s41687-024-00732-w,Quality of life in individuals with neurofibromatosis type 1 associated cutaneous neurofibromas: validation of the Dutch cNF-Skindex.,,0.8,computational_tool,SPSS version 28.0,Computational Tool,,,,,
PMID:37378983,10.1001/jamanetworkopen.2023.20599,Effect of Mind-Body Skills Training on Quality of Life for Geographically Diverse Adults With Neurofibromatosis: A Fully Remote Randomized Clinical Trial.,,0.95,clinical_assessment_tool,World Health Organization Quality of Life Brief Version (WHOQOL-BREF),Clinical Assessment Tool,,,,,
PMID:37378983,10.1001/jamanetworkopen.2023.20599,Effect of Mind-Body Skills Training on Quality of Life for Geographically Diverse Adults With Neurofibromatosis: A Fully Remote Randomized Clinical Trial.,,0.9,clinical_assessment_tool,Perceived Stress Scale,Clinical Assessment Tool,,,,,
PMID:37378983,10.1001/jamanetworkopen.2023.20599,Effect of Mind-Body Skills Training on Quality of Life for Geographically Diverse Adults With Neurofibromatosis: A Fully Remote Randomized Clinical Trial.,,0.85,clinical_assessment_tool,Relaxation Response Resiliency Program for NF (3RP-NF),Clinical Assessment Tool,,,,,
PMID:37378983,10.1001/jamanetworkopen.2023.20599,Effect of Mind-Body Skills Training on Quality of Life for Geographically Diverse Adults With Neurofibromatosis: A Fully Remote Randomized Clinical Trial.,,0.85,clinical_assessment_tool,Health Enhancement Program for NF (HEP-NF),Clinical Assessment Tool,,,,,
PMID:37378983,10.1001/jamanetworkopen.2023.20599,Effect of Mind-Body Skills Training on Quality of Life for Geographically Diverse Adults With Neurofibromatosis: A Fully Remote Randomized Clinical Trial.,,0.8,computational_tool,REDCap,Computational Tool,,,,,
PMID:37378983,10.1001/jamanetworkopen.2023.20599,Effect of Mind-Body Skills Training on Quality of Life for Geographically Diverse Adults With Neurofibromatosis: A Fully Remote Randomized Clinical Trial.,,0.85,computational_tool,"SAS, version 9.4",Computational Tool,,,,,
PMID:29897904,10.1371/journal.pone.0197350,Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2.,,0.85,genetic_reagent,GSK2126458,Genetic Reagent,,,,,
PMID:29897904,10.1371/journal.pone.0197350,Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2.,,0.85,genetic_reagent,Panobinostat,Genetic Reagent,,,,,
PMID:29897904,10.1371/journal.pone.0197350,Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2.,,0.85,genetic_reagent,CUDC-907,Genetic Reagent,,,,,
PMID:29897904,10.1371/journal.pone.0197350,Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2.,,0.9,computational_tool,www.synapse.org/SynodosNF2,Computational Tool,,,,,
PMID:30617350,10.1038/s41596-018-0105-7,"A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma.",,0.85,animal_model,FVB/C57BL/6 mice,Animal Model,,,,,
PMID:30617350,10.1038/s41596-018-0105-7,"A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma.",,0.85,animal_model,nude mice (nu/nu),Animal Model,,,,,
PMID:30617350,10.1038/s41596-018-0105-7,"A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma.",,0.85,animal_model,NOD SCID mice,Animal Model,,,,,
PMID:30617350,10.1038/s41596-018-0105-7,"A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma.",,0.9,cell_line,murine NF2 −/− Schwann cell line,Cell Line,,,,,
PMID:30617350,10.1038/s41596-018-0105-7,"A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma.",,0.9,cell_line,HEI-193,Cell Line,,,,,
PMID:30617350,10.1038/s41596-018-0105-7,"A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma.",,0.85,genetic_reagent,GLuc reporter gene,Genetic Reagent,,,,,
PMID:30617350,10.1038/s41596-018-0105-7,"A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma.",,0.85,genetic_reagent,"GLuc vector (Thermo Fisher Scientific, cat. no. 16146)",Genetic Reagent,,,,,
PMID:30617350,10.1038/s41596-018-0105-7,"A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma.",,0.85,genetic_reagent,"GLuc vector (New England BioLabs, cat. no. N8084S)",Genetic Reagent,,,,,
PMID:30617350,10.1038/s41596-018-0105-7,"A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma.",,0.8,computational_tool,"LabVIEW (National Instruments, cat. no. 784503–35)",Computational Tool,,,,,
PMID:30617350,10.1038/s41596-018-0105-7,"A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma.",,0.85,clinical_assessment_tool,DPOAE,Clinical Assessment Tool,,,,,
PMID:30617350,10.1038/s41596-018-0105-7,"A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma.",,0.85,clinical_assessment_tool,ABR,Clinical Assessment Tool,,,,,
PMID:30617350,10.1038/s41596-018-0105-7,"A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma.",,0.8,clinical_assessment_tool,hind-limb clasping test,Clinical Assessment Tool,,,,,
PMID:30617350,10.1038/s41596-018-0105-7,"A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma.",,0.8,clinical_assessment_tool,ledge test,Clinical Assessment Tool,,,,,
PMID:30617350,10.1038/s41596-018-0105-7,"A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma.",,0.8,clinical_assessment_tool,gait test,Clinical Assessment Tool,,,,,
PMID:30617350,10.1038/s41596-018-0105-7,"A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma.",,0.8,clinical_assessment_tool,rotarod assay,Clinical Assessment Tool,,,,,
PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,0.9,genetic_reagent,mGeCKOa lentiviral library,Genetic Reagent,,,,,
PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,0.85,genetic_reagent,pX330 vector,Genetic Reagent,,,,,
PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,0.85,genetic_reagent,lentiV2,Genetic Reagent,,,,,
PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,0.9,cell_line,p53−/− mouse embryonic liver progenitor cells,Cell Line,,,,,
PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,0.9,animal_model,Nu/Nu mice,Animal Model,,,,,
PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,0.85,animal_model,p53 flox/flox mice,Animal Model,,,,,
PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,0.85,animal_model,Albumin-Cre mice,Animal Model,,,,,
PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,0.85,animal_model,Kras LSL-G12D/+ mice,Animal Model,,,,,
PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,0.9,antibody,anti-Hmga2 antibody (Biocheck),Antibody,,,,,
PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,0.9,antibody,anti-beta-Catenin antibody (BD bioscience),Antibody,,,,,
PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,0.9,antibody,anti-Ck19 antibody (Abcam),Antibody,,,,,
PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,0.9,antibody,anti-Sox9 antibody (Millipore),Antibody,,,,,
PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,0.9,antibody,anti-Hsp90 antibody (BD Biosciences),Antibody,,,,,
PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,0.9,antibody,anti-pErk antibody (Cell Signaling),Antibody,,,,,
PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,0.8,computational_tool,FastQC (version 0.11.2),Computational Tool,,,,,
PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,0.8,computational_tool,Bowtie (version 1.0.0),Computational Tool,,,,,
PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,0.8,computational_tool,BWA version 0.7.5,Computational Tool,,,,,
PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,0.8,computational_tool,SAMtools (version 0.1.19),Computational Tool,,,,,
PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,0.8,computational_tool,VarScan2 (version 2.3),Computational Tool,,,,,
PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,0.8,computational_tool,STAR (version 2.3.0e),Computational Tool,,,,,
PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,0.8,computational_tool,DESeq (version 1.18.0),Computational Tool,,,,,
PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,0.85,genetic_reagent,pT3-EF1α-Myc plasmid,Genetic Reagent,,,,,
PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,0.85,genetic_reagent,CMV-SB10 transposase plasmid,Genetic Reagent,,,,,
PMID:27956228,10.1053/j.gastro.2016.12.002,Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.,,0.8,cell_line,293fs cells,Cell Line,,,,,
PMID:35741605,10.3390/brainsci12060720,Integrated Drug Mining Reveals Actionable Strategies Inhibiting Plexiform Neurofibromas.,,0.85,computational_tool,synapser,Computational Tool,,,,,
PMID:35741605,10.3390/brainsci12060720,Integrated Drug Mining Reveals Actionable Strategies Inhibiting Plexiform Neurofibromas.,,0.85,computational_tool,tidyverse,Computational Tool,,,,,
PMID:35741605,10.3390/brainsci12060720,Integrated Drug Mining Reveals Actionable Strategies Inhibiting Plexiform Neurofibromas.,,0.85,computational_tool,dplyr,Computational Tool,,,,,
PMID:35741605,10.3390/brainsci12060720,Integrated Drug Mining Reveals Actionable Strategies Inhibiting Plexiform Neurofibromas.,,0.9,computational_tool,WGCNA,Computational Tool,,,,,
PMID:35741605,10.3390/brainsci12060720,Integrated Drug Mining Reveals Actionable Strategies Inhibiting Plexiform Neurofibromas.,,0.85,computational_tool,ggplot2,Computational Tool,,,,,
PMID:35741605,10.3390/brainsci12060720,Integrated Drug Mining Reveals Actionable Strategies Inhibiting Plexiform Neurofibromas.,,0.85,computational_tool,enrichplot,Computational Tool,,,,,
PMID:35741605,10.3390/brainsci12060720,Integrated Drug Mining Reveals Actionable Strategies Inhibiting Plexiform Neurofibromas.,,0.9,computational_tool,ConsensusClusterPlus,Computational Tool,,,,,
PMID:35741605,10.3390/brainsci12060720,Integrated Drug Mining Reveals Actionable Strategies Inhibiting Plexiform Neurofibromas.,,0.95,cell_line,ipNF05.5 (mixed clone),Cell Line,,,,,
PMID:35741605,10.3390/brainsci12060720,Integrated Drug Mining Reveals Actionable Strategies Inhibiting Plexiform Neurofibromas.,,0.95,cell_line,ipNF05.5 (single clone),Cell Line,,,,,
PMID:35741605,10.3390/brainsci12060720,Integrated Drug Mining Reveals Actionable Strategies Inhibiting Plexiform Neurofibromas.,,0.95,cell_line,ipNF95.11bC,Cell Line,,,,,
PMID:35741605,10.3390/brainsci12060720,Integrated Drug Mining Reveals Actionable Strategies Inhibiting Plexiform Neurofibromas.,,0.95,cell_line,ipNF95.6,Cell Line,,,,,
PMID:35741605,10.3390/brainsci12060720,Integrated Drug Mining Reveals Actionable Strategies Inhibiting Plexiform Neurofibromas.,,0.95,cell_line,ipnNF95.11c,Cell Line,,,,,
PMID:35741605,10.3390/brainsci12060720,Integrated Drug Mining Reveals Actionable Strategies Inhibiting Plexiform Neurofibromas.,,0.9,computational_tool,Mechanism Interrogation PlatE (MIPE 4.0) library,Computational Tool,,,,,
PMID:35741605,10.3390/brainsci12060720,Integrated Drug Mining Reveals Actionable Strategies Inhibiting Plexiform Neurofibromas.,,0.85,computational_tool,ChEMBL database,Computational Tool,,,,,
PMID:35741605,10.3390/brainsci12060720,Integrated Drug Mining Reveals Actionable Strategies Inhibiting Plexiform Neurofibromas.,,0.9,computational_tool,IDAPredict.2drug function package,Computational Tool,,,,,
PMID:41598414,10.3390/jcm15020475,Dermoscopy-Guided High-Frequency Ultrasound Imaging of Subcentimeter Cutaneous and Subcutaneous Neurofibromas in Patients with Neurofibromatosis Type 1.,,0.85,clinical_assessment_tool,Dermus SkinScanner,Clinical Assessment Tool,,,,,
PMID:41598414,10.3390/jcm15020475,Dermoscopy-Guided High-Frequency Ultrasound Imaging of Subcentimeter Cutaneous and Subcutaneous Neurofibromas in Patients with Neurofibromatosis Type 1.,,0.8,computational_tool,SkinAid cloud software,Computational Tool,,,,,
PMID:24595234,10.1371/journal.pone.0090853,In vivo functional analysis of the human NF2 tumor suppressor gene in Drosophila.,,0.85,genetic_reagent,pUASt transformation vector,Genetic Reagent,,,,,
PMID:24595234,10.1371/journal.pone.0090853,In vivo functional analysis of the human NF2 tumor suppressor gene in Drosophila.,,0.9,animal_model,y w Mer4,Animal Model,,,,,
PMID:24595234,10.1371/journal.pone.0090853,In vivo functional analysis of the human NF2 tumor suppressor gene in Drosophila.,,0.85,animal_model,4/FM7; T80-Gal4 y w Mer4,Animal Model,,,,,
PMID:24595234,10.1371/journal.pone.0090853,In vivo functional analysis of the human NF2 tumor suppressor gene in Drosophila.,,0.9,antibody,Mouse anti-Flag,Antibody,,,,,
PMID:24595234,10.1371/journal.pone.0090853,In vivo functional analysis of the human NF2 tumor suppressor gene in Drosophila.,,0.85,antibody,guinea-pig anti-Merlin,Antibody,,,,,
PMID:24595234,10.1371/journal.pone.0090853,In vivo functional analysis of the human NF2 tumor suppressor gene in Drosophila.,,0.85,genetic_reagent,apterous-Gal4 driver,Genetic Reagent,,,,,
PMID:24595234,10.1371/journal.pone.0090853,In vivo functional analysis of the human NF2 tumor suppressor gene in Drosophila.,,0.8,computational_tool,Zeiss LSM 410,Computational Tool,,,,,
PMID:24595234,10.1371/journal.pone.0090853,In vivo functional analysis of the human NF2 tumor suppressor gene in Drosophila.,,0.8,computational_tool,Zeiss LSM 510,Computational Tool,,,,,
PMID:24595234,10.1371/journal.pone.0090853,In vivo functional analysis of the human NF2 tumor suppressor gene in Drosophila.,,0.75,computational_tool,Zeiss Axioplan 2ie compound microscope,Computational Tool,,,,,
PMID:24595234,10.1371/journal.pone.0090853,In vivo functional analysis of the human NF2 tumor suppressor gene in Drosophila.,,0.85,computational_tool,LightCycler FastStart SYBR green system,Computational Tool,,,,,
PMID:40394150,10.1038/s41416-025-03055-9,Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin.,,0.85,genetic_reagent,Complete Mini protease inhibitors,Genetic Reagent,,,,,
PMID:40394150,10.1038/s41416-025-03055-9,Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin.,,0.9,computational_tool,Barocycler NEP 2320,Computational Tool,,,,,
PMID:40394150,10.1038/s41416-025-03055-9,Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin.,,0.85,genetic_reagent,S-Trap micro spin columns,Genetic Reagent,,,,,
PMID:40394150,10.1038/s41416-025-03055-9,Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin.,,0.9,computational_tool,Easy-nLC 1200,Computational Tool,,,,,
PMID:40394150,10.1038/s41416-025-03055-9,Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin.,,0.9,computational_tool,Q Exactive HF mass spectrometer,Computational Tool,,,,,
PMID:40394150,10.1038/s41416-025-03055-9,Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin.,,0.95,computational_tool,Thermo Xcalibur 4.1,Computational Tool,,,,,
PMID:40394150,10.1038/s41416-025-03055-9,Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin.,,0.95,computational_tool,Spectronaut Pulsar,Computational Tool,,,,,
PMID:40394150,10.1038/s41416-025-03055-9,Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin.,,0.9,computational_tool,BenchMark Ultra system,Computational Tool,,,,,
PMID:40394150,10.1038/s41416-025-03055-9,Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin.,,0.95,antibody,CONFIRM anti-Ki67 (clone 30-9),Antibody,,,,,
PMID:40394150,10.1038/s41416-025-03055-9,Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin.,,0.95,antibody,"anti-collagen XV (Sigma-Aldrich, HPA017913)",Antibody,,,,,
PMID:40394150,10.1038/s41416-025-03055-9,Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin.,,0.95,antibody,anti-collagen XVIII (DB144-N2),Antibody,,,,,
PMID:40394150,10.1038/s41416-025-03055-9,Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin.,,0.85,genetic_reagent,UltraView Universal DAB detection kit,Genetic Reagent,,,,,
PMID:40394150,10.1038/s41416-025-03055-9,Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin.,,0.85,genetic_reagent,Dako EnVision kit,Genetic Reagent,,,,,
PMID:40394150,10.1038/s41416-025-03055-9,Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin.,,0.9,computational_tool,NanoZoomer S60 digital slide scanner,Computational Tool,,,,,
PMID:40394150,10.1038/s41416-025-03055-9,Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin.,,0.9,computational_tool,Pannoramic Midi FL slide scanner,Computational Tool,,,,,
PMID:40394150,10.1038/s41416-025-03055-9,Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin.,,0.95,computational_tool,R software version 4.0.0,Computational Tool,,,,,
PMID:40394150,10.1038/s41416-025-03055-9,Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin.,,0.95,computational_tool,lmerTest package version 3.1-2,Computational Tool,,,,,
PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,,0.9,animal_model,K14 Cre mice,Animal Model,,,,,
PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,,0.95,animal_model,PLP CreERT2; Nf1 f/−; ROSA-LacZ mice,Animal Model,,,,,
PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,,0.9,antibody,"K1 antibody (BioLegend, 905601)",Antibody,,,,,
PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,,0.9,antibody,NF1 antibody (Santa Cruz; sc-67),Antibody,,,,,
PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,,0.9,antibody,"H3K27Me3 antibody (Cell Signaling, 9733 S)",Antibody,,,,,
PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,,0.9,antibody,"S100 antibody (DAKO, Z0311)",Antibody,,,,,
PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,,0.9,antibody,NF1 antibody (Santa Cruz; H-12),Antibody,,,,,
PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,,0.9,antibody,LUMICAN antibody (Santa Cruz; sc-166871),Antibody,,,,,
PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,,0.8,genetic_reagent,pan-T-cell isolation kit (Miltenyi Biotec),Genetic Reagent,,,,,
PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,,0.9,antibody,anti-CD3 Ab (eBioscience; cat. no. 16-0031-86),Antibody,,,,,
PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,,0.9,antibody,anti-CD28 mAb (eBioscience; cat. no. 16-0281-85),Antibody,,,,,
PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,,0.9,antibody,FITC-anti-CD69 mAb (eBioscience; cat. no. 11-0691-85),Antibody,,,,,
PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,,0.9,antibody,CD4 antibody (eBioscience; cat. no. 17-0042-83),Antibody,,,,,
PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,,0.9,antibody,CD8 antibody (Lifetech; cat. no. A15836),Antibody,,,,,
PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,,0.9,antibody,FoxP3 antibody (eBioscience; cat. no. 12-57773-80),Antibody,,,,,
PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,,0.9,antibody,B220 antibody (eBioscience; cat. no. 11-0452-85),Antibody,,,,,
PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,,0.9,antibody,CD45 antibody (eBioscience; cat. no. 25-0451-82),Antibody,,,,,
PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,,0.8,genetic_reagent,7-aminoactinomycin D (Biolegend; 420403),Genetic Reagent,,,,,
PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,,0.8,genetic_reagent,"Vecta Stain Elite ABC kit (Vectorlabs, PK-6100)",Genetic Reagent,,,,,
PMID:21726432,10.1186/1741-7015-9-82,MIA is a potential biomarker for tumour load in neurofibromatosis type 1.,,0.9,animal_model,Nf1Prx1 mouse model,Animal Model,,,,,
PMID:21726432,10.1186/1741-7015-9-82,MIA is a potential biomarker for tumour load in neurofibromatosis type 1.,,0.85,animal_model,Nf1flox mice,Animal Model,,,,,
PMID:21726432,10.1186/1741-7015-9-82,MIA is a potential biomarker for tumour load in neurofibromatosis type 1.,,0.9,antibody,monoclonal anti-human MIA antibody,Antibody,,,,,
PMID:21726432,10.1186/1741-7015-9-82,MIA is a potential biomarker for tumour load in neurofibromatosis type 1.,,0.85,clinical_assessment_tool,MIA ELISA kit,Clinical Assessment Tool,,,,,
PMID:21726432,10.1186/1741-7015-9-82,MIA is a potential biomarker for tumour load in neurofibromatosis type 1.,,0.8,genetic_reagent,peqGOLD TriFast,Genetic Reagent,,,,,
PMID:21726432,10.1186/1741-7015-9-82,MIA is a potential biomarker for tumour load in neurofibromatosis type 1.,,0.8,genetic_reagent,MuLV Reverse Transcriptase,Genetic Reagent,,,,,
PMID:21726432,10.1186/1741-7015-9-82,MIA is a potential biomarker for tumour load in neurofibromatosis type 1.,,0.8,genetic_reagent,TaqMan Universal PCR Master Mix,Genetic Reagent,,,,,
PMID:21726432,10.1186/1741-7015-9-82,MIA is a potential biomarker for tumour load in neurofibromatosis type 1.,,0.75,computational_tool,ABI PRISM 7900 Cycler,Computational Tool,,,,,
PMID:21726432,10.1186/1741-7015-9-82,MIA is a potential biomarker for tumour load in neurofibromatosis type 1.,,0.8,computational_tool,AxioVision 4.1 software,Computational Tool,,,,,
PMID:21726432,10.1186/1741-7015-9-82,MIA is a potential biomarker for tumour load in neurofibromatosis type 1.,,0.8,computational_tool,analySIS 5.0 software,Computational Tool,,,,,
PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,0.9,animal_model,Nf1flox/flox,Animal Model,,,,,
PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,0.9,animal_model,Nf1GFAP CKO,Animal Model,,,,,
PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,0.85,computational_tool,Affymetrix Mouse Genome 430 2.0 GeneChip,Computational Tool,,,,,
PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,0.8,computational_tool,Spotfire DecisionSite for Functional Genomics,Computational Tool,,,,,
PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,0.8,computational_tool,MetaMorph,Computational Tool,,,,,
PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,0.8,computational_tool,Gel-Pro Analyzer 4.0,Computational Tool,,,,,
PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,0.8,computational_tool,GraphPad Prism 4.0,Computational Tool,,,,,
PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,0.9,antibody,GFAP antibody (Sigma),Antibody,,,,,
PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,0.9,antibody,AQP4 antibody (Chemicon),Antibody,,,,,
PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,0.9,antibody,NG2 antibody (Chemicon),Antibody,,,,,
PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,0.9,antibody,O4 antibody (Chemicon),Antibody,,,,,
PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,0.9,antibody,LHX2 antibody (Chemicon),Antibody,,,,,
PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,0.9,antibody,APC antibody (Calbiochem),Antibody,,,,,
PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,0.9,antibody,FOXG1 antibody (Abcam),Antibody,,,,,
PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,0.9,antibody,FOXP2 antibody (Abcam),Antibody,,,,,
PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,0.9,antibody,HOXB3 antibody (Santa Cruz),Antibody,,,,,
PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,0.85,antibody,GLAST antibody,Antibody,,,,,
PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,0.9,antibody,GFAP antibody (Zymed),Antibody,,,,,
PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,0.9,antibody,Ki-67 antibody (BD Pharmingen),Antibody,,,,,
PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,0.9,antibody,NF1GRP-D antibody (Santa Cruz),Antibody,,,,,
PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,0.9,antibody,α-tubulin antibody (Sigma),Antibody,,,,,
PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,0.9,genetic_reagent,Ad5-Cre adenovirus,Genetic Reagent,,,,,
PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,0.9,genetic_reagent,Ad5-LacZ adenovirus,Genetic Reagent,,,,,
PMID:29402968,10.1038/s41598-018-20894-0,Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pipeline of RASopathies.,,0.85,genetic_reagent,Haloplex custom target enrichment system,Genetic Reagent,,,,,
PMID:29402968,10.1038/s41598-018-20894-0,Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pipeline of RASopathies.,,0.8,computational_tool,MiSeq sequencing platform,Computational Tool,,,,,
PMID:29402968,10.1038/s41598-018-20894-0,Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pipeline of RASopathies.,,0.9,computational_tool,NextGENe software v.2.3.4.1,Computational Tool,,,,,
PMID:29402968,10.1038/s41598-018-20894-0,Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pipeline of RASopathies.,,0.85,genetic_reagent,Q5® Site-Directed Mutagenesis Kit,Genetic Reagent,,,,,
PMID:29402968,10.1038/s41598-018-20894-0,Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pipeline of RASopathies.,,0.9,cell_line,HEK-293T cells,Cell Line,,,,,
PMID:29402968,10.1038/s41598-018-20894-0,Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pipeline of RASopathies.,,0.85,genetic_reagent,pGal-LUC,Genetic Reagent,,,,,
PMID:29402968,10.1038/s41598-018-20894-0,Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pipeline of RASopathies.,,0.85,genetic_reagent,pGal-ELK1,Genetic Reagent,,,,,
PMID:29402968,10.1038/s41598-018-20894-0,Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pipeline of RASopathies.,,0.85,genetic_reagent,Dual-Luciferase® Reporter assay system,Genetic Reagent,,,,,
PMID:29402968,10.1038/s41598-018-20894-0,Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pipeline of RASopathies.,,0.85,genetic_reagent,pSV-RLuc,Genetic Reagent,,,,,
PMID:29402968,10.1038/s41598-018-20894-0,Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pipeline of RASopathies.,,0.85,antibody,anti-DDK antibodies,Antibody,,,,,
PMID:29402968,10.1038/s41598-018-20894-0,Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pipeline of RASopathies.,,0.85,genetic_reagent,pCMV6-AC-GFP vector,Genetic Reagent,,,,,
PMID:29402968,10.1038/s41598-018-20894-0,Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pipeline of RASopathies.,,0.85,genetic_reagent,mMESSAGE mMACHINE T7 Transcription Kit,Genetic Reagent,,,,,
PMID:29402968,10.1038/s41598-018-20894-0,Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pipeline of RASopathies.,,0.9,animal_model,zebrafish embryos,Animal Model,,,,,
PMID:29402968,10.1038/s41598-018-20894-0,Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pipeline of RASopathies.,,0.85,computational_tool,ImageJ software,Computational Tool,,,,,
PMID:29402968,10.1038/s41598-018-20894-0,Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pipeline of RASopathies.,,0.85,genetic_reagent,digoxigenin-labelled cmlc1,Genetic Reagent,,,,,
PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,0.9,cell_line,HEK 293T,Cell Line,,,,,
PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,0.95,cell_line,immortalized mouse Nf2 Schwann cells,Cell Line,,,,,
PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,0.9,antibody,Anti-Merlin monoclonal antibody 4B5,Antibody,,,,,
PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,0.9,antibody,HRP conjugated antibody specific for GFP (cat. no. 600–103-215),Antibody,,,,,
PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,0.9,antibody,antibody specific for RFP (cat no. ab34767),Antibody,,,,,
PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,0.85,antibody,Antibody specific for YAP1,Antibody,,,,,
PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,0.9,genetic_reagent,mApple-N1 (Addgene plasmid no. 54567),Genetic Reagent,,,,,
PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,0.9,genetic_reagent,pSK ZO-1 (Addgene plasmid no. 30316),Genetic Reagent,,,,,
PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,0.9,genetic_reagent,CMV-GFP-NMHC II-B (Addgene plasmid no. 11348),Genetic Reagent,,,,,
PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,0.9,genetic_reagent,pGFP(C3)-vinculin (Addgene plasmid no. 30312),Genetic Reagent,,,,,
PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,0.9,genetic_reagent,pKvenus-Scrib (Addgene plasmid no. 58738),Genetic Reagent,,,,,
PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,0.9,genetic_reagent,pEGFP-C3-hYAP1 (Addgene plasmid no. 19053),Genetic Reagent,,,,,
PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,0.9,genetic_reagent,pEGFP C3-Lats1 (Addgene plasmid no. 17843),Genetic Reagent,,,,,
PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,0.9,genetic_reagent,HA-AMOT p130 (Addgene plasmid no. 32821),Genetic Reagent,,,,,
PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,0.9,genetic_reagent,pcDNA3.1-ccdB-NLuc (Addgene plasmid no. 87067),Genetic Reagent,,,,,
PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,0.9,genetic_reagent,p4XBS2WT-Luc (Addgene plasmid no. 16593),Genetic Reagent,,,,,
PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,0.9,genetic_reagent,p8xGTIIC-luciferase (Addgene plasmid no. 34615),Genetic Reagent,,,,,
PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,0.9,genetic_reagent,pcDNA3 p53 WT (Addgene plasmid no. 69003),Genetic Reagent,,,,,
PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,0.85,genetic_reagent,pTRE3G-BI-ZsGreen,Genetic Reagent,,,,,
PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,0.85,genetic_reagent,pCMV-Tet3G,Genetic Reagent,,,,,
PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,0.9,computational_tool,g:Profiler,Computational Tool,,,,,
PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,0.9,computational_tool,BioVenn,Computational Tool,,,,,
PMID:31015291,10.1126/scisignal.aau8749,Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.,,0.9,computational_tool,PathVisio software,Computational Tool,,,,,
PMID:40225167,10.1155/2023/9628049,Functional Assays Combined with Pre-mRNA-Splicing Analysis Improve Variant Classification and Diagnostics for Individuals with Neurofibromatosis Type 1 and Legius Syndrome.,,0.9,computational_tool,"Alamut Visual Plus, version 1.5.1",Computational Tool,,,,,
PMID:40225167,10.1155/2023/9628049,Functional Assays Combined with Pre-mRNA-Splicing Analysis Improve Variant Classification and Diagnostics for Individuals with Neurofibromatosis Type 1 and Legius Syndrome.,,0.85,antibody,rabbit anti-HA,Antibody,,,,,
PMID:40225167,10.1155/2023/9628049,Functional Assays Combined with Pre-mRNA-Splicing Analysis Improve Variant Classification and Diagnostics for Individuals with Neurofibromatosis Type 1 and Legius Syndrome.,,0.85,antibody,mouse anti-HA,Antibody,,,,,
PMID:40225167,10.1155/2023/9628049,Functional Assays Combined with Pre-mRNA-Splicing Analysis Improve Variant Classification and Diagnostics for Individuals with Neurofibromatosis Type 1 and Legius Syndrome.,,0.9,antibody,9B11 mouse anti-myc,Antibody,,,,,
PMID:40225167,10.1155/2023/9628049,Functional Assays Combined with Pre-mRNA-Splicing Analysis Improve Variant Classification and Diagnostics for Individuals with Neurofibromatosis Type 1 and Legius Syndrome.,,0.85,antibody,mouse anti-V5,Antibody,,,,,
PMID:40225167,10.1155/2023/9628049,Functional Assays Combined with Pre-mRNA-Splicing Analysis Improve Variant Classification and Diagnostics for Individuals with Neurofibromatosis Type 1 and Legius Syndrome.,,0.85,antibody,mouse anti-FLAG,Antibody,,,,,
PMID:40225167,10.1155/2023/9628049,Functional Assays Combined with Pre-mRNA-Splicing Analysis Improve Variant Classification and Diagnostics for Individuals with Neurofibromatosis Type 1 and Legius Syndrome.,,0.85,antibody,rabbit anti-FLAG,Antibody,,,,,
PMID:40225167,10.1155/2023/9628049,Functional Assays Combined with Pre-mRNA-Splicing Analysis Improve Variant Classification and Diagnostics for Individuals with Neurofibromatosis Type 1 and Legius Syndrome.,,0.85,antibody,goat anti-rabbit 680 nm,Antibody,,,,,
PMID:40225167,10.1155/2023/9628049,Functional Assays Combined with Pre-mRNA-Splicing Analysis Improve Variant Classification and Diagnostics for Individuals with Neurofibromatosis Type 1 and Legius Syndrome.,,0.85,antibody,goat anti-mouse 800 nm,Antibody,,,,,
PMID:40225167,10.1155/2023/9628049,Functional Assays Combined with Pre-mRNA-Splicing Analysis Improve Variant Classification and Diagnostics for Individuals with Neurofibromatosis Type 1 and Legius Syndrome.,,0.9,cell_line,HEK 293T,Cell Line,,,,,
PMID:40225167,10.1155/2023/9628049,Functional Assays Combined with Pre-mRNA-Splicing Analysis Improve Variant Classification and Diagnostics for Individuals with Neurofibromatosis Type 1 and Legius Syndrome.,,0.9,cell_line,COS-7,Cell Line,,,,,
PMID:40225167,10.1155/2023/9628049,Functional Assays Combined with Pre-mRNA-Splicing Analysis Improve Variant Classification and Diagnostics for Individuals with Neurofibromatosis Type 1 and Legius Syndrome.,,0.85,genetic_reagent,HA-H-RAS,Genetic Reagent,,,,,
PMID:40225167,10.1155/2023/9628049,Functional Assays Combined with Pre-mRNA-Splicing Analysis Improve Variant Classification and Diagnostics for Individuals with Neurofibromatosis Type 1 and Legius Syndrome.,,0.85,genetic_reagent,FLAG-SPRED1,Genetic Reagent,,,,,
PMID:40225167,10.1155/2023/9628049,Functional Assays Combined with Pre-mRNA-Splicing Analysis Improve Variant Classification and Diagnostics for Individuals with Neurofibromatosis Type 1 and Legius Syndrome.,,0.85,genetic_reagent,GST-RAF-RBD,Genetic Reagent,,,,,
PMID:23225063,10.1002/ana.23793,Dopamine deficiency underlies learning deficits in neurofibromatosis-1 mice.,,0.9,animal_model,Nf1 +/− GFAP CKO,Animal Model,,,,,
PMID:23225063,10.1002/ana.23793,Dopamine deficiency underlies learning deficits in neurofibromatosis-1 mice.,,0.9,animal_model,Nf1 flox/flox,Animal Model,,,,,
PMID:21199799,10.1158/0008-5472.CAN-10-2732,Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.,,0.95,animal_model,Nf1+/- mice,Animal Model,,,,,
PMID:21199799,10.1158/0008-5472.CAN-10-2732,Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.,,0.85,computational_tool,"cesium-137 source (J.L. Shepherd & Associates, San Fernando, CA)",Computational Tool,,,,,
PMID:21199799,10.1158/0008-5472.CAN-10-2732,Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.,,0.8,computational_tool,Hemavet,Computational Tool,,,,,
PMID:21199799,10.1158/0008-5472.CAN-10-2732,Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.,,0.9,antibody,Phosphorylated ERK Thr202/Tyr204 (catalog #4376),Antibody,,,,,
PMID:21199799,10.1158/0008-5472.CAN-10-2732,Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.,,0.9,antibody,phosphorylated Akt Ser473 (#9271),Antibody,,,,,
PMID:21199799,10.1158/0008-5472.CAN-10-2732,Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.,,0.9,antibody,phosphorylated S6 Ser235/236 (#2211),Antibody,,,,,
PMID:21199799,10.1158/0008-5472.CAN-10-2732,Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.,,0.85,computational_tool,"Openlab (Improvision, Waltham, MA)",Computational Tool,,,,,
PMID:21199799,10.1158/0008-5472.CAN-10-2732,Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.,,0.85,computational_tool,Peak Scanner software from Applied Biosystems,Computational Tool,,,,,
PMID:21199799,10.1158/0008-5472.CAN-10-2732,Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.,,0.9,cell_line,Nf1-/- mouse embryo fibroblasts,Cell Line,,,,,
PMID:21199799,10.1158/0008-5472.CAN-10-2732,Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.,,0.9,cell_line,Nf1+/- mouse embryo fibroblasts,Cell Line,,,,,
PMID:21199799,10.1158/0008-5472.CAN-10-2732,Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.,,0.9,antibody,anti-γH2AX Ser139 antibody (Millipore),Antibody,,,,,
PMID:21199799,10.1158/0008-5472.CAN-10-2732,Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.,,0.9,antibody,anti-rabbit AlexaFluor 488 secondary antibody (Molecular Probes),Antibody,,,,,
PMID:21199799,10.1158/0008-5472.CAN-10-2732,Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.,,0.85,computational_tool,Zeiss LSM 510 Meta confocal microscope,Computational Tool,,,,,
PMID:21199799,10.1158/0008-5472.CAN-10-2732,Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.,,0.85,computational_tool,R 2.7.0,Computational Tool,,,,,
PMID:24824755,10.1371/journal.pone.0096733,BNIP3 regulates AT101 [(-)-gossypol] induced death in malignant peripheral nerve sheath tumor cells.,,0.9,cell_line,T265-2c,Cell Line,,,,,
PMID:24824755,10.1371/journal.pone.0096733,BNIP3 regulates AT101 [(-)-gossypol] induced death in malignant peripheral nerve sheath tumor cells.,,0.9,cell_line,ST88-14,Cell Line,,,,,
PMID:24824755,10.1371/journal.pone.0096733,BNIP3 regulates AT101 [(-)-gossypol] induced death in malignant peripheral nerve sheath tumor cells.,,0.9,cell_line,90-8,Cell Line,,,,,
PMID:24824755,10.1371/journal.pone.0096733,BNIP3 regulates AT101 [(-)-gossypol] induced death in malignant peripheral nerve sheath tumor cells.,,0.85,antibody,HIF-1α antibody,Antibody,,,,,
PMID:24824755,10.1371/journal.pone.0096733,BNIP3 regulates AT101 [(-)-gossypol] induced death in malignant peripheral nerve sheath tumor cells.,,0.85,antibody,BNIP3 antibody,Antibody,,,,,
PMID:24824755,10.1371/journal.pone.0096733,BNIP3 regulates AT101 [(-)-gossypol] induced death in malignant peripheral nerve sheath tumor cells.,,0.85,antibody,BECLIN1 antibody,Antibody,,,,,
PMID:24824755,10.1371/journal.pone.0096733,BNIP3 regulates AT101 [(-)-gossypol] induced death in malignant peripheral nerve sheath tumor cells.,,0.85,antibody,LC3 antibody,Antibody,,,,,
PMID:24824755,10.1371/journal.pone.0096733,BNIP3 regulates AT101 [(-)-gossypol] induced death in malignant peripheral nerve sheath tumor cells.,,0.85,antibody,GAPDH antibody,Antibody,,,,,
PMID:24824755,10.1371/journal.pone.0096733,BNIP3 regulates AT101 [(-)-gossypol] induced death in malignant peripheral nerve sheath tumor cells.,,0.8,genetic_reagent,AT101,Genetic Reagent,,,,,
PMID:24824755,10.1371/journal.pone.0096733,BNIP3 regulates AT101 [(-)-gossypol] induced death in malignant peripheral nerve sheath tumor cells.,,0.85,genetic_reagent,BNIP3 siRNA,Genetic Reagent,,,,,
PMID:24824755,10.1371/journal.pone.0096733,BNIP3 regulates AT101 [(-)-gossypol] induced death in malignant peripheral nerve sheath tumor cells.,,0.85,genetic_reagent,HIF-1α siRNA,Genetic Reagent,,,,,
PMID:24824755,10.1371/journal.pone.0096733,BNIP3 regulates AT101 [(-)-gossypol] induced death in malignant peripheral nerve sheath tumor cells.,,0.8,computational_tool,Stepone Plus Real-Time PCR System,Computational Tool,,,,,
PMID:24824755,10.1371/journal.pone.0096733,BNIP3 regulates AT101 [(-)-gossypol] induced death in malignant peripheral nerve sheath tumor cells.,,0.85,computational_tool,Axio Vision Rel. 4.8 software,Computational Tool,,,,,
PMID:24824755,10.1371/journal.pone.0096733,BNIP3 regulates AT101 [(-)-gossypol] induced death in malignant peripheral nerve sheath tumor cells.,,0.8,computational_tool,Graphpad Prism 6,Computational Tool,,,,,
PMID:21439418,10.1016/j.bone.2011.03.760,Primary osteopathy of vertebrae in a neurofibromatosis type 1 murine model.,,0.95,animal_model,Nf1(flox/-);Col2.3Cre(+) mice,Animal Model,,,,,
PMID:21439418,10.1016/j.bone.2011.03.760,Primary osteopathy of vertebrae in a neurofibromatosis type 1 murine model.,,0.9,animal_model,Nf1 +/− mice,Animal Model,,,,,
PMID:21439418,10.1016/j.bone.2011.03.760,Primary osteopathy of vertebrae in a neurofibromatosis type 1 murine model.,,0.9,animal_model,Nf1 flox/flox mice,Animal Model,,,,,
PMID:21439418,10.1016/j.bone.2011.03.760,Primary osteopathy of vertebrae in a neurofibromatosis type 1 murine model.,,0.85,animal_model,Col2.3Cre transgenic mice,Animal Model,,,,,
PMID:21439418,10.1016/j.bone.2011.03.760,Primary osteopathy of vertebrae in a neurofibromatosis type 1 murine model.,,0.85,animal_model,ROSA26 reporter mice,Animal Model,,,,,
PMID:21439418,10.1016/j.bone.2011.03.760,Primary osteopathy of vertebrae in a neurofibromatosis type 1 murine model.,,0.8,computational_tool,piXarray 100 DSR System,Computational Tool,,,,,
PMID:21439418,10.1016/j.bone.2011.03.760,Primary osteopathy of vertebrae in a neurofibromatosis type 1 murine model.,,0.8,computational_tool,PIXImus II,Computational Tool,,,,,
PMID:21439418,10.1016/j.bone.2011.03.760,Primary osteopathy of vertebrae in a neurofibromatosis type 1 murine model.,,0.8,computational_tool,XCT Research SA + peripheral quantitative computed tomography (pQCT) scanner,Computational Tool,,,,,
PMID:21439418,10.1016/j.bone.2011.03.760,Primary osteopathy of vertebrae in a neurofibromatosis type 1 murine model.,,0.8,computational_tool,MtestwR software,Computational Tool,,,,,
PMID:27081657,10.1002/acn3.288,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.,,0.9,clinical_assessment_tool,Wechsler Abbreviated Scale of Intelligence (WASI),Clinical Assessment Tool,,,,,
PMID:27081657,10.1002/acn3.288,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.,,0.9,clinical_assessment_tool,Brief Visuospatial Memory Test – Revised (BVMT),Clinical Assessment Tool,,,,,
PMID:27081657,10.1002/acn3.288,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.,,0.9,clinical_assessment_tool,Letter‐Number Sequencing task (LNS),Clinical Assessment Tool,,,,,
PMID:27081657,10.1002/acn3.288,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.,,0.85,clinical_assessment_tool,Digit Cancellation,Clinical Assessment Tool,,,,,
PMID:27081657,10.1002/acn3.288,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.,,0.9,clinical_assessment_tool,Hopkins Verbal Learning Test (HVLT),Clinical Assessment Tool,,,,,
PMID:27081657,10.1002/acn3.288,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.,,0.9,clinical_assessment_tool,WISC‐III Object Assembly,Clinical Assessment Tool,,,,,
PMID:27081657,10.1002/acn3.288,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.,,0.9,clinical_assessment_tool,Achenbach Child Behavior Checklist (CBCL),Clinical Assessment Tool,,,,,
PMID:27081657,10.1002/acn3.288,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.,,0.9,clinical_assessment_tool,Young Adult Self Report (YASR),Clinical Assessment Tool,,,,,
PMID:27081657,10.1002/acn3.288,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.,,0.85,clinical_assessment_tool,Neuropsychological Assessment Battery (NAB) Mazes,Clinical Assessment Tool,,,,,
PMID:27081657,10.1002/acn3.288,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.,,0.9,clinical_assessment_tool,Delis–Kaplan Executive Function Scale (D‐KEFS) verbal fluency,Clinical Assessment Tool,,,,,
PMID:27081657,10.1002/acn3.288,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.,,0.9,clinical_assessment_tool,Behavior Rating Inventory of Executive Function (BRIEF),Clinical Assessment Tool,,,,,
PMID:27081657,10.1002/acn3.288,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.,,0.85,clinical_assessment_tool,Spatial capacity working memory (SCAP) task,Clinical Assessment Tool,,,,,
PMID:27081657,10.1002/acn3.288,A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.,,0.9,computational_tool,FMRIB software library (FSL),Computational Tool,,,,,
PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,0.85,animal_model,p53floxE2–10,Animal Model,,,,,
PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,0.85,animal_model,p53LSLR172H,Animal Model,,,,,
PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,0.9,animal_model,hGFAP-cre+; p53floxE2–10/floxE2–10,Animal Model,,,,,
PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,0.9,animal_model,hGFAP-cre+; p53LSLR172H/floxE2–10,Animal Model,,,,,
PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,0.95,antibody,rabbit anti-p53,Antibody,,,,,
PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,0.95,antibody,mouse anti-Ki67,Antibody,,,,,
PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,0.95,antibody,rabbit anti-Olig2,Antibody,,,,,
PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,0.9,antibody,Guinea pig anti-Olig2,Antibody,,,,,
PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,0.95,antibody,mouse anti-GFAP,Antibody,,,,,
PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,0.95,antibody,rabbit anti-Pten,Antibody,,,,,
PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,0.95,antibody,rabbit anti-p-S6,Antibody,,,,,
PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,0.95,antibody,rat anti-BrdU,Antibody,,,,,
PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,0.95,antibody,rabbit anti-p-Erk,Antibody,,,,,
PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,0.85,computational_tool,MATLAB,Computational Tool,,,,,
PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,0.9,computational_tool,Burrows–Wheeler Aligner,Computational Tool,,,,,
PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,0.9,computational_tool,SAMtools,Computational Tool,,,,,
PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,0.9,computational_tool,GATK,Computational Tool,,,,,
PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,0.9,computational_tool,ANNOVAR,Computational Tool,,,,,
PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,0.9,computational_tool,control-FREEC,Computational Tool,,,,,
PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,0.85,computational_tool,FlowJo,Computational Tool,,,,,
PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,0.85,computational_tool,ImageJ,Computational Tool,,,,,
PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,0.9,computational_tool,RStudio,Computational Tool,,,,,
PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,0.9,computational_tool,APE,Computational Tool,,,,,
PMID:32699356,10.1038/s41467-020-17382-3,Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution.,,0.9,computational_tool,MEGAX,Computational Tool,,,,,
PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,,0.9,animal_model,C57BL/6,Animal Model,,,,,
PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,,0.95,animal_model,"B6J.129(B6N)-Gt(ROSA)26Sor tm1(CAG-cas9*,-EGFP)Fezh/J",Animal Model,,,,,
PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,,0.95,animal_model,NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ,Animal Model,,,,,
PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,,0.9,antibody,PAX8 antibody,Antibody,,,,,
PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,,0.9,antibody,Ac-alpha-Tubulin antibody,Antibody,,,,,
PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,,0.9,antibody,KI67 antibody,Antibody,,,,,
PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,,0.9,antibody,Cytokeratin-8 antibody,Antibody,,,,,
PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,,0.9,antibody,GFP antibody,Antibody,,,,,
PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,,0.9,antibody,Cleaved Caspase-3 antibody,Antibody,,,,,
PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,,0.9,antibody,γH2A.X antibody,Antibody,,,,,
PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,,0.9,antibody,p53 antibody,Antibody,,,,,
PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,,0.9,antibody,GAPDH antibody,Antibody,,,,,
PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,,0.95,advanced_cellular_model,oviductal organoids,Advanced Cellular Model,,,,,
PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,,0.95,advanced_cellular_model,OSE organoids,Advanced Cellular Model,,,,,
PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,,0.9,genetic_reagent,Trp53 sgRNA,Genetic Reagent,,,,,
PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,,0.9,genetic_reagent,Brca1 sgRNA,Genetic Reagent,,,,,
PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,,0.95,genetic_reagent,Nf1 sgRNA,Genetic Reagent,,,,,
PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,,0.9,genetic_reagent,Pten sgRNA,Genetic Reagent,,,,,
PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,,0.9,computational_tool,ImageJ,Computational Tool,,,,,
PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,,0.9,computational_tool,DESeq2,Computational Tool,,,,,
PMID:32461556,10.1038/s41467-020-16432-0,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids.,,0.9,computational_tool,GSEA,Computational Tool,,,,,
PMID:24040940,10.1186/1479-5876-11-213,Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors.,,0.9,cell_line,NF96.2,Cell Line,,,,,
PMID:24040940,10.1186/1479-5876-11-213,Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors.,,0.9,cell_line,NF02.2,Cell Line,,,,,
PMID:24040940,10.1186/1479-5876-11-213,Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors.,,0.9,cell_line,NF94.3,Cell Line,,,,,
PMID:24040940,10.1186/1479-5876-11-213,Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors.,,0.95,antibody,ABCC1 antibody (Abcam ab24102),Antibody,,,,,
PMID:24040940,10.1186/1479-5876-11-213,Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors.,,0.95,antibody,S100 antibody (Dako Z0311),Antibody,,,,,
PMID:24040940,10.1186/1479-5876-11-213,Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors.,,0.85,computational_tool,XenoBase version 3.5,Computational Tool,,,,,
PMID:24040940,10.1186/1479-5876-11-213,Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors.,,0.8,computational_tool,Affymetrix Expression Console MAS 5.0,Computational Tool,,,,,
PMID:24040940,10.1186/1479-5876-11-213,Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors.,,0.85,computational_tool,StepOne Software v2.3,Computational Tool,,,,,
PMID:24040940,10.1186/1479-5876-11-213,Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors.,,0.8,computational_tool,Gene Targeted Therapy Map,Computational Tool,,,,,
PMID:24040940,10.1186/1479-5876-11-213,Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors.,,0.8,computational_tool,PGSEA,Computational Tool,,,,,
PMID:24040940,10.1186/1479-5876-11-213,Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors.,,0.8,computational_tool,CMAP,Computational Tool,,,,,
PMID:32642741,10.1093/noajnl/vdaa037,Effect of age and neurofibromatosis type 1 status on white matter integrity in the optic radiations.,,0.85,computational_tool,FSL version 5.0.7,Computational Tool,,,,,
PMID:32642741,10.1093/noajnl/vdaa037,Effect of age and neurofibromatosis type 1 status on white matter integrity in the optic radiations.,,0.8,computational_tool,PROBTRACKX,Computational Tool,,,,,
PMID:32642741,10.1093/noajnl/vdaa037,Effect of age and neurofibromatosis type 1 status on white matter integrity in the optic radiations.,,0.85,computational_tool,Tract-Based Spatial Statistics (TBSS),Computational Tool,,,,,
PMID:32642741,10.1093/noajnl/vdaa037,Effect of age and neurofibromatosis type 1 status on white matter integrity in the optic radiations.,,0.75,computational_tool,Montreal Neurologic Institute 152 T1 map,Computational Tool,,,,,
PMID:39824854,10.1038/s41598-025-85386-4,Comparison of 1D and 3D volume measurement techniques in NF2-associated vestibular schwannoma monitoring.,,0.9,computational_tool,"iPlan Net software (Brainlab, Feldkirchen, Germany)",Computational Tool,,,,,
PMID:39824854,10.1038/s41598-025-85386-4,Comparison of 1D and 3D volume measurement techniques in NF2-associated vestibular schwannoma monitoring.,,0.8,computational_tool,"Statistical Package for Social Studies (SPSS 10.0 for Windows, SPSS Inc.)",Computational Tool,,,,,
PMID:39824854,10.1038/s41598-025-85386-4,Comparison of 1D and 3D volume measurement techniques in NF2-associated vestibular schwannoma monitoring.,,0.85,clinical_assessment_tool,Hannover classification system,Clinical Assessment Tool,,,,,
PMID:39824854,10.1038/s41598-025-85386-4,Comparison of 1D and 3D volume measurement techniques in NF2-associated vestibular schwannoma monitoring.,,0.85,clinical_assessment_tool,Koos classification system,Clinical Assessment Tool,,,,,
PMID:39824854,10.1038/s41598-025-85386-4,Comparison of 1D and 3D volume measurement techniques in NF2-associated vestibular schwannoma monitoring.,,0.8,clinical_assessment_tool,RECIST guidelines,Clinical Assessment Tool,,,,,
PMID:33673681,10.3390/cancers13050999,Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles of ,,0.85,genetic_reagent,PAXgene whole blood samples,Genetic Reagent,,,,,
PMID:33673681,10.3390/cancers13050999,Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles of ,,0.85,genetic_reagent,PAXgene™ Blood RNA System,Genetic Reagent,,,,,
PMID:33673681,10.3390/cancers13050999,Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles of ,,0.8,computational_tool,Abi Prism 3700,Computational Tool,,,,,
PMID:33673681,10.3390/cancers13050999,Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles of ,,0.85,genetic_reagent,Haloplex HS,Genetic Reagent,,,,,
PMID:33673681,10.3390/cancers13050999,Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles of ,,0.85,genetic_reagent,SureSelect kits,Genetic Reagent,,,,,
PMID:33673681,10.3390/cancers13050999,Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles of ,,0.8,computational_tool,MiniSeq apparatus,Computational Tool,,,,,
PMID:33673681,10.3390/cancers13050999,Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles of ,,0.9,genetic_reagent,SALSA MLPA kits P081/P082,Genetic Reagent,,,,,
PMID:33673681,10.3390/cancers13050999,Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles of ,,0.85,genetic_reagent,Gentra Puregene kit,Genetic Reagent,,,,,
PMID:33673681,10.3390/cancers13050999,Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles of ,,0.9,computational_tool,Human Splicing Finder (HSF) Version 2.4.1,Computational Tool,,,,,
PMID:33673681,10.3390/cancers13050999,Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles of ,,0.85,computational_tool,Mutation taster,Computational Tool,,,,,
PMID:33673681,10.3390/cancers13050999,Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles of ,,0.9,computational_tool,Combined Annotation Dependent Depletion (CADD) v1.6,Computational Tool,,,,,
PMID:33673681,10.3390/cancers13050999,Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles of ,,0.85,computational_tool,Multalin,Computational Tool,,,,,
PMID:33673681,10.3390/cancers13050999,Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles of ,,0.9,genetic_reagent,beta-globin vector,Genetic Reagent,,,,,
PMID:33673681,10.3390/cancers13050999,Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles of ,,0.95,cell_line,HEK293 cells,Cell Line,,,,,
PMID:33673681,10.3390/cancers13050999,Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles of ,,0.85,genetic_reagent,Lipofectamine 2000,Genetic Reagent,,,,,
PMID:33673681,10.3390/cancers13050999,Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles of ,,0.85,genetic_reagent,TRIzolTM,Genetic Reagent,,,,,
PMID:33673681,10.3390/cancers13050999,Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles of ,,0.85,genetic_reagent,SuperScript II reverse transcriptase,Genetic Reagent,,,,,
PMID:33673681,10.3390/cancers13050999,Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles of ,,0.85,genetic_reagent,TOPO TA Cloning kit,Genetic Reagent,,,,,
PMID:33673681,10.3390/cancers13050999,Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles of ,,0.9,computational_tool,ImageJ,Computational Tool,,,,,
PMID:34630515,10.3389/fgene.2021.721045,Assessment of Mosaicism and Detection of Cryptic Alleles in CRISPR/Cas9-Engineered Neurofibromatosis Type 1 and ,,0.85,cell_line,LLC-PK1 ATCC CL-101,Cell Line,,,,,
PMID:34630515,10.3389/fgene.2021.721045,Assessment of Mosaicism and Detection of Cryptic Alleles in CRISPR/Cas9-Engineered Neurofibromatosis Type 1 and ,,0.9,computational_tool,CRISPOR,Computational Tool,,,,,
PMID:34630515,10.3389/fgene.2021.721045,Assessment of Mosaicism and Detection of Cryptic Alleles in CRISPR/Cas9-Engineered Neurofibromatosis Type 1 and ,,0.85,computational_tool,CRISPResso,Computational Tool,,,,,
PMID:34630515,10.3389/fgene.2021.721045,Assessment of Mosaicism and Detection of Cryptic Alleles in CRISPR/Cas9-Engineered Neurofibromatosis Type 1 and ,,0.85,computational_tool,CRISPResso2,Computational Tool,,,,,
PMID:34630515,10.3389/fgene.2021.721045,Assessment of Mosaicism and Detection of Cryptic Alleles in CRISPR/Cas9-Engineered Neurofibromatosis Type 1 and ,,0.8,computational_tool,JMP Pro 15.0.0,Computational Tool,,,,,
PMID:34630515,10.3389/fgene.2021.721045,Assessment of Mosaicism and Detection of Cryptic Alleles in CRISPR/Cas9-Engineered Neurofibromatosis Type 1 and ,,0.85,genetic_reagent,Phusion polymerase (M0530S),Genetic Reagent,,,,,
PMID:34630515,10.3389/fgene.2021.721045,Assessment of Mosaicism and Detection of Cryptic Alleles in CRISPR/Cas9-Engineered Neurofibromatosis Type 1 and ,,0.85,genetic_reagent,MEGAshortscript T7 Transcription Kit (AM1354),Genetic Reagent,,,,,
PMID:34630515,10.3389/fgene.2021.721045,Assessment of Mosaicism and Detection of Cryptic Alleles in CRISPR/Cas9-Engineered Neurofibromatosis Type 1 and ,,0.9,genetic_reagent,Cas9 Nuclease V3,Genetic Reagent,,,,,
PMID:34630515,10.3389/fgene.2021.721045,Assessment of Mosaicism and Detection of Cryptic Alleles in CRISPR/Cas9-Engineered Neurofibromatosis Type 1 and ,,0.85,genetic_reagent,Q5® Hot Start High-Fidelity DNA Polymerase,Genetic Reagent,,,,,
PMID:34630515,10.3389/fgene.2021.721045,Assessment of Mosaicism and Detection of Cryptic Alleles in CRISPR/Cas9-Engineered Neurofibromatosis Type 1 and ,,0.85,genetic_reagent,PrimeSTAR GXL DNA polymerase,Genetic Reagent,,,,,
PMID:34630515,10.3389/fgene.2021.721045,Assessment of Mosaicism and Detection of Cryptic Alleles in CRISPR/Cas9-Engineered Neurofibromatosis Type 1 and ,,0.9,genetic_reagent,S. pyogenes Cas9 mRNA,Genetic Reagent,,,,,
PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,0.9,animal_model,1016 tuba1a:GFP,Animal Model,,,,,
PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,0.9,animal_model,gfap:GFP,Animal Model,,,,,
PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,0.9,animal_model,hsp70:DN-MAML-GFP,Animal Model,,,,,
PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,0.9,animal_model,gfap:mCherry,Animal Model,,,,,
PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,0.9,animal_model,tp1:mCherry,Animal Model,,,,,
PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,0.9,genetic_reagent,hsp70:dll4-P2A-GFP,Genetic Reagent,,,,,
PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,0.9,genetic_reagent,hsp70:GFP-P2A-dlb,Genetic Reagent,,,,,
PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,0.9,genetic_reagent,hsp70:GFP-P2A-hey1,Genetic Reagent,,,,,
PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,0.9,genetic_reagent,hsp70:id2b-P2A-GFP,Genetic Reagent,,,,,
PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,0.9,genetic_reagent,ubi:Cas9,Genetic Reagent,,,,,
PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,0.9,genetic_reagent,u6:dll4-gRNAs,Genetic Reagent,,,,,
PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,0.9,genetic_reagent,u6:n3-gRNAs,Genetic Reagent,,,,,
PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,0.95,antibody,"Rabbit anti-GFP, Thermo Fisher, Cat. # A6455",Antibody,,,,,
PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,0.95,antibody,"Mouse anti-mCherry, Abcam, Cat. # ab125096",Antibody,,,,,
PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,0.95,antibody,"mouse anti-glutamine synthetase (GS), Sigma-Aldrich, Cat. #MAB302",Antibody,,,,,
PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,0.95,antibody,"Alexa Flour 555 Donkey anti Mouse-IgG (H+L), Thermo Fisher Cat. # A31570",Antibody,,,,,
PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,0.95,antibody,"Alexa flour 555 Donkey anti Rabbit IgG (H+L), Thermo Fisher, Cat # A31572",Antibody,,,,,
PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,0.95,antibody,Alexa Flour 488 donkey anti mouse Thermo Fisher Cat. # A21202,Antibody,,,,,
PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,0.95,antibody,Alexa Flour 488 goat anti rabbit Thermo Fisher Cat. # A11008,Antibody,,,,,
PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,0.9,cell_line,HEK 293T,Cell Line,,,,,
PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,0.9,genetic_reagent,3kb-hey1:luciferase,Genetic Reagent,,,,,
PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,0.9,genetic_reagent,pCS2+dlb-EGFP,Genetic Reagent,,,,,
PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,0.9,genetic_reagent,pCS2+n3-EGFP,Genetic Reagent,,,,,
PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,0.9,genetic_reagent,pCS2+id2b-EGFP,Genetic Reagent,,,,,
PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,0.85,computational_tool,CRISPRscan,Computational Tool,,,,,
PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,0.85,computational_tool,Cell Ranger,Computational Tool,,,,,
PMID:34415582,10.1002/glia.24075,Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury.,,0.85,computational_tool,Seurat,Computational Tool,,,,,
PMID:32457840,10.3389/fonc.2020.00687,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",,0.85,cell_line,MIAPaCa-2,Cell Line,,,,,
PMID:32457840,10.3389/fonc.2020.00687,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",,0.85,cell_line,Panc-1,Cell Line,,,,,
PMID:32457840,10.3389/fonc.2020.00687,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",,0.85,cell_line,BxPC-3,Cell Line,,,,,
PMID:32457840,10.3389/fonc.2020.00687,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",,0.85,cell_line,AsPC-1,Cell Line,,,,,
PMID:32457840,10.3389/fonc.2020.00687,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",,0.85,cell_line,HPDE H6c7,Cell Line,,,,,
PMID:32457840,10.3389/fonc.2020.00687,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",,0.9,antibody,mouse anti-β-actin,Antibody,,,,,
PMID:32457840,10.3389/fonc.2020.00687,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",,0.95,antibody,rabbit anti-Merlin,Antibody,,,,,
PMID:32457840,10.3389/fonc.2020.00687,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",,0.9,antibody,mouse anti-NHE1 (clone 54),Antibody,,,,,
PMID:32457840,10.3389/fonc.2020.00687,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",,0.85,genetic_reagent,NHE1 siRNA: ON-TARGET SMART pool,Genetic Reagent,,,,,
PMID:32457840,10.3389/fonc.2020.00687,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",,0.9,genetic_reagent,Merlin siRNA (SASI_Hs_01_00188862),Genetic Reagent,,,,,
PMID:32457840,10.3389/fonc.2020.00687,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",,0.85,computational_tool,UN-SCAN-IT gel 6.1,Computational Tool,,,,,
PMID:32457840,10.3389/fonc.2020.00687,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",,0.85,computational_tool,Olympus CellSens dimension,Computational Tool,,,,,
PMID:32457840,10.3389/fonc.2020.00687,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",,0.85,computational_tool,EasyRatioPro imaging software,Computational Tool,,,,,
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.9,cell_line,Ben-Men-1,Cell Line,,,,,
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.85,cell_line,AC-CRISPR,Cell Line,,,,,
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.85,cell_line,MN1-LF,Cell Line,,,,,
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.9,genetic_reagent,NF2-CSCW2,Genetic Reagent,,,,,
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.8,genetic_reagent,V-CSCW2,Genetic Reagent,,,,,
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.9,antibody,ERBB3 Y1197 antibody,Antibody,,,,,
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.9,antibody,ERBB3 antibody,Antibody,,,,,
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.9,antibody,EPHA2 S897 antibody,Antibody,,,,,
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.9,antibody,NDRG1 T346 antibody,Antibody,,,,,
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.9,antibody,Akt S473 antibody,Antibody,,,,,
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.9,antibody,Akt T308 antibody,Antibody,,,,,
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.9,antibody,Akt antibody,Antibody,,,,,
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.9,antibody,p70S6K T389 antibody,Antibody,,,,,
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.9,antibody,p70S6K antibody,Antibody,,,,,
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.9,antibody,ribosomal S6 S240/244 antibody,Antibody,,,,,
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.9,antibody,S6 antibody,Antibody,,,,,
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.9,antibody,IGF1R Y1135/36/IR Y1150/51 antibody,Antibody,,,,,
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.9,antibody,IGF1R antibody,Antibody,,,,,
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.9,antibody,FOXO1/3a T24/T32 antibody,Antibody,,,,,
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.9,antibody,FOXO3 antibody,Antibody,,,,,
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.9,antibody,EPHA2 antibody,Antibody,,,,,
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.9,antibody,secreted form of NRG1 antibody,Antibody,,,,,
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.9,antibody,NDRG1 antibody,Antibody,,,,,
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.9,antibody,GAPDH antibody,Antibody,,,,,
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.9,antibody,Anti-NF2/merlin polyclonal antibody,Antibody,,,,,
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.85,genetic_reagent,INK128,Genetic Reagent,,,,,
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.85,genetic_reagent,TAK-228,Genetic Reagent,,,,,
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.85,genetic_reagent,BMS-754807,Genetic Reagent,,,,,
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.85,genetic_reagent,lapatinib,Genetic Reagent,,,,,
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.85,genetic_reagent,erlotinib,Genetic Reagent,,,,,
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.85,genetic_reagent,rapamycin,Genetic Reagent,,,,,
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.85,genetic_reagent,AZD2014,Genetic Reagent,,,,,
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.85,genetic_reagent,MM-121,Genetic Reagent,,,,,
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.9,computational_tool,STAR,Computational Tool,,,,,
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.9,computational_tool,edgeR,Computational Tool,,,,,
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.8,computational_tool,fastQC,Computational Tool,,,,,
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.9,computational_tool,SynergyFinder,Computational Tool,,,,,
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.85,computational_tool,GraphPad Prism 8,Computational Tool,,,,,
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,0.9,genetic_reagent,CellTiter-Glo cell viability kit,Genetic Reagent,,,,,
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,animal_model,cisNP mouse model,Animal Model,,,,,
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.85,animal_model,athymic nude mice,Animal Model,,,,,
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.8,cell_line,H358 cells,Cell Line,,,,,
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,cell_line,S462 cells,Cell Line,,,,,
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,cell_line,cis MPNST cell line,Cell Line,,,,,
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,cell_line,HTS-Luc MPNST cell line,Cell Line,,,,,
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,antibody,"STING antibody (13647S, Cell Signaling Technology)",Antibody,,,,,
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,antibody,"TBK1 antibody (3504T, Cell Signaling Technology)",Antibody,,,,,
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,antibody,"p-TBK1 antibody (5483T, Cell Signaling Technology)",Antibody,,,,,
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,antibody,"IRF3 antibody (MA5-32348, Invitrogen)",Antibody,,,,,
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,antibody,"p-IRF3 antibody (4947S, Cell Signaling Technology)",Antibody,,,,,
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,antibody,"NF-κB antibody (ab16502, Abcam)",Antibody,,,,,
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,antibody,"p–NF-κB antibody (3033S, Cell Signaling Technology)",Antibody,,,,,
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,antibody,"PD-L1 antibody (ab213480, Abcam)",Antibody,,,,,
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,antibody,"GAPDH antibody (SC-32233, Santa Cruz Biotechnology)",Antibody,,,,,
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,antibody,"vinculin antibody (4650S, Cell Signaling Technology)",Antibody,,,,,
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,antibody,"Foxp3 antibody (ab215206, Abcam)",Antibody,,,,,
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,antibody,"CTLA-4 antibody (BE0164, Bio X Cell)",Antibody,,,,,
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,antibody,"CD20 antibody (BS-0080R, Bioss)",Antibody,,,,,
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,antibody,"CD3 antibody (ab16669, Abcam)",Antibody,,,,,
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,antibody,"CD4 antibody (ab183685, Abcam)",Antibody,,,,,
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.85,antibody,CD8α antibody (PA5-81344),Antibody,,,,,
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,antibody,"Iba1 antibody (019-19741, Thermo Fisher Scientific)",Antibody,,,,,
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,antibody,"iNOS antibody (ab15323, Abcam)",Antibody,,,,,
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,antibody,"mannose receptor antibody (ab64693, Abcam)",Antibody,,,,,
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,antibody,"p-H3 antibody (9701s, Cell Signaling Technology)",Antibody,,,,,
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,antibody,"cleaved caspase 3 antibody (9661S, Cell Signaling Technology)",Antibody,,,,,
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,antibody,"cleaved PARP antibody (9488S, Cell Signaling Technology)",Antibody,,,,,
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,antibody,"anti–PD-1 antibody (ab214421, Abcam)",Antibody,,,,,
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,antibody,"mouse monoclonal anti–PD-1 antibody (BE0146, Bio X Cell)",Antibody,,,,,
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,antibody,"mouse monoclonal anti–PD-L1 antibody (BE0146, Bio X Cell)",Antibody,,,,,
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,antibody,"mouse monoclonal anti–CTLA-4 antibody (BE0164, Bio X Cell)",Antibody,,,,,
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,genetic_reagent,ADU-S100,Genetic Reagent,,,,,
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,genetic_reagent,SA3,Genetic Reagent,,,,,
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.85,computational_tool,QuantStudio 3 Real-Time PCR System,Computational Tool,,,,,
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,0.9,computational_tool,ImageJ Cell Counter extension,Computational Tool,,,,,
PMID:38321701,10.1177/17407745231217279,Patient-reported measures of tinnitus for individuals with neurofibromatosis type 2-related schwannomatosis: Recommendations for clinical trials.,,0.95,clinical_assessment_tool,Tinnitus Functional Index,Clinical Assessment Tool,,,,,
PMID:38321701,10.1177/17407745231217279,Patient-reported measures of tinnitus for individuals with neurofibromatosis type 2-related schwannomatosis: Recommendations for clinical trials.,,0.9,clinical_assessment_tool,Patient-Reported Outcomes Rating Acceptance Tool for Endpoints (PRO-RATE),Clinical Assessment Tool,,,,,
PMID:38321701,10.1177/17407745231217279,Patient-reported measures of tinnitus for individuals with neurofibromatosis type 2-related schwannomatosis: Recommendations for clinical trials.,,0.85,clinical_assessment_tool,Client Oriented Scale of Improvement-Tinnitus,Clinical Assessment Tool,,,,,
PMID:30542164,10.1038/s41586-018-0774-y,Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome.,,0.85,animal_model,C57Bl/6 mice,Animal Model,,,,,
PMID:30542164,10.1038/s41586-018-0774-y,Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome.,,0.85,animal_model,BALB/C mice,Animal Model,,,,,
PMID:30542164,10.1038/s41586-018-0774-y,Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome.,,0.9,animal_model,NSG-SGM3 (NSGS) mice,Animal Model,,,,,
PMID:30542164,10.1038/s41586-018-0774-y,Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome.,,0.9,animal_model,LysMcre-conditional Th-knockout mice,Animal Model,,,,,
PMID:30542164,10.1038/s41586-018-0774-y,Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome.,,0.95,antibody,Anti-mCD3 (145–2C11),Antibody,,,,,
PMID:30542164,10.1038/s41586-018-0774-y,Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome.,,0.95,antibody,Anti-mIL6 receptor (15A7),Antibody,,,,,
PMID:30542164,10.1038/s41586-018-0774-y,Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome.,,0.95,antibody,Anti-mTNFα antibody (R023),Antibody,,,,,
PMID:30542164,10.1038/s41586-018-0774-y,Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome.,,0.95,antibody,Anti-mIL3 antibody (MP2–8F8),Antibody,,,,,
PMID:30542164,10.1038/s41586-018-0774-y,Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome.,,0.95,antibody,Anti-CD11b (ab133357),Antibody,,,,,
PMID:30542164,10.1038/s41586-018-0774-y,Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome.,,0.9,cell_line,CT26,Cell Line,,,,,
PMID:30542164,10.1038/s41586-018-0774-y,Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome.,,0.9,cell_line,U937,Cell Line,,,,,
PMID:30542164,10.1038/s41586-018-0774-y,Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome.,,0.9,cell_line,Raji,Cell Line,,,,,
PMID:30542164,10.1038/s41586-018-0774-y,Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome.,,0.9,cell_line,Eμ-ALL,Cell Line,,,,,
PMID:30542164,10.1038/s41586-018-0774-y,Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome.,,0.85,cell_line,Human CD19scFv-CD28–4–1BB-CD3ζ CAR-T cells (PM-CAR1003),Cell Line,,,,,
PMID:30542164,10.1038/s41586-018-0774-y,Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome.,,0.8,computational_tool,GraphPad Prism 7,Computational Tool,,,,,
PMID:30542164,10.1038/s41586-018-0774-y,Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome.,,0.8,computational_tool,R version 3.5.1,Computational Tool,,,,,
PMID:32572180,10.1038/s41436-020-0873-7,Late morbidity and mortality in adult survivors of childhood glioma with neurofibromatosis type 1: report from the Childhood Cancer Survivor Study.,,0.9,clinical_assessment_tool,Brief Symptom Inventory 18 (BSI-18),Clinical Assessment Tool,,,,,
PMID:32572180,10.1038/s41436-020-0873-7,Late morbidity and mortality in adult survivors of childhood glioma with neurofibromatosis type 1: report from the Childhood Cancer Survivor Study.,,0.9,clinical_assessment_tool,Behavior Problem Index (BPI),Clinical Assessment Tool,,,,,
PMID:32572180,10.1038/s41436-020-0873-7,Late morbidity and mortality in adult survivors of childhood glioma with neurofibromatosis type 1: report from the Childhood Cancer Survivor Study.,,0.9,clinical_assessment_tool,CCSS Neurocognitive Questionnaire,Clinical Assessment Tool,,,,,
PMID:32572180,10.1038/s41436-020-0873-7,Late morbidity and mortality in adult survivors of childhood glioma with neurofibromatosis type 1: report from the Childhood Cancer Survivor Study.,,0.9,clinical_assessment_tool,"Common Terminology Criteria for Adverse Events, version 4.0 (CTCAE v4.0)",Clinical Assessment Tool,,,,,
PMID:32572180,10.1038/s41436-020-0873-7,Late morbidity and mortality in adult survivors of childhood glioma with neurofibromatosis type 1: report from the Childhood Cancer Survivor Study.,,0.8,computational_tool,SAS version 9.4,Computational Tool,,,,,
PMID:32572180,10.1038/s41436-020-0873-7,Late morbidity and mortality in adult survivors of childhood glioma with neurofibromatosis type 1: report from the Childhood Cancer Survivor Study.,,0.8,computational_tool,R version 3.5.0,Computational Tool,,,,,
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,0.9,cell_line,pNF9511bc,Cell Line,,,,,
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,0.9,cell_line,ipNF03.3,Cell Line,,,,,
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,0.9,cell_line,ipn023λ,Cell Line,,,,,
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,0.95,cell_line,ST88-14,Cell Line,,,,,
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,0.95,cell_line,S462,Cell Line,,,,,
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,0.9,cell_line,RHT92,Cell Line,,,,,
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,0.9,cell_line,LN229,Cell Line,,,,,
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,0.85,cell_line,2V6.11,Cell Line,,,,,
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,0.9,animal_model,NSG mice,Animal Model,,,,,
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,0.9,cell_line,FiPS,Cell Line,,,,,
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,0.9,cell_line,"NF1−/−−/− edited FiPS Ctrl1-SV4F-7, D12",Cell Line,,,,,
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,0.9,cell_line,3PNF_SiPSsv_MM_11,Cell Line,,,,,
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,0.95,antibody,A300-140A,Antibody,,,,,
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,0.95,antibody,#9101,Antibody,,,,,
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,0.95,antibody,#9102,Antibody,,,,,
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,0.95,antibody,#2555,Antibody,,,,,
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,0.95,antibody,600-101-215,Antibody,,,,,
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,0.95,antibody,Tuj1,Antibody,,,,,
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,0.95,antibody,AB-N07,Antibody,,,,,
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,0.95,antibody,Z0311,Antibody,,,,,
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,0.95,antibody,SC-1615HRP,Antibody,,,,,
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,0.95,antibody,26183,Antibody,,,,,
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,0.95,antibody,235-1 R,Antibody,,,,,
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,0.9,patient_derived_model,JH-2-002,Patient-Derived Model,,,,,
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,0.9,patient_derived_model,JH-2-031,Patient-Derived Model,,,,,
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,0.9,genetic_reagent,pscAAV-GRDC24,Genetic Reagent,,,,,
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,0.95,genetic_reagent,AAV-NF,Genetic Reagent,,,,,
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,0.9,advanced_cellular_model,neurofibromaspheres,Advanced Cellular Model,,,,,
PMID:39269317,10.1158/1078-0432.CCR-24-1750,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor.,,0.95,cell_line,ST88-14,Cell Line,,,,,
PMID:39269317,10.1158/1078-0432.CCR-24-1750,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor.,,0.95,cell_line,M724,Cell Line,,,,,
PMID:39269317,10.1158/1078-0432.CCR-24-1750,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor.,,0.95,cell_line,SNF96.2,Cell Line,,,,,
PMID:39269317,10.1158/1078-0432.CCR-24-1750,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor.,,0.9,cell_line,HEK-293T,Cell Line,,,,,
PMID:39269317,10.1158/1078-0432.CCR-24-1750,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor.,,0.95,cell_line,M1,Cell Line,,,,,
PMID:39269317,10.1158/1078-0432.CCR-24-1750,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor.,,0.95,cell_line,M3,Cell Line,,,,,
PMID:39269317,10.1158/1078-0432.CCR-24-1750,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor.,,0.95,cell_line,M4,Cell Line,,,,,
PMID:39269317,10.1158/1078-0432.CCR-24-1750,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor.,,0.95,cell_line,M5,Cell Line,,,,,
PMID:39269317,10.1158/1078-0432.CCR-24-1750,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor.,,0.95,cell_line,M6,Cell Line,,,,,
PMID:39269317,10.1158/1078-0432.CCR-24-1750,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor.,,0.9,animal_model,CB17 SCID mice,Animal Model,,,,,
PMID:39269317,10.1158/1078-0432.CCR-24-1750,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor.,,0.85,genetic_reagent,Human Phospho-RTK Array Kit,Genetic Reagent,,,,,
PMID:39269317,10.1158/1078-0432.CCR-24-1750,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor.,,0.95,genetic_reagent,LentiCRISPR-v2,Genetic Reagent,,,,,
PMID:39269317,10.1158/1078-0432.CCR-24-1750,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor.,,0.95,genetic_reagent,LentiGuide-Puro,Genetic Reagent,,,,,
PMID:39269317,10.1158/1078-0432.CCR-24-1750,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor.,,0.95,genetic_reagent,LentiCas9-Blast,Genetic Reagent,,,,,
PMID:39269317,10.1158/1078-0432.CCR-24-1750,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor.,,0.9,computational_tool,GraphPad Prism,Computational Tool,,,,,
PMID:39269317,10.1158/1078-0432.CCR-24-1750,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor.,,0.85,computational_tool,Combenefit platform,Computational Tool,,,,,
PMID:39269317,10.1158/1078-0432.CCR-24-1750,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor.,,0.9,computational_tool,Image Studio Lite software,Computational Tool,,,,,
PMID:39269317,10.1158/1078-0432.CCR-24-1750,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor.,,0.85,computational_tool,NCBI Primer-BLAST tool,Computational Tool,,,,,
PMID:39269317,10.1158/1078-0432.CCR-24-1750,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor.,,0.9,patient_derived_model,patient-derived xenograft (PDX),Patient-Derived Model,,,,,
PMID:34106871,10.1109/JBHI.2021.3087735,DINs: Deep Interactive Networks for Neurofibroma Segmentation in Neurofibromatosis Type 1 on Whole-Body MRI.,,0.95,computational_tool,DINs (Deep Interactive Networks),Computational Tool,,,,,
PMID:34106871,10.1109/JBHI.2021.3087735,DINs: Deep Interactive Networks for Neurofibroma Segmentation in Neurofibromatosis Type 1 on Whole-Body MRI.,,0.85,computational_tool,3D U-Net,Computational Tool,,,,,
PMID:34106871,10.1109/JBHI.2021.3087735,DINs: Deep Interactive Networks for Neurofibroma Segmentation in Neurofibromatosis Type 1 on Whole-Body MRI.,,0.85,computational_tool,nnU-Net,Computational Tool,,,,,
PMID:34106871,10.1109/JBHI.2021.3087735,DINs: Deep Interactive Networks for Neurofibroma Segmentation in Neurofibromatosis Type 1 on Whole-Body MRI.,,0.9,computational_tool,3DQI software,Computational Tool,,,,,
PMID:34106871,10.1109/JBHI.2021.3087735,DINs: Deep Interactive Networks for Neurofibroma Segmentation in Neurofibromatosis Type 1 on Whole-Body MRI.,,0.9,computational_tool,MEDx software,Computational Tool,,,,,
PMID:34106871,10.1109/JBHI.2021.3087735,DINs: Deep Interactive Networks for Neurofibroma Segmentation in Neurofibromatosis Type 1 on Whole-Body MRI.,,0.8,computational_tool,Random Walk (RW),Computational Tool,,,,,
PMID:34106871,10.1109/JBHI.2021.3087735,DINs: Deep Interactive Networks for Neurofibroma Segmentation in Neurofibromatosis Type 1 on Whole-Body MRI.,,0.8,computational_tool,Graph Cut (GC),Computational Tool,,,,,
PMID:34106871,10.1109/JBHI.2021.3087735,DINs: Deep Interactive Networks for Neurofibroma Segmentation in Neurofibromatosis Type 1 on Whole-Body MRI.,,0.8,computational_tool,Active Contour (AC),Computational Tool,,,,,
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,0.9,cell_line,Drosophila Schneider (S2R+) cells,Cell Line,,,,,
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,0.95,cell_line,dNF1‐KO,Cell Line,,,,,
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,0.9,cell_line,hTERT ipn02.3 2λ CRL‐3392,Cell Line,,,,,
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,0.95,cell_line,"ipnNF95.11C (hTERT NF1 ipnNF95.11c, RRID: CVCL_UI69)",Cell Line,,,,,
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,0.95,cell_line,"ipNF95.11b 'C' (hTERT NF1 ipNF95.11b C, RRID: CVCL_UI67)",Cell Line,,,,,
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,0.95,cell_line,"ipnNF09.4 (hTERT NF1 ipnNF09.4, RRID: CVCL_UI73)",Cell Line,,,,,
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,0.95,cell_line,"ipNF05.5 (hTERT NF1 ipNF05.5, RRID: CVCL_UI71)",Cell Line,,,,,
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,0.9,cell_line,ST88‐14 (RRID: CVCL_8916),Cell Line,,,,,
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,0.85,genetic_reagent,pl018 plasmid,Genetic Reagent,,,,,
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,0.85,genetic_reagent,pAct‐GFP plasmid,Genetic Reagent,,,,,
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,0.9,genetic_reagent,lentiCRISPR v1 plasmid,Genetic Reagent,,,,,
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,0.9,genetic_reagent,UAS‐dNf1 transgene,Genetic Reagent,,,,,
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,0.9,animal_model,y [1] sc[*] v [1] sev [21]; P{y[+t7.7] v[+t1.8] = TKO.GS01796}attP40,Animal Model,,,,,
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,0.9,animal_model,y [1] M{w[+mC] = nos‐Cas9.P}ZH‐2A w[*],Animal Model,,,,,
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,0.9,animal_model,P{ KK101909 }VIE‐260B (VDRC #109637),Animal Model,,,,,
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,0.95,animal_model,CD‐1 nude mice (Crl:NU(NCr)‐Foxn1nu),Animal Model,,,,,
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,0.9,animal_model,C57BL/6J Inbred Mice (JAX® Mice Strain),Animal Model,,,,,
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,0.9,antibody,anti‐human neurofibromin (Abcam; ab238142),Antibody,,,,,
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,0.9,antibody,"anti‐ Drosophila neurofibromin (mouse, ascites purified mAb21 and mAb30)",Antibody,,,,,
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,0.9,antibody,"anti‐human neurofibromin (rabbit, Infixion r07E)",Antibody,,,,,
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,0.9,antibody,"anti‐phospho‐ERK (mouse, Sigma M8159)",Antibody,,,,,
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,0.9,antibody,"total ERK (rabbit, CST 9102)",Antibody,,,,,
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,0.9,antibody,"anti‐β‐tubulin (mouse, Developmental Studies Hybridoma Bank E7)",Antibody,,,,,
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,0.9,antibody,"GAPDH (rabbit, Proteintech 10 494‐1‐AP)",Antibody,,,,,
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,0.9,antibody,"anti‐PARP (rabbit, Cell Signaling 952)",Antibody,,,,,
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,0.9,antibody,"anti‐LC3B (rabbit, Cell Signaling 2775)",Antibody,,,,,
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,0.8,computational_tool,CellTiter‐Glo assay (Promega; G7570),Computational Tool,,,,,
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,0.8,computational_tool,autophagy assay kit (Abcam; ab139484),Computational Tool,,,,,
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,0.8,computational_tool,Annexin V‐FITC apoptosis kit (Abcam; ab14085),Computational Tool,,,,,
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,0.8,computational_tool,generic caspase activity assay kit (Abcam; ab112130),Computational Tool,,,,,
PMID:30571760,10.1371/journal.pone.0208835,Neurofibromin haploinsufficiency results in altered spermatogenesis in a mouse model of neurofibromatosis type 1.,,0.95,animal_model,Nf1Dsk9/+ mouse model,Animal Model,,,,,
PMID:30571760,10.1371/journal.pone.0208835,Neurofibromin haploinsufficiency results in altered spermatogenesis in a mouse model of neurofibromatosis type 1.,,0.85,computational_tool,Olympus BX61 upright light microscope,Computational Tool,,,,,
PMID:30571760,10.1371/journal.pone.0208835,Neurofibromin haploinsufficiency results in altered spermatogenesis in a mouse model of neurofibromatosis type 1.,,0.85,computational_tool,Q imaging Retiga Exi camera,Computational Tool,,,,,
PMID:30571760,10.1371/journal.pone.0208835,Neurofibromin haploinsufficiency results in altered spermatogenesis in a mouse model of neurofibromatosis type 1.,,0.9,computational_tool,InVivo 3.2.0 software,Computational Tool,,,,,
PMID:30571760,10.1371/journal.pone.0208835,Neurofibromin haploinsufficiency results in altered spermatogenesis in a mouse model of neurofibromatosis type 1.,,0.9,computational_tool,Image-Pro Plus software,Computational Tool,,,,,
PMID:30571760,10.1371/journal.pone.0208835,Neurofibromin haploinsufficiency results in altered spermatogenesis in a mouse model of neurofibromatosis type 1.,,0.9,computational_tool,"Image J1.45s, version 1.44p",Computational Tool,,,,,
PMID:30571760,10.1371/journal.pone.0208835,Neurofibromin haploinsufficiency results in altered spermatogenesis in a mouse model of neurofibromatosis type 1.,,0.95,antibody,p44/42 MAPK (ERK1/2) antibody,Antibody,,,,,
PMID:30571760,10.1371/journal.pone.0208835,Neurofibromin haploinsufficiency results in altered spermatogenesis in a mouse model of neurofibromatosis type 1.,,0.95,antibody,p44/42 MAPK phosphorylated at threonine 202 and tyrosine 204 (p-ERK1/2) antibody,Antibody,,,,,
PMID:30571760,10.1371/journal.pone.0208835,Neurofibromin haploinsufficiency results in altered spermatogenesis in a mouse model of neurofibromatosis type 1.,,0.95,antibody,phosphatidylinositol 3-kinase (PI3K) antibody,Antibody,,,,,
PMID:30571760,10.1371/journal.pone.0208835,Neurofibromin haploinsufficiency results in altered spermatogenesis in a mouse model of neurofibromatosis type 1.,,0.9,antibody,anti-rabbit conjugated secondary antibody,Antibody,,,,,
PMID:30571760,10.1371/journal.pone.0208835,Neurofibromin haploinsufficiency results in altered spermatogenesis in a mouse model of neurofibromatosis type 1.,,0.85,computational_tool,GraphPad 5 Prism software,Computational Tool,,,,,
PMID:37269078,10.1177/17407745231178839,Perspectives of adolescents with neurofibromatosis 1 and cutaneous neurofibromas: Implications for clinical trials.,,0.85,clinical_assessment_tool,Children's Tumor Foundation NF Registry,Clinical Assessment Tool,,,,,
PMID:37269078,10.1177/17407745231178839,Perspectives of adolescents with neurofibromatosis 1 and cutaneous neurofibromas: Implications for clinical trials.,,0.9,computational_tool,REDCap,Computational Tool,,,,,
PMID:37269078,10.1177/17407745231178839,Perspectives of adolescents with neurofibromatosis 1 and cutaneous neurofibromas: Implications for clinical trials.,,0.8,clinical_assessment_tool,5-point Likert-type scales,Clinical Assessment Tool,,,,,
PMID:37269078,10.1177/17407745231178839,Perspectives of adolescents with neurofibromatosis 1 and cutaneous neurofibromas: Implications for clinical trials.,,0.75,computational_tool,Weighted Kappa statistic,Computational Tool,,,,,
PMID:38475852,10.1186/s13023-024-03093-1,Pilot study of the effectiveness of a telehealth group for improving peer relationships for adolescents with neurofibromatosis type 1.,,0.95,clinical_assessment_tool,PEERS® intervention,Clinical Assessment Tool,,,,,
PMID:38475852,10.1186/s13023-024-03093-1,Pilot study of the effectiveness of a telehealth group for improving peer relationships for adolescents with neurofibromatosis type 1.,,0.9,clinical_assessment_tool,Kaufman Brief Intelligence Test– Second Edition (KBIT-2),Clinical Assessment Tool,,,,,
PMID:38475852,10.1186/s13023-024-03093-1,Pilot study of the effectiveness of a telehealth group for improving peer relationships for adolescents with neurofibromatosis type 1.,,0.9,clinical_assessment_tool,Wechsler Individual Achievement Test– Third Edition (WIAT-III) Word Reading subtest,Clinical Assessment Tool,,,,,
PMID:38475852,10.1186/s13023-024-03093-1,Pilot study of the effectiveness of a telehealth group for improving peer relationships for adolescents with neurofibromatosis type 1.,,0.9,clinical_assessment_tool,Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version– Attention Deficit/Hyperactivity Disorder module (KSADS-ADHD),Clinical Assessment Tool,,,,,
PMID:38475852,10.1186/s13023-024-03093-1,Pilot study of the effectiveness of a telehealth group for improving peer relationships for adolescents with neurofibromatosis type 1.,,0.9,clinical_assessment_tool,Social Communication Questionnaire (SCQ),Clinical Assessment Tool,,,,,
PMID:38475852,10.1186/s13023-024-03093-1,Pilot study of the effectiveness of a telehealth group for improving peer relationships for adolescents with neurofibromatosis type 1.,,0.95,clinical_assessment_tool,Social Skills Improvement System Social-Emotional Learning (SSIS-SEL),Clinical Assessment Tool,,,,,
PMID:38475852,10.1186/s13023-024-03093-1,Pilot study of the effectiveness of a telehealth group for improving peer relationships for adolescents with neurofibromatosis type 1.,,0.9,clinical_assessment_tool,Social Responsiveness Scale– Second Edition (SRS-2),Clinical Assessment Tool,,,,,
PMID:38475852,10.1186/s13023-024-03093-1,Pilot study of the effectiveness of a telehealth group for improving peer relationships for adolescents with neurofibromatosis type 1.,,0.9,clinical_assessment_tool,Friendship Qualities Scale (FQS),Clinical Assessment Tool,,,,,
PMID:38475852,10.1186/s13023-024-03093-1,Pilot study of the effectiveness of a telehealth group for improving peer relationships for adolescents with neurofibromatosis type 1.,,0.9,clinical_assessment_tool,Quality of Socialization Questionnaire (QSQ),Clinical Assessment Tool,,,,,
PMID:38475852,10.1186/s13023-024-03093-1,Pilot study of the effectiveness of a telehealth group for improving peer relationships for adolescents with neurofibromatosis type 1.,,0.9,clinical_assessment_tool,Test of Adolescent Social Skills Knowledge (TASSK),Clinical Assessment Tool,,,,,
PMID:38475852,10.1186/s13023-024-03093-1,Pilot study of the effectiveness of a telehealth group for improving peer relationships for adolescents with neurofibromatosis type 1.,,0.85,computational_tool,"IBM SPSS for Windows, version 28",Computational Tool,,,,,
PMID:38475852,10.1186/s13023-024-03093-1,Pilot study of the effectiveness of a telehealth group for improving peer relationships for adolescents with neurofibromatosis type 1.,,0.85,computational_tool,GPower 3.1,Computational Tool,,,,,
PMID:30531922,10.1038/s41591-018-0263-8,The molecular landscape of glioma in patients with Neurofibromatosis 1.,,0.85,genetic_reagent,Agilent SureSelect Human All Exon kit,Genetic Reagent,,,,,
PMID:30531922,10.1038/s41591-018-0263-8,The molecular landscape of glioma in patients with Neurofibromatosis 1.,,0.8,computational_tool,Burrows-Wheeler Aligner,Computational Tool,,,,,
PMID:30531922,10.1038/s41591-018-0263-8,The molecular landscape of glioma in patients with Neurofibromatosis 1.,,0.8,computational_tool,SAMtools,Computational Tool,,,,,
PMID:30531922,10.1038/s41591-018-0263-8,The molecular landscape of glioma in patients with Neurofibromatosis 1.,,0.85,computational_tool,GATK,Computational Tool,,,,,
PMID:30531922,10.1038/s41591-018-0263-8,The molecular landscape of glioma in patients with Neurofibromatosis 1.,,0.85,computational_tool,VarScan2,Computational Tool,,,,,
PMID:30531922,10.1038/s41591-018-0263-8,The molecular landscape of glioma in patients with Neurofibromatosis 1.,,0.85,computational_tool,Freebayes,Computational Tool,,,,,
PMID:30531922,10.1038/s41591-018-0263-8,The molecular landscape of glioma in patients with Neurofibromatosis 1.,,0.85,computational_tool,Strelka,Computational Tool,,,,,
PMID:30531922,10.1038/s41591-018-0263-8,The molecular landscape of glioma in patients with Neurofibromatosis 1.,,0.85,computational_tool,MuTect,Computational Tool,,,,,
PMID:30531922,10.1038/s41591-018-0263-8,The molecular landscape of glioma in patients with Neurofibromatosis 1.,,0.85,computational_tool,VarDict,Computational Tool,,,,,
PMID:30531922,10.1038/s41591-018-0263-8,The molecular landscape of glioma in patients with Neurofibromatosis 1.,,0.85,computational_tool,AnnoVar,Computational Tool,,,,,
PMID:30531922,10.1038/s41591-018-0263-8,The molecular landscape of glioma in patients with Neurofibromatosis 1.,,0.85,computational_tool,MutationTaster2,Computational Tool,,,,,
PMID:30531922,10.1038/s41591-018-0263-8,The molecular landscape of glioma in patients with Neurofibromatosis 1.,,0.85,computational_tool,Polyphen2,Computational Tool,,,,,
PMID:30531922,10.1038/s41591-018-0263-8,The molecular landscape of glioma in patients with Neurofibromatosis 1.,,0.85,computational_tool,SIFT,Computational Tool,,,,,
PMID:30531922,10.1038/s41591-018-0263-8,The molecular landscape of glioma in patients with Neurofibromatosis 1.,,0.85,computational_tool,STAR,Computational Tool,,,,,
PMID:30531922,10.1038/s41591-018-0263-8,The molecular landscape of glioma in patients with Neurofibromatosis 1.,,0.85,computational_tool,featureCounts,Computational Tool,,,,,
PMID:30531922,10.1038/s41591-018-0263-8,The molecular landscape of glioma in patients with Neurofibromatosis 1.,,0.9,computational_tool,netMHCpan-4.0,Computational Tool,,,,,
PMID:30531922,10.1038/s41591-018-0263-8,The molecular landscape of glioma in patients with Neurofibromatosis 1.,,0.85,cell_line,U2OS,Cell Line,,,,,
PMID:30531922,10.1038/s41591-018-0263-8,The molecular landscape of glioma in patients with Neurofibromatosis 1.,,0.85,cell_line,HEK293,Cell Line,,,,,
PMID:30531922,10.1038/s41591-018-0263-8,The molecular landscape of glioma in patients with Neurofibromatosis 1.,,0.9,antibody,"ATRX antibody (Sigma-Aldrich, HPA001906)",Antibody,,,,,
PMID:30531922,10.1038/s41591-018-0263-8,The molecular landscape of glioma in patients with Neurofibromatosis 1.,,0.9,antibody,"CD3 antibody (Dako, A0452)",Antibody,,,,,
PMID:30531922,10.1038/s41591-018-0263-8,The molecular landscape of glioma in patients with Neurofibromatosis 1.,,0.9,antibody,CD8 antibody (Leica NCL-L-CD8–4B11),Antibody,,,,,
PMID:30531922,10.1038/s41591-018-0263-8,The molecular landscape of glioma in patients with Neurofibromatosis 1.,,0.9,antibody,"GZMB antibody (Leica, PA0291)",Antibody,,,,,
PMID:30531922,10.1038/s41591-018-0263-8,The molecular landscape of glioma in patients with Neurofibromatosis 1.,,0.9,antibody,"CD20 antibody (Leica, NCL-L-CD20-L26)",Antibody,,,,,
PMID:30531922,10.1038/s41591-018-0263-8,The molecular landscape of glioma in patients with Neurofibromatosis 1.,,0.9,antibody,"CD68 antibody (Sigma, HPA048982)",Antibody,,,,,
PMID:25377441,10.1111/pme.12620,Development and validation of the English Pain Interference Index and Pain Interference Index-Parent report.,,0.95,clinical_assessment_tool,Pain Interference Index (PII),Clinical Assessment Tool,,,,,
PMID:25377441,10.1111/pme.12620,Development and validation of the English Pain Interference Index and Pain Interference Index-Parent report.,,0.95,clinical_assessment_tool,Pain Interference Index-Parent report (PII-P),Clinical Assessment Tool,,,,,
PMID:25377441,10.1111/pme.12620,Development and validation of the English Pain Interference Index and Pain Interference Index-Parent report.,,0.9,clinical_assessment_tool,Modified Brief Pain Inventory (MBPI),Clinical Assessment Tool,,,,,
PMID:25377441,10.1111/pme.12620,Development and validation of the English Pain Interference Index and Pain Interference Index-Parent report.,,0.9,clinical_assessment_tool,Faces Pain Scale-Revised (FPS-R),Clinical Assessment Tool,,,,,
PMID:25377441,10.1111/pme.12620,Development and validation of the English Pain Interference Index and Pain Interference Index-Parent report.,,0.85,clinical_assessment_tool,Pain Rating Scale (PRS),Clinical Assessment Tool,,,,,
PMID:25377441,10.1111/pme.12620,Development and validation of the English Pain Interference Index and Pain Interference Index-Parent report.,,0.85,clinical_assessment_tool,Pain Rating Scale-Parent version (PRS-P),Clinical Assessment Tool,,,,,
PMID:25377441,10.1111/pme.12620,Development and validation of the English Pain Interference Index and Pain Interference Index-Parent report.,,0.8,clinical_assessment_tool,NF Disease Severity Scale,Clinical Assessment Tool,,,,,
PMID:25377441,10.1111/pme.12620,Development and validation of the English Pain Interference Index and Pain Interference Index-Parent report.,,0.8,clinical_assessment_tool,NF1 Disease Complications Scale,Clinical Assessment Tool,,,,,
PMID:29408605,10.1016/j.neuroscience.2018.01.054,Nf2 Mutation in Schwann Cells Delays Functional Neural Recovery Following Injury.,,0.95,animal_model,P0SchΔ39-121 transgenic mice,Animal Model,,,,,
PMID:29408605,10.1016/j.neuroscience.2018.01.054,Nf2 Mutation in Schwann Cells Delays Functional Neural Recovery Following Injury.,,0.85,animal_model,FVB mice,Animal Model,,,,,
PMID:29408605,10.1016/j.neuroscience.2018.01.054,Nf2 Mutation in Schwann Cells Delays Functional Neural Recovery Following Injury.,,0.9,computational_tool,CatWalk XT,Computational Tool,,,,,
PMID:29408605,10.1016/j.neuroscience.2018.01.054,Nf2 Mutation in Schwann Cells Delays Functional Neural Recovery Following Injury.,,0.8,computational_tool,Grass neurostimulator,Computational Tool,,,,,
PMID:29408605,10.1016/j.neuroscience.2018.01.054,Nf2 Mutation in Schwann Cells Delays Functional Neural Recovery Following Injury.,,0.85,computational_tool,Windaq DI-720 hardware with Pro+ software,Computational Tool,,,,,
PMID:29408605,10.1016/j.neuroscience.2018.01.054,Nf2 Mutation in Schwann Cells Delays Functional Neural Recovery Following Injury.,,0.85,computational_tool,Metamorph software,Computational Tool,,,,,
PMID:29408605,10.1016/j.neuroscience.2018.01.054,Nf2 Mutation in Schwann Cells Delays Functional Neural Recovery Following Injury.,,0.85,computational_tool,ImageJ software,Computational Tool,,,,,
PMID:29408605,10.1016/j.neuroscience.2018.01.054,Nf2 Mutation in Schwann Cells Delays Functional Neural Recovery Following Injury.,,0.8,computational_tool,SigmaPlot software,Computational Tool,,,,,
PMID:21111000,10.1016/j.jneumeth.2010.10.021,A novel imaging-compatible sciatic nerve schwannoma model.,,0.95,cell_line,HEI-193,Cell Line,,,,,
PMID:21111000,10.1016/j.jneumeth.2010.10.021,A novel imaging-compatible sciatic nerve schwannoma model.,,0.9,animal_model,athymic mice (nu/nu),Animal Model,,,,,
PMID:21111000,10.1016/j.jneumeth.2010.10.021,A novel imaging-compatible sciatic nerve schwannoma model.,,0.85,antibody,S100 antibody,Antibody,,,,,
PMID:21111000,10.1016/j.jneumeth.2010.10.021,A novel imaging-compatible sciatic nerve schwannoma model.,,0.85,genetic_reagent,lentivirus expressing Fluc and mCherry,Genetic Reagent,,,,,
PMID:21111000,10.1016/j.jneumeth.2010.10.021,A novel imaging-compatible sciatic nerve schwannoma model.,,0.8,computational_tool,Nikon Eclipse E800 microscope,Computational Tool,,,,,
PMID:24958239,10.1186/gb-2014-15-6-r80,SVA retrotransposon insertion-associated deletion represents a novel mutational mechanism underlying large genomic copy number changes with non-recurrent breakpoints.,,0.85,genetic_reagent,P122-C1 NF1-area kit,Genetic Reagent,,,,,
PMID:24958239,10.1186/gb-2014-15-6-r80,SVA retrotransposon insertion-associated deletion represents a novel mutational mechanism underlying large genomic copy number changes with non-recurrent breakpoints.,,0.8,genetic_reagent,Expand Long Template PCR system,Genetic Reagent,,,,,
PMID:24958239,10.1186/gb-2014-15-6-r80,SVA retrotransposon insertion-associated deletion represents a novel mutational mechanism underlying large genomic copy number changes with non-recurrent breakpoints.,,0.8,genetic_reagent,BigDye Terminator v3.1 Cycle Sequencing Kit,Genetic Reagent,,,,,
PMID:24958239,10.1186/gb-2014-15-6-r80,SVA retrotransposon insertion-associated deletion represents a novel mutational mechanism underlying large genomic copy number changes with non-recurrent breakpoints.,,0.85,cell_line,Epstein-Barr virus-transformed cell lines,Cell Line,,,,,
PMID:24958239,10.1186/gb-2014-15-6-r80,SVA retrotransposon insertion-associated deletion represents a novel mutational mechanism underlying large genomic copy number changes with non-recurrent breakpoints.,,0.8,genetic_reagent,GenomeWalker™,Genetic Reagent,,,,,
PMID:24958239,10.1186/gb-2014-15-6-r80,SVA retrotransposon insertion-associated deletion represents a novel mutational mechanism underlying large genomic copy number changes with non-recurrent breakpoints.,,0.8,genetic_reagent,Advantage® 2 PCR Kit,Genetic Reagent,,,,,
PMID:24958239,10.1186/gb-2014-15-6-r80,SVA retrotransposon insertion-associated deletion represents a novel mutational mechanism underlying large genomic copy number changes with non-recurrent breakpoints.,,0.85,computational_tool,non-B DNA Motif Search Tool,Computational Tool,,,,,
PMID:24958239,10.1186/gb-2014-15-6-r80,SVA retrotransposon insertion-associated deletion represents a novel mutational mechanism underlying large genomic copy number changes with non-recurrent breakpoints.,,0.85,computational_tool,MEME suite software,Computational Tool,,,,,
PMID:24958239,10.1186/gb-2014-15-6-r80,SVA retrotransposon insertion-associated deletion represents a novel mutational mechanism underlying large genomic copy number changes with non-recurrent breakpoints.,,0.85,computational_tool,UCSC Repeat Masker,Computational Tool,,,,,
PMID:24958239,10.1186/gb-2014-15-6-r80,SVA retrotransposon insertion-associated deletion represents a novel mutational mechanism underlying large genomic copy number changes with non-recurrent breakpoints.,,0.85,computational_tool,BLASTN,Computational Tool,,,,,
PMID:32642737,10.1093/noajnl/vdz050,Assessing interobserver variability and accuracy in the histological diagnosis and classification of cutaneous neurofibromass.,,0.85,computational_tool,Aperio XT scanner,Computational Tool,,,,,
PMID:32642737,10.1093/noajnl/vdz050,Assessing interobserver variability and accuracy in the histological diagnosis and classification of cutaneous neurofibromass.,,0.8,computational_tool,REDcap database,Computational Tool,,,,,
PMID:32642737,10.1093/noajnl/vdz050,Assessing interobserver variability and accuracy in the histological diagnosis and classification of cutaneous neurofibromass.,,0.85,computational_tool,CaloPix viewer,Computational Tool,,,,,
PMID:38931352,10.3390/ph17060685,PET Imaging of Neurofibromatosis Type 1 with a Fluorine-18 Labeled Tryptophan Radiotracer.,,0.95,animal_model,"Trp53, Nf1, Suz12 triple mutant mice",Animal Model,,,,,
PMID:38931352,10.3390/ph17060685,PET Imaging of Neurofibromatosis Type 1 with a Fluorine-18 Labeled Tryptophan Radiotracer.,,0.9,genetic_reagent,L-[18F]FETrp,Genetic Reagent,,,,,
PMID:38931352,10.3390/ph17060685,PET Imaging of Neurofibromatosis Type 1 with a Fluorine-18 Labeled Tryptophan Radiotracer.,,0.85,computational_tool,PETCHEM module,Computational Tool,,,,,
PMID:38931352,10.3390/ph17060685,PET Imaging of Neurofibromatosis Type 1 with a Fluorine-18 Labeled Tryptophan Radiotracer.,,0.9,computational_tool,Agilent ChemStation software (version C.01.07),Computational Tool,,,,,
PMID:38931352,10.3390/ph17060685,PET Imaging of Neurofibromatosis Type 1 with a Fluorine-18 Labeled Tryptophan Radiotracer.,,0.85,computational_tool,PerkinElmer G4 microPET scanner,Computational Tool,,,,,
PMID:38931352,10.3390/ph17060685,PET Imaging of Neurofibromatosis Type 1 with a Fluorine-18 Labeled Tryptophan Radiotracer.,,0.95,computational_tool,VivoQuant software version 4.0,Computational Tool,,,,,
PMID:38931352,10.3390/ph17060685,PET Imaging of Neurofibromatosis Type 1 with a Fluorine-18 Labeled Tryptophan Radiotracer.,,0.95,antibody,"indoleamine 2,3-dioxygenase rabbit monoclonal (1:100, Abcam, Cambridge, UK)",Antibody,,,,,
PMID:38931352,10.3390/ph17060685,PET Imaging of Neurofibromatosis Type 1 with a Fluorine-18 Labeled Tryptophan Radiotracer.,,0.95,antibody,"AHR antibody mouse monoclonal (1:50, Santa Cruz, Dallas, TX, USA)",Antibody,,,,,
PMID:38931352,10.3390/ph17060685,PET Imaging of Neurofibromatosis Type 1 with a Fluorine-18 Labeled Tryptophan Radiotracer.,,0.95,antibody,"antibody-TDO2, rabbit/IgG polyclonal (1:100, Proteintech, Rosemont, IL, USA)",Antibody,,,,,
PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,,0.85,cell_line,Human meningeal cells (HMC),Cell Line,,,,,
PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,,0.9,cell_line,Ben-Men-1 cells,Cell Line,,,,,
PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,,0.8,genetic_reagent,phospho-protein purification kit from Qiagen®,Genetic Reagent,,,,,
PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,,0.85,computational_tool,Ultimate 3000 UPLC system,Computational Tool,,,,,
PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,,0.85,computational_tool,Orbitrap Velos Pro mass spectrometer,Computational Tool,,,,,
PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,,0.95,computational_tool,MaxQuant version 1.3.05,Computational Tool,,,,,
PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,,0.9,computational_tool,Perseus,Computational Tool,,,,,
PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,,0.9,computational_tool,DAVID software,Computational Tool,,,,,
PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,,0.9,antibody,Merlin antibody,Antibody,,,,,
PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,,0.9,antibody,pMerlin antibody,Antibody,,,,,
PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,,0.9,antibody,HDAC1 antibody,Antibody,,,,,
PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,,0.9,antibody,PDLIM2 antibody (Cell Signaling Technology),Antibody,,,,,
PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,,0.9,antibody,PDLIM2 antibody (Santa Cruz Biotechnology),Antibody,,,,,
PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,,0.9,antibody,GAPDH antibody,Antibody,,,,,
PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,,0.85,computational_tool,Leica DMI6000B microscope,Computational Tool,,,,,
PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,,0.9,genetic_reagent,pLKO.1-puro plasmid,Genetic Reagent,,,,,
PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,,0.85,genetic_reagent,λ-phosphatase (New England Biolabs),Genetic Reagent,,,,,
PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,,0.8,genetic_reagent,cytoplasmic and nuclear extraction assay (Thermo Scientific),Genetic Reagent,,,,,
PMID:39996452,10.1111/cns.70287,Cas9 Mouse Model of Skull Base Meningioma Driven by Combinational Gene Inactivation in Meningeal Cells.,,0.95,animal_model,Rosa26-LSL-Cas9 knockin mice,Animal Model,,,,,
PMID:39996452,10.1111/cns.70287,Cas9 Mouse Model of Skull Base Meningioma Driven by Combinational Gene Inactivation in Meningeal Cells.,,0.9,genetic_reagent,pLentiCre/gRNA,Genetic Reagent,,,,,
PMID:39996452,10.1111/cns.70287,Cas9 Mouse Model of Skull Base Meningioma Driven by Combinational Gene Inactivation in Meningeal Cells.,,0.9,genetic_reagent,pAAVCre/gRNA,Genetic Reagent,,,,,
PMID:39996452,10.1111/cns.70287,Cas9 Mouse Model of Skull Base Meningioma Driven by Combinational Gene Inactivation in Meningeal Cells.,,0.85,antibody,EMA antibody,Antibody,,,,,
PMID:39996452,10.1111/cns.70287,Cas9 Mouse Model of Skull Base Meningioma Driven by Combinational Gene Inactivation in Meningeal Cells.,,0.85,antibody,vimentin antibody,Antibody,,,,,
PMID:39996452,10.1111/cns.70287,Cas9 Mouse Model of Skull Base Meningioma Driven by Combinational Gene Inactivation in Meningeal Cells.,,0.85,antibody,MIB-1 antibody,Antibody,,,,,
PMID:39996452,10.1111/cns.70287,Cas9 Mouse Model of Skull Base Meningioma Driven by Combinational Gene Inactivation in Meningeal Cells.,,0.8,computational_tool,Bruker 7.0 T scanner,Computational Tool,,,,,
PMID:41168866,10.1186/s13023-025-04093-5,Artificial intelligence-based tools for precision diagnosis and treatment of neurofibromatosis type 1 associated peripheral and central glial tumors.,,0.8,computational_tool,PubMed/MEDLINE,Computational Tool,,,,,
PMID:41168866,10.1186/s13023-025-04093-5,Artificial intelligence-based tools for precision diagnosis and treatment of neurofibromatosis type 1 associated peripheral and central glial tumors.,,0.8,computational_tool,Google Scholar,Computational Tool,,,,,
PMID:41168866,10.1186/s13023-025-04093-5,Artificial intelligence-based tools for precision diagnosis and treatment of neurofibromatosis type 1 associated peripheral and central glial tumors.,,0.85,computational_tool,SYNAPSE,Computational Tool,,,,,
PMID:41168866,10.1186/s13023-025-04093-5,Artificial intelligence-based tools for precision diagnosis and treatment of neurofibromatosis type 1 associated peripheral and central glial tumors.,,0.85,computational_tool,CTF data portal,Computational Tool,,,,,
PMID:41168866,10.1186/s13023-025-04093-5,Artificial intelligence-based tools for precision diagnosis and treatment of neurofibromatosis type 1 associated peripheral and central glial tumors.,,0.8,computational_tool,BioArchives,Computational Tool,,,,,
PMID:40063513,10.1158/1078-0432.CCR-24-3029,DLK1 Distinguishes Subsets of NF1-Associated Malignant Peripheral Nerve Sheath Tumors with Divergent Molecular Signatures.,,0.8,computational_tool,GraphPad Prism,Computational Tool,,,,,
PMID:40063513,10.1158/1078-0432.CCR-24-3029,DLK1 Distinguishes Subsets of NF1-Associated Malignant Peripheral Nerve Sheath Tumors with Divergent Molecular Signatures.,,0.85,clinical_assessment_tool,Hematoxylin and eosin (H&E),Clinical Assessment Tool,,,,,
PMID:40063513,10.1158/1078-0432.CCR-24-3029,DLK1 Distinguishes Subsets of NF1-Associated Malignant Peripheral Nerve Sheath Tumors with Divergent Molecular Signatures.,,0.9,computational_tool,log-rank Mantel-Cox test,Computational Tool,,,,,
PMID:40063513,10.1158/1078-0432.CCR-24-3029,DLK1 Distinguishes Subsets of NF1-Associated Malignant Peripheral Nerve Sheath Tumors with Divergent Molecular Signatures.,,0.85,computational_tool,Kaplan-Meier plots,Computational Tool,,,,,
PMID:40063513,10.1158/1078-0432.CCR-24-3029,DLK1 Distinguishes Subsets of NF1-Associated Malignant Peripheral Nerve Sheath Tumors with Divergent Molecular Signatures.,,0.9,computational_tool,bulk RNA sequencing,Computational Tool,,,,,
PMID:40063513,10.1158/1078-0432.CCR-24-3029,DLK1 Distinguishes Subsets of NF1-Associated Malignant Peripheral Nerve Sheath Tumors with Divergent Molecular Signatures.,,0.9,computational_tool,whole exome sequencing,Computational Tool,,,,,
PMID:40063513,10.1158/1078-0432.CCR-24-3029,DLK1 Distinguishes Subsets of NF1-Associated Malignant Peripheral Nerve Sheath Tumors with Divergent Molecular Signatures.,,0.9,computational_tool,spatial transcriptomics profiling,Computational Tool,,,,,
PMID:40063513,10.1158/1078-0432.CCR-24-3029,DLK1 Distinguishes Subsets of NF1-Associated Malignant Peripheral Nerve Sheath Tumors with Divergent Molecular Signatures.,,0.85,clinical_assessment_tool,immunohistochemical staining,Clinical Assessment Tool,,,,,
PMID:34935315,10.1117/1.JBO.26.12.125001,Analysis of muscle tissue in vivo using fiber-optic autofluorescence and diffuse reflectance spectroscopy.,,0.95,animal_model,Nf1Prx1-/-,Animal Model,,,,,
PMID:34935315,10.1117/1.JBO.26.12.125001,Analysis of muscle tissue in vivo using fiber-optic autofluorescence and diffuse reflectance spectroscopy.,,0.9,animal_model,mdx,Animal Model,,,,,
PMID:34935315,10.1117/1.JBO.26.12.125001,Analysis of muscle tissue in vivo using fiber-optic autofluorescence and diffuse reflectance spectroscopy.,,0.85,animal_model,C57BL/6 mice,Animal Model,,,,,
PMID:34935315,10.1117/1.JBO.26.12.125001,Analysis of muscle tissue in vivo using fiber-optic autofluorescence and diffuse reflectance spectroscopy.,,0.9,animal_model,Nf1flox/flox,Animal Model,,,,,
PMID:34935315,10.1117/1.JBO.26.12.125001,Analysis of muscle tissue in vivo using fiber-optic autofluorescence and diffuse reflectance spectroscopy.,,0.9,animal_model,Prx1-Cre transgenic mice,Animal Model,,,,,
PMID:34935315,10.1117/1.JBO.26.12.125001,Analysis of muscle tissue in vivo using fiber-optic autofluorescence and diffuse reflectance spectroscopy.,,0.9,animal_model,B10 mdx,Animal Model,,,,,
PMID:34935315,10.1117/1.JBO.26.12.125001,Analysis of muscle tissue in vivo using fiber-optic autofluorescence and diffuse reflectance spectroscopy.,,0.85,computational_tool,MATLAB,Computational Tool,,,,,
PMID:34935315,10.1117/1.JBO.26.12.125001,Analysis of muscle tissue in vivo using fiber-optic autofluorescence and diffuse reflectance spectroscopy.,,0.8,computational_tool,Arduino,Computational Tool,,,,,
PMID:34935315,10.1117/1.JBO.26.12.125001,Analysis of muscle tissue in vivo using fiber-optic autofluorescence and diffuse reflectance spectroscopy.,,0.75,computational_tool,Leica CM1950 Clinical Cryostat,Computational Tool,,,,,
PMID:8582272,10.1242/dev.121.11.3583,Neurofibromin-deficient fibroblasts fail to form perineurium in vitro.,,0.9,animal_model,C57BL/6J mice,Animal Model,,,,,
PMID:8582272,10.1242/dev.121.11.3583,Neurofibromin-deficient fibroblasts fail to form perineurium in vitro.,,0.95,animal_model,Nf1 (+/-) mice,Animal Model,,,,,
PMID:8582272,10.1242/dev.121.11.3583,Neurofibromin-deficient fibroblasts fail to form perineurium in vitro.,,0.95,animal_model,Nf1 (-/-) embryos,Animal Model,,,,,
PMID:8582272,10.1242/dev.121.11.3583,Neurofibromin-deficient fibroblasts fail to form perineurium in vitro.,,0.8,genetic_reagent,Taq polymerase (Perkin-Elmer Cetus),Genetic Reagent,,,,,
PMID:8582272,10.1242/dev.121.11.3583,Neurofibromin-deficient fibroblasts fail to form perineurium in vitro.,,0.85,genetic_reagent,NeoTkp primer,Genetic Reagent,,,,,
PMID:8582272,10.1242/dev.121.11.3583,Neurofibromin-deficient fibroblasts fail to form perineurium in vitro.,,0.85,genetic_reagent,NF31a primer,Genetic Reagent,,,,,
PMID:8582272,10.1242/dev.121.11.3583,Neurofibromin-deficient fibroblasts fail to form perineurium in vitro.,,0.85,genetic_reagent,NF31b primer,Genetic Reagent,,,,,
PMID:8582272,10.1242/dev.121.11.3583,Neurofibromin-deficient fibroblasts fail to form perineurium in vitro.,,0.75,genetic_reagent,Leibovitz's L15 medium (Gibco),Genetic Reagent,,,,,
PMID:8582272,10.1242/dev.121.11.3583,Neurofibromin-deficient fibroblasts fail to form perineurium in vitro.,,0.75,genetic_reagent,"Dulbecco's Modified Eagle Medium (DMEM, Gibco)",Genetic Reagent,,,,,
PMID:8582272,10.1242/dev.121.11.3583,Neurofibromin-deficient fibroblasts fail to form perineurium in vitro.,,0.8,genetic_reagent,2.5S NGF (Harlan Bio-products),Genetic Reagent,,,,,
PMID:8582272,10.1242/dev.121.11.3583,Neurofibromin-deficient fibroblasts fail to form perineurium in vitro.,,0.8,genetic_reagent,"recombinant human glial growth factor (rhGGF2, Cambridge Neuroscience)",Genetic Reagent,,,,,
PMID:8582272,10.1242/dev.121.11.3583,Neurofibromin-deficient fibroblasts fail to form perineurium in vitro.,,0.8,computational_tool,JOEL-10 CX electron microscope,Computational Tool,,,,,
PMID:25329635,10.1371/journal.pgen.1004575,Genetic modifiers of neurofibromatosis type 1-associated café-au-lait macule count identified using multi-platform analysis.,,0.85,cell_line,lymphoblastoid cell lines,Cell Line,,,,,
PMID:25329635,10.1371/journal.pgen.1004575,Genetic modifiers of neurofibromatosis type 1-associated café-au-lait macule count identified using multi-platform analysis.,,0.9,computational_tool,HumanRef-8_v2 Sentrix BeadChips,Computational Tool,,,,,
PMID:25329635,10.1371/journal.pgen.1004575,Genetic modifiers of neurofibromatosis type 1-associated café-au-lait macule count identified using multi-platform analysis.,,0.85,computational_tool,Illumina BeadStation 500 scanner,Computational Tool,,,,,
PMID:25329635,10.1371/journal.pgen.1004575,Genetic modifiers of neurofibromatosis type 1-associated café-au-lait macule count identified using multi-platform analysis.,,0.8,computational_tool,BeadScan,Computational Tool,,,,,
PMID:25329635,10.1371/journal.pgen.1004575,Genetic modifiers of neurofibromatosis type 1-associated café-au-lait macule count identified using multi-platform analysis.,,0.8,computational_tool,BeadStudio,Computational Tool,,,,,
PMID:25329635,10.1371/journal.pgen.1004575,Genetic modifiers of neurofibromatosis type 1-associated café-au-lait macule count identified using multi-platform analysis.,,0.75,computational_tool,384-well microfluidic cards,Computational Tool,,,,,
PMID:25329635,10.1371/journal.pgen.1004575,Genetic modifiers of neurofibromatosis type 1-associated café-au-lait macule count identified using multi-platform analysis.,,0.85,computational_tool,PedCheck,Computational Tool,,,,,
PMID:25329635,10.1371/journal.pgen.1004575,Genetic modifiers of neurofibromatosis type 1-associated café-au-lait macule count identified using multi-platform analysis.,,0.85,computational_tool,PEDSTATS,Computational Tool,,,,,
PMID:25329635,10.1371/journal.pgen.1004575,Genetic modifiers of neurofibromatosis type 1-associated café-au-lait macule count identified using multi-platform analysis.,,0.9,computational_tool,TRAP (Tiled Regression Analysis Package),Computational Tool,,,,,
PMID:25329635,10.1371/journal.pgen.1004575,Genetic modifiers of neurofibromatosis type 1-associated café-au-lait macule count identified using multi-platform analysis.,,0.85,computational_tool,Illumina Human OmniQuad-1M SNP-arrays,Computational Tool,,,,,
PMID:25329635,10.1371/journal.pgen.1004575,Genetic modifiers of neurofibromatosis type 1-associated café-au-lait macule count identified using multi-platform analysis.,,0.9,computational_tool,GenomeStudio (v. 2010.2),Computational Tool,,,,,
PMID:25329635,10.1371/journal.pgen.1004575,Genetic modifiers of neurofibromatosis type 1-associated café-au-lait macule count identified using multi-platform analysis.,,0.85,computational_tool,Ion Ampliseq Designer v3.0,Computational Tool,,,,,
PMID:25329635,10.1371/journal.pgen.1004575,Genetic modifiers of neurofibromatosis type 1-associated café-au-lait macule count identified using multi-platform analysis.,,0.85,computational_tool,Ion Torrent PGM Sequencer,Computational Tool,,,,,
PMID:25329635,10.1371/journal.pgen.1004575,Genetic modifiers of neurofibromatosis type 1-associated café-au-lait macule count identified using multi-platform analysis.,,0.8,computational_tool,HaploReg,Computational Tool,,,,,
PMID:25329635,10.1371/journal.pgen.1004575,Genetic modifiers of neurofibromatosis type 1-associated café-au-lait macule count identified using multi-platform analysis.,,0.8,computational_tool,RegulomeDB,Computational Tool,,,,,
PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,0.95,animal_model,Nf1flox/flox;PostnCre mice,Animal Model,,,,,
PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,0.9,clinical_assessment_tool,NRS-11,Clinical Assessment Tool,,,,,
PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,0.9,clinical_assessment_tool,BPI-PI Scale,Clinical Assessment Tool,,,,,
PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,0.95,clinical_assessment_tool,PedsQL NF1 Module,Clinical Assessment Tool,,,,,
PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,0.9,cell_line,iPNF95.6,Cell Line,,,,,
PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,0.95,antibody,CD31 antibody (ab28364),Antibody,,,,,
PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,0.95,antibody,AXL antibody (ab227871),Antibody,,,,,
PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,0.95,antibody,pAXL antibody (Cat#5724),Antibody,,,,,
PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,0.95,antibody,AXL antibody (Cat#ab215205),Antibody,,,,,
PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,0.95,antibody,pAKT antibody (Cat #9271),Antibody,,,,,
PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,0.95,antibody,pGSK-3β antibody (Cat#9323),Antibody,,,,,
PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,0.95,antibody,pMEK1/2 antibody (Cat#9121),Antibody,,,,,
PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,0.95,antibody,GAPDH antibody (#CST-5174),Antibody,,,,,
PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,0.9,computational_tool,MaxQuant (version 1.6.10.43),Computational Tool,,,,,
PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,0.9,computational_tool,Perseus (version 1.6.10.50),Computational Tool,,,,,
PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,0.9,computational_tool,FlowJo Software (version 9.9.6),Computational Tool,,,,,
PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,0.9,computational_tool,ImageJ (version 1.47),Computational Tool,,,,,
PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,0.9,computational_tool,HALO Image Analysis Software (version 2.3),Computational Tool,,,,,
PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,0.85,clinical_assessment_tool,"Human AXL DuoSet ELISA kit (R&D Systems, DY154)",Clinical Assessment Tool,,,,,
PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,0.85,clinical_assessment_tool,"Mouse AXL DuoSet ELISA kit (R&D Systems, DY854)",Clinical Assessment Tool,,,,,
PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,0.8,clinical_assessment_tool,FragEL DNA Fragmentation Detection Kit (Sigma Aldrich #QIA21),Clinical Assessment Tool,,,,,
PMID:33442015,10.1038/s41591-020-01193-6,Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.,,0.8,clinical_assessment_tool,"Caspase 3/7 Glo activity (#G8093, Promega)",Clinical Assessment Tool,,,,,
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,0.9,animal_model,NG2-EYFP mice,Animal Model,,,,,
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,0.85,animal_model,C57Bl6/J mice,Animal Model,,,,,
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,0.9,antibody,"anti-CalbindinD-28K (rabbit polyclonal, 1:2000 Swant CB-38a)",Antibody,,,,,
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,0.9,antibody,anti-CalbindinD-28K (mouse monoclonal 1:1000 Sigma-Aldrich clone CB-955),Antibody,,,,,
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,0.9,antibody,"anti-Merlin (rabbit polyclonal antibody, A-19 sc-331)",Antibody,,,,,
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,0.9,antibody,"anti-Merlin (rabbit polyclonal antibody, C-18 sc-332)",Antibody,,,,,
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,0.9,antibody,"anti-Olig2 (mouse monoclonal antibody, 1:500; Millipore AB9610)",Antibody,,,,,
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,0.9,antibody,"anti-MBP (mouse monoclonal antibody, 1:500; Chemikon MAB384)",Antibody,,,,,
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,0.9,antibody,"anti-Merlin (HPA003097, 1:100, Atlas Antibodies)",Antibody,,,,,
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,0.9,antibody,"anti-GFP (A11122, 1:500, Thermo Fisher)",Antibody,,,,,
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,0.9,antibody,"anti Ki67 (15580, 1:500, Abcam)",Antibody,,,,,
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,0.9,antibody,"anti phospho-Histone H3 (pH3-Ser10, 06–570, 1:1000, Millipore)",Antibody,,,,,
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,0.9,antibody,"anti-NF2 clone C-18, 1:500, Santa Cruz",Antibody,,,,,
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,0.9,antibody,"anti-phospho S518-Merlin 1:1000, Abcam",Antibody,,,,,
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,0.9,antibody,"anti-cyclophilin B 1:4000, Abcam",Antibody,,,,,
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,0.9,cell_line,OLN93 mouse oligodendrocyte cell line,Cell Line,,,,,
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,0.95,cell_line,SC4-immortalized Nf2-/- primary Schwann cells,Cell Line,,,,,
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,0.9,cell_line,RT4-D6PT2 schwannoma cell line,Cell Line,,,,,
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,0.9,cell_line,TC620 human oligodendroglioma cell line,Cell Line,,,,,
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,0.9,genetic_reagent,pcNf2hflag,Genetic Reagent,,,,,
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,0.85,genetic_reagent,pcDNA3.1,Genetic Reagent,,,,,
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,0.9,computational_tool,XCELLigence Real Time Cell Analysis System,Computational Tool,,,,,
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,0.8,computational_tool,ImageJ,Computational Tool,,,,,
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,0.8,computational_tool,R,Computational Tool,,,,,
PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,0.85,cell_line,Normal human Schwann cells (NHSC),Cell Line,,,,,
PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,0.9,cell_line,MPNST cell lines,Cell Line,,,,,
PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,0.95,cell_line,MPNST 88-14 cells,Cell Line,,,,,
PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,0.95,cell_line,MPNST S462-TY cells,Cell Line,,,,,
PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,0.9,animal_model,athymic nude (nu/nu) mice,Animal Model,,,,,
PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,0.9,genetic_reagent,Ad-NF1-GRD,Genetic Reagent,,,,,
PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,0.85,genetic_reagent,Ad-GFP,Genetic Reagent,,,,,
PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,0.95,genetic_reagent,"mCherry tagged MAF (EX-Y2046-Lv111, GeneCopoeia)",Genetic Reagent,,,,,
PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,0.9,genetic_reagent,pLVX-Tight-Puro vector (GeneCopoeia),Genetic Reagent,,,,,
PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,0.9,genetic_reagent,pLVX-Tet-On doxycycline inducible vector (Clonetech),Genetic Reagent,,,,,
PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,0.9,genetic_reagent,AP-1 luciferase (Stratagene),Genetic Reagent,,,,,
PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,0.9,antibody,MAF antibody (Imgenex),Antibody,,,,,
PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,0.9,antibody,pS6 antibody (Cell Signaling),Antibody,,,,,
PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,0.9,antibody,pERK antibody (Cell Signaling),Antibody,,,,,
PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,0.9,antibody,DEPTOR antibody (Novus),Antibody,,,,,
PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,0.9,antibody,SOX9 antibody (Santa Cruz),Antibody,,,,,
PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,0.9,antibody,S100β antibody (Dako),Antibody,,,,,
PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,0.9,antibody,MBP antibody (Chemicon),Antibody,,,,,
PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,0.9,antibody,BLBP antibody (Millipore),Antibody,,,,,
PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,0.9,antibody,cleaved-caspase 3 antibody (Cell Signaling),Antibody,,,,,
PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,0.9,antibody,β-ACTIN antibody (Cell Signaling),Antibody,,,,,
PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,0.85,computational_tool,ImageJ software (NIH),Computational Tool,,,,,
PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,0.85,computational_tool,FlowJo software,Computational Tool,,,,,
PMID:33767727,10.3389/fgene.2021.603195,Molecular Diagnosis of Neurofibromatosis by Multigene Panel Testing.,,0.85,genetic_reagent,AxyPrep Blood Genomic DNA Miniprep Kit,Genetic Reagent,,,,,
PMID:33767727,10.3389/fgene.2021.603195,Molecular Diagnosis of Neurofibromatosis by Multigene Panel Testing.,,0.85,genetic_reagent,DNeasy Blood & Tissue Kit,Genetic Reagent,,,,,
PMID:33767727,10.3389/fgene.2021.603195,Molecular Diagnosis of Neurofibromatosis by Multigene Panel Testing.,,0.8,computational_tool,NanoDrop one spectrophotometer,Computational Tool,,,,,
PMID:33767727,10.3389/fgene.2021.603195,Molecular Diagnosis of Neurofibromatosis by Multigene Panel Testing.,,0.8,computational_tool,Qubit 2.0 Fluorometer,Computational Tool,,,,,
PMID:33767727,10.3389/fgene.2021.603195,Molecular Diagnosis of Neurofibromatosis by Multigene Panel Testing.,,0.85,genetic_reagent,Qubit dsDNA HS Assay Kit,Genetic Reagent,,,,,
PMID:33767727,10.3389/fgene.2021.603195,Molecular Diagnosis of Neurofibromatosis by Multigene Panel Testing.,,0.9,genetic_reagent,Roche NimbleGen Sequence Capture SeqCap EZ Library,Genetic Reagent,,,,,
PMID:33767727,10.3389/fgene.2021.603195,Molecular Diagnosis of Neurofibromatosis by Multigene Panel Testing.,,0.8,computational_tool,Covaris M220,Computational Tool,,,,,
PMID:33767727,10.3389/fgene.2021.603195,Molecular Diagnosis of Neurofibromatosis by Multigene Panel Testing.,,0.9,computational_tool,Illumina HiSeq X Ten System,Computational Tool,,,,,
PMID:33767727,10.3389/fgene.2021.603195,Molecular Diagnosis of Neurofibromatosis by Multigene Panel Testing.,,0.85,computational_tool,ABI PRISM 3730XL analyzer,Computational Tool,,,,,
PMID:33767727,10.3389/fgene.2021.603195,Molecular Diagnosis of Neurofibromatosis by Multigene Panel Testing.,,0.85,computational_tool,Primer 3.0,Computational Tool,,,,,
PMID:33767727,10.3389/fgene.2021.603195,Molecular Diagnosis of Neurofibromatosis by Multigene Panel Testing.,,0.85,antibody,S100,Antibody,,,,,
PMID:33767727,10.3389/fgene.2021.603195,Molecular Diagnosis of Neurofibromatosis by Multigene Panel Testing.,,0.85,antibody,CD34,Antibody,,,,,
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,0.85,animal_model,NOD/SCID mice,Animal Model,,,,,
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,0.9,cell_line,S462 cell line,Cell Line,,,,,
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,0.9,cell_line,2884 cell line,Cell Line,,,,,
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,0.9,cell_line,2885 cell line,Cell Line,,,,,
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,0.8,genetic_reagent,MLN8237,Genetic Reagent,,,,,
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,0.75,genetic_reagent,C1368,Genetic Reagent,,,,,
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,0.75,genetic_reagent,VX680,Genetic Reagent,,,,,
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,0.85,antibody,RHAMM antibody,Antibody,,,,,
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,0.85,antibody,TPX2 antibody,Antibody,,,,,
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,0.85,antibody,nestin antibody,Antibody,,,,,
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,0.85,antibody,Tuj1 antibody,Antibody,,,,,
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,0.85,antibody,β-actin antibody,Antibody,,,,,
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,0.85,antibody,AURKA antibody,Antibody,,,,,
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,0.85,antibody,phospho-AURKA (Thr288) antibody,Antibody,,,,,
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,0.85,antibody,p-histone H3 (Ser10) antibody,Antibody,,,,,
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,0.85,antibody,caspase 9 antibody,Antibody,,,,,
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,0.9,antibody,p-RHAMM (Thr703) polyclonal antibody,Antibody,,,,,
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,0.85,genetic_reagent,pLKO.1 plasmids,Genetic Reagent,,,,,
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,0.85,genetic_reagent,shRNA against RHAMM,Genetic Reagent,,,,,
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,0.85,genetic_reagent,shRNA against TPX2,Genetic Reagent,,,,,
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,0.8,computational_tool,Olympus FV10i confocal microscope,Computational Tool,,,,,
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,0.8,computational_tool,Applied Biosystems 7000 series machine,Computational Tool,,,,,
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,0.85,computational_tool,Feature Extraction 10.5,Computational Tool,,,,,
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,0.85,computational_tool,Agilent Genomic Workbench 6.5,Computational Tool,,,,,
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,0.85,computational_tool,Image J software,Computational Tool,,,,,
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,0.85,computational_tool,CellQuestPro software,Computational Tool,,,,,
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,0.85,advanced_cellular_model,S462 spheres,Advanced Cellular Model,,,,,
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,animal_model,Lats1/2-mut mice,Animal Model,,,,,
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,animal_model,NPE-mutant mice,Animal Model,,,,,
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.85,animal_model,CAG-tdTomato reporter mice,Animal Model,,,,,
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.85,animal_model,CAG-CAT-EGFP reporter mice,Animal Model,,,,,
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.85,animal_model,NBSGW mice,Animal Model,,,,,
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.85,animal_model,NCR nude mice,Animal Model,,,,,
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,cell_line,hTERT NF1 ipn02.3 2λ,Cell Line,,,,,
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,cell_line,ipn95.11bC,Cell Line,,,,,
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,cell_line,sNF96.2,Cell Line,,,,,
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,cell_line,MPNST642,Cell Line,,,,,
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,cell_line,T265,Cell Line,,,,,
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,cell_line,STS26T,Cell Line,,,,,
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,antibody,"PDGFRβ antibody (Abcam, ab32570)",Antibody,,,,,
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,antibody,"α-SMA antibody (Sigma-Aldrich, A2547)",Antibody,,,,,
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,antibody,"IBA1 antibody (Wako Chemicals, 019-19741)",Antibody,,,,,
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,antibody,"CD3 antibody (Bio-Rad, MCA1477)",Antibody,,,,,
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,antibody,"GLUT1 antibody (Abcam, ab652)",Antibody,,,,,
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,antibody,"cleaved caspase-3 antibody (Cell Signaling Technology, #9661)",Antibody,,,,,
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,antibody,"BrdU antibody (Abcam, ab6326)",Antibody,,,,,
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,antibody,"VEGFA antibody (ABclonal, A0280)",Antibody,,,,,
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,antibody,"ALDH1A1 antibody (Proteintech, 15910-1-AP)",Antibody,,,,,
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,antibody,"ZEB1 antibody (ABclonal, A5600)",Antibody,,,,,
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,antibody,"IGFBP2 antibody (Cell Signaling Technology, #3922)",Antibody,,,,,
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,antibody,"Nestin antibody (Millipore, MAB353)",Antibody,,,,,
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,antibody,"EYA4 antibody (Thermo Fisher Scientific, PA5-52113)",Antibody,,,,,
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,antibody,"SOX2 antibody (Santa Cruz Biotechnology, sc-17320)",Antibody,,,,,
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,antibody,"YAP/TAZ antibody (Cell Signaling Technology, #8418)",Antibody,,,,,
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,genetic_reagent,"ZEB1 siRNA (Sigma-Aldrich, SASI_Hs02_00330526)",Genetic Reagent,,,,,
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,genetic_reagent,"ALDH1A1 siRNA (Sigma-Aldrich, SASI_Hs01_00244055)",Genetic Reagent,,,,,
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.85,genetic_reagent,ZEB1 shRNA lentivirus,Genetic Reagent,,,,,
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,computational_tool,Drop-seq tools (version 1.12),Computational Tool,,,,,
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,computational_tool,Cellranger v5.0.1,Computational Tool,,,,,
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,computational_tool,Seurat (version 3.1.0),Computational Tool,,,,,
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.85,computational_tool,scREF,Computational Tool,,,,,
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,computational_tool,CIBERSORTx,Computational Tool,,,,,
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,computational_tool,inferCNV,Computational Tool,,,,,
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,computational_tool,VECTOR,Computational Tool,,,,,
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,computational_tool,Slingshot,Computational Tool,,,,,
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,computational_tool,CytoTRACE version 0.3.3,Computational Tool,,,,,
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,computational_tool,ArchR,Computational Tool,,,,,
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,computational_tool,CellChat,Computational Tool,,,,,
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.9,computational_tool,DGIdb (version 3.0.2),Computational Tool,,,,,
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,0.85,computational_tool,OmicsNet,Computational Tool,,,,,
PMID:21551250,10.1158/0008-5472.CAN-10-4577,Susceptible stages in Schwann cells for NF1-associated plexiform neurofibroma development.,,0.9,animal_model,NF1 flox/− mice,Animal Model,,,,,
PMID:21551250,10.1158/0008-5472.CAN-10-4577,Susceptible stages in Schwann cells for NF1-associated plexiform neurofibroma development.,,0.85,animal_model,PLPCre-ERT2 transgenic mice,Animal Model,,,,,
PMID:21551250,10.1158/0008-5472.CAN-10-4577,Susceptible stages in Schwann cells for NF1-associated plexiform neurofibroma development.,,0.85,animal_model,ROSA26R,Animal Model,,,,,
PMID:21551250,10.1158/0008-5472.CAN-10-4577,Susceptible stages in Schwann cells for NF1-associated plexiform neurofibroma development.,,0.9,antibody,GAP43 antibody,Antibody,,,,,
PMID:21551250,10.1158/0008-5472.CAN-10-4577,Susceptible stages in Schwann cells for NF1-associated plexiform neurofibroma development.,,0.9,antibody,S100β antibody,Antibody,,,,,
PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,,0.9,cell_line,ipn97.4 immortalized human Schwann cells,Cell Line,,,,,
PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,,0.85,genetic_reagent,CRISPR Cas9,Genetic Reagent,,,,,
PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,,0.9,computational_tool,Trim Galore (version 0.6.10),Computational Tool,,,,,
PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,,0.9,computational_tool,Broad's Genome Analysis ToolKit (version 4.6.0),Computational Tool,,,,,
PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,,0.9,computational_tool,BWA (version 0.7.17-r1188),Computational Tool,,,,,
PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,,0.9,computational_tool,Picard tools (version 3.2.0),Computational Tool,,,,,
PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,,0.85,computational_tool,Delly,Computational Tool,,,,,
PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,,0.85,computational_tool,Manta,Computational Tool,,,,,
PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,,0.9,genetic_reagent,mNf1 cDNA (GeneCopoeia NM_010897.2),Genetic Reagent,,,,,
PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,,0.85,genetic_reagent,StepTactin XT System,Genetic Reagent,,,,,
PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,,0.8,genetic_reagent,"M-PER™ Mammalian Protein Extraction Reagent (Thermo Fisher Scientific, Cat.# 78501)",Genetic Reagent,,,,,
PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,,0.8,genetic_reagent,"Pierce BCA Protein Assay Kit (Thermo Fisher Scientific, Cat.# PI23225)",Genetic Reagent,,,,,
PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,,0.85,computational_tool,Thermo Q Exactive HFx mass spectrometer,Computational Tool,,,,,
PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,,0.85,computational_tool,Thermo Velos Pro Orbitrap mass spectrometer,Computational Tool,,,,,
PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,,0.9,computational_tool,ReAdW v. 3.5.1,Computational Tool,,,,,
PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,,0.9,computational_tool,MzXML2Search (included in TPP v. 3.5),Computational Tool,,,,,
PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,,0.85,computational_tool,MASCOT,Computational Tool,,,,,
PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,,0.85,computational_tool,SEQUEST,Computational Tool,,,,,
PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,,0.9,computational_tool,"Scaffold (Protein Sciences, Portland Oregon)",Computational Tool,,,,,
PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,,0.9,computational_tool,Human Protein Atlas (proteinatlas.org),Computational Tool,,,,,
PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,,0.9,computational_tool,QIAGEN Ingenuity Pathway Analysis (IPA),Computational Tool,,,,,
PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,,0.9,antibody,neurofibromin antibody (Cell Signaling Technologies Cat. #: 14623 S),Antibody,,,,,
PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,,0.85,computational_tool,O2K system (Oroboros Instruments),Computational Tool,,,,,
PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,0.95,animal_model,NF1 R1947/+ minipigs,Animal Model,,,,,
PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,0.85,genetic_reagent,TALENs,Genetic Reagent,,,,,
PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,0.8,computational_tool,Neon Transfection System,Computational Tool,,,,,
PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,0.75,genetic_reagent,DNeasy blood and tissue kit,Genetic Reagent,,,,,
PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,0.9,antibody,p75 NGFR antibody,Antibody,,,,,
PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,0.85,computational_tool,CytoFLEX flow cytometer,Computational Tool,,,,,
PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,0.85,computational_tool,FlowJo software,Computational Tool,,,,,
PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,0.75,genetic_reagent,RNeasy mini kit,Genetic Reagent,,,,,
PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,0.85,computational_tool,Bio-Rad CFX96 Real-Time System,Computational Tool,,,,,
PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,0.85,computational_tool,Illumina NovaSeq 6000,Computational Tool,,,,,
PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,0.9,computational_tool,HISAT2,Computational Tool,,,,,
PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,0.9,computational_tool,StringTie,Computational Tool,,,,,
PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,0.85,computational_tool,R,Computational Tool,,,,,
PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,0.85,computational_tool,tidyverse,Computational Tool,,,,,
PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,0.85,computational_tool,Li-Cor Odyssey Fc Imaging System,Computational Tool,,,,,
PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,0.85,computational_tool,Cytation 5 cell imaging reader,Computational Tool,,,,,
PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,0.8,genetic_reagent,alamarBlue cell viability assay,Genetic Reagent,,,,,
PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,0.9,genetic_reagent,Gentamicin,Genetic Reagent,,,,,
PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,0.9,genetic_reagent,G418,Genetic Reagent,,,,,
PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,0.9,genetic_reagent,Ataluren,Genetic Reagent,,,,,
PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,0.95,genetic_reagent,NF1 DLR plasmid,Genetic Reagent,,,,,
PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,0.85,genetic_reagent,PBSB transposon vector,Genetic Reagent,,,,,
PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,0.9,genetic_reagent,UPF1 siRNA,Genetic Reagent,,,,,
PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,0.85,computational_tool,GraphPad Prism V9,Computational Tool,,,,,
PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,0.9,cell_line,Schwann cells,Cell Line,,,,,
PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,0.9,animal_model,Nf1fl/fl mice,Animal Model,,,,,
PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,0.9,animal_model,OPG Nf1fl/mut (Nf1+/−) mice,Animal Model,,,,,
PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,0.85,animal_model,Thy1::ChR2-YFP mice (line 20),Animal Model,,,,,
PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,0.85,animal_model,Nlgn3KO mice,Animal Model,,,,,
PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,0.8,cell_line,optic glioma cells,Cell Line,,,,,
PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,0.9,antibody,mouse anti-Ki67 (BD Biosciences 556003),Antibody,,,,,
PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,0.9,antibody,rabbit anti-CD8 (Cell Signaling Technology 98941T),Antibody,,,,,
PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,0.9,antibody,goat anti-PDGFRα (R&D Systems AF1062),Antibody,,,,,
PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,0.9,antibody,rabbit anti-S100β (Abcam ab52642),Antibody,,,,,
PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,0.9,antibody,rabbit anti-IBA1 (Abcam ab178846),Antibody,,,,,
PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,0.9,antibody,mouse anti-BRN3A (Santa Cruz Biotechnology sc-8429),Antibody,,,,,
PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,0.9,antibody,rabbit anti-NLGN3 (Novus NBP1-90080),Antibody,,,,,
PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,0.9,antibody,rabbit anti-β-actin (Cell Signaling 4970),Antibody,,,,,
PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,0.9,antibody,rabbit anti-ADAM10 (Abcam ab124695),Antibody,,,,,
PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,0.9,antibody,rabbit anti-cleaved caspase-3 (R&D Systems MAB835),Antibody,,,,,
PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,0.9,antibody,rabbit anti-caspase-3 (Cell Signaling 9662),Antibody,,,,,
PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,0.8,genetic_reagent,Click-iT EdU Alexa Fluor 594 imaging kit (Thermo Fisher Scientific C10339),Genetic Reagent,,,,,
PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,0.8,computational_tool,Celeris ERG stimulator (Diagnosys),Computational Tool,,,,,
PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,0.9,computational_tool,Partek Flow software (v.9.0),Computational Tool,,,,,
PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,0.9,computational_tool,STAR (v.2.7.3a),Computational Tool,,,,,
PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,0.85,computational_tool,DESeq2,Computational Tool,,,,,
PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,0.9,computational_tool,ImageJ (v.2.0.0),Computational Tool,,,,,
PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,0.9,computational_tool,Cell Profiler (v.3.1.9),Computational Tool,,,,,
PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,0.9,computational_tool,Stereo Investigator software (mbfbioscience v2019),Computational Tool,,,,,
PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,0.9,computational_tool,Image Lab software (v.6),Computational Tool,,,,,
PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,0.9,computational_tool,Image Studio Lite (v.5.0.21),Computational Tool,,,,,
PMID:21949590,10.2478/v10134-010-0025-8,ALTERED CALCIUM CURRENTS AND AXONAL GROWTH IN Nf1 HAPLOINSUFFICIENT MICE.,,0.95,animal_model,Nf1+/- mice,Animal Model,,,,,
PMID:21949590,10.2478/v10134-010-0025-8,ALTERED CALCIUM CURRENTS AND AXONAL GROWTH IN Nf1 HAPLOINSUFFICIENT MICE.,,0.9,animal_model,C57BL/6J,Animal Model,,,,,
PMID:21949590,10.2478/v10134-010-0025-8,ALTERED CALCIUM CURRENTS AND AXONAL GROWTH IN Nf1 HAPLOINSUFFICIENT MICE.,,0.85,computational_tool,EPC 10 Amplifier,Computational Tool,,,,,
PMID:21949590,10.2478/v10134-010-0025-8,ALTERED CALCIUM CURRENTS AND AXONAL GROWTH IN Nf1 HAPLOINSUFFICIENT MICE.,,0.8,computational_tool,P-97 electrode puller,Computational Tool,,,,,
PMID:21949590,10.2478/v10134-010-0025-8,ALTERED CALCIUM CURRENTS AND AXONAL GROWTH IN Nf1 HAPLOINSUFFICIENT MICE.,,0.85,computational_tool,Fitmaster,Computational Tool,,,,,
PMID:21949590,10.2478/v10134-010-0025-8,ALTERED CALCIUM CURRENTS AND AXONAL GROWTH IN Nf1 HAPLOINSUFFICIENT MICE.,,0.85,computational_tool,origin8.1,Computational Tool,,,,,
PMID:21949590,10.2478/v10134-010-0025-8,ALTERED CALCIUM CURRENTS AND AXONAL GROWTH IN Nf1 HAPLOINSUFFICIENT MICE.,,0.9,genetic_reagent,Amplex Red glutamic acid/glutamate oxidase assay kit,Genetic Reagent,,,,,
PMID:21949590,10.2478/v10134-010-0025-8,ALTERED CALCIUM CURRENTS AND AXONAL GROWTH IN Nf1 HAPLOINSUFFICIENT MICE.,,0.85,computational_tool,Victor 3 V multilabel plate reader,Computational Tool,,,,,
PMID:21949590,10.2478/v10134-010-0025-8,ALTERED CALCIUM CURRENTS AND AXONAL GROWTH IN Nf1 HAPLOINSUFFICIENT MICE.,,0.85,antibody,tau 1 antibodies,Antibody,,,,,
PMID:21949590,10.2478/v10134-010-0025-8,ALTERED CALCIUM CURRENTS AND AXONAL GROWTH IN Nf1 HAPLOINSUFFICIENT MICE.,,0.9,genetic_reagent,EGFP,Genetic Reagent,,,,,
PMID:21949590,10.2478/v10134-010-0025-8,ALTERED CALCIUM CURRENTS AND AXONAL GROWTH IN Nf1 HAPLOINSUFFICIENT MICE.,,0.85,genetic_reagent,Lipofectamine,Genetic Reagent,,,,,
PMID:21949590,10.2478/v10134-010-0025-8,ALTERED CALCIUM CURRENTS AND AXONAL GROWTH IN Nf1 HAPLOINSUFFICIENT MICE.,,0.9,computational_tool,Nikon Elements software,Computational Tool,,,,,
PMID:21949590,10.2478/v10134-010-0025-8,ALTERED CALCIUM CURRENTS AND AXONAL GROWTH IN Nf1 HAPLOINSUFFICIENT MICE.,,0.9,computational_tool,ImageJ,Computational Tool,,,,,
PMID:21949590,10.2478/v10134-010-0025-8,ALTERED CALCIUM CURRENTS AND AXONAL GROWTH IN Nf1 HAPLOINSUFFICIENT MICE.,,0.85,computational_tool,automated Sholl analysis plugin,Computational Tool,,,,,
PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,0.85,genetic_reagent,DNeasy Blood and Tissue Kit,Genetic Reagent,,,,,
PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,0.85,genetic_reagent,RNeasy Mini Kit,Genetic Reagent,,,,,
PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,0.9,computational_tool,Illumina Infinium MethylationEPIC BeadChip array,Computational Tool,,,,,
PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,0.85,computational_tool,minfi package,Computational Tool,,,,,
PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,0.85,computational_tool,ConsensusClusterPlus package,Computational Tool,,,,,
PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,0.85,computational_tool,limma,Computational Tool,,,,,
PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,0.9,computational_tool,BWA-MEM v 0.7.12,Computational Tool,,,,,
PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,0.9,computational_tool,GATK v3.6.0,Computational Tool,,,,,
PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,0.9,computational_tool,Mutect V1.1.6,Computational Tool,,,,,
PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,0.9,computational_tool,Strelka v1.0.13,Computational Tool,,,,,
PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,0.9,computational_tool,STAR aligner (v.2.6.0),Computational Tool,,,,,
PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,0.85,computational_tool,edgeR,Computational Tool,,,,,
PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,0.9,computational_tool,FusionCatcher v1.1.0,Computational Tool,,,,,
PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,0.85,computational_tool,CellRanger,Computational Tool,,,,,
PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,0.9,computational_tool,Seurat version 3.0,Computational Tool,,,,,
PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,0.85,computational_tool,Monocle2,Computational Tool,,,,,
PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,0.9,computational_tool,inferCNV (v.1.1.1),Computational Tool,,,,,
PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,0.9,cell_line,HSC1λ,Cell Line,,,,,
PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,0.9,cell_line,ipNF06.2A,Cell Line,,,,,
PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,0.9,cell_line,STS-26T,Cell Line,,,,,
PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,0.9,cell_line,S462,Cell Line,,,,,
PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,0.9,cell_line,S462TY,Cell Line,,,,,
PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,0.9,cell_line,T265,Cell Line,,,,,
PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,0.9,genetic_reagent,pX330,Genetic Reagent,,,,,
PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,0.9,antibody,"B-Actin antibody (Cat #8457S, Cell Signaling Technologies)",Antibody,,,,,
PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,0.9,antibody,"Vinculin antibody (Cat #V9264, Sigma Aldrich)",Antibody,,,,,
PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,0.9,antibody,"PTCH1 antibody (Cat#MAB41051, R&D systems)",Antibody,,,,,
PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,0.9,antibody,"APC antibody (Cat #15270, Abcam)",Antibody,,,,,
PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,0.9,animal_model,NOD-Rag1 null IL2rg mice,Animal Model,,,,,
PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,0.9,animal_model,NOD-SCID-Prkdc scid mice,Animal Model,,,,,
PMID:25772366,10.1016/j.celrep.2015.02.041,Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,,0.9,animal_model,Nf1 flox/flox,Animal Model,,,,,
PMID:25772366,10.1016/j.celrep.2015.02.041,Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,,0.9,animal_model,Nf1 +/−,Animal Model,,,,,
PMID:25772366,10.1016/j.celrep.2015.02.041,Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,,0.9,animal_model,Nf1 +/− GFAP CKO,Animal Model,,,,,
PMID:25772366,10.1016/j.celrep.2015.02.041,Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,,0.9,animal_model,B6.Cg/NTac-Foxn1nu NE10,Animal Model,,,,,
PMID:25772366,10.1016/j.celrep.2015.02.041,Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,,0.85,genetic_reagent,Ad5-LacZ,Genetic Reagent,,,,,
PMID:25772366,10.1016/j.celrep.2015.02.041,Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,,0.85,genetic_reagent,Ad5-Cre,Genetic Reagent,,,,,
PMID:25772366,10.1016/j.celrep.2015.02.041,Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,,0.85,genetic_reagent,Abcg1 shRNA,Genetic Reagent,,,,,
PMID:25772366,10.1016/j.celrep.2015.02.041,Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,,0.8,genetic_reagent,pLKO.1,Genetic Reagent,,,,,
PMID:25772366,10.1016/j.celrep.2015.02.041,Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,,0.85,antibody,Tuj-1,Antibody,,,,,
PMID:25772366,10.1016/j.celrep.2015.02.041,Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,,0.85,antibody,O4,Antibody,,,,,
PMID:25772366,10.1016/j.celrep.2015.02.041,Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,,0.85,antibody,GFAP,Antibody,,,,,
PMID:25772366,10.1016/j.celrep.2015.02.041,Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,,0.9,computational_tool,Affymetrix GeneChip Mouse Genome 430 2.0 Array,Computational Tool,,,,,
PMID:25772366,10.1016/j.celrep.2015.02.041,Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,,0.9,computational_tool,Partex Genomics Suite Version 6.6 beta,Computational Tool,,,,,
PMID:25772366,10.1016/j.celrep.2015.02.041,Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,,0.8,advanced_cellular_model,optic glioma neurospheres,Advanced Cellular Model,,,,,
PMID:25772366,10.1016/j.celrep.2015.02.041,Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,,0.8,cell_line,TVZ NSCs,Cell Line,,,,,
PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,0.9,cell_line,iHSC1λ,Cell Line,,,,,
PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,0.9,cell_line,iHSC2λ,Cell Line,,,,,
PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,0.85,cell_line,S462,Cell Line,,,,,
PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,0.85,cell_line,S462-TY,Cell Line,,,,,
PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,0.85,cell_line,ST8814,Cell Line,,,,,
PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,0.85,cell_line,T265,Cell Line,,,,,
PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,0.85,cell_line,STS-26T,Cell Line,,,,,
PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,0.9,antibody,β-catenin antibody (Cell Signaling),Antibody,,,,,
PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,0.9,antibody,activated β-catenin antibody (Cell Signaling),Antibody,,,,,
PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,0.9,antibody,total β-catenin antibody (Cell Signaling),Antibody,,,,,
PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,0.9,antibody,GSK3B antibody (Cell Signaling),Antibody,,,,,
PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,0.9,antibody,AXIN1 antibody (Cell Signaling),Antibody,,,,,
PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,0.9,antibody,GAPDH antibody (Cell Signaling),Antibody,,,,,
PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,0.9,antibody,"CCND1 (SP4) monoclonal antibody (Neomarkers, Thermo Scientific)",Antibody,,,,,
PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,0.9,antibody,β-catenin (6B3) monoclonal antibody (Cell Signaling),Antibody,,,,,
PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,0.85,animal_model,Foxn1 nu/nu mice (Charles Rivers Laboratory),Animal Model,,,,,
PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,0.85,genetic_reagent,GSK3B shRNA (OpenBiosystems),Genetic Reagent,,,,,
PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,0.85,genetic_reagent,AXIN1 shRNA (OpenBiosystems),Genetic Reagent,,,,,
PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,0.85,genetic_reagent,CTNNB1 shRNA (OpenBiosystems),Genetic Reagent,,,,,
PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,0.85,genetic_reagent,TNKS shRNA (OpenBiosystems),Genetic Reagent,,,,,
PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,0.85,genetic_reagent,RSPO2 shRNA (OpenBiosystems),Genetic Reagent,,,,,
PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,0.85,genetic_reagent,CTNNB1 S33Y overexpression construct,Genetic Reagent,,,,,
PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,0.85,genetic_reagent,GSK3B overexpression construct,Genetic Reagent,,,,,
PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,0.8,computational_tool,ImageJ,Computational Tool,,,,,
PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,0.8,computational_tool,pheatmap package,Computational Tool,,,,,
PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,0.8,computational_tool,Limma package,Computational Tool,,,,,
PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,0.8,computational_tool,GeneSpring GXv7.3.1,Computational Tool,,,,,
PMID:23535903,10.1158/2159-8290.CD-13-0081,"Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,0.8,computational_tool,CalcuSyn Version 2.1,Computational Tool,,,,,
PMID:38173515,10.1016/j.heliyon.2023.e23445,Development of a semi-automatic segmentation technique based on mean magnetic resonance imaging intensity thresholding for volumetric quantification of plexiform neurofibromas.,,0.85,computational_tool,"Matlab script (Version 9.9.0, Natick, MA)",Computational Tool,,,,,
PMID:38173515,10.1016/j.heliyon.2023.e23445,Development of a semi-automatic segmentation technique based on mean magnetic resonance imaging intensity thresholding for volumetric quantification of plexiform neurofibromas.,,0.8,computational_tool,FSLeyes,Computational Tool,,,,,
PMID:38173515,10.1016/j.heliyon.2023.e23445,Development of a semi-automatic segmentation technique based on mean magnetic resonance imaging intensity thresholding for volumetric quantification of plexiform neurofibromas.,,0.9,computational_tool,SSTMean,Computational Tool,,,,,
PMID:38173515,10.1016/j.heliyon.2023.e23445,Development of a semi-automatic segmentation technique based on mean magnetic resonance imaging intensity thresholding for volumetric quantification of plexiform neurofibromas.,,0.85,computational_tool,SSTMini,Computational Tool,,,,,
PMID:22901811,10.1016/j.cell.2012.06.034,ERK inhibition rescues defects in fate specification of Nf1-deficient neural progenitors and brain abnormalities.,,0.9,genetic_reagent,hGFAP-cre,Genetic Reagent,,,,,
PMID:22901811,10.1016/j.cell.2012.06.034,ERK inhibition rescues defects in fate specification of Nf1-deficient neural progenitors and brain abnormalities.,,0.95,genetic_reagent,Nf1 flox,Genetic Reagent,,,,,
PMID:22901811,10.1016/j.cell.2012.06.034,ERK inhibition rescues defects in fate specification of Nf1-deficient neural progenitors and brain abnormalities.,,0.9,genetic_reagent,Nf1 KO,Genetic Reagent,,,,,
PMID:22901811,10.1016/j.cell.2012.06.034,ERK inhibition rescues defects in fate specification of Nf1-deficient neural progenitors and brain abnormalities.,,0.9,genetic_reagent,Nestin-cre ER,Genetic Reagent,,,,,
PMID:22901811,10.1016/j.cell.2012.06.034,ERK inhibition rescues defects in fate specification of Nf1-deficient neural progenitors and brain abnormalities.,,0.85,genetic_reagent,R26 LacZR,Genetic Reagent,,,,,
PMID:22901811,10.1016/j.cell.2012.06.034,ERK inhibition rescues defects in fate specification of Nf1-deficient neural progenitors and brain abnormalities.,,0.95,animal_model,Nf1 hGFAP CKO,Animal Model,,,,,
PMID:22901811,10.1016/j.cell.2012.06.034,ERK inhibition rescues defects in fate specification of Nf1-deficient neural progenitors and brain abnormalities.,,0.9,animal_model,Nf1 NcreER CKO,Animal Model,,,,,
PMID:22901811,10.1016/j.cell.2012.06.034,ERK inhibition rescues defects in fate specification of Nf1-deficient neural progenitors and brain abnormalities.,,0.9,genetic_reagent,PD0325901,Genetic Reagent,,,,,
PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,0.85,cell_line,HeLa cells,Cell Line,,,,,
PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,0.85,cell_line,MDA-MB-231 cells,Cell Line,,,,,
PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,0.95,cell_line,S462 cells,Cell Line,,,,,
PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,0.95,cell_line,PN 04.4 cells,Cell Line,,,,,
PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,0.85,cell_line,4T1 cells,Cell Line,,,,,
PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,0.85,cell_line,CT26 cells,Cell Line,,,,,
PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,0.85,cell_line,RAW 264.7 cells,Cell Line,,,,,
PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,0.85,cell_line,C2C12 cells,Cell Line,,,,,
PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,0.85,cell_line,COLO 741 cells,Cell Line,,,,,
PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,0.85,cell_line,MEC1 cells,Cell Line,,,,,
PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,0.95,antibody,"anti-HK2 (sc-6521, Santa Cruz)",Antibody,,,,,
PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,0.95,antibody,"anti-MPP2 (ab92536, Abcam)",Antibody,,,,,
PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,0.95,antibody,"anti-GAPDH (#2118, Cell Signaling)",Antibody,,,,,
PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,0.95,antibody,"ATP5A (ab14748, Abcam)",Antibody,,,,,
PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,0.95,antibody,"anti-UQCRC2 (ab14745, Abcam)",Antibody,,,,,
PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,0.95,antibody,"anti-MMP9 (ab137867, Abcam)",Antibody,,,,,
PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,0.95,antibody,"TOM20 (sc-11415, Santa Cruz)",Antibody,,,,,
PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,0.95,antibody,"rabbit monoclonal anti-HK2 (H.738.7, Thermo Scientific)",Antibody,,,,,
PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,0.95,antibody,"mouse monoclonal anti-TOM20 (sc-17764, Santa Cruz)",Antibody,,,,,
PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,0.85,animal_model,Balb/c mice,Animal Model,,,,,
PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,0.85,computational_tool,ImageJ,Computational Tool,,,,,
PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,0.9,genetic_reagent,"Human HK2 recombinant protein (HXK0703, ATGEN)",Genetic Reagent,,,,,
PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,0.9,genetic_reagent,D4ER Ca2+ probe,Genetic Reagent,,,,,
PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,0.9,genetic_reagent,GCAMP6f,Genetic Reagent,,,,,
PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,0.9,genetic_reagent,mit-Aeqmut,Genetic Reagent,,,,,
PMID:32383545,10.15252/embr.201949117,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,0.9,genetic_reagent,GFP-PHD,Genetic Reagent,,,,,
PMID:34464388,10.1371/journal.pmed.1003734,Cell-free DNA ultra-low-pass whole genome sequencing to distinguish malignant peripheral nerve sheath tumor (MPNST) from its benign precursor lesion: A cross-sectional study.,,0.85,genetic_reagent,QIAamp Circulating Nucleic Acid kit,Genetic Reagent,,,,,
PMID:34464388,10.1371/journal.pmed.1003734,Cell-free DNA ultra-low-pass whole genome sequencing to distinguish malignant peripheral nerve sheath tumor (MPNST) from its benign precursor lesion: A cross-sectional study.,,0.85,genetic_reagent,DNeasy Blood and Tissue kit,Genetic Reagent,,,,,
PMID:34464388,10.1371/journal.pmed.1003734,Cell-free DNA ultra-low-pass whole genome sequencing to distinguish malignant peripheral nerve sheath tumor (MPNST) from its benign precursor lesion: A cross-sectional study.,,0.85,genetic_reagent,PAXgene Blood DNA tubes and kit,Genetic Reagent,,,,,
PMID:34464388,10.1371/journal.pmed.1003734,Cell-free DNA ultra-low-pass whole genome sequencing to distinguish malignant peripheral nerve sheath tumor (MPNST) from its benign precursor lesion: A cross-sectional study.,,0.85,genetic_reagent,AllPrep DNA/RNA FFPE kit,Genetic Reagent,,,,,
PMID:34464388,10.1371/journal.pmed.1003734,Cell-free DNA ultra-low-pass whole genome sequencing to distinguish malignant peripheral nerve sheath tumor (MPNST) from its benign precursor lesion: A cross-sectional study.,,0.85,genetic_reagent,TruSeq Nano,Genetic Reagent,,,,,
PMID:34464388,10.1371/journal.pmed.1003734,Cell-free DNA ultra-low-pass whole genome sequencing to distinguish malignant peripheral nerve sheath tumor (MPNST) from its benign precursor lesion: A cross-sectional study.,,0.85,genetic_reagent,Kapa HyperPrep,Genetic Reagent,,,,,
PMID:34464388,10.1371/journal.pmed.1003734,Cell-free DNA ultra-low-pass whole genome sequencing to distinguish malignant peripheral nerve sheath tumor (MPNST) from its benign precursor lesion: A cross-sectional study.,,0.9,computational_tool,fastp v.0.2,Computational Tool,,,,,
PMID:34464388,10.1371/journal.pmed.1003734,Cell-free DNA ultra-low-pass whole genome sequencing to distinguish malignant peripheral nerve sheath tumor (MPNST) from its benign precursor lesion: A cross-sectional study.,,0.9,computational_tool,BWA v.0.7.17,Computational Tool,,,,,
PMID:34464388,10.1371/journal.pmed.1003734,Cell-free DNA ultra-low-pass whole genome sequencing to distinguish malignant peripheral nerve sheath tumor (MPNST) from its benign precursor lesion: A cross-sectional study.,,0.9,computational_tool,Samtools v.1.7,Computational Tool,,,,,
PMID:34464388,10.1371/journal.pmed.1003734,Cell-free DNA ultra-low-pass whole genome sequencing to distinguish malignant peripheral nerve sheath tumor (MPNST) from its benign precursor lesion: A cross-sectional study.,,0.85,computational_tool,MosDepth,Computational Tool,,,,,
PMID:34464388,10.1371/journal.pmed.1003734,Cell-free DNA ultra-low-pass whole genome sequencing to distinguish malignant peripheral nerve sheath tumor (MPNST) from its benign precursor lesion: A cross-sectional study.,,0.95,computational_tool,ichorCNA tool (Broad v.0.2.0),Computational Tool,,,,,
PMID:34464388,10.1371/journal.pmed.1003734,Cell-free DNA ultra-low-pass whole genome sequencing to distinguish malignant peripheral nerve sheath tumor (MPNST) from its benign precursor lesion: A cross-sectional study.,,0.9,computational_tool,deepTools bamPEFragmentSize,Computational Tool,,,,,
PMID:34464388,10.1371/journal.pmed.1003734,Cell-free DNA ultra-low-pass whole genome sequencing to distinguish malignant peripheral nerve sheath tumor (MPNST) from its benign precursor lesion: A cross-sectional study.,,0.9,computational_tool,ultra-low-pass whole genome sequencing (ULP-WGS),Computational Tool,,,,,
PMID:34464388,10.1371/journal.pmed.1003734,Cell-free DNA ultra-low-pass whole genome sequencing to distinguish malignant peripheral nerve sheath tumor (MPNST) from its benign precursor lesion: A cross-sectional study.,,0.95,clinical_assessment_tool,RECIST 1.1,Clinical Assessment Tool,,,,,
PMID:38481529,10.3389/fcell.2024.1359561,Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1.,,0.9,cell_line,NF1-1 hiPSC line,Cell Line,,,,,
PMID:38481529,10.3389/fcell.2024.1359561,Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1.,,0.9,cell_line,NF1-2 hiPSC line,Cell Line,,,,,
PMID:38481529,10.3389/fcell.2024.1359561,Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1.,,0.85,cell_line,WT-1 hiPSC line,Cell Line,,,,,
PMID:38481529,10.3389/fcell.2024.1359561,Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1.,,0.85,cell_line,WT-2 hiPSC line,Cell Line,,,,,
PMID:38481529,10.3389/fcell.2024.1359561,Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1.,,0.9,computational_tool,CRISPOR software,Computational Tool,,,,,
PMID:38481529,10.3389/fcell.2024.1359561,Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1.,,0.95,genetic_reagent,sgRNA1 (5′-TAACTGCGCAACCTTCTTTA-3′),Genetic Reagent,,,,,
PMID:38481529,10.3389/fcell.2024.1359561,Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1.,,0.95,genetic_reagent,sgRNA2 (5′-GTTAGCAGTTATAAATAGCC-3′),Genetic Reagent,,,,,
PMID:38481529,10.3389/fcell.2024.1359561,Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1.,,0.95,antibody,"anti-neurofibromin antibody (abcam, ab17963)",Antibody,,,,,
PMID:38481529,10.3389/fcell.2024.1359561,Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1.,,0.9,antibody,"Anti-beta-Actin antibody (Santa Cruz Biotechnologies, sc4778)",Antibody,,,,,
PMID:38481529,10.3389/fcell.2024.1359561,Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1.,,0.9,antibody,"anti-vinculin (abcam, ab129002)",Antibody,,,,,
PMID:38481529,10.3389/fcell.2024.1359561,Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1.,,0.85,computational_tool,FlowJo software,Computational Tool,,,,,
PMID:38481529,10.3389/fcell.2024.1359561,Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1.,,0.85,computational_tool,GraphPad Prism 9,Computational Tool,,,,,
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,0.95,animal_model,Nf1+/- mice,Animal Model,,,,,
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,0.9,animal_model,Fbxw11+/- mice,Animal Model,,,,,
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,0.9,animal_model,Fbxw11fl/fl mice,Animal Model,,,,,
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,0.95,cell_line,HEK293T cells,Cell Line,,,,,
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,0.95,cell_line,HeLa cells,Cell Line,,,,,
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,0.85,cell_line,LUVA cells,Cell Line,,,,,
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,0.95,antibody,neurofibromin/NF1 antibody (sc-67),Antibody,,,,,
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,0.95,antibody,neurofibromin/NF1 antibody (sc-376886),Antibody,,,,,
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,0.95,antibody,neurofibromin/NF1 antibody (ab238142),Antibody,,,,,
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,0.95,antibody,Flag antibody (F7425),Antibody,,,,,
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,0.95,antibody,GFP antibody (ab1218),Antibody,,,,,
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,0.95,antibody,FBXW11/bTrCP2 antibody (GTX33193),Antibody,,,,,
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,0.95,antibody,ERK1/2 antibody (9102),Antibody,,,,,
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,0.95,antibody,anti-pERK antibody (4377),Antibody,,,,,
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,0.95,genetic_reagent,GFP-tagged human neurofibromin cDNA (RG220425),Genetic Reagent,,,,,
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,0.95,genetic_reagent,Myc-DDK–tagged human FBXW11 cDNA (RC218905),Genetic Reagent,,,,,
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,0.95,genetic_reagent,AAV5-CMV-GFP,Genetic Reagent,,,,,
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,0.95,genetic_reagent,AAV5-CMV-Cre-GFP,Genetic Reagent,,,,,
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,0.9,computational_tool,AnyMaze software,Computational Tool,,,,,
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,0.9,computational_tool,ImageJ software,Computational Tool,,,,,
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,0.9,computational_tool,GraphPad Prism version 5.0d,Computational Tool,,,,,
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,0.85,clinical_assessment_tool,3-chamber social preference task,Clinical Assessment Tool,,,,,
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,0.85,clinical_assessment_tool,Open field test,Clinical Assessment Tool,,,,,
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,0.85,clinical_assessment_tool,Delay discounting task,Clinical Assessment Tool,,,,,
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,0.85,clinical_assessment_tool,Cliff avoidance reaction test,Clinical Assessment Tool,,,,,
PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,,0.85,cell_line,U87 glioblastoma cells,Cell Line,,,,,
PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,,0.95,cell_line,sMPNST cells,Cell Line,,,,,
PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,,0.9,genetic_reagent,lenti CRISPRv2 system,Genetic Reagent,,,,,
PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,,0.95,genetic_reagent,"lentiCRISPRv2 (Addgene, https://www.addgene.org/52961/)",Genetic Reagent,,,,,
PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,,0.9,antibody,anti-human TRAP1 (sc-73604),Antibody,,,,,
PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,,0.9,antibody,anti ATP50/OSCP (ab110276),Antibody,,,,,
PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,,0.9,antibody,anti-ATPB (ab14730),Antibody,,,,,
PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,,0.9,antibody,anti SDHA (sc-166947),Antibody,,,,,
PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,,0.9,antibody,anti-Cyclophilin (ab110324),Antibody,,,,,
PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,,0.85,genetic_reagent,pSUMO-Cyclophilin D plasmid,Genetic Reagent,,,,,
PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,,0.85,genetic_reagent,pcDNA3 mito-GFP1-9,Genetic Reagent,,,,,
PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,,0.85,genetic_reagent,pcDNA3-TRAP1-GFP10,Genetic Reagent,,,,,
PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,,0.85,genetic_reagent,pcDNA3CyPD-GFP11,Genetic Reagent,,,,,
PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,,0.85,genetic_reagent,pcDNA3ATP50-GFP11,Genetic Reagent,,,,,
PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,,0.8,computational_tool,Biacore T100 biosensor system,Computational Tool,,,,,
PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,,0.85,computational_tool,ProteON Manager software,Computational Tool,,,,,
PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,,0.85,computational_tool,pClamp software suite,Computational Tool,,,,,
PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,,0.85,computational_tool,ImageJ,Computational Tool,,,,,
PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,,0.85,computational_tool,Origin 8,Computational Tool,,,,,
PMID:35614131,10.1038/s41418-022-01020-0,The mitochondrial chaperone TRAP1 regulates F-ATP synthase channel formation.,,0.85,computational_tool,Prism 6.0,Computational Tool,,,,,
PMID:23432799,10.1186/1477-7525-11-21,"Development of the adult PedsQL™ neurofibromatosis type 1 module: initial feasibility, reliability and validity.",,0.95,clinical_assessment_tool,PedsQL™ NF1 Module,Clinical Assessment Tool,,,,,
PMID:23432799,10.1186/1477-7525-11-21,"Development of the adult PedsQL™ neurofibromatosis type 1 module: initial feasibility, reliability and validity.",,0.85,clinical_assessment_tool,PedsQL™ 4.0 Generic Core Scales,Clinical Assessment Tool,,,,,
PMID:23432799,10.1186/1477-7525-11-21,"Development of the adult PedsQL™ neurofibromatosis type 1 module: initial feasibility, reliability and validity.",,0.8,clinical_assessment_tool,PedsQL™ Arthritis Module,Clinical Assessment Tool,,,,,
PMID:23432799,10.1186/1477-7525-11-21,"Development of the adult PedsQL™ neurofibromatosis type 1 module: initial feasibility, reliability and validity.",,0.8,clinical_assessment_tool,PedsQL™ Cancer Module,Clinical Assessment Tool,,,,,
PMID:23432799,10.1186/1477-7525-11-21,"Development of the adult PedsQL™ neurofibromatosis type 1 module: initial feasibility, reliability and validity.",,0.8,clinical_assessment_tool,PedsQL™ Cerebral Palsy Module,Clinical Assessment Tool,,,,,
PMID:23432799,10.1186/1477-7525-11-21,"Development of the adult PedsQL™ neurofibromatosis type 1 module: initial feasibility, reliability and validity.",,0.8,clinical_assessment_tool,PedsQL™ Family Impact Module,Clinical Assessment Tool,,,,,
PMID:23432799,10.1186/1477-7525-11-21,"Development of the adult PedsQL™ neurofibromatosis type 1 module: initial feasibility, reliability and validity.",,0.85,computational_tool,Cronbach's alpha,Computational Tool,,,,,
PMID:23432799,10.1186/1477-7525-11-21,"Development of the adult PedsQL™ neurofibromatosis type 1 module: initial feasibility, reliability and validity.",,0.9,computational_tool,SPSS 18,Computational Tool,,,,,
PMID:23432799,10.1186/1477-7525-11-21,"Development of the adult PedsQL™ neurofibromatosis type 1 module: initial feasibility, reliability and validity.",,0.9,computational_tool,SAS 9.3,Computational Tool,,,,,
PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,0.9,antibody,GFAP,Antibody,,,,,
PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,0.9,antibody,OLIG2,Antibody,,,,,
PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,0.9,antibody,SOX10,Antibody,,,,,
PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,0.9,antibody,synaptophysin,Antibody,,,,,
PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,0.9,antibody,p16,Antibody,,,,,
PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,0.9,antibody,ATRX,Antibody,,,,,
PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,0.9,antibody,p53,Antibody,,,,,
PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,0.9,antibody,histone H3 K27M mutant protein,Antibody,,,,,
PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,0.9,antibody,histone H3 lysine 27 trimethylation,Antibody,,,,,
PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,0.9,antibody,Ki-67,Antibody,,,,,
PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,0.9,computational_tool,UCSF500 NGS Panel,Computational Tool,,,,,
PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,0.8,computational_tool,BWA,Computational Tool,,,,,
PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,0.8,computational_tool,GATK,Computational Tool,,,,,
PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,0.8,computational_tool,FreeBayes,Computational Tool,,,,,
PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,0.8,computational_tool,Unified Genotyper,Computational Tool,,,,,
PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,0.8,computational_tool,Pindel,Computational Tool,,,,,
PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,0.8,computational_tool,Delly,Computational Tool,,,,,
PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,0.8,computational_tool,Annovar,Computational Tool,,,,,
PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,0.8,computational_tool,Integrative Genome Viewer,Computational Tool,,,,,
PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,0.8,computational_tool,CNVkit,Computational Tool,,,,,
PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,0.8,computational_tool,NxClinical,Computational Tool,,,,,
PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,0.9,computational_tool,minfi,Computational Tool,,,,,
PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,0.9,computational_tool,Rtsne,Computational Tool,,,,,
PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,0.8,computational_tool,ggplot2,Computational Tool,,,,,
PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,0.9,computational_tool,Limma,Computational Tool,,,,,
PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,0.9,computational_tool,ComplexHeatmap,Computational Tool,,,,,
PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,0.8,genetic_reagent,trametinib,Genetic Reagent,,,,,
PMID:35945463,10.1007/s00401-022-02478-5,Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.,,0.8,genetic_reagent,selumetinib,Genetic Reagent,,,,,
PMID:21681782,10.1002/ajh.22035,Nf1 mutant mice with p19ARF gene loss develop accelerated hematopoietic disease resembling acute leukemia with a variable phenotype.,,0.9,animal_model,p19 knockout mice,Animal Model,,,,,
PMID:21681782,10.1002/ajh.22035,Nf1 mutant mice with p19ARF gene loss develop accelerated hematopoietic disease resembling acute leukemia with a variable phenotype.,,0.9,animal_model,Mx1-Cre mice,Animal Model,,,,,
PMID:21681782,10.1002/ajh.22035,Nf1 mutant mice with p19ARF gene loss develop accelerated hematopoietic disease resembling acute leukemia with a variable phenotype.,,0.95,animal_model,Nf1 flox mice,Animal Model,,,,,
PMID:21681782,10.1002/ajh.22035,Nf1 mutant mice with p19ARF gene loss develop accelerated hematopoietic disease resembling acute leukemia with a variable phenotype.,,0.95,animal_model,Nf1 fcr mice,Animal Model,,,,,
PMID:21681782,10.1002/ajh.22035,Nf1 mutant mice with p19ARF gene loss develop accelerated hematopoietic disease resembling acute leukemia with a variable phenotype.,,0.85,animal_model,C57BL/6J mice,Animal Model,,,,,
PMID:21681782,10.1002/ajh.22035,Nf1 mutant mice with p19ARF gene loss develop accelerated hematopoietic disease resembling acute leukemia with a variable phenotype.,,0.85,animal_model,129/Sv mice,Animal Model,,,,,
PMID:21681782,10.1002/ajh.22035,Nf1 mutant mice with p19ARF gene loss develop accelerated hematopoietic disease resembling acute leukemia with a variable phenotype.,,0.9,antibody,anti-CD16/CD32,Antibody,,,,,
PMID:21681782,10.1002/ajh.22035,Nf1 mutant mice with p19ARF gene loss develop accelerated hematopoietic disease resembling acute leukemia with a variable phenotype.,,0.8,computational_tool,FACS Calibur,Computational Tool,,,,,
PMID:21681782,10.1002/ajh.22035,Nf1 mutant mice with p19ARF gene loss develop accelerated hematopoietic disease resembling acute leukemia with a variable phenotype.,,0.85,computational_tool,CellQuest Pro software,Computational Tool,,,,,
PMID:21681782,10.1002/ajh.22035,Nf1 mutant mice with p19ARF gene loss develop accelerated hematopoietic disease resembling acute leukemia with a variable phenotype.,,0.8,computational_tool,HemaVet Mascot 800 hematology analyzer,Computational Tool,,,,,
PMID:21681782,10.1002/ajh.22035,Nf1 mutant mice with p19ARF gene loss develop accelerated hematopoietic disease resembling acute leukemia with a variable phenotype.,,0.85,computational_tool,Prism 4.0,Computational Tool,,,,,
PMID:23175151,10.1038/bjc.2012.518,MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression.,,0.95,cell_line,sNF96.2,Cell Line,,,,,
PMID:23175151,10.1038/bjc.2012.518,MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression.,,0.85,cell_line,HEK293T,Cell Line,,,,,
PMID:23175151,10.1038/bjc.2012.518,MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression.,,0.85,cell_line,HT1080,Cell Line,,,,,
PMID:23175151,10.1038/bjc.2012.518,MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression.,,0.9,genetic_reagent,miRNAeasy kit,Genetic Reagent,,,,,
PMID:23175151,10.1038/bjc.2012.518,MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression.,,0.95,genetic_reagent,Agilent Human miRNA Microarray V2,Genetic Reagent,,,,,
PMID:23175151,10.1038/bjc.2012.518,MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression.,,0.9,genetic_reagent,TaqMan miRNA assays,Genetic Reagent,,,,,
PMID:23175151,10.1038/bjc.2012.518,MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression.,,0.9,genetic_reagent,miRNA mimics,Genetic Reagent,,,,,
PMID:23175151,10.1038/bjc.2012.518,MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression.,,0.95,antibody,MMP2 antibody (CA-4001),Antibody,,,,,
PMID:23175151,10.1038/bjc.2012.518,MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression.,,0.95,antibody,MMP9 antibody (EP1254),Antibody,,,,,
PMID:23175151,10.1038/bjc.2012.518,MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression.,,0.85,antibody,MMP3 antibody,Antibody,,,,,
PMID:23175151,10.1038/bjc.2012.518,MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression.,,0.95,antibody,GAPDH antibody (6C5),Antibody,,,,,
PMID:23175151,10.1038/bjc.2012.518,MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression.,,0.9,computational_tool,Feature extractionTM software,Computational Tool,,,,,
PMID:23175151,10.1038/bjc.2012.518,MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression.,,0.9,computational_tool,limma package,Computational Tool,,,,,
PMID:23175151,10.1038/bjc.2012.518,MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression.,,0.85,computational_tool,IncuCyte,Computational Tool,,,,,
PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.95,animal_model,Wisconsin Miniature SwineTM,Animal Model,,,,,
PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.9,animal_model,WMSTM-WT,Animal Model,,,,,
PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.9,animal_model,WMSTM-FH,Animal Model,,,,,
PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.85,genetic_reagent,Circulomics Nanobind CBB Big DNA kit,Genetic Reagent,,,,,
PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.85,genetic_reagent,SQK-LSK109 ligation sequencing kit,Genetic Reagent,,,,,
PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.9,computational_tool,Filtlong v0.2.0,Computational Tool,,,,,
PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.9,computational_tool,Porechop v0.2.4,Computational Tool,,,,,
PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.9,computational_tool,Flye v2.5,Computational Tool,,,,,
PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.9,computational_tool,GCpp v1.0.0-1807624,Computational Tool,,,,,
PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.9,computational_tool,purge_haplotigs,Computational Tool,,,,,
PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.9,computational_tool,Juicer v1.6.2,Computational Tool,,,,,
PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.9,computational_tool,3D-DNA v180114,Computational Tool,,,,,
PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.9,computational_tool,BUSCO v5.7.0,Computational Tool,,,,,
PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.9,computational_tool,QUASTv5.0.2,Computational Tool,,,,,
PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.9,computational_tool,Liftoff v1.6.3,Computational Tool,,,,,
PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.9,computational_tool,SnapGeneTM Version 7.2.1,Computational Tool,,,,,
PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.9,computational_tool,AlphaFold 3,Computational Tool,,,,,
PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.9,computational_tool,PyMOL Version 3.0.5,Computational Tool,,,,,
PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.9,computational_tool,Skewer v0.2.2.b,Computational Tool,,,,,
PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.9,computational_tool,Tassel pipeline version 2,Computational Tool,,,,,
PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.85,computational_tool,Bowtie2,Computational Tool,,,,,
PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.9,computational_tool,VCFtools v.0.1.16,Computational Tool,,,,,
PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.9,computational_tool,Beagle v4.1,Computational Tool,,,,,
PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.85,computational_tool,RAxML,Computational Tool,,,,,
PMID:40191916,10.1093/g3journal/jkaf067,"The draft genome of the Wisconsin Miniature SwineTM, a valuable biomedical research tool.",,0.9,computational_tool,itol v6.9.1,Computational Tool,,,,,
PMID:40217315,10.1186/s13073-025-01462-4,A single-cell atlas of Schwannoma across genetic backgrounds and anatomic locations.,,0.85,genetic_reagent,papain-based tumor dissociation kit (Miltenyi Biotec),Genetic Reagent,,,,,
PMID:40217315,10.1186/s13073-025-01462-4,A single-cell atlas of Schwannoma across genetic backgrounds and anatomic locations.,,0.95,antibody,"CD45-Vioblue direct antibody conjugate (clone REA747, Miltenyi Biotec)",Antibody,,,,,
PMID:40217315,10.1186/s13073-025-01462-4,A single-cell atlas of Schwannoma across genetic backgrounds and anatomic locations.,,0.8,genetic_reagent,calcein AM (Life Technologies),Genetic Reagent,,,,,
PMID:40217315,10.1186/s13073-025-01462-4,A single-cell atlas of Schwannoma across genetic backgrounds and anatomic locations.,,0.8,genetic_reagent,TO-PRO-3 iodide (Life Technologies),Genetic Reagent,,,,,
PMID:40217315,10.1186/s13073-025-01462-4,A single-cell atlas of Schwannoma across genetic backgrounds and anatomic locations.,,0.95,antibody,"CD24-APC (human antibody, clone REA832, Miltenyi Biotec)",Antibody,,,,,
PMID:40217315,10.1186/s13073-025-01462-4,A single-cell atlas of Schwannoma across genetic backgrounds and anatomic locations.,,0.95,antibody,"CD44-VioBlue (human antibody, clone REA690, Miltenyi Biotec)",Antibody,,,,,
PMID:40217315,10.1186/s13073-025-01462-4,A single-cell atlas of Schwannoma across genetic backgrounds and anatomic locations.,,0.85,computational_tool,FACS Aria Fusion Special Order System (Becton Dickinson),Computational Tool,,,,,
PMID:40217315,10.1186/s13073-025-01462-4,A single-cell atlas of Schwannoma across genetic backgrounds and anatomic locations.,,0.9,computational_tool,Smart-seq2,Computational Tool,,,,,
PMID:40217315,10.1186/s13073-025-01462-4,A single-cell atlas of Schwannoma across genetic backgrounds and anatomic locations.,,0.85,computational_tool,igraph,Computational Tool,,,,,
PMID:40217315,10.1186/s13073-025-01462-4,A single-cell atlas of Schwannoma across genetic backgrounds and anatomic locations.,,0.9,computational_tool,scdDblFinder,Computational Tool,,,,,
PMID:40217315,10.1186/s13073-025-01462-4,A single-cell atlas of Schwannoma across genetic backgrounds and anatomic locations.,,0.9,computational_tool,scran,Computational Tool,,,,,
PMID:40217315,10.1186/s13073-025-01462-4,A single-cell atlas of Schwannoma across genetic backgrounds and anatomic locations.,,0.9,computational_tool,QuPath,Computational Tool,,,,,
PMID:40217315,10.1186/s13073-025-01462-4,A single-cell atlas of Schwannoma across genetic backgrounds and anatomic locations.,,0.95,antibody,"anti-HLA Class I ABC antibody, ab225636, Abcam",Antibody,,,,,
PMID:40217315,10.1186/s13073-025-01462-4,A single-cell atlas of Schwannoma across genetic backgrounds and anatomic locations.,,0.95,antibody,"anti-MHC Class II antibody, ab55152, Abcam",Antibody,,,,,
PMID:33507258,10.1001/jamanetworkopen.2020.35479,Assessment of RAS Dependency for BRAF Alterations Using Cancer Genomic Databases.,,0.85,computational_tool,ACE (Advanced Cohort Explorer),Computational Tool,,,,,
PMID:33507258,10.1001/jamanetworkopen.2020.35479,Assessment of RAS Dependency for BRAF Alterations Using Cancer Genomic Databases.,,0.9,computational_tool,GENIE (Genomics Evidence Neoplasia Information Exchange),Computational Tool,,,,,
PMID:33507258,10.1001/jamanetworkopen.2020.35479,Assessment of RAS Dependency for BRAF Alterations Using Cancer Genomic Databases.,,0.9,computational_tool,cBioPortal,Computational Tool,,,,,
PMID:33507258,10.1001/jamanetworkopen.2020.35479,Assessment of RAS Dependency for BRAF Alterations Using Cancer Genomic Databases.,,0.9,computational_tool,TCGA (The Cancer Genome Atlas),Computational Tool,,,,,
PMID:33507258,10.1001/jamanetworkopen.2020.35479,Assessment of RAS Dependency for BRAF Alterations Using Cancer Genomic Databases.,,0.85,computational_tool,Catalogue of Somatic Mutations in Cancer,Computational Tool,,,,,
PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,,0.95,cell_line,HEI-193,Cell Line,,,,,
PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,,0.9,cell_line,"Human Schwann Cells (HSC, ScienCell Research Laboratories #1700)",Cell Line,,,,,
PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,,0.9,cell_line,"Mouse Schwann Cells (MSC, ScienCell Research Laboratories #M1700-57)",Cell Line,,,,,
PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,,0.85,cell_line,HEK-293T,Cell Line,,,,,
PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,,0.9,antibody,"SOX10 (API 3099, Biocare)",Antibody,,,,,
PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,,0.9,antibody,"Pericentrin (PA5-54109, Thermo Fisher Scientific)",Antibody,,,,,
PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,,0.9,antibody,"γTubulin (T5192, Sigma)",Antibody,,,,,
PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,,0.9,antibody,"Acetylated Tubulin (T6793, Sigma)",Antibody,,,,,
PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,,0.9,antibody,"CD3 (A0452, Agilent Technologies)",Antibody,,,,,
PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,,0.9,antibody,"CD68 (M0814, Agilent Technologies)",Antibody,,,,,
PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,,0.85,computational_tool,minfi,Computational Tool,,,,,
PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,,0.85,computational_tool,Seurat,Computational Tool,,,,,
PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,,0.85,computational_tool,Cell Ranger,Computational Tool,,,,,
PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,,0.85,computational_tool,HISAT2,Computational Tool,,,,,
PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,,0.85,computational_tool,DESeq2,Computational Tool,,,,,
PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,,0.85,computational_tool,MaxQuant,Computational Tool,,,,,
PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,,0.85,computational_tool,MSstats,Computational Tool,,,,,
PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,,0.85,computational_tool,Skyline,Computational Tool,,,,,
PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,,0.85,computational_tool,ChromVAR,Computational Tool,,,,,
PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,,0.85,computational_tool,Signac,Computational Tool,,,,,
PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,,0.85,computational_tool,CONICS,Computational Tool,,,,,
PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,,0.85,computational_tool,Enrichr,Computational Tool,,,,,
PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,,0.85,computational_tool,caret,Computational Tool,,,,,
PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,,0.85,computational_tool,Harmony,Computational Tool,,,,,
PMID:39858077,10.3390/cancers17020295,A Mixed Methods Study of Medication Adherence in Adults with Neurofibromatosis Type 1 (NF1) on a Clinical Trial of Selumetinib.,,0.85,clinical_assessment_tool,Life Events Checklist (LEC),Clinical Assessment Tool,,,,,
PMID:39858077,10.3390/cancers17020295,A Mixed Methods Study of Medication Adherence in Adults with Neurofibromatosis Type 1 (NF1) on a Clinical Trial of Selumetinib.,,0.85,clinical_assessment_tool,Rating of Overall Stress Scale (ROSS),Clinical Assessment Tool,,,,,
PMID:39858077,10.3390/cancers17020295,A Mixed Methods Study of Medication Adherence in Adults with Neurofibromatosis Type 1 (NF1) on a Clinical Trial of Selumetinib.,,0.9,clinical_assessment_tool,PROMIS depression short form,Clinical Assessment Tool,,,,,
PMID:39858077,10.3390/cancers17020295,A Mixed Methods Study of Medication Adherence in Adults with Neurofibromatosis Type 1 (NF1) on a Clinical Trial of Selumetinib.,,0.9,clinical_assessment_tool,PROMIS pain interference short form,Clinical Assessment Tool,,,,,
PMID:39858077,10.3390/cancers17020295,A Mixed Methods Study of Medication Adherence in Adults with Neurofibromatosis Type 1 (NF1) on a Clinical Trial of Selumetinib.,,0.9,clinical_assessment_tool,PROMIS cognitive function short form,Clinical Assessment Tool,,,,,
PMID:39858077,10.3390/cancers17020295,A Mixed Methods Study of Medication Adherence in Adults with Neurofibromatosis Type 1 (NF1) on a Clinical Trial of Selumetinib.,,0.85,clinical_assessment_tool,MEMS Cap,Clinical Assessment Tool,,,,,
PMID:39858077,10.3390/cancers17020295,A Mixed Methods Study of Medication Adherence in Adults with Neurofibromatosis Type 1 (NF1) on a Clinical Trial of Selumetinib.,,0.8,clinical_assessment_tool,Barriers to Adherence Questionnaire,Clinical Assessment Tool,,,,,
PMID:39858077,10.3390/cancers17020295,A Mixed Methods Study of Medication Adherence in Adults with Neurofibromatosis Type 1 (NF1) on a Clinical Trial of Selumetinib.,,0.85,computational_tool,Aardex MEMS Adherence Software (ElectronReader 0.9.9),Computational Tool,,,,,
PMID:27999334,10.3390/genes7120133,Hybridization Capture-Based Next-Generation Sequencing to Evaluate Coding Sequence and Deep Intronic Mutations in the NF1 Gene.,,0.85,genetic_reagent,QIAamp DNA Blood Mini kit,Genetic Reagent,,,,,
PMID:27999334,10.3390/genes7120133,Hybridization Capture-Based Next-Generation Sequencing to Evaluate Coding Sequence and Deep Intronic Mutations in the NF1 Gene.,,0.9,computational_tool,NanoDrop 2000,Computational Tool,,,,,
PMID:27999334,10.3390/genes7120133,Hybridization Capture-Based Next-Generation Sequencing to Evaluate Coding Sequence and Deep Intronic Mutations in the NF1 Gene.,,0.85,computational_tool,Qubit fluorometer,Computational Tool,,,,,
PMID:27999334,10.3390/genes7120133,Hybridization Capture-Based Next-Generation Sequencing to Evaluate Coding Sequence and Deep Intronic Mutations in the NF1 Gene.,,0.9,genetic_reagent,Ion TargetSeq Custom Enrichment kit,Genetic Reagent,,,,,
PMID:27999334,10.3390/genes7120133,Hybridization Capture-Based Next-Generation Sequencing to Evaluate Coding Sequence and Deep Intronic Mutations in the NF1 Gene.,,0.8,computational_tool,Bioruptor sonicator,Computational Tool,,,,,
PMID:27999334,10.3390/genes7120133,Hybridization Capture-Based Next-Generation Sequencing to Evaluate Coding Sequence and Deep Intronic Mutations in the NF1 Gene.,,0.95,computational_tool,Ion Torrent Personal Genome Machine—Ion Torrent PGM™,Computational Tool,,,,,
PMID:27999334,10.3390/genes7120133,Hybridization Capture-Based Next-Generation Sequencing to Evaluate Coding Sequence and Deep Intronic Mutations in the NF1 Gene.,,0.9,computational_tool,Torrent Suite software,Computational Tool,,,,,
PMID:27999334,10.3390/genes7120133,Hybridization Capture-Based Next-Generation Sequencing to Evaluate Coding Sequence and Deep Intronic Mutations in the NF1 Gene.,,0.85,computational_tool,TMAP,Computational Tool,,,,,
PMID:27999334,10.3390/genes7120133,Hybridization Capture-Based Next-Generation Sequencing to Evaluate Coding Sequence and Deep Intronic Mutations in the NF1 Gene.,,0.9,computational_tool,Ingenuity Variant Analysis software,Computational Tool,,,,,
PMID:27999334,10.3390/genes7120133,Hybridization Capture-Based Next-Generation Sequencing to Evaluate Coding Sequence and Deep Intronic Mutations in the NF1 Gene.,,0.85,computational_tool,SNPnexus web server,Computational Tool,,,,,
PMID:27999334,10.3390/genes7120133,Hybridization Capture-Based Next-Generation Sequencing to Evaluate Coding Sequence and Deep Intronic Mutations in the NF1 Gene.,,0.9,computational_tool,Integrative Genomics Viewer,Computational Tool,,,,,
PMID:27999334,10.3390/genes7120133,Hybridization Capture-Based Next-Generation Sequencing to Evaluate Coding Sequence and Deep Intronic Mutations in the NF1 Gene.,,0.9,computational_tool,Alamut Visual,Computational Tool,,,,,
PMID:27999334,10.3390/genes7120133,Hybridization Capture-Based Next-Generation Sequencing to Evaluate Coding Sequence and Deep Intronic Mutations in the NF1 Gene.,,0.85,computational_tool,PolyPhen2,Computational Tool,,,,,
PMID:27999334,10.3390/genes7120133,Hybridization Capture-Based Next-Generation Sequencing to Evaluate Coding Sequence and Deep Intronic Mutations in the NF1 Gene.,,0.85,computational_tool,SIFT,Computational Tool,,,,,
PMID:27999334,10.3390/genes7120133,Hybridization Capture-Based Next-Generation Sequencing to Evaluate Coding Sequence and Deep Intronic Mutations in the NF1 Gene.,,0.85,computational_tool,Human Splicing Finder,Computational Tool,,,,,
PMID:27999334,10.3390/genes7120133,Hybridization Capture-Based Next-Generation Sequencing to Evaluate Coding Sequence and Deep Intronic Mutations in the NF1 Gene.,,0.9,computational_tool,AB3130 Genetic Analyzer,Computational Tool,,,,,
PMID:27999334,10.3390/genes7120133,Hybridization Capture-Based Next-Generation Sequencing to Evaluate Coding Sequence and Deep Intronic Mutations in the NF1 Gene.,,0.85,computational_tool,NCBI's Primer BLAST tool,Computational Tool,,,,,
PMID:27999334,10.3390/genes7120133,Hybridization Capture-Based Next-Generation Sequencing to Evaluate Coding Sequence and Deep Intronic Mutations in the NF1 Gene.,,0.85,computational_tool,Sequencing Analysis software,Computational Tool,,,,,
PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,0.9,antibody,"CD13/FITC (22A5, Caltag Medsystems, UK)",Antibody,,,,,
PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,0.9,antibody,"CD14/PE (M5E2, BD Biosciences, CA, USA)",Antibody,,,,,
PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,0.9,antibody,"CD34/FITC (581, BD Biosciences)",Antibody,,,,,
PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,0.9,antibody,"CD45/ALexa405 (HI30, Caltag Medsystems)",Antibody,,,,,
PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,0.9,antibody,"CD90/PECy5 (5E10, BioLegend, CA, USA)",Antibody,,,,,
PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,0.9,antibody,"CD105/APC (45A5A3, BioLegend)",Antibody,,,,,
PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,0.9,antibody,"CD146/PE (P1H12, BD Biosciences)",Antibody,,,,,
PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,0.9,antibody,"CD271/APC (C401457, BD Biosciences)",Antibody,,,,,
PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,0.9,antibody,"anti-Ki-67 (1:80; M7240; Dako Corporation, CA, USA)",Antibody,,,,,
PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,0.85,cell_line,NF37,Cell Line,,,,,
PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,0.85,cell_line,NF87,Cell Line,,,,,
PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,0.85,cell_line,CT10,Cell Line,,,,,
PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,0.85,cell_line,CT11,Cell Line,,,,,
PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,0.85,cell_line,CT12,Cell Line,,,,,
PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,0.8,computational_tool,FACSCanto II (BD Bioscienses),Computational Tool,,,,,
PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,0.8,computational_tool,FACSDiva (BD Biosciences),Computational Tool,,,,,
PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,0.9,computational_tool,FlowJo 7.6.5,Computational Tool,,,,,
PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,0.9,computational_tool,"ImageJ software v.1.49 (NIH, USA)",Computational Tool,,,,,
PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,0.8,computational_tool,"Countess II FL Automated Cell Counter (ThermoFisher Scientific, MA, USA)",Computational Tool,,,,,
PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,0.8,computational_tool,SPSS v. 20.0,Computational Tool,,,,,
PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,,0.85,cell_line,CTL BJFF.6 hiPSCs,Cell Line,,,,,
PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,,0.8,genetic_reagent,Promokine Mycoplasma Test Kit I/C,Genetic Reagent,,,,,
PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,,0.75,computational_tool,iScan machine,Computational Tool,,,,,
PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,,0.85,computational_tool,Karyostudio 1.3 software,Computational Tool,,,,,
PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,,0.8,genetic_reagent,GenePrint 10 System,Genetic Reagent,,,,,
PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,,0.85,genetic_reagent,STEMdiff hematopoietic kit,Genetic Reagent,,,,,
PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,,0.9,antibody,OCT3/4 antibody,Antibody,,,,,
PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,,0.9,antibody,NANOG antibody,Antibody,,,,,
PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,,0.9,antibody,TRA-1-60 antibody,Antibody,,,,,
PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,,0.9,antibody,SSEA-4 antibody,Antibody,,,,,
PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,,0.9,antibody,IBA1 antibody,Antibody,,,,,
PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,,0.85,genetic_reagent,ReliaPrep RNA tissue kit,Genetic Reagent,,,,,
PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,,0.85,genetic_reagent,PrimeScript RT reagent kit,Genetic Reagent,,,,,
PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,,0.8,genetic_reagent,IncuCyte cell migration kit,Genetic Reagent,,,,,
PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,,0.85,computational_tool,IncuCyte Zoom live cell analysis system,Computational Tool,,,,,
PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,,0.85,genetic_reagent,cAMP ELISA kit,Genetic Reagent,,,,,
PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,,0.85,genetic_reagent,MILLIPLEX MAP human cytokine/chemokine/growth factor panel A,Genetic Reagent,,,,,
PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,,0.9,computational_tool,Partek Flow software,Computational Tool,,,,,
PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,,0.85,computational_tool,STAR,Computational Tool,,,,,
PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,,0.85,computational_tool,DESeq2,Computational Tool,,,,,
PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,,0.9,computational_tool,Imaris software,Computational Tool,,,,,
PMID:37990867,10.1242/dmm.049861,Neurofibromin 1 mutations impair the function of human induced pluripotent stem cell-derived microglia.,,0.95,advanced_cellular_model,hiMGL cells,Advanced Cellular Model,,,,,
PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,,0.9,computational_tool,Illumina EPIC 850K methylation array,Computational Tool,,,,,
PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,,0.85,genetic_reagent,Zymo EZ DNA Methylation Kit,Genetic Reagent,,,,,
PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,,0.9,computational_tool,ChAMP,Computational Tool,,,,,
PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,,0.85,computational_tool,glmmTMB,Computational Tool,,,,,
PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,,0.85,computational_tool,DMRcate,Computational Tool,,,,,
PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,,0.85,computational_tool,compartmap,Computational Tool,,,,,
PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,,0.85,computational_tool,missMethyl,Computational Tool,,,,,
PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,,0.85,computational_tool,PAMES,Computational Tool,,,,,
PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,,0.85,computational_tool,SeSAMe,Computational Tool,,,,,
PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,,0.9,computational_tool,STAR,Computational Tool,,,,,
PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,,0.85,computational_tool,edgeR,Computational Tool,,,,,
PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,,0.9,antibody,MKK3 antibody,Antibody,,,,,
PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,,0.9,antibody,p38 antibody,Antibody,,,,,
PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,,0.9,antibody,phospho-p38 antibody,Antibody,,,,,
PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,,0.9,antibody,phospho-ERK1/2 antibody,Antibody,,,,,
PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,,0.9,antibody,β-Actin antibody,Antibody,,,,,
PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,,0.85,computational_tool,betareg,Computational Tool,,,,,
PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,,0.85,computational_tool,emmeans,Computational Tool,,,,,
PMID:33436083,10.1186/s13072-020-00380-6,Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.,,0.85,computational_tool,ggplot2,Computational Tool,,,,,
PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,0.9,animal_model,Lats1 lox/lox Lats2 lox/lox mice,Animal Model,,,,,
PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,0.9,animal_model,Dhh-Cre mice,Animal Model,,,,,
PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,0.9,animal_model,Plp1-CreERT mice,Animal Model,,,,,
PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,0.9,animal_model,CAG-tdTomato reporter mice,Animal Model,,,,,
PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,0.9,animal_model,CAG-CATEGFP reporter mice,Animal Model,,,,,
PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,0.9,animal_model,Taz lox/lox Yap1 lox/lox mice,Animal Model,,,,,
PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,0.95,cell_line,SNF02.2,Cell Line,,,,,
PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,0.95,cell_line,SNF96.2,Cell Line,,,,,
PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,0.9,antibody,TAZ antibody (Rabbit; Proteintech 23306-1),Antibody,,,,,
PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,0.9,antibody,"YAP antibody (Rabbit; Cell Signaling Technology, #4912)",Antibody,,,,,
PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,0.9,antibody,"TAZ/YAP antibody (Rabbit; Cell Signaling Technology, #8418)",Antibody,,,,,
PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,0.9,antibody,"Sox10 antibody (Goat, Santa Cruz Biotechnology, sc-17342)",Antibody,,,,,
PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,0.9,antibody,"Sox10 antibody (Rabbit, Abcam ab180862)",Antibody,,,,,
PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,0.9,antibody,"Krox20 antibody (Rabbit; Covance, PRB-236P)",Antibody,,,,,
PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,0.9,antibody,"Ki67 antibody (Rabbit; Thermo Fisher Scientific, RM-9106)",Antibody,,,,,
PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,0.9,antibody,"BrdU antibody (Rat; Abcam, ab6326)",Antibody,,,,,
PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,0.9,antibody,"TEAD1 antibody (Mouse, Santa Cruz Biotechnology sc-393976)",Antibody,,,,,
PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,0.9,antibody,"neurofibromin antibody (Rabbit, Santa Cruz Biotechnology sc-67)",Antibody,,,,,
PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,0.9,antibody,"TEAD1 antibody (Mouse, BD Biosciences, 610922)",Antibody,,,,,
PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,0.8,computational_tool,TopHat,Computational Tool,,,,,
PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,0.8,computational_tool,Cuff-diff,Computational Tool,,,,,
PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,0.8,computational_tool,GSEA,Computational Tool,,,,,
PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,0.8,computational_tool,ToppCluster,Computational Tool,,,,,
PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,0.9,computational_tool,MACS version 1.4.2,Computational Tool,,,,,
PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,0.8,computational_tool,EaSeq,Computational Tool,,,,,
PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,0.8,computational_tool,HOMER software,Computational Tool,,,,,
PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,0.8,computational_tool,AltAnalyze,Computational Tool,,,,,
PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,0.8,genetic_reagent,verteporfin,Genetic Reagent,,,,,
PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,0.8,genetic_reagent,sorafenib p-Toluenesulfonate salt,Genetic Reagent,,,,,
PMID:29438698,10.1016/j.ccell.2018.01.005,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.,,0.8,genetic_reagent,imatinib mesylate,Genetic Reagent,,,,,
PMID:28193237,10.1186/s12955-017-0607-y,Evaluation of quality of life in adults with neurofibromatosis 1 (NF1) using the Impact of NF1 on Quality Of Life (INF1-QOL) questionnaire.,,0.95,clinical_assessment_tool,Impact of NF1 on Quality Of Life (INF1-QOL) questionnaire,Clinical Assessment Tool,,,,,
PMID:28193237,10.1186/s12955-017-0607-y,Evaluation of quality of life in adults with neurofibromatosis 1 (NF1) using the Impact of NF1 on Quality Of Life (INF1-QOL) questionnaire.,,0.9,clinical_assessment_tool,EuroQol (EQ 5D),Clinical Assessment Tool,,,,,
PMID:28193237,10.1186/s12955-017-0607-y,Evaluation of quality of life in adults with neurofibromatosis 1 (NF1) using the Impact of NF1 on Quality Of Life (INF1-QOL) questionnaire.,,0.85,clinical_assessment_tool,Riccardi NF severity grade classification,Clinical Assessment Tool,,,,,
PMID:28193237,10.1186/s12955-017-0607-y,Evaluation of quality of life in adults with neurofibromatosis 1 (NF1) using the Impact of NF1 on Quality Of Life (INF1-QOL) questionnaire.,,0.8,clinical_assessment_tool,NIH Consensus Development Conference 1987 diagnostic criteria,Clinical Assessment Tool,,,,,
PMID:27021207,10.1002/ajmg.a.37623,Acceptance and commitment therapy in youth with neurofibromatosis type 1 (NF1) and chronic pain and their parents: A pilot study of feasibility and preliminary efficacy.,,0.85,clinical_assessment_tool,Impact of Pediatric Illness Scale,Clinical Assessment Tool,,,,,
PMID:27021207,10.1002/ajmg.a.37623,Acceptance and commitment therapy in youth with neurofibromatosis type 1 (NF1) and chronic pain and their parents: A pilot study of feasibility and preliminary efficacy.,,0.8,clinical_assessment_tool,Pain Management Inventory,Clinical Assessment Tool,,,,,
PMID:27021207,10.1002/ajmg.a.37623,Acceptance and commitment therapy in youth with neurofibromatosis type 1 (NF1) and chronic pain and their parents: A pilot study of feasibility and preliminary efficacy.,,0.8,clinical_assessment_tool,Post-Treatment Questionnaire,Clinical Assessment Tool,,,,,
PMID:27021207,10.1002/ajmg.a.37623,Acceptance and commitment therapy in youth with neurofibromatosis type 1 (NF1) and chronic pain and their parents: A pilot study of feasibility and preliminary efficacy.,,0.75,computational_tool,Wilcoxon signed rank test,Computational Tool,,,,,
PMID:40437318,10.1186/s41747-025-00594-x,Quantitative MRI of dorsal root ganglion alterations in neurofibromatosis type 1 patients with or without pain.,,0.85,computational_tool,PRISMAfit,Computational Tool,,,,,
PMID:40437318,10.1186/s41747-025-00594-x,Quantitative MRI of dorsal root ganglion alterations in neurofibromatosis type 1 patients with or without pain.,,0.8,computational_tool,MATLAB,Computational Tool,,,,,
PMID:40437318,10.1186/s41747-025-00594-x,Quantitative MRI of dorsal root ganglion alterations in neurofibromatosis type 1 patients with or without pain.,,0.9,computational_tool,3D Slicer,Computational Tool,,,,,
PMID:40437318,10.1186/s41747-025-00594-x,Quantitative MRI of dorsal root ganglion alterations in neurofibromatosis type 1 patients with or without pain.,,0.8,computational_tool,R,Computational Tool,,,,,
PMID:40437318,10.1186/s41747-025-00594-x,Quantitative MRI of dorsal root ganglion alterations in neurofibromatosis type 1 patients with or without pain.,,0.8,computational_tool,GraphPad Prism,Computational Tool,,,,,
PMID:40437318,10.1186/s41747-025-00594-x,Quantitative MRI of dorsal root ganglion alterations in neurofibromatosis type 1 patients with or without pain.,,0.9,clinical_assessment_tool,visual analogue scale,Clinical Assessment Tool,,,,,
PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,,0.9,animal_model,Nf1+/- mice,Animal Model,,,,,
PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,,0.9,animal_model,Nf1flox/flox mice,Animal Model,,,,,
PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,,0.85,animal_model,Tie2cre mice,Animal Model,,,,,
PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,,0.85,animal_model,VE-cadherin cre mice,Animal Model,,,,,
PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,,0.9,cell_line,human endothelial colony forming cells (ECFC),Cell Line,,,,,
PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,,0.9,cell_line,human microvascular endothelial cells (HMVEC),Cell Line,,,,,
PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,,0.85,cell_line,293FT packaging cells,Cell Line,,,,,
PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,,0.95,genetic_reagent,NF1 small hairpin RNA (TRCN000023878),Genetic Reagent,,,,,
PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,,0.95,genetic_reagent,NF1 small hairpin RNA (TRCN0000039713),Genetic Reagent,,,,,
PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,,0.9,antibody,anti-neurofibromin antibody (#A300),Antibody,,,,,
PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,,0.9,antibody,anti-phospho-Akt XP antibody (#4060),Antibody,,,,,
PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,,0.9,antibody,anti-Akt antibody (#2938S),Antibody,,,,,
PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,,0.9,antibody,anti-phospho-Erk XP antibody (#4370),Antibody,,,,,
PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,,0.9,antibody,anti-Erk antibody (#4695S),Antibody,,,,,
PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,,0.9,antibody,FITC-anti-CD31 antibody,Antibody,,,,,
PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,,0.85,antibody,anti-GAPDH antibody,Antibody,,,,,
PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,,0.85,computational_tool,ImageJ,Computational Tool,,,,,
PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,,0.8,computational_tool,Swift_NV macro,Computational Tool,,,,,
PMID:29847659,10.1167/iovs.17-22588,Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization.,,0.85,computational_tool,GraphPad Prism version 6.0h,Computational Tool,,,,,
PMID:34646065,10.1155/2021/9386823,Survival and ,,0.8,computational_tool,EPIC electronic medical record service,Computational Tool,,,,,
PMID:34646065,10.1155/2021/9386823,Survival and ,,0.8,computational_tool,Enneking/Anspach Research Center database,Computational Tool,,,,,
PMID:34646065,10.1155/2021/9386823,Survival and ,,0.85,antibody,S100 B,Antibody,,,,,
PMID:34646065,10.1155/2021/9386823,Survival and ,,0.9,genetic_reagent,TaqMan NF1 copy-number assays,Genetic Reagent,,,,,
PMID:34646065,10.1155/2021/9386823,Survival and ,,0.8,computational_tool,SPSS 25,Computational Tool,,,,,
PMID:36316421,10.1038/s41598-022-21907-9,Non-invasive brain stimulation modulates GABAergic activity in neurofibromatosis 1.,,0.85,clinical_assessment_tool,NeuroConn DC-STIMULATOR MR,Clinical Assessment Tool,,,,,
PMID:36316421,10.1038/s41598-022-21907-9,Non-invasive brain stimulation modulates GABAergic activity in neurofibromatosis 1.,,0.9,computational_tool,SimNIBS 3.2,Computational Tool,,,,,
PMID:36316421,10.1038/s41598-022-21907-9,Non-invasive brain stimulation modulates GABAergic activity in neurofibromatosis 1.,,0.85,computational_tool,headreco pipeline,Computational Tool,,,,,
PMID:36316421,10.1038/s41598-022-21907-9,Non-invasive brain stimulation modulates GABAergic activity in neurofibromatosis 1.,,0.9,computational_tool,SPM8,Computational Tool,,,,,
PMID:36316421,10.1038/s41598-022-21907-9,Non-invasive brain stimulation modulates GABAergic activity in neurofibromatosis 1.,,0.9,computational_tool,jMRUI5.1,Computational Tool,,,,,
PMID:36316421,10.1038/s41598-022-21907-9,Non-invasive brain stimulation modulates GABAergic activity in neurofibromatosis 1.,,0.9,computational_tool,SPM12,Computational Tool,,,,,
PMID:36316421,10.1038/s41598-022-21907-9,Non-invasive brain stimulation modulates GABAergic activity in neurofibromatosis 1.,,0.85,computational_tool,DARTEL,Computational Tool,,,,,
PMID:36316421,10.1038/s41598-022-21907-9,Non-invasive brain stimulation modulates GABAergic activity in neurofibromatosis 1.,,0.85,computational_tool,Marsbar,Computational Tool,,,,,
PMID:36316421,10.1038/s41598-022-21907-9,Non-invasive brain stimulation modulates GABAergic activity in neurofibromatosis 1.,,0.85,computational_tool,E-Prime,Computational Tool,,,,,
PMID:36316421,10.1038/s41598-022-21907-9,Non-invasive brain stimulation modulates GABAergic activity in neurofibromatosis 1.,,0.95,clinical_assessment_tool,Vineland Adaptive Behaviour Scale—third edition,Clinical Assessment Tool,,,,,
PMID:36316421,10.1038/s41598-022-21907-9,Non-invasive brain stimulation modulates GABAergic activity in neurofibromatosis 1.,,0.95,clinical_assessment_tool,Conners 3 rating scale,Clinical Assessment Tool,,,,,
PMID:36316421,10.1038/s41598-022-21907-9,Non-invasive brain stimulation modulates GABAergic activity in neurofibromatosis 1.,,0.85,computational_tool,Psychology Experiment Building Language (PEBL),Computational Tool,,,,,
PMID:36316421,10.1038/s41598-022-21907-9,Non-invasive brain stimulation modulates GABAergic activity in neurofibromatosis 1.,,0.85,computational_tool,Psychopy2,Computational Tool,,,,,
PMID:36316421,10.1038/s41598-022-21907-9,Non-invasive brain stimulation modulates GABAergic activity in neurofibromatosis 1.,,0.85,computational_tool,SPSS version25,Computational Tool,,,,,
PMID:36316421,10.1038/s41598-022-21907-9,Non-invasive brain stimulation modulates GABAergic activity in neurofibromatosis 1.,,0.85,computational_tool,R version 1.2,Computational Tool,,,,,
PMID:36316421,10.1038/s41598-022-21907-9,Non-invasive brain stimulation modulates GABAergic activity in neurofibromatosis 1.,,0.85,computational_tool,nlme package,Computational Tool,,,,,
PMID:36316421,10.1038/s41598-022-21907-9,Non-invasive brain stimulation modulates GABAergic activity in neurofibromatosis 1.,,0.85,computational_tool,MATLAB R2014a,Computational Tool,,,,,
PMID:26822862,10.1038/srep20010,Capturing the wide variety of impaired fracture healing phenotypes in Neurofibromatosis Type 1 with eight key factors: a computational study.,,0.85,computational_tool,JMP,Computational Tool,,,,,
PMID:26822862,10.1038/srep20010,Capturing the wide variety of impaired fracture healing phenotypes in Neurofibromatosis Type 1 with eight key factors: a computational study.,,0.8,computational_tool,VSC (Flemish Supercomputer Center),Computational Tool,,,,,
PMID:26822862,10.1038/srep20010,Capturing the wide variety of impaired fracture healing phenotypes in Neurofibromatosis Type 1 with eight key factors: a computational study.,,0.75,animal_model,standardised femoral rat fracture model,Animal Model,,,,,
PMID:26822862,10.1038/srep20010,Capturing the wide variety of impaired fracture healing phenotypes in Neurofibromatosis Type 1 with eight key factors: a computational study.,,0.75,computational_tool,agent-based model of Bentley et al.,Computational Tool,,,,,
PMID:36890585,10.1186/s40478-023-01525-w,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic.,,0.95,animal_model,Nf1 ± mice,Animal Model,,,,,
PMID:36890585,10.1186/s40478-023-01525-w,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic.,,0.9,animal_model,MacGreen (Csf1r-eGFP),Animal Model,,,,,
PMID:36890585,10.1186/s40478-023-01525-w,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic.,,0.9,animal_model,CX3CR1-CreER,Animal Model,,,,,
PMID:36890585,10.1186/s40478-023-01525-w,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic.,,0.95,animal_model,Nf1 flox/flox,Animal Model,,,,,
PMID:36890585,10.1186/s40478-023-01525-w,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic.,,0.9,animal_model,R26R-EYFP mice,Animal Model,,,,,
PMID:36890585,10.1186/s40478-023-01525-w,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic.,,0.9,animal_model,hGFAP-Cre,Animal Model,,,,,
PMID:36890585,10.1186/s40478-023-01525-w,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic.,,0.95,antibody,goat monoclonal Iba-1 antibody,Antibody,,,,,
PMID:36890585,10.1186/s40478-023-01525-w,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic.,,0.9,antibody,chicken polyclonal GFP antibody,Antibody,,,,,
PMID:36890585,10.1186/s40478-023-01525-w,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic.,,0.9,antibody,mouse anti-NeuN,Antibody,,,,,
PMID:36890585,10.1186/s40478-023-01525-w,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic.,,0.85,antibody,donkey anti-goat IgG conjugated with Cy5,Antibody,,,,,
PMID:36890585,10.1186/s40478-023-01525-w,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic.,,0.85,antibody,donkey anti-goat IgG conjugated with Alexa488,Antibody,,,,,
PMID:36890585,10.1186/s40478-023-01525-w,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic.,,0.85,antibody,donkey anti-chicken IgY conjugated with Alexa488,Antibody,,,,,
PMID:36890585,10.1186/s40478-023-01525-w,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic.,,0.85,antibody,donkey anti-chicken IgY conjugated with Cy5,Antibody,,,,,
PMID:36890585,10.1186/s40478-023-01525-w,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic.,,0.85,antibody,donkey anti-mouse IgG (H + L) conjugated with Cy3,Antibody,,,,,
PMID:36890585,10.1186/s40478-023-01525-w,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic.,,0.9,antibody,anti-mouse CD11b antibodies coupled to magnetic beads,Antibody,,,,,
PMID:36890585,10.1186/s40478-023-01525-w,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic.,,0.95,computational_tool,Imaris × 64 version 9.6–9.9,Computational Tool,,,,,
PMID:36890585,10.1186/s40478-023-01525-w,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic.,,0.9,computational_tool,IGOR Pro 6.37,Computational Tool,,,,,
PMID:36890585,10.1186/s40478-023-01525-w,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic.,,0.95,computational_tool,MaxQuant version 1.6.10.43,Computational Tool,,,,,
PMID:36890585,10.1186/s40478-023-01525-w,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic.,,0.85,computational_tool,limma R package,Computational Tool,,,,,
PMID:36890585,10.1186/s40478-023-01525-w,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic.,,0.9,computational_tool,Prism 7,Computational Tool,,,,,
PMID:25549701,,Exome sequencing on malignant meningiomas identified mutations in neurofibromatosis type 2 (NF2) and meningioma 1 (MN1) genes.,,0.85,computational_tool,Illumina HiSeq2000,Computational Tool,,,,,
PMID:25549701,,Exome sequencing on malignant meningiomas identified mutations in neurofibromatosis type 2 (NF2) and meningioma 1 (MN1) genes.,,0.9,genetic_reagent,Agilent SureSelect Human All Exon kits,Genetic Reagent,,,,,
PMID:25549701,,Exome sequencing on malignant meningiomas identified mutations in neurofibromatosis type 2 (NF2) and meningioma 1 (MN1) genes.,,0.9,computational_tool,wANNOVAR web server,Computational Tool,,,,,
PMID:25549701,,Exome sequencing on malignant meningiomas identified mutations in neurofibromatosis type 2 (NF2) and meningioma 1 (MN1) genes.,,0.85,genetic_reagent,NimbleGen targeted region arrays,Genetic Reagent,,,,,
PMID:25549701,,Exome sequencing on malignant meningiomas identified mutations in neurofibromatosis type 2 (NF2) and meningioma 1 (MN1) genes.,,0.85,genetic_reagent,QIAamp DNA FFPE kit,Genetic Reagent,,,,,
PMID:25549701,,Exome sequencing on malignant meningiomas identified mutations in neurofibromatosis type 2 (NF2) and meningioma 1 (MN1) genes.,,0.8,computational_tool,Covaris E210,Computational Tool,,,,,
PMID:25549701,,Exome sequencing on malignant meningiomas identified mutations in neurofibromatosis type 2 (NF2) and meningioma 1 (MN1) genes.,,0.85,genetic_reagent,AMpure XP beads,Genetic Reagent,,,,,
PMID:25549701,,Exome sequencing on malignant meningiomas identified mutations in neurofibromatosis type 2 (NF2) and meningioma 1 (MN1) genes.,,0.9,computational_tool,SeqMule,Computational Tool,,,,,
PMID:25549701,,Exome sequencing on malignant meningiomas identified mutations in neurofibromatosis type 2 (NF2) and meningioma 1 (MN1) genes.,,0.85,computational_tool,BWA,Computational Tool,,,,,
PMID:25549701,,Exome sequencing on malignant meningiomas identified mutations in neurofibromatosis type 2 (NF2) and meningioma 1 (MN1) genes.,,0.85,computational_tool,GATK,Computational Tool,,,,,
PMID:25549701,,Exome sequencing on malignant meningiomas identified mutations in neurofibromatosis type 2 (NF2) and meningioma 1 (MN1) genes.,,0.85,computational_tool,SAMtools,Computational Tool,,,,,
PMID:25549701,,Exome sequencing on malignant meningiomas identified mutations in neurofibromatosis type 2 (NF2) and meningioma 1 (MN1) genes.,,0.85,computational_tool,VarScan2,Computational Tool,,,,,
PMID:25549701,,Exome sequencing on malignant meningiomas identified mutations in neurofibromatosis type 2 (NF2) and meningioma 1 (MN1) genes.,,0.85,computational_tool,Codon Code Aligner,Computational Tool,,,,,
PMID:25549701,,Exome sequencing on malignant meningiomas identified mutations in neurofibromatosis type 2 (NF2) and meningioma 1 (MN1) genes.,,0.9,computational_tool,primer 3 (v. 0.4.0),Computational Tool,,,,,
PMID:25549701,,Exome sequencing on malignant meningiomas identified mutations in neurofibromatosis type 2 (NF2) and meningioma 1 (MN1) genes.,,0.85,genetic_reagent,AccuPrime™ Taq High Fidelit,Genetic Reagent,,,,,
PMID:27458360,10.3389/fnhum.2016.00334,COMT Val(158)Met Polymorphism Is Associated with Verbal Working Memory in Neurofibromatosis Type 1.,,0.9,clinical_assessment_tool,Wechsler Adult and Children Intelligence Scales,Clinical Assessment Tool,,,,,
PMID:27458360,10.3389/fnhum.2016.00334,COMT Val(158)Met Polymorphism Is Associated with Verbal Working Memory in Neurofibromatosis Type 1.,,0.85,clinical_assessment_tool,Corsi block-tapping task,Clinical Assessment Tool,,,,,
PMID:27458360,10.3389/fnhum.2016.00334,COMT Val(158)Met Polymorphism Is Associated with Verbal Working Memory in Neurofibromatosis Type 1.,,0.9,clinical_assessment_tool,Brazilian Wechsler Intelligence Scales (WAIS-III or WISC-III),Clinical Assessment Tool,,,,,
PMID:27458360,10.3389/fnhum.2016.00334,COMT Val(158)Met Polymorphism Is Associated with Verbal Working Memory in Neurofibromatosis Type 1.,,0.85,clinical_assessment_tool,School Achievement Test,Clinical Assessment Tool,,,,,
PMID:27458360,10.3389/fnhum.2016.00334,COMT Val(158)Met Polymorphism Is Associated with Verbal Working Memory in Neurofibromatosis Type 1.,,0.8,clinical_assessment_tool,Brazilian Criterion for Economic Classification (CCEB),Clinical Assessment Tool,,,,,
PMID:27458360,10.3389/fnhum.2016.00334,COMT Val(158)Met Polymorphism Is Associated with Verbal Working Memory in Neurofibromatosis Type 1.,,0.85,genetic_reagent,TaqMan Genotyping Master Mix,Genetic Reagent,,,,,
PMID:27458360,10.3389/fnhum.2016.00334,COMT Val(158)Met Polymorphism Is Associated with Verbal Working Memory in Neurofibromatosis Type 1.,,0.8,computational_tool,Stratagene Mx3005 – MxPro QPCR-Software,Computational Tool,,,,,
PMID:27458360,10.3389/fnhum.2016.00334,COMT Val(158)Met Polymorphism Is Associated with Verbal Working Memory in Neurofibromatosis Type 1.,,0.75,computational_tool,SPSS 20.0,Computational Tool,,,,,
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,0.95,cell_line,TM-31,Cell Line,,,,,
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,0.9,cell_line,LN319,Cell Line,,,,,
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,0.95,cell_line,17,Cell Line,,,,,
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,0.95,cell_line,5653,Cell Line,,,,,
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,0.95,cell_line,5746,Cell Line,,,,,
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,0.9,animal_model,NPcis genetically engineered mouse model,Animal Model,,,,,
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,0.95,antibody,pERK antibody,Antibody,,,,,
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,0.95,antibody,total ERK antibody,Antibody,,,,,
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,0.95,antibody,pAKT antibody,Antibody,,,,,
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,0.95,antibody,total AKT antibody,Antibody,,,,,
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,0.95,antibody,Ubiquitin antibody,Antibody,,,,,
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,0.95,antibody,MYC antibody,Antibody,,,,,
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,0.95,antibody,pCHEK1 S296 antibody,Antibody,,,,,
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,0.95,antibody,BMI1 antibody,Antibody,,,,,
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,0.95,antibody,H3K27Ac antibody,Antibody,,,,,
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,0.95,antibody,total H3 antibody,Antibody,,,,,
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,0.95,antibody,CDK9 antibody,Antibody,,,,,
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,0.95,antibody,Vinculin antibody,Antibody,,,,,
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,0.95,antibody,CPNase antibody,Antibody,,,,,
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,0.95,antibody,MAG antibody,Antibody,,,,,
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,0.95,antibody,Beta-Actin antibody,Antibody,,,,,
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,0.95,antibody,pS2 RNApol II antibody,Antibody,,,,,
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,0.95,antibody,SOX2 antibody,Antibody,,,,,
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,0.95,antibody,NG2 antibody,Antibody,,,,,
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,0.9,genetic_reagent,Incucyte Nuclight Red Lentivirus,Genetic Reagent,,,,,
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,0.9,computational_tool,Incucyte S3 Live-Cell Analysis System,Computational Tool,,,,,
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,0.95,computational_tool,synergyfinder,Computational Tool,,,,,
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,0.85,computational_tool,GraphPad Prism 9,Computational Tool,,,,,
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,0.9,advanced_cellular_model,spheroid culture system,Advanced Cellular Model,,,,,
PMID:20195187,10.1097/MAO.0b013e3181d2777f,Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis.,,0.9,cell_line,"Human Schwann cells (HSC; ScienCell, Carlsbad, CA)",Cell Line,,,,,
PMID:20195187,10.1097/MAO.0b013e3181d2777f,Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis.,,0.95,genetic_reagent,"neurofibromin 2 ON-TARGETplus SMARTpool; Dharmacon, Lafayette, CO",Genetic Reagent,,,,,
PMID:20195187,10.1097/MAO.0b013e3181d2777f,Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis.,,0.85,genetic_reagent,"non-targeting, random sequence siRNA (Dharmacon)",Genetic Reagent,,,,,
PMID:20195187,10.1097/MAO.0b013e3181d2777f,Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis.,,0.8,genetic_reagent,"RNeasy Mini Kit (Qiagen Sciences, Germantown, MD)",Genetic Reagent,,,,,
PMID:20195187,10.1097/MAO.0b013e3181d2777f,Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis.,,0.8,genetic_reagent,"TaqMan reverse transcription reagents (Applied Biosystems, Foster city, CA)",Genetic Reagent,,,,,
PMID:20195187,10.1097/MAO.0b013e3181d2777f,Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis.,,0.9,antibody,"monoclonal anti-EGFR (1:250; Capralogics, Hardwick, MA)",Antibody,,,,,
PMID:20195187,10.1097/MAO.0b013e3181d2777f,Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis.,,0.9,antibody,"polyclonal anti-ErbB2 (1:250; Santa Cruz Biotechnology, Santa Cruz, CA)",Antibody,,,,,
PMID:20195187,10.1097/MAO.0b013e3181d2777f,Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis.,,0.9,antibody,polyclonal anti-ErbB3 (1:250; Santa Cruz),Antibody,,,,,
PMID:20195187,10.1097/MAO.0b013e3181d2777f,Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis.,,0.9,antibody,"polyclonal anti-merlin (1:250, Santa Cruz)",Antibody,,,,,
PMID:20195187,10.1097/MAO.0b013e3181d2777f,Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis.,,0.9,antibody,"monoclonal anti-actin (BD Biosciences, San Jose, CA)",Antibody,,,,,
PMID:20195187,10.1097/MAO.0b013e3181d2777f,Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis.,,0.95,antibody,"Rabbit polyclonal anti-merlin (1:100; Santa Cruz Biotechnology, Santa Cruz, CA)",Antibody,,,,,
PMID:20195187,10.1097/MAO.0b013e3181d2777f,Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis.,,0.8,genetic_reagent,Zymed ® BrdU Staining Kit (Invitrogen),Genetic Reagent,,,,,
PMID:20195187,10.1097/MAO.0b013e3181d2777f,Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis.,,0.8,genetic_reagent,"Annexin V-FITC Apoptosis Detection kit (Calbiochem, San Diego, Cat # PF032)",Genetic Reagent,,,,,
PMID:20195187,10.1097/MAO.0b013e3181d2777f,Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis.,,0.85,computational_tool,"ABI Prism 7000 Sequence Detection System (Applied Biosystems, version 1.1 software)",Computational Tool,,,,,
PMID:20195187,10.1097/MAO.0b013e3181d2777f,Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis.,,0.8,computational_tool,Olympus FV1000 point scanning confocal microscope,Computational Tool,,,,,
PMID:18413802,10.1158/1535-7163.MCT-07-0518,Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,0.85,cell_line,MPNST,Cell Line,,,,,
PMID:18413802,10.1158/1535-7163.MCT-07-0518,Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,0.9,cell_line,ST8814,Cell Line,,,,,
PMID:18413802,10.1158/1535-7163.MCT-07-0518,Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,0.8,cell_line,LS141,Cell Line,,,,,
PMID:18413802,10.1158/1535-7163.MCT-07-0518,Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,0.8,cell_line,DDLS,Cell Line,,,,,
PMID:18413802,10.1158/1535-7163.MCT-07-0518,Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,0.85,genetic_reagent,EZ-Detect Ras Activation Kit,Genetic Reagent,,,,,
PMID:18413802,10.1158/1535-7163.MCT-07-0518,Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,0.8,genetic_reagent,Cell Counting Kit 8,Genetic Reagent,,,,,
PMID:18413802,10.1158/1535-7163.MCT-07-0518,Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,0.85,antibody,MPM-2 antibody,Antibody,,,,,
PMID:18413802,10.1158/1535-7163.MCT-07-0518,Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,0.85,antibody,pan-Ras antibody,Antibody,,,,,
PMID:18413802,10.1158/1535-7163.MCT-07-0518,Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,0.85,antibody,Cyclin D1 antibody,Antibody,,,,,
PMID:18413802,10.1158/1535-7163.MCT-07-0518,Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,0.85,antibody,ERK antibody,Antibody,,,,,
PMID:18413802,10.1158/1535-7163.MCT-07-0518,Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,0.85,antibody,phospho-ERK antibody,Antibody,,,,,
PMID:18413802,10.1158/1535-7163.MCT-07-0518,Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,0.85,antibody,B-Raf antibody,Antibody,,,,,
PMID:18413802,10.1158/1535-7163.MCT-07-0518,Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,0.85,antibody,phospho-MEK1/2 antibody,Antibody,,,,,
PMID:18413802,10.1158/1535-7163.MCT-07-0518,Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,0.85,antibody,phospho-Rb antibody,Antibody,,,,,
PMID:18413802,10.1158/1535-7163.MCT-07-0518,Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,0.9,genetic_reagent,B-Raf siRNA,Genetic Reagent,,,,,
PMID:18413802,10.1158/1535-7163.MCT-07-0518,Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,0.9,genetic_reagent,C-Raf siRNA,Genetic Reagent,,,,,
PMID:18413802,10.1158/1535-7163.MCT-07-0518,Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,0.8,computational_tool,FlowJo software,Computational Tool,,,,,
PMID:40352015,10.7759/cureus.82033,Development of a Machine Learning Algorithm for the Prediction of WHO Grade 1 Meningioma Recurrence.,,0.85,computational_tool,Risk-Calibrated Superspase Linear Integer Model (Risk-SLIM),Computational Tool,,,,,
PMID:40352015,10.7759/cureus.82033,Development of a Machine Learning Algorithm for the Prediction of WHO Grade 1 Meningioma Recurrence.,,0.8,computational_tool,Python version 3.10,Computational Tool,,,,,
PMID:40352015,10.7759/cureus.82033,Development of a Machine Learning Algorithm for the Prediction of WHO Grade 1 Meningioma Recurrence.,,0.75,clinical_assessment_tool,Ki-67/MIB-1 index,Clinical Assessment Tool,,,,,
PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,,0.85,cell_line,Human Schwann cells (HSCs),Cell Line,,,,,
PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,,0.9,cell_line,RT4-D6P2T schwannoma cells,Cell Line,,,,,
PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,,0.9,cell_line,HEI-193,Cell Line,,,,,
PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,,0.85,animal_model,BALB/c nude mice,Animal Model,,,,,
PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,,0.8,genetic_reagent,Nutlin-3,Genetic Reagent,,,,,
PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,,0.8,genetic_reagent,MG-132,Genetic Reagent,,,,,
PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,,0.9,antibody,merlin antibody (HPA003097),Antibody,,,,,
PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,,0.9,antibody,p53 antibody (P6874),Antibody,,,,,
PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,,0.9,antibody,MDM2 antibody (M43084),Antibody,,,,,
PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,,0.9,antibody,cyclinD1 antibody (C7464),Antibody,,,,,
PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,,0.9,antibody,caspase-3 antibody (9662),Antibody,,,,,
PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,,0.85,antibody,β-actin antibody (AA128),Antibody,,,,,
PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,,0.9,genetic_reagent,NF2 shRNA vectors,Genetic Reagent,,,,,
PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,,0.9,genetic_reagent,P53 shRNA vector,Genetic Reagent,,,,,
PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,,0.9,genetic_reagent,HA-tagged NF2 plasmid,Genetic Reagent,,,,,
PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,,0.9,genetic_reagent,Flag-tagged P53 plasmid,Genetic Reagent,,,,,
PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,,0.75,genetic_reagent,Cell Counting Kit-8 (CCK-8),Genetic Reagent,,,,,
PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,,0.8,computational_tool,SPSS 17.0,Computational Tool,,,,,
PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,,0.85,computational_tool,Imaris software,Computational Tool,,,,,
PMID:18632543,10.1001/jama.300.3.287,Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial.,,0.9,clinical_assessment_tool,Rey complex figure test,Clinical Assessment Tool,,,,,
PMID:18632543,10.1001/jama.300.3.287,Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial.,,0.85,clinical_assessment_tool,cancellation test,Clinical Assessment Tool,,,,,
PMID:18632543,10.1001/jama.300.3.287,Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial.,,0.8,clinical_assessment_tool,prism adaptation task,Clinical Assessment Tool,,,,,
PMID:18632543,10.1001/jama.300.3.287,Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial.,,0.9,clinical_assessment_tool,Stroop color word test,Clinical Assessment Tool,,,,,
PMID:18632543,10.1001/jama.300.3.287,Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial.,,0.95,clinical_assessment_tool,Wechsler Intelligence Scale for Children–Revised,Clinical Assessment Tool,,,,,
PMID:18632543,10.1001/jama.300.3.287,Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial.,,0.9,clinical_assessment_tool,Beery developmental test of visual-motor integration,Clinical Assessment Tool,,,,,
PMID:18632543,10.1001/jama.300.3.287,Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial.,,0.85,clinical_assessment_tool,judgment of line orientation task,Clinical Assessment Tool,,,,,
PMID:18632543,10.1001/jama.300.3.287,Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial.,,0.8,computational_tool,SPSS 12.0,Computational Tool,,,,,
PMID:18632543,10.1001/jama.300.3.287,Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial.,,0.85,animal_model,Nf1 mice,Animal Model,,,,,
PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,0.85,cell_line,HEK 293T cell line,Cell Line,,,,,
PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,0.85,cell_line,LN428 human glioblastoma multiforme (GBM) cell line,Cell Line,,,,,
PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,0.95,animal_model,"Nf1 flox/mut; GFAP-Cre, Nf1+/− GFAP CKO",Animal Model,,,,,
PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,0.9,antibody,goat anti-CXCL12 antibody,Antibody,,,,,
PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,0.9,antibody,rabbit anti CXCL12 antibody,Antibody,,,,,
PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,0.9,antibody,Rat anti-GFAP antibody,Antibody,,,,,
PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,0.9,antibody,Goat anti-Endoglin antibody,Antibody,,,,,
PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,0.9,antibody,rabbit anti-IBA-1 antibody,Antibody,,,,,
PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,0.9,antibody,p-PKA substrate antibody,Antibody,,,,,
PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,0.9,antibody,pan-AKT antibody,Antibody,,,,,
PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,0.9,antibody,pS473-AKT antibody,Antibody,,,,,
PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,0.9,antibody,pan-CXCR4 antibody,Antibody,,,,,
PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,0.9,antibody,mouse anti-CNPase antibody,Antibody,,,,,
PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,0.9,antibody,pCXCR4 antibody,Antibody,,,,,
PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,0.9,antibody,rabbit anti Olig2 antibody (DF-308),Antibody,,,,,
PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,0.85,genetic_reagent,Murine CXCL12 cDNA lentiviral vector,Genetic Reagent,,,,,
PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,0.85,genetic_reagent,FUW-FLG lentiviral vector,Genetic Reagent,,,,,
PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,0.8,computational_tool,IVIS 50 system,Computational Tool,,,,,
PMID:22384355,10.1534/g3.111.000687,The SPRED1 Variants Repository for Legius Syndrome.,,0.8,computational_tool,PubMed,Computational Tool,,,,,
PMID:22384355,10.1534/g3.111.000687,The SPRED1 Variants Repository for Legius Syndrome.,,0.8,computational_tool,Google,Computational Tool,,,,,
PMID:22384355,10.1534/g3.111.000687,The SPRED1 Variants Repository for Legius Syndrome.,,0.9,computational_tool,Mutalyzer 2.0,Computational Tool,,,,,
PMID:22384355,10.1534/g3.111.000687,The SPRED1 Variants Repository for Legius Syndrome.,,0.85,computational_tool,MySQL,Computational Tool,,,,,
PMID:22384355,10.1534/g3.111.000687,The SPRED1 Variants Repository for Legius Syndrome.,,0.8,computational_tool,PHP,Computational Tool,,,,,
PMID:22384355,10.1534/g3.111.000687,The SPRED1 Variants Repository for Legius Syndrome.,,0.9,computational_tool,FusionCharts v3,Computational Tool,,,,,
PMID:22384355,10.1534/g3.111.000687,The SPRED1 Variants Repository for Legius Syndrome.,,0.85,computational_tool,phpmyadmin,Computational Tool,,,,,
PMID:22384355,10.1534/g3.111.000687,The SPRED1 Variants Repository for Legius Syndrome.,,0.8,computational_tool,Mac OS X Apache server,Computational Tool,,,,,
PMID:37446790,10.3390/molecules28135128,Icariin Promotes Osteogenic Differentiation in a Cell Model with NF1 Gene Knockout by Activating the cAMP/PKA/CREB Pathway.,,0.85,cell_line,C2C12,Cell Line,,,,,
PMID:37446790,10.3390/molecules28135128,Icariin Promotes Osteogenic Differentiation in a Cell Model with NF1 Gene Knockout by Activating the cAMP/PKA/CREB Pathway.,,0.9,genetic_reagent,CRISPR/Cas9 single-vector lentivirus,Genetic Reagent,,,,,
PMID:37446790,10.3390/molecules28135128,Icariin Promotes Osteogenic Differentiation in a Cell Model with NF1 Gene Knockout by Activating the cAMP/PKA/CREB Pathway.,,0.95,antibody,GAPDH antibody (cat. no. 5174S),Antibody,,,,,
PMID:37446790,10.3390/molecules28135128,Icariin Promotes Osteogenic Differentiation in a Cell Model with NF1 Gene Knockout by Activating the cAMP/PKA/CREB Pathway.,,0.95,antibody,phosphorylated PKA antibody (cat. no. 5661S),Antibody,,,,,
PMID:37446790,10.3390/molecules28135128,Icariin Promotes Osteogenic Differentiation in a Cell Model with NF1 Gene Knockout by Activating the cAMP/PKA/CREB Pathway.,,0.95,antibody,PKA antibody (cat. no. 4782S),Antibody,,,,,
PMID:37446790,10.3390/molecules28135128,Icariin Promotes Osteogenic Differentiation in a Cell Model with NF1 Gene Knockout by Activating the cAMP/PKA/CREB Pathway.,,0.95,antibody,phosphorylated CREB antibody (cat. no. 9198S),Antibody,,,,,
PMID:37446790,10.3390/molecules28135128,Icariin Promotes Osteogenic Differentiation in a Cell Model with NF1 Gene Knockout by Activating the cAMP/PKA/CREB Pathway.,,0.95,antibody,CREB antibody (cat. no. 9197T),Antibody,,,,,
PMID:37446790,10.3390/molecules28135128,Icariin Promotes Osteogenic Differentiation in a Cell Model with NF1 Gene Knockout by Activating the cAMP/PKA/CREB Pathway.,,0.95,antibody,neurofibromin antibody (cat. no. ab17963),Antibody,,,,,
PMID:37446790,10.3390/molecules28135128,Icariin Promotes Osteogenic Differentiation in a Cell Model with NF1 Gene Knockout by Activating the cAMP/PKA/CREB Pathway.,,0.9,computational_tool,DESeq2 (version 1.12.4),Computational Tool,,,,,
PMID:37446790,10.3390/molecules28135128,Icariin Promotes Osteogenic Differentiation in a Cell Model with NF1 Gene Knockout by Activating the cAMP/PKA/CREB Pathway.,,0.85,computational_tool,HiSeq XTen sequencers,Computational Tool,,,,,
PMID:37446790,10.3390/molecules28135128,Icariin Promotes Osteogenic Differentiation in a Cell Model with NF1 Gene Knockout by Activating the cAMP/PKA/CREB Pathway.,,0.85,computational_tool,LightCycler 480 II Real-Time PCR System,Computational Tool,,,,,
PMID:37446790,10.3390/molecules28135128,Icariin Promotes Osteogenic Differentiation in a Cell Model with NF1 Gene Knockout by Activating the cAMP/PKA/CREB Pathway.,,0.8,computational_tool,PRISM (version 8),Computational Tool,,,,,
PMID:40862755,10.3390/cells14161276,Fibroblasts Attenuate Anti-Tumor Drug Efficacy in Tumor Cells via Paracrine Interactions with Tumor Cells in 3D Plexiform Neurofibroma Cultures.,,0.9,cell_line,ipNF95.11b C,Cell Line,,,,,
PMID:40862755,10.3390/cells14161276,Fibroblasts Attenuate Anti-Tumor Drug Efficacy in Tumor Cells via Paracrine Interactions with Tumor Cells in 3D Plexiform Neurofibroma Cultures.,,0.9,cell_line,ipNF05.5,Cell Line,,,,,
PMID:40862755,10.3390/cells14161276,Fibroblasts Attenuate Anti-Tumor Drug Efficacy in Tumor Cells via Paracrine Interactions with Tumor Cells in 3D Plexiform Neurofibroma Cultures.,,0.85,advanced_cellular_model,TAME chips,Advanced Cellular Model,,,,,
PMID:40862755,10.3390/cells14161276,Fibroblasts Attenuate Anti-Tumor Drug Efficacy in Tumor Cells via Paracrine Interactions with Tumor Cells in 3D Plexiform Neurofibroma Cultures.,,0.9,antibody,Anti-P-glycoprotein primary antibody (ab170904),Antibody,,,,,
PMID:40862755,10.3390/cells14161276,Fibroblasts Attenuate Anti-Tumor Drug Efficacy in Tumor Cells via Paracrine Interactions with Tumor Cells in 3D Plexiform Neurofibroma Cultures.,,0.8,computational_tool,Zeiss LSM 780 confocal microscope,Computational Tool,,,,,
PMID:40862755,10.3390/cells14161276,Fibroblasts Attenuate Anti-Tumor Drug Efficacy in Tumor Cells via Paracrine Interactions with Tumor Cells in 3D Plexiform Neurofibroma Cultures.,,0.8,computational_tool,Leica Stellaris 5 system,Computational Tool,,,,,
PMID:40862755,10.3390/cells14161276,Fibroblasts Attenuate Anti-Tumor Drug Efficacy in Tumor Cells via Paracrine Interactions with Tumor Cells in 3D Plexiform Neurofibroma Cultures.,,0.9,computational_tool,Volocity software (Version 7.0.0),Computational Tool,,,,,
PMID:40862755,10.3390/cells14161276,Fibroblasts Attenuate Anti-Tumor Drug Efficacy in Tumor Cells via Paracrine Interactions with Tumor Cells in 3D Plexiform Neurofibroma Cultures.,,0.85,computational_tool,ImageJ 1.54g software,Computational Tool,,,,,
PMID:40862755,10.3390/cells14161276,Fibroblasts Attenuate Anti-Tumor Drug Efficacy in Tumor Cells via Paracrine Interactions with Tumor Cells in 3D Plexiform Neurofibroma Cultures.,,0.8,computational_tool,SpectraMax Plus 384 microplate reader,Computational Tool,,,,,
PMID:29958847,10.1016/j.neurad.2018.05.006,Radiomic biomarkers informative of cancerous transformation in neurofibromatosis-1 plexiform tumors.,,0.85,computational_tool,Insight Toolkit,Computational Tool,,,,,
PMID:29958847,10.1016/j.neurad.2018.05.006,Radiomic biomarkers informative of cancerous transformation in neurofibromatosis-1 plexiform tumors.,,0.85,computational_tool,Slicer,Computational Tool,,,,,
PMID:29958847,10.1016/j.neurad.2018.05.006,Radiomic biomarkers informative of cancerous transformation in neurofibromatosis-1 plexiform tumors.,,0.8,computational_tool,Law's texture energy measures,Computational Tool,,,,,
PMID:29958847,10.1016/j.neurad.2018.05.006,Radiomic biomarkers informative of cancerous transformation in neurofibromatosis-1 plexiform tumors.,,0.8,computational_tool,grey-level co-occurrence matrices,Computational Tool,,,,,
PMID:29958847,10.1016/j.neurad.2018.05.006,Radiomic biomarkers informative of cancerous transformation in neurofibromatosis-1 plexiform tumors.,,0.8,computational_tool,neighborhood grey-tone difference matrices,Computational Tool,,,,,
PMID:29958847,10.1016/j.neurad.2018.05.006,Radiomic biomarkers informative of cancerous transformation in neurofibromatosis-1 plexiform tumors.,,0.75,computational_tool,Jarque-Bera normality test,Computational Tool,,,,,
PMID:29958847,10.1016/j.neurad.2018.05.006,Radiomic biomarkers informative of cancerous transformation in neurofibromatosis-1 plexiform tumors.,,0.75,computational_tool,Levene's test,Computational Tool,,,,,
PMID:29958847,10.1016/j.neurad.2018.05.006,Radiomic biomarkers informative of cancerous transformation in neurofibromatosis-1 plexiform tumors.,,0.75,computational_tool,k-medoid clustering,Computational Tool,,,,,
PMID:28831766,10.1007/s12104-017-9768-1,NMR resonance assignments of the EVH1 domain of neurofibromin's recruitment factor Spred1.,,0.85,genetic_reagent,pET-Spred1(EVH1),Genetic Reagent,,,,,
PMID:28831766,10.1007/s12104-017-9768-1,NMR resonance assignments of the EVH1 domain of neurofibromin's recruitment factor Spred1.,,0.9,cell_line,BL21(DE3) Star,Cell Line,,,,,
PMID:28831766,10.1007/s12104-017-9768-1,NMR resonance assignments of the EVH1 domain of neurofibromin's recruitment factor Spred1.,,0.8,computational_tool,NMRPipe,Computational Tool,,,,,
PMID:28831766,10.1007/s12104-017-9768-1,NMR resonance assignments of the EVH1 domain of neurofibromin's recruitment factor Spred1.,,0.8,computational_tool,CcpNMR,Computational Tool,,,,,
PMID:28831766,10.1007/s12104-017-9768-1,NMR resonance assignments of the EVH1 domain of neurofibromin's recruitment factor Spred1.,,0.85,computational_tool,TALOS+,Computational Tool,,,,,
PMID:24681606,10.18632/oncotarget.1609,Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.,,0.9,cell_line,iHSC1λ,Cell Line,,,,,
PMID:24681606,10.18632/oncotarget.1609,Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.,,0.9,cell_line,iHSC2λ,Cell Line,,,,,
PMID:24681606,10.18632/oncotarget.1609,Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.,,0.9,cell_line,S462,Cell Line,,,,,
PMID:24681606,10.18632/oncotarget.1609,Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.,,0.9,cell_line,S462-TY,Cell Line,,,,,
PMID:24681606,10.18632/oncotarget.1609,Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.,,0.9,cell_line,ST8814,Cell Line,,,,,
PMID:24681606,10.18632/oncotarget.1609,Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.,,0.9,cell_line,T265,Cell Line,,,,,
PMID:24681606,10.18632/oncotarget.1609,Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.,,0.9,cell_line,STS-26T,Cell Line,,,,,
PMID:24681606,10.18632/oncotarget.1609,Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.,,0.8,genetic_reagent,Everolimus,Genetic Reagent,,,,,
PMID:24681606,10.18632/oncotarget.1609,Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.,,0.8,genetic_reagent,PD-0325901,Genetic Reagent,,,,,
PMID:24681606,10.18632/oncotarget.1609,Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.,,0.9,computational_tool,CalcuSyn Version 2.1,Computational Tool,,,,,
PMID:24681606,10.18632/oncotarget.1609,Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.,,0.9,antibody,S100 antibody,Antibody,,,,,
PMID:24681606,10.18632/oncotarget.1609,Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.,,0.9,antibody,Ki67 antibody,Antibody,,,,,
PMID:24681606,10.18632/oncotarget.1609,Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.,,0.9,antibody,p-AKT S473 antibody,Antibody,,,,,
PMID:24681606,10.18632/oncotarget.1609,Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.,,0.9,antibody,p-4EBP antibody,Antibody,,,,,
PMID:24681606,10.18632/oncotarget.1609,Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.,,0.9,antibody,p-ERK antibody,Antibody,,,,,
PMID:24681606,10.18632/oncotarget.1609,Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.,,0.9,antibody,GAPDH antibody,Antibody,,,,,
PMID:24681606,10.18632/oncotarget.1609,Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.,,0.9,computational_tool,ImageJ,Computational Tool,,,,,
PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,0.85,cell_line,NF1-null 293T cells,Cell Line,,,,,
PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,0.9,cell_line,ipNF95.11b C,Cell Line,,,,,
PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,0.85,genetic_reagent,Addgene plasmid 70423,Genetic Reagent,,,,,
PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,0.8,genetic_reagent,pCAN-FLAG-DEST,Genetic Reagent,,,,,
PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,0.8,genetic_reagent,pCAN-HA-DEST,Genetic Reagent,,,,,
PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,0.85,genetic_reagent,pLIX403,Genetic Reagent,,,,,
PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,0.8,genetic_reagent,psPAX2,Genetic Reagent,,,,,
PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,0.8,genetic_reagent,pMD2.G,Genetic Reagent,,,,,
PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,0.9,antibody,Anti-FLAG M2,Antibody,,,,,
PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,0.9,antibody,FLAG-M2,Antibody,,,,,
PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,0.85,antibody,KRAS antibody,Antibody,,,,,
PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,0.85,antibody,HA antibody,Antibody,,,,,
PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,0.85,antibody,HSP70 antibody,Antibody,,,,,
PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,0.85,antibody,Ubiquitin antibody,Antibody,,,,,
PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,0.85,antibody,pan-RAS antibody,Antibody,,,,,
PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,0.85,antibody,GST antibody,Antibody,,,,,
PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,0.85,antibody,Vinculin antibody,Antibody,,,,,
PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,0.85,antibody,RASA1 antibody,Antibody,,,,,
PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,0.9,computational_tool,RELION,Computational Tool,,,,,
PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,0.85,computational_tool,MotionCorr,Computational Tool,,,,,
PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,0.85,computational_tool,CTFFIND4,Computational Tool,,,,,
PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,0.85,computational_tool,Chimera,Computational Tool,,,,,
PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,0.85,computational_tool,Coot,Computational Tool,,,,,
PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,0.85,computational_tool,Phenix,Computational Tool,,,,,
PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,0.85,computational_tool,Servalcat,Computational Tool,,,,,
PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,0.8,computational_tool,Image-Studio,Computational Tool,,,,,
PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,0.8,computational_tool,SerialEM,Computational Tool,,,,,
PMID:32107864,10.1002/mgg3.1180,Expanding the Noonan spectrum/RASopathy NGS panel: Benefits of adding NF1 and SPRED1.,,0.85,genetic_reagent,PureGene Blood Core Kit B,Genetic Reagent,,,,,
PMID:32107864,10.1002/mgg3.1180,Expanding the Noonan spectrum/RASopathy NGS panel: Benefits of adding NF1 and SPRED1.,,0.8,genetic_reagent,SureSelect,Genetic Reagent,,,,,
PMID:32107864,10.1002/mgg3.1180,Expanding the Noonan spectrum/RASopathy NGS panel: Benefits of adding NF1 and SPRED1.,,0.9,computational_tool,MiSeq-M01450,Computational Tool,,,,,
PMID:32107864,10.1002/mgg3.1180,Expanding the Noonan spectrum/RASopathy NGS panel: Benefits of adding NF1 and SPRED1.,,0.95,computational_tool,bwa-mem v0.7.10,Computational Tool,,,,,
PMID:32107864,10.1002/mgg3.1180,Expanding the Noonan spectrum/RASopathy NGS panel: Benefits of adding NF1 and SPRED1.,,0.95,computational_tool,"GATK, version 1.0.4705",Computational Tool,,,,,
PMID:32107864,10.1002/mgg3.1180,Expanding the Noonan spectrum/RASopathy NGS panel: Benefits of adding NF1 and SPRED1.,,0.9,computational_tool,VisCap,Computational Tool,,,,,
PMID:32107864,10.1002/mgg3.1180,Expanding the Noonan spectrum/RASopathy NGS panel: Benefits of adding NF1 and SPRED1.,,0.85,computational_tool,ddPCR,Computational Tool,,,,,
PMID:38990917,10.1371/journal.pone.0305548,Optical coherence tomography of the macular ganglion cell layer in children with neurofibromatosis type 1 is a useful tool in the assessment for optic pathway gliomas.,,0.9,clinical_assessment_tool,Cirrus HD-OCT,Clinical Assessment Tool,,,,,
PMID:38990917,10.1371/journal.pone.0305548,Optical coherence tomography of the macular ganglion cell layer in children with neurofibromatosis type 1 is a useful tool in the assessment for optic pathway gliomas.,,0.85,clinical_assessment_tool,Teller acuity cards,Clinical Assessment Tool,,,,,
PMID:38990917,10.1371/journal.pone.0305548,Optical coherence tomography of the macular ganglion cell layer in children with neurofibromatosis type 1 is a useful tool in the assessment for optic pathway gliomas.,,0.85,clinical_assessment_tool,Cardiff acuity cards,Clinical Assessment Tool,,,,,
PMID:38990917,10.1371/journal.pone.0305548,Optical coherence tomography of the macular ganglion cell layer in children with neurofibromatosis type 1 is a useful tool in the assessment for optic pathway gliomas.,,0.85,clinical_assessment_tool,Lea cards,Clinical Assessment Tool,,,,,
PMID:38990917,10.1371/journal.pone.0305548,Optical coherence tomography of the macular ganglion cell layer in children with neurofibromatosis type 1 is a useful tool in the assessment for optic pathway gliomas.,,0.85,clinical_assessment_tool,KM (Konstantin Moutakis) cards,Clinical Assessment Tool,,,,,
PMID:38990917,10.1371/journal.pone.0305548,Optical coherence tomography of the macular ganglion cell layer in children with neurofibromatosis type 1 is a useful tool in the assessment for optic pathway gliomas.,,0.9,clinical_assessment_tool,Humphrey Field Analyzer perimetry,Clinical Assessment Tool,,,,,
PMID:38990917,10.1371/journal.pone.0305548,Optical coherence tomography of the macular ganglion cell layer in children with neurofibromatosis type 1 is a useful tool in the assessment for optic pathway gliomas.,,0.9,clinical_assessment_tool,World Health Organization Categories of Childhood VI scale,Clinical Assessment Tool,,,,,
PMID:34065204,10.3390/ijms22105367,RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.,,0.9,cell_line,Primary human Schwann cells (NHSC),Cell Line,,,,,
PMID:34065204,10.3390/ijms22105367,RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.,,0.85,cell_line,Mouse embryonic fibroblasts (MEFs),Cell Line,,,,,
PMID:34065204,10.3390/ijms22105367,RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.,,0.9,animal_model,Rabl6m/m C57Bl/6N mice,Animal Model,,,,,
PMID:34065204,10.3390/ijms22105367,RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.,,0.9,genetic_reagent,RABL6A shRNAs in pLKO.1 lentiviral vector,Genetic Reagent,,,,,
PMID:34065204,10.3390/ijms22105367,RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.,,0.9,genetic_reagent,RB1 shRNAs in pLKO.1 lentiviral vector,Genetic Reagent,,,,,
PMID:34065204,10.3390/ijms22105367,RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.,,0.95,antibody,p-RB1-S807/811 antibody (Cell Signaling #8516),Antibody,,,,,
PMID:34065204,10.3390/ijms22105367,RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.,,0.9,antibody,RB1 antibody (Cell Signaling #9309),Antibody,,,,,
PMID:34065204,10.3390/ijms22105367,RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.,,0.9,antibody,RB1 antibody (Cell Signaling #9313),Antibody,,,,,
PMID:34065204,10.3390/ijms22105367,RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.,,0.9,antibody,human p16 antibody (Abcam ab108349),Antibody,,,,,
PMID:34065204,10.3390/ijms22105367,RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.,,0.9,antibody,GAPDH antibody (Abcam Ab8245),Antibody,,,,,
PMID:34065204,10.3390/ijms22105367,RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.,,0.9,antibody,mouse p16 antibody (Santa Cruz sc-1207),Antibody,,,,,
PMID:34065204,10.3390/ijms22105367,RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.,,0.85,antibody,HRP-coupled secondary antibodies (Sigma NA934),Antibody,,,,,
PMID:34065204,10.3390/ijms22105367,RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.,,0.85,antibody,HRP-coupled secondary antibodies (Sigma NA935),Antibody,,,,,
PMID:34065204,10.3390/ijms22105367,RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.,,0.9,antibody,RABL6A antibodies (Quelle laboratory),Antibody,,,,,
PMID:34065204,10.3390/ijms22105367,RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.,,0.85,antibody,Alexa Fluor 488 secondary antibody,Antibody,,,,,
PMID:34065204,10.3390/ijms22105367,RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.,,0.85,antibody,Alexa Fluor 647 secondary antibody,Antibody,,,,,
PMID:34065204,10.3390/ijms22105367,RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.,,0.8,genetic_reagent,Senescence β-Galactosidase Staining Kit (Cell Signaling #9860),Genetic Reagent,,,,,
PMID:34065204,10.3390/ijms22105367,RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.,,0.8,computational_tool,MOD Fit LT software,Computational Tool,,,,,
PMID:34065204,10.3390/ijms22105367,RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.,,0.85,computational_tool,ImageJ,Computational Tool,,,,,
PMID:32187457,10.1056/NEJMoa1912735,Selumetinib in Children with Inoperable Plexiform Neurofibromas.,,0.95,clinical_assessment_tool,Numerical Rating Scale (NRS-11),Clinical Assessment Tool,,,,,
PMID:32187457,10.1056/NEJMoa1912735,Selumetinib in Children with Inoperable Plexiform Neurofibromas.,,0.9,clinical_assessment_tool,Pain Interference Index,Clinical Assessment Tool,,,,,
PMID:32187457,10.1056/NEJMoa1912735,Selumetinib in Children with Inoperable Plexiform Neurofibromas.,,0.95,clinical_assessment_tool,Pediatric Quality of Life Inventory (PedsQL) Generic Core Scales,Clinical Assessment Tool,,,,,
PMID:32187457,10.1056/NEJMoa1912735,Selumetinib in Children with Inoperable Plexiform Neurofibromas.,,0.9,clinical_assessment_tool,Global Impression of Change scale,Clinical Assessment Tool,,,,,
PMID:32187457,10.1056/NEJMoa1912735,Selumetinib in Children with Inoperable Plexiform Neurofibromas.,,0.95,clinical_assessment_tool,Patient-Reported Outcomes Measurement Information System (PROMIS) Mobility short form,Clinical Assessment Tool,,,,,
PMID:32187457,10.1056/NEJMoa1912735,Selumetinib in Children with Inoperable Plexiform Neurofibromas.,,0.95,clinical_assessment_tool,Patient-Reported Outcomes Measurement Information System (PROMIS) Upper Extremity short form,Clinical Assessment Tool,,,,,
PMID:32187457,10.1056/NEJMoa1912735,Selumetinib in Children with Inoperable Plexiform Neurofibromas.,,0.95,clinical_assessment_tool,"NCI Common Terminology Criteria for Adverse Events, version 4.0",Clinical Assessment Tool,,,,,
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,0.9,cell_line,JH-2-002,Cell Line,,,,,
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,0.9,cell_line,JH-2-031,Cell Line,,,,,
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,0.9,cell_line,JH-2-079c,Cell Line,,,,,
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,0.9,cell_line,JH-2-103,Cell Line,,,,,
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,0.9,patient_derived_model,JH-2-002 PDX,Patient-Derived Model,,,,,
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,0.9,patient_derived_model,JH-2-031 PDX,Patient-Derived Model,,,,,
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,0.9,patient_derived_model,JH-2-079c PDX,Patient-Derived Model,,,,,
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,0.9,patient_derived_model,WU-225 PDX,Patient-Derived Model,,,,,
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,0.9,patient_derived_model,WU-386 PDX,Patient-Derived Model,,,,,
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,0.9,patient_derived_model,WU-545 PDX,Patient-Derived Model,,,,,
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,0.9,patient_derived_model,MN-2 PDX,Patient-Derived Model,,,,,
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,0.9,patient_derived_model,MN-3-002 PDX,Patient-Derived Model,,,,,
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,0.85,animal_model,NRG mice,Animal Model,,,,,
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,0.85,genetic_reagent,Tet-pLKO-puro vector,Genetic Reagent,,,,,
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,0.85,genetic_reagent,TTIGFP-MLUEX vector,Genetic Reagent,,,,,
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,0.9,genetic_reagent,shPTPN11 #5003,Genetic Reagent,,,,,
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,0.9,genetic_reagent,shPTPN11 #818,Genetic Reagent,,,,,
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,0.85,genetic_reagent,NF1-GRD construct,Genetic Reagent,,,,,
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,0.8,computational_tool,Trimmomatic v0.39,Computational Tool,,,,,
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,0.8,computational_tool,BWA-MEM,Computational Tool,,,,,
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,0.8,computational_tool,GATK V4.2,Computational Tool,,,,,
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,0.8,computational_tool,VarScan2,Computational Tool,,,,,
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,0.8,computational_tool,Strelka2,Computational Tool,,,,,
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,0.8,computational_tool,MuTect2,Computational Tool,,,,,
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,0.8,computational_tool,Pindel,Computational Tool,,,,,
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,0.8,computational_tool,Salmon algorithm,Computational Tool,,,,,
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,0.8,computational_tool,DESeq2,Computational Tool,,,,,
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,0.8,computational_tool,MAGINE,Computational Tool,,,,,
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,0.8,computational_tool,FlowJo 10.8,Computational Tool,,,,,
PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,0.9,animal_model,Nf1 P1,Animal Model,,,,,
PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,0.85,animal_model,w CS10,Animal Model,,,,,
PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,0.9,genetic_reagent,UAS-Nf1-eGFP,Genetic Reagent,,,,,
PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,0.8,genetic_reagent,Q5 Site-Directed Mutagenesis Kit,Genetic Reagent,,,,,
PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,0.85,genetic_reagent,VDRC #109637,Genetic Reagent,,,,,
PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,0.85,genetic_reagent,UAS-rl Sem,Genetic Reagent,,,,,
PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,0.85,genetic_reagent,nSyb (BDSC #51635),Genetic Reagent,,,,,
PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,0.85,genetic_reagent,R57C10 (39171),Genetic Reagent,,,,,
PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,0.85,genetic_reagent,tsh-Gal4 (3040),Genetic Reagent,,,,,
PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,0.85,genetic_reagent,Oct-TyrR-Gal4 (36494),Genetic Reagent,,,,,
PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,0.85,genetic_reagent,PCB-Gal4,Genetic Reagent,,,,,
PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,0.9,antibody,mAb21 anti-Nf1 monoclonal antibody,Antibody,,,,,
PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,0.9,antibody,"anti-phospho-ERK (mouse, Sigma M8159)",Antibody,,,,,
PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,0.9,antibody,"total ERK (rabbit, CST 9102)",Antibody,,,,,
PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,0.9,antibody,"anti-β-tubulin (mouse, Developmental Studies Hybridoma Bank E7)",Antibody,,,,,
PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,0.9,antibody,"rabbit anti-GFP (Invitrogen, A11122)",Antibody,,,,,
PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,0.9,antibody,"mouse anti-nc82 (1:50, DSHB)",Antibody,,,,,
PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,0.8,computational_tool,PhenoCapture 3.3,Computational Tool,,,,,
PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,0.8,computational_tool,Fiji 2.0,Computational Tool,,,,,
PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,0.85,computational_tool,Sleep and Activity Metabolic Monitor (SAMM) system,Computational Tool,,,,,
PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,0.8,computational_tool,Noah.py,Computational Tool,,,,,
PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,0.8,computational_tool,LAS X software,Computational Tool,,,,,
PMID:34257279,10.1038/s41467-021-24505-x,Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila.,,0.8,computational_tool,AlphaImager HP system,Computational Tool,,,,,
PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,0.9,animal_model,Cnp-Cre; R26-lsl-SB11; T2/Onc15,Animal Model,,,,,
PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,0.85,genetic_reagent,R26-lsl-SB11,Genetic Reagent,,,,,
PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,0.85,genetic_reagent,Cnp-Cre,Genetic Reagent,,,,,
PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,0.85,genetic_reagent,T2/Onc15,Genetic Reagent,,,,,
PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,0.85,genetic_reagent,Cnp-EGFR,Genetic Reagent,,,,,
PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,0.9,cell_line,iHSCs,Cell Line,,,,,
PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,0.9,cell_line,ST88-14,Cell Line,,,,,
PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,0.9,cell_line,STS26T,Cell Line,,,,,
PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,0.9,cell_line,S462,Cell Line,,,,,
PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,0.9,cell_line,S462-TY,Cell Line,,,,,
PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,0.9,cell_line,T265,Cell Line,,,,,
PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,0.8,cell_line,K562,Cell Line,,,,,
PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,0.9,antibody,FOXR2 antibody (SIGMA),Antibody,,,,,
PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,0.9,antibody,GAPDH antibody (Cell Signaling Tech.),Antibody,,,,,
PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,0.9,antibody,CNPase antibody (Santa Cruz),Antibody,,,,,
PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,0.85,genetic_reagent,GIPZ lentiviral constructs,Genetic Reagent,,,,,
PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,0.85,genetic_reagent,piggyBac (PB) transposon vector,Genetic Reagent,,,,,
PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,0.85,genetic_reagent,FOXR2 TALENs,Genetic Reagent,,,,,
PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,0.85,genetic_reagent,HPRT TALEN,Genetic Reagent,,,,,
PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,0.8,computational_tool,TAPDANCE,Computational Tool,,,,,
PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,0.9,computational_tool,GeneSpring GX v7.3.1,Computational Tool,,,,,
PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,0.85,computational_tool,GenoCNA,Computational Tool,,,,,
PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,0.8,computational_tool,ImageJ,Computational Tool,,,,,
PMID:23685747,10.1038/ng.2641,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis.,,0.8,computational_tool,AxioVision,Computational Tool,,,,,
PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,0.95,cell_line,icNF 97.2a,Cell Line,,,,,
PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,0.95,cell_line,icNF 97.2b,Cell Line,,,,,
PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,0.95,cell_line,icNF 98.4d,Cell Line,,,,,
PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,0.9,antibody,TotalSeq™ anti-Nuclear Pore Complex Proteins Hashtag Antibody B0451,Antibody,,,,,
PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,0.9,antibody,TotalSeq™ anti-Nuclear Pore Complex Proteins Hashtag Antibody B0452,Antibody,,,,,
PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,0.9,antibody,TotalSeq™ anti-Nuclear Pore Complex Proteins Hashtag Antibody B0453,Antibody,,,,,
PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,0.9,antibody,TotalSeq™ anti-Nuclear Pore Complex Proteins Hashtag Antibody B0457,Antibody,,,,,
PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,0.95,antibody,CD11b antibody (abcam Cat # ab52478),Antibody,,,,,
PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,0.95,antibody,SOX10 antibody (abcam Cat # ab155279),Antibody,,,,,
PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,0.85,antibody,"Goat anti-Rabbit, Alexa Fluor™ 488",Antibody,,,,,
PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,0.85,antibody,"Goat anti-Rabbit, Alexa Fluor™ 594",Antibody,,,,,
PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,0.9,computational_tool,Cell Ranger pipeline v7.1.0,Computational Tool,,,,,
PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,0.9,computational_tool,Seurat v4.3.0–v5,Computational Tool,,,,,
PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,0.85,computational_tool,Harmony,Computational Tool,,,,,
PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,0.9,computational_tool,Ingenuity Pathway Analysis (IPA),Computational Tool,,,,,
PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,0.85,computational_tool,scanpy,Computational Tool,,,,,
PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,0.85,computational_tool,palantir,Computational Tool,,,,,
PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,0.85,computational_tool,scFates,Computational Tool,,,,,
PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,0.9,computational_tool,CellChat,Computational Tool,,,,,
PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,0.85,computational_tool,velocyto,Computational Tool,,,,,
PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,0.85,computational_tool,scvelo,Computational Tool,,,,,
PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,0.85,computational_tool,Scriabin,Computational Tool,,,,,
PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,0.9,genetic_reagent,KCNMA1 primer (QT00024157),Genetic Reagent,,,,,
PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,0.9,genetic_reagent,PRKCE primer (QT00016352),Genetic Reagent,,,,,
PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,0.9,genetic_reagent,OPCML primer (QT01005361),Genetic Reagent,,,,,
PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,0.9,genetic_reagent,GRIK2 primer (QT00016597),Genetic Reagent,,,,,
PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,0.9,genetic_reagent,CADM2 primer (QT00048888),Genetic Reagent,,,,,
PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,0.9,genetic_reagent,CREB5 primer (QT00054488),Genetic Reagent,,,,,
PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,0.9,genetic_reagent,CAMK1D primer (QT00036344),Genetic Reagent,,,,,
PMID:38907342,10.1186/s40478-024-01821-z,"snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,0.9,genetic_reagent,ITGB8 primer (QT00038507),Genetic Reagent,,,,,
PMID:35244537,10.7554/eLife.74238,Detection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis using aneuploidy and mutation identification in plasma.,,0.85,genetic_reagent,Illumina TruSeq library construction,Genetic Reagent,,,,,
PMID:35244537,10.7554/eLife.74238,Detection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis using aneuploidy and mutation identification in plasma.,,0.8,genetic_reagent,Agencourt AMPure XP beads,Genetic Reagent,,,,,
PMID:35244537,10.7554/eLife.74238,Detection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis using aneuploidy and mutation identification in plasma.,,0.9,genetic_reagent,"End Repair Enzyme Mix (cat# E6050, NEB)",Genetic Reagent,,,,,
PMID:35244537,10.7554/eLife.74238,Detection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis using aneuploidy and mutation identification in plasma.,,0.9,genetic_reagent,"Klenow (exo-)(cat# E6053, NEB)",Genetic Reagent,,,,,
PMID:35244537,10.7554/eLife.74238,Detection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis using aneuploidy and mutation identification in plasma.,,0.9,genetic_reagent,"Quick T4 DNA ligase (cat# E6056, NEB)",Genetic Reagent,,,,,
PMID:35244537,10.7554/eLife.74238,Detection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis using aneuploidy and mutation identification in plasma.,,0.85,genetic_reagent,Agilent SureSelect v.4 kit,Genetic Reagent,,,,,
PMID:35244537,10.7554/eLife.74238,Detection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis using aneuploidy and mutation identification in plasma.,,0.85,computational_tool,"Illumina HiSeq 2,500",Computational Tool,,,,,
PMID:35244537,10.7554/eLife.74238,Detection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis using aneuploidy and mutation identification in plasma.,,0.9,genetic_reagent,BioChain cfDNA Extraction Kit (cat #K5011610),Genetic Reagent,,,,,
PMID:35244537,10.7554/eLife.74238,Detection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis using aneuploidy and mutation identification in plasma.,,0.85,computational_tool,VariantDx,Computational Tool,,,,,
PMID:35244537,10.7554/eLife.74238,Detection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis using aneuploidy and mutation identification in plasma.,,0.9,computational_tool,Illumina CASAVA software (v1.8),Computational Tool,,,,,
PMID:35244537,10.7554/eLife.74238,Detection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis using aneuploidy and mutation identification in plasma.,,0.85,computational_tool,ELAND software,Computational Tool,,,,,
PMID:35244537,10.7554/eLife.74238,Detection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis using aneuploidy and mutation identification in plasma.,,0.85,computational_tool,snpEff,Computational Tool,,,,,
PMID:35244537,10.7554/eLife.74238,Detection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis using aneuploidy and mutation identification in plasma.,,0.9,genetic_reagent,QIAGEN circulating nucleic acid kit (Catalog# 55114),Genetic Reagent,,,,,
PMID:35244537,10.7554/eLife.74238,Detection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis using aneuploidy and mutation identification in plasma.,,0.85,computational_tool,BioRad QX200 droplet digital PCR system,Computational Tool,,,,,
PMID:35244537,10.7554/eLife.74238,Detection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis using aneuploidy and mutation identification in plasma.,,0.9,computational_tool,RealSeqS,Computational Tool,,,,,
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,0.85,cell_line,293T cells,Cell Line,,,,,
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,0.95,cell_line,sNF96.2,Cell Line,,,,,
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,0.8,cell_line,HFFs,Cell Line,,,,,
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,0.8,cell_line,NCI-H266,Cell Line,,,,,
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,0.8,cell_line,K562,Cell Line,,,,,
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,0.9,antibody,"rabbit anti-human HER1 (Abcam, ab52894)",Antibody,,,,,
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,0.9,antibody,"rabbit anti-human HER2 (ZSGB-BIO, ZA-0023)",Antibody,,,,,
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,0.9,antibody,"rabbit anti-human VEGFR2 (CST, 9698S)",Antibody,,,,,
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,0.9,antibody,"rabbit anti-human B7H3 (CST, #14058)",Antibody,,,,,
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,0.9,antibody,"rabbit anti-human CD171 (Abcam, ab208155)",Antibody,,,,,
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,0.9,antibody,"rabbit anti-human EGFRvIII (ZSGB-BIO, ZA-0643)",Antibody,,,,,
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,0.9,antibody,"rabbit anti-human TGFβ1 (Abcam, ab215715)",Antibody,,,,,
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,0.9,antibody,"rabbit anti-human PDL1 (Genetex, GTX104763)",Antibody,,,,,
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,0.9,antibody,"rabbit anti-human S100 (ZSGB-BIO, ZA-0225)",Antibody,,,,,
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,0.9,antibody,"S100β-Alexa Fluor 647 (Abcam, ab196175)",Antibody,,,,,
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,0.85,antibody,HER1-PE (352904),Antibody,,,,,
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,0.85,antibody,CD4-PE (317410),Antibody,,,,,
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,0.85,antibody,CD8a-APC (301014),Antibody,,,,,
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,0.85,antibody,CD45RO-PE (304206),Antibody,,,,,
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,0.85,antibody,CCR7-Percp (353242),Antibody,,,,,
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,0.9,genetic_reagent,anti-HER1 CAR (806),Genetic Reagent,,,,,
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,0.9,genetic_reagent,anti-HER1 CAR (E2),Genetic Reagent,,,,,
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,0.9,genetic_reagent,anti-HER1 CAR (NEC),Genetic Reagent,,,,,
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,0.85,computational_tool,BWA version 0.7.15,Computational Tool,,,,,
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,0.85,computational_tool,GATK MuTect2 (version 4.1),Computational Tool,,,,,
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,0.85,computational_tool,ANNOVAR (version 2016-02-01),Computational Tool,,,,,
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,0.85,computational_tool,TIDE (Tracking Indels by Decomposition),Computational Tool,,,,,
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,0.9,advanced_cellular_model,3D tumor spheroid model,Advanced Cellular Model,,,,,
PMID:34011935,10.1038/s41419-021-03802-9,Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.,,0.85,cell_line,Neurofibromatosis 1 fibroblasts,Cell Line,,,,,
PMID:34011935,10.1038/s41419-021-03802-9,Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.,,0.9,antibody,β-actin antibody (#13E5),Antibody,,,,,
PMID:34011935,10.1038/s41419-021-03802-9,Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.,,0.85,antibody,MEK1/2 antibody,Antibody,,,,,
PMID:34011935,10.1038/s41419-021-03802-9,Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.,,0.9,antibody,phospho-MEK1/2 antibody (#41G9),Antibody,,,,,
PMID:34011935,10.1038/s41419-021-03802-9,Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.,,0.9,antibody,phospho-ERK antibody (#D13.14.4E),Antibody,,,,,
PMID:34011935,10.1038/s41419-021-03802-9,Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.,,0.9,antibody,MMP1 antibody (#E9S9N),Antibody,,,,,
PMID:34011935,10.1038/s41419-021-03802-9,Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.,,0.9,antibody,NF1 antibody (#D7R7D),Antibody,,,,,
PMID:34011935,10.1038/s41419-021-03802-9,Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.,,0.9,antibody,Aryl hydrocarbon receptor antibody (#H-211),Antibody,,,,,
PMID:34011935,10.1038/s41419-021-03802-9,Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.,,0.9,antibody,collagen I antibody (#EPR7785),Antibody,,,,,
PMID:34011935,10.1038/s41419-021-03802-9,Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.,,0.85,antibody,anti-S100 protein antibody,Antibody,,,,,
PMID:34011935,10.1038/s41419-021-03802-9,Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.,,0.9,genetic_reagent,siRNA targeting NF1 (s221793),Genetic Reagent,,,,,
PMID:34011935,10.1038/s41419-021-03802-9,Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.,,0.9,genetic_reagent,siRNA targeting AHR (s1200),Genetic Reagent,,,,,
PMID:34011935,10.1038/s41419-021-03802-9,Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.,,0.8,computational_tool,CFX Connect System,Computational Tool,,,,,
PMID:34011935,10.1038/s41419-021-03802-9,Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.,,0.8,computational_tool,ChemiDoc XRS,Computational Tool,,,,,
PMID:34011935,10.1038/s41419-021-03802-9,Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.,,0.8,computational_tool,EVOS Cell Imaging Systems,Computational Tool,,,,,
PMID:34011935,10.1038/s41419-021-03802-9,Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.,,0.8,computational_tool,JMP Pro software,Computational Tool,,,,,
PMID:41444363,10.1038/s41598-025-32031-9,Focused ultrasound-mediated drug delivery of bevacizumab in treating NF2-related schwannomatosis in an animal model.,,0.95,animal_model,Postn-Cre; Nf2flox/flox,Animal Model,,,,,
PMID:41444363,10.1038/s41598-025-32031-9,Focused ultrasound-mediated drug delivery of bevacizumab in treating NF2-related schwannomatosis in an animal model.,,0.9,animal_model,Nf2flox/flox,Animal Model,,,,,
PMID:41444363,10.1038/s41598-025-32031-9,Focused ultrasound-mediated drug delivery of bevacizumab in treating NF2-related schwannomatosis in an animal model.,,0.9,animal_model,Postn-Cre,Animal Model,,,,,
PMID:41444363,10.1038/s41598-025-32031-9,Focused ultrasound-mediated drug delivery of bevacizumab in treating NF2-related schwannomatosis in an animal model.,,0.85,genetic_reagent,Avastin,Genetic Reagent,,,,,
PMID:41444363,10.1038/s41598-025-32031-9,Focused ultrasound-mediated drug delivery of bevacizumab in treating NF2-related schwannomatosis in an animal model.,,0.85,genetic_reagent,B20-4.1.1,Genetic Reagent,,,,,
PMID:41444363,10.1038/s41598-025-32031-9,Focused ultrasound-mediated drug delivery of bevacizumab in treating NF2-related schwannomatosis in an animal model.,,0.8,computational_tool,BioSpec 70/30 USR,Computational Tool,,,,,
PMID:41444363,10.1038/s41598-025-32031-9,Focused ultrasound-mediated drug delivery of bevacizumab in treating NF2-related schwannomatosis in an animal model.,,0.8,computational_tool,LP-100 FUS system,Computational Tool,,,,,
PMID:41444363,10.1038/s41598-025-32031-9,Focused ultrasound-mediated drug delivery of bevacizumab in treating NF2-related schwannomatosis in an animal model.,,0.9,antibody,Anti-CD31,Antibody,,,,,
PMID:41444363,10.1038/s41598-025-32031-9,Focused ultrasound-mediated drug delivery of bevacizumab in treating NF2-related schwannomatosis in an animal model.,,0.9,antibody,Anti-S100B,Antibody,,,,,
PMID:41444363,10.1038/s41598-025-32031-9,Focused ultrasound-mediated drug delivery of bevacizumab in treating NF2-related schwannomatosis in an animal model.,,0.85,computational_tool,Aedes software,Computational Tool,,,,,
PMID:41444363,10.1038/s41598-025-32031-9,Focused ultrasound-mediated drug delivery of bevacizumab in treating NF2-related schwannomatosis in an animal model.,,0.85,computational_tool,SAS 9.4,Computational Tool,,,,,
PMID:41444363,10.1038/s41598-025-32031-9,Focused ultrasound-mediated drug delivery of bevacizumab in treating NF2-related schwannomatosis in an animal model.,,0.85,computational_tool,ParaVision 6.0.1,Computational Tool,,,,,
PMID:41444363,10.1038/s41598-025-32031-9,Focused ultrasound-mediated drug delivery of bevacizumab in treating NF2-related schwannomatosis in an animal model.,,0.8,genetic_reagent,Gadovist,Genetic Reagent,,,,,
PMID:41444363,10.1038/s41598-025-32031-9,Focused ultrasound-mediated drug delivery of bevacizumab in treating NF2-related schwannomatosis in an animal model.,,0.8,genetic_reagent,Definity,Genetic Reagent,,,,,
PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,0.85,cell_line,iHSCs,Cell Line,,,,,
PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,0.9,cell_line,S462-TY,Cell Line,,,,,
PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,0.85,cell_line,ST88-14,Cell Line,,,,,
PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,0.9,animal_model,athymic nude mice (RRID: JAX:002019),Animal Model,,,,,
PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,0.9,animal_model,"NOD-Rag1 null IL2rg null, NOD rag gamma, NOD-RG (NRG) mice (RRID: JAX:007799)",Animal Model,,,,,
PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,0.85,animal_model,NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ mice,Animal Model,,,,,
PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,0.9,animal_model,"Dhh::Cre, Nf1fl/fl, Pten",Animal Model,,,,,
PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,0.95,antibody,neurofibromin 1 (D7R7D) rabbit mAb 14623 (RRID: AB_2798543),Antibody,,,,,
PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,0.85,antibody,"anti-rabbit IgG, and horseradish peroxidase–linked secondary 7074 (RRID: AB_2099233)",Antibody,,,,,
PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,0.9,antibody,β-actin (13E5) rabbit mAb #4970 (RRID: AB_2223172),Antibody,,,,,
PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,0.85,genetic_reagent,U6-gRNA vectors,Genetic Reagent,,,,,
PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,0.85,genetic_reagent,Flag-hCas9,Genetic Reagent,,,,,
PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,0.9,genetic_reagent,PB-CAGG-Luciferase-IRES-GFP-PGK-PuroR,Genetic Reagent,,,,,
PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,0.85,genetic_reagent,CMV-PB7 transposase,Genetic Reagent,,,,,
PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,0.85,computational_tool,Trimmomatic (v0.33),Computational Tool,,,,,
PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,0.85,computational_tool,HISAT2 (v2.1.0),Computational Tool,,,,,
PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,0.85,computational_tool,StringTie (v1.3.4d),Computational Tool,,,,,
PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,0.85,computational_tool,DESeq2 (v1.42.0),Computational Tool,,,,,
PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,0.8,computational_tool,GeneAnalytics(v),Computational Tool,,,,,
PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,0.9,patient_derived_model,Patient-derived xenograft (PDX) MPNST model,Patient-Derived Model,,,,,
PMID:30055648,10.1186/s13104-018-3630-0,Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts.,,0.9,cell_line,S462,Cell Line,,,,,
PMID:30055648,10.1186/s13104-018-3630-0,Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts.,,0.9,cell_line,T265,Cell Line,,,,,
PMID:30055648,10.1186/s13104-018-3630-0,Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts.,,0.95,animal_model,Balb/cAnNRj-Foxn1nu/Foxn1nu,Animal Model,,,,,
PMID:30055648,10.1186/s13104-018-3630-0,Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts.,,0.95,animal_model,Crl:NU-Foxn1nu,Animal Model,,,,,
PMID:30055648,10.1186/s13104-018-3630-0,Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts.,,0.95,animal_model,Crl:SHO-PrkdcscidHrhr,Animal Model,,,,,
PMID:30055648,10.1186/s13104-018-3630-0,Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts.,,0.95,animal_model,NOD.Cg-PrkdcscidHrhr/NCrHsd,Animal Model,,,,,
PMID:30055648,10.1186/s13104-018-3630-0,Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts.,,0.9,antibody,S100-4C4.9,Antibody,,,,,
PMID:30055648,10.1186/s13104-018-3630-0,Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts.,,0.9,antibody,Ki-67-30.9,Antibody,,,,,
PMID:30055648,10.1186/s13104-018-3630-0,Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts.,,0.9,antibody,QBEnd/10,Antibody,,,,,
PMID:30055648,10.1186/s13104-018-3630-0,Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts.,,0.9,antibody,Bp-53-11,Antibody,,,,,
PMID:30055648,10.1186/s13104-018-3630-0,Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts.,,0.9,antibody,725-4713,Antibody,,,,,
PMID:30055648,10.1186/s13104-018-3630-0,Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts.,,0.9,antibody,V9,Antibody,,,,,
PMID:30055648,10.1186/s13104-018-3630-0,Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts.,,0.9,antibody,1A4,Antibody,,,,,
PMID:30055648,10.1186/s13104-018-3630-0,Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts.,,0.85,computational_tool,ImageJ,Computational Tool,,,,,
PMID:30055648,10.1186/s13104-018-3630-0,Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts.,,0.8,computational_tool,IBM SPSS Statistics Standard,Computational Tool,,,,,
PMID:30055648,10.1186/s13104-018-3630-0,Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts.,,0.85,genetic_reagent,PD0325901,Genetic Reagent,,,,,
PMID:30055648,10.1186/s13104-018-3630-0,Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts.,,0.85,genetic_reagent,ATRA,Genetic Reagent,,,,,
PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,,0.85,animal_model,Mut3,Animal Model,,,,,
PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,,0.85,animal_model,Mut4,Animal Model,,,,,
PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,,0.9,animal_model,loxP-Pten (Pten f),Animal Model,,,,,
PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,,0.9,animal_model,p53 f,Animal Model,,,,,
PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,,0.95,antibody,Ki67 antigen antibody (Novocastra),Antibody,,,,,
PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,,0.95,antibody,glial fibrillary acidic protein antibody (Gfap; Sigma),Antibody,,,,,
PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,,0.95,antibody,Pten antibody (NeoMarkers),Antibody,,,,,
PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,,0.95,antibody,nestin antibody (BD Bioscience),Antibody,,,,,
PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,,0.95,antibody,phosphorylated Akt antibody (p-Akt; Cell Signaling),Antibody,,,,,
PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,,0.95,antibody,BrdUrd antibody (DAKO),Antibody,,,,,
PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,,0.95,antibody,Olig2 antibody (Chemicon),Antibody,,,,,
PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,,0.95,antibody,doublecortin antibody (Santa Cruz),Antibody,,,,,
PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,,0.95,antibody,β3-tubulin antibody (TuJ1; Covance),Antibody,,,,,
PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,,0.95,antibody,Gfap antibody (Dako),Antibody,,,,,
PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,,0.95,antibody,CNPase antibody (Chemicon),Antibody,,,,,
PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,,0.95,antibody,Pten antibody (Cell Signaling),Antibody,,,,,
PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,,0.95,antibody,β-actin antibody (Sigma),Antibody,,,,,
PMID:18451155,10.1158/0008-5472.CAN-07-6867,Pten haploinsufficiency accelerates formation of high-grade astrocytomas.,,0.9,advanced_cellular_model,neurosphere cultures,Advanced Cellular Model,,,,,
PMID:26883872,10.1016/j.jprot.2016.02.004,3-D imaging mass spectrometry of protein distributions in mouse Neurofibromatosis 1 (NF1)-associated optic glioma.,,0.9,animal_model,Nf1^flox/flox;GFAP-Cre mice,Animal Model,,,,,
PMID:26883872,10.1016/j.jprot.2016.02.004,3-D imaging mass spectrometry of protein distributions in mouse Neurofibromatosis 1 (NF1)-associated optic glioma.,,0.85,antibody,polyclonal anti-S100A10 antibodies,Antibody,,,,,
PMID:26883872,10.1016/j.jprot.2016.02.004,3-D imaging mass spectrometry of protein distributions in mouse Neurofibromatosis 1 (NF1)-associated optic glioma.,,0.8,antibody,horseradish peroxidase-conjugated secondary antibodies,Antibody,,,,,
PMID:26883872,10.1016/j.jprot.2016.02.004,3-D imaging mass spectrometry of protein distributions in mouse Neurofibromatosis 1 (NF1)-associated optic glioma.,,0.9,computational_tool,Bruker AutoFlex III mass spectrometer,Computational Tool,,,,,
PMID:26883872,10.1016/j.jprot.2016.02.004,3-D imaging mass spectrometry of protein distributions in mouse Neurofibromatosis 1 (NF1)-associated optic glioma.,,0.9,computational_tool,FlexImaging 4.0,Computational Tool,,,,,
PMID:26883872,10.1016/j.jprot.2016.02.004,3-D imaging mass spectrometry of protein distributions in mouse Neurofibromatosis 1 (NF1)-associated optic glioma.,,0.85,computational_tool,MATLAB,Computational Tool,,,,,
PMID:26883872,10.1016/j.jprot.2016.02.004,3-D imaging mass spectrometry of protein distributions in mouse Neurofibromatosis 1 (NF1)-associated optic glioma.,,0.8,computational_tool,Bioinformatics Toolbox,Computational Tool,,,,,
PMID:26883872,10.1016/j.jprot.2016.02.004,3-D imaging mass spectrometry of protein distributions in mouse Neurofibromatosis 1 (NF1)-associated optic glioma.,,0.8,computational_tool,Sliceomatic,Computational Tool,,,,,
PMID:26883872,10.1016/j.jprot.2016.02.004,3-D imaging mass spectrometry of protein distributions in mouse Neurofibromatosis 1 (NF1)-associated optic glioma.,,0.9,computational_tool,Thermo LTQ Velos Orbitrap mass spectrometer,Computational Tool,,,,,
PMID:26883872,10.1016/j.jprot.2016.02.004,3-D imaging mass spectrometry of protein distributions in mouse Neurofibromatosis 1 (NF1)-associated optic glioma.,,0.85,computational_tool,TagIdent,Computational Tool,,,,,
PMID:26883872,10.1016/j.jprot.2016.02.004,3-D imaging mass spectrometry of protein distributions in mouse Neurofibromatosis 1 (NF1)-associated optic glioma.,,0.85,computational_tool,protein prospector MS-product,Computational Tool,,,,,
PMID:26883872,10.1016/j.jprot.2016.02.004,3-D imaging mass spectrometry of protein distributions in mouse Neurofibromatosis 1 (NF1)-associated optic glioma.,,0.85,computational_tool,Scaffold,Computational Tool,,,,,
PMID:26883872,10.1016/j.jprot.2016.02.004,3-D imaging mass spectrometry of protein distributions in mouse Neurofibromatosis 1 (NF1)-associated optic glioma.,,0.85,computational_tool,SEQUEST,Computational Tool,,,,,
PMID:26883872,10.1016/j.jprot.2016.02.004,3-D imaging mass spectrometry of protein distributions in mouse Neurofibromatosis 1 (NF1)-associated optic glioma.,,0.85,computational_tool,Leica LAS EZ image analysis software,Computational Tool,,,,,
PMID:32733557,10.1155/2020/5976465,"Gene Expression, Network Analysis, and Drug Discovery of Neurofibromatosis Type 2-Associated Vestibular Schwannomas Based on Bioinformatics Analysis.",,0.85,computational_tool,GSE108524,Computational Tool,,,,,
PMID:32733557,10.1155/2020/5976465,"Gene Expression, Network Analysis, and Drug Discovery of Neurofibromatosis Type 2-Associated Vestibular Schwannomas Based on Bioinformatics Analysis.",,0.9,computational_tool,GPL17586 Platform [HTA-2_0] Affymetrix Human Transcriptome Array 2.0,Computational Tool,,,,,
PMID:32733557,10.1155/2020/5976465,"Gene Expression, Network Analysis, and Drug Discovery of Neurofibromatosis Type 2-Associated Vestibular Schwannomas Based on Bioinformatics Analysis.",,0.85,computational_tool,GEO2R,Computational Tool,,,,,
PMID:32733557,10.1155/2020/5976465,"Gene Expression, Network Analysis, and Drug Discovery of Neurofibromatosis Type 2-Associated Vestibular Schwannomas Based on Bioinformatics Analysis.",,0.9,computational_tool,DAVID,Computational Tool,,,,,
PMID:32733557,10.1155/2020/5976465,"Gene Expression, Network Analysis, and Drug Discovery of Neurofibromatosis Type 2-Associated Vestibular Schwannomas Based on Bioinformatics Analysis.",,0.85,computational_tool,STRING,Computational Tool,,,,,
PMID:32733557,10.1155/2020/5976465,"Gene Expression, Network Analysis, and Drug Discovery of Neurofibromatosis Type 2-Associated Vestibular Schwannomas Based on Bioinformatics Analysis.",,0.9,computational_tool,Cytoscape,Computational Tool,,,,,
PMID:32733557,10.1155/2020/5976465,"Gene Expression, Network Analysis, and Drug Discovery of Neurofibromatosis Type 2-Associated Vestibular Schwannomas Based on Bioinformatics Analysis.",,0.8,computational_tool,CentiScaPe,Computational Tool,,,,,
PMID:32733557,10.1155/2020/5976465,"Gene Expression, Network Analysis, and Drug Discovery of Neurofibromatosis Type 2-Associated Vestibular Schwannomas Based on Bioinformatics Analysis.",,0.85,computational_tool,MCODE,Computational Tool,,,,,
PMID:32733557,10.1155/2020/5976465,"Gene Expression, Network Analysis, and Drug Discovery of Neurofibromatosis Type 2-Associated Vestibular Schwannomas Based on Bioinformatics Analysis.",,0.85,computational_tool,DGIdb,Computational Tool,,,,,
PMID:32733557,10.1155/2020/5976465,"Gene Expression, Network Analysis, and Drug Discovery of Neurofibromatosis Type 2-Associated Vestibular Schwannomas Based on Bioinformatics Analysis.",,0.8,computational_tool,ClinicalTrials.gov,Computational Tool,,,,,
PMID:32733557,10.1155/2020/5976465,"Gene Expression, Network Analysis, and Drug Discovery of Neurofibromatosis Type 2-Associated Vestibular Schwannomas Based on Bioinformatics Analysis.",,0.85,genetic_reagent,SYBR premix EX Taq,Genetic Reagent,,,,,
PMID:32733557,10.1155/2020/5976465,"Gene Expression, Network Analysis, and Drug Discovery of Neurofibromatosis Type 2-Associated Vestibular Schwannomas Based on Bioinformatics Analysis.",,0.85,genetic_reagent,SYBR Premix Ex Taq II,Genetic Reagent,,,,,
PMID:32733557,10.1155/2020/5976465,"Gene Expression, Network Analysis, and Drug Discovery of Neurofibromatosis Type 2-Associated Vestibular Schwannomas Based on Bioinformatics Analysis.",,0.8,computational_tool,SPSS 20.0,Computational Tool,,,,,
PMID:24980480,10.1186/1479-7364-8-10,Novel age-dependent targets in vestibular schwannomas.,,0.85,computational_tool,Human Genome U133 Plus 2.0 Array,Computational Tool,,,,,
PMID:24980480,10.1186/1479-7364-8-10,Novel age-dependent targets in vestibular schwannomas.,,0.8,computational_tool,DNA Engine Opticon 2 Continuous Fluorescence Detection System,Computational Tool,,,,,
PMID:24980480,10.1186/1479-7364-8-10,Novel age-dependent targets in vestibular schwannomas.,,0.9,computational_tool,Bioconductor limma package,Computational Tool,,,,,
PMID:24980480,10.1186/1479-7364-8-10,Novel age-dependent targets in vestibular schwannomas.,,0.75,genetic_reagent,Human Universal Reference RNA,Genetic Reagent,,,,,
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,0.9,cell_line,MPNST-SP-01,Cell Line,,,,,
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,0.9,cell_line,MPNST-NF1-08,Cell Line,,,,,
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,0.9,cell_line,MPNST-NF1-9,Cell Line,,,,,
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,0.85,cell_line,STS-26T,Cell Line,,,,,
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,0.85,cell_line,HS-PSS,Cell Line,,,,,
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,0.85,cell_line,HS-sch2,Cell Line,,,,,
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,0.85,cell_line,S462,Cell Line,,,,,
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,0.9,cell_line,sNF96.2,Cell Line,,,,,
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,0.8,cell_line,Human Foreskin Fibroblast (HFF),Cell Line,,,,,
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,0.9,patient_derived_model,MPNST-SP-01 PDOX,Patient-Derived Model,,,,,
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,0.9,patient_derived_model,MPNST-NF1-09 PDOX,Patient-Derived Model,,,,,
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,0.85,computational_tool,NCATS Mechanism Interrogation PlatE (MIPE) library,Computational Tool,,,,,
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,0.85,computational_tool,CompuSyn Software,Computational Tool,,,,,
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,0.8,computational_tool,GraphPad Prism Version 6,Computational Tool,,,,,
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,0.9,antibody,Cdk1 antibody (77055S),Antibody,,,,,
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,0.9,antibody,phospho-Cdk1 Tyr15 antibody (9111T),Antibody,,,,,
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,0.9,antibody,Caspase-3 antibody (9662S),Antibody,,,,,
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,0.9,antibody,Cleaved Caspase-3 antibody (9661S),Antibody,,,,,
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,0.9,antibody,Histone H3 antibody (9715S),Antibody,,,,,
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,0.9,antibody,Acetyl-Histone H3 Lys18 antibody (9675S),Antibody,,,,,
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,0.9,antibody,SAPK/JNK antibody (9252T),Antibody,,,,,
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,0.9,antibody,phospho-SAPK/JNK Thr183/Tyr185 antibody (4668T),Antibody,,,,,
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,0.9,antibody,p70S6 Kinase antibody (9202S),Antibody,,,,,
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,0.9,antibody,phospho-p70 Thr389 S6 Kinase antibody (9234S),Antibody,,,,,
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,0.85,animal_model,athymic nude mice,Animal Model,,,,,
PMID:28029918,10.1056/NEJMoa1605943,Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.,,0.95,animal_model,DhhCre;Nf1fl/fl,Animal Model,,,,,
PMID:28029918,10.1056/NEJMoa1605943,Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.,,0.85,clinical_assessment_tool,volumetric magnetic resonance imaging analysis,Clinical Assessment Tool,,,,,
PMID:28029918,10.1056/NEJMoa1605943,Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.,,0.8,clinical_assessment_tool,Responsibility for Medication Questionnaire,Clinical Assessment Tool,,,,,
PMID:28029918,10.1056/NEJMoa1605943,Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.,,0.9,clinical_assessment_tool,"National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0",Clinical Assessment Tool,,,,,
PMID:28029918,10.1056/NEJMoa1605943,Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.,,0.85,clinical_assessment_tool,Response Evaluation Criteria In Solid Tumors (RECIST),Clinical Assessment Tool,,,,,
PMID:28029918,10.1056/NEJMoa1605943,Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.,,0.85,clinical_assessment_tool,World Health Organization (WHO) criteria,Clinical Assessment Tool,,,,,
PMID:39061138,10.3390/cancers16142498,A Fibroblast-Derived Secretome Stimulates the Growth and Invasiveness of 3D Plexiform Neurofibroma Spheroids.,,0.9,cell_line,ipNF95.11b C,Cell Line,,,,,
PMID:39061138,10.3390/cancers16142498,A Fibroblast-Derived Secretome Stimulates the Growth and Invasiveness of 3D Plexiform Neurofibroma Spheroids.,,0.9,cell_line,ipNF95.11b C-RFP,Cell Line,,,,,
PMID:39061138,10.3390/cancers16142498,A Fibroblast-Derived Secretome Stimulates the Growth and Invasiveness of 3D Plexiform Neurofibroma Spheroids.,,0.9,cell_line,ipNF 05.5,Cell Line,,,,,
PMID:39061138,10.3390/cancers16142498,A Fibroblast-Derived Secretome Stimulates the Growth and Invasiveness of 3D Plexiform Neurofibroma Spheroids.,,0.85,advanced_cellular_model,3D rBM overlay model,Advanced Cellular Model,,,,,
PMID:39061138,10.3390/cancers16142498,A Fibroblast-Derived Secretome Stimulates the Growth and Invasiveness of 3D Plexiform Neurofibroma Spheroids.,,0.8,computational_tool,Zeiss LSM 780,Computational Tool,,,,,
PMID:39061138,10.3390/cancers16142498,A Fibroblast-Derived Secretome Stimulates the Growth and Invasiveness of 3D Plexiform Neurofibroma Spheroids.,,0.8,computational_tool,Stellaris 5,Computational Tool,,,,,
PMID:39061138,10.3390/cancers16142498,A Fibroblast-Derived Secretome Stimulates the Growth and Invasiveness of 3D Plexiform Neurofibroma Spheroids.,,0.9,computational_tool,Volocity software 7.0.0,Computational Tool,,,,,
PMID:39061138,10.3390/cancers16142498,A Fibroblast-Derived Secretome Stimulates the Growth and Invasiveness of 3D Plexiform Neurofibroma Spheroids.,,0.9,computational_tool,Nanoparticle Tracking Analysis software version 3.3 Dev Build 3.3.104,Computational Tool,,,,,
PMID:39061138,10.3390/cancers16142498,A Fibroblast-Derived Secretome Stimulates the Growth and Invasiveness of 3D Plexiform Neurofibroma Spheroids.,,0.85,computational_tool,ImageJ software,Computational Tool,,,,,
PMID:39061138,10.3390/cancers16142498,A Fibroblast-Derived Secretome Stimulates the Growth and Invasiveness of 3D Plexiform Neurofibroma Spheroids.,,0.8,computational_tool,GraphPad Prism version 8.0.1,Computational Tool,,,,,
PMID:39061138,10.3390/cancers16142498,A Fibroblast-Derived Secretome Stimulates the Growth and Invasiveness of 3D Plexiform Neurofibroma Spheroids.,,0.8,computational_tool,NanoSight NS300,Computational Tool,,,,,
PMID:18636037,10.1097/MAO.0b013e31817f7398,The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary study.,,0.9,animal_model,athymic Ncr Nu/Nu mice,Animal Model,,,,,
PMID:18636037,10.1097/MAO.0b013e31817f7398,The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary study.,,0.85,genetic_reagent,trastuzumab,Genetic Reagent,,,,,
PMID:18636037,10.1097/MAO.0b013e31817f7398,The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary study.,,0.85,genetic_reagent,erlotinib,Genetic Reagent,,,,,
PMID:18636037,10.1097/MAO.0b013e31817f7398,The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary study.,,0.9,antibody,mouse monoclonal anti-BrdU,Antibody,,,,,
PMID:18636037,10.1097/MAO.0b013e31817f7398,The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary study.,,0.9,antibody,rabbit anti-S100,Antibody,,,,,
PMID:18636037,10.1097/MAO.0b013e31817f7398,The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary study.,,0.85,antibody,anti-mouse Alexa Fluor 568,Antibody,,,,,
PMID:18636037,10.1097/MAO.0b013e31817f7398,The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary study.,,0.85,antibody,anti-rabbit Alexa Fluor 488,Antibody,,,,,
PMID:18636037,10.1097/MAO.0b013e31817f7398,The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary study.,,0.8,computational_tool,Varian Unity/INOVA 4.7 Tesla scanner,Computational Tool,,,,,
PMID:18636037,10.1097/MAO.0b013e31817f7398,The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary study.,,0.9,computational_tool,Image J software,Computational Tool,,,,,
PMID:18636037,10.1097/MAO.0b013e31817f7398,The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary study.,,0.9,patient_derived_model,vestibular schwannoma xenografts,Patient-Derived Model,,,,,
PMID:40842873,10.3389/fradi.2025.1618261,Evaluating the effect of voxel size on the accuracy of 3D volumetric analysis measurements of brain tumors.,,0.85,computational_tool,Simpleware,Computational Tool,,,,,
PMID:40842873,10.3389/fradi.2025.1618261,Evaluating the effect of voxel size on the accuracy of 3D volumetric analysis measurements of brain tumors.,,0.8,computational_tool,R,Computational Tool,,,,,
PMID:40842873,10.3389/fradi.2025.1618261,Evaluating the effect of voxel size on the accuracy of 3D volumetric analysis measurements of brain tumors.,,0.85,computational_tool,ggplot2,Computational Tool,,,,,
PMID:40842873,10.3389/fradi.2025.1618261,Evaluating the effect of voxel size on the accuracy of 3D volumetric analysis measurements of brain tumors.,,0.85,computational_tool,tidyverse,Computational Tool,,,,,
PMID:40842873,10.3389/fradi.2025.1618261,Evaluating the effect of voxel size on the accuracy of 3D volumetric analysis measurements of brain tumors.,,0.75,computational_tool,Dice similarity coefficient,Computational Tool,,,,,
PMID:40842873,10.3389/fradi.2025.1618261,Evaluating the effect of voxel size on the accuracy of 3D volumetric analysis measurements of brain tumors.,,0.75,computational_tool,Hausdorff distance,Computational Tool,,,,,
PMID:40842873,10.3389/fradi.2025.1618261,Evaluating the effect of voxel size on the accuracy of 3D volumetric analysis measurements of brain tumors.,,0.75,computational_tool,Wilcoxon signed-rank test,Computational Tool,,,,,
PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,0.9,cell_line,Ben-Men-1,Cell Line,,,,,
PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,0.9,cell_line,AC007-hTERT,Cell Line,,,,,
PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,0.85,cell_line,AC028,Cell Line,,,,,
PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,0.8,cell_line,293T,Cell Line,,,,,
PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,0.85,genetic_reagent,AZD2014,Genetic Reagent,,,,,
PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,0.8,genetic_reagent,FRAX597,Genetic Reagent,,,,,
PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,0.9,genetic_reagent,pLKO-puromycin system,Genetic Reagent,,,,,
PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,0.9,genetic_reagent,TRCN0000194957,Genetic Reagent,,,,,
PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,0.9,genetic_reagent,TRCN0000197238,Genetic Reagent,,,,,
PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,0.9,genetic_reagent,TRCN0000010424,Genetic Reagent,,,,,
PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,0.9,genetic_reagent,lenti-CRISPR-NF2_sg1,Genetic Reagent,,,,,
PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,0.9,antibody,AlexaFlour488 conjugated-pS6 (Ser240/244) antibody,Antibody,,,,,
PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,0.9,antibody,phospho-S6 (S240/244) antibody,Antibody,,,,,
PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,0.9,antibody,S6 antibody,Antibody,,,,,
PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,0.9,antibody,phospho-p70 S6K (T389) antibody,Antibody,,,,,
PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,0.9,antibody,p70 S6K antibody,Antibody,,,,,
PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,0.9,antibody,phospho-Akt (S473) antibody,Antibody,,,,,
PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,0.9,antibody,Akt antibody,Antibody,,,,,
PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,0.9,antibody,phospho-NDRG1 (T346) antibody,Antibody,,,,,
PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,0.9,antibody,SGK1 antibody,Antibody,,,,,
PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,0.9,antibody,phospho-PAK1 (S144) antibody,Antibody,,,,,
PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,0.9,antibody,PAK1 antibody,Antibody,,,,,
PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,0.9,antibody,4EBP1 antibody,Antibody,,,,,
PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,0.9,antibody,NDRG1 antibody,Antibody,,,,,
PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,0.9,antibody,Rac1 antibody,Antibody,,,,,
PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,0.9,antibody,GAPDH antibody,Antibody,,,,,
PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,0.9,antibody,Rheb antibody (3M6 monoclonal),Antibody,,,,,
PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,0.9,antibody,NF2 polyclonal C26 antibody,Antibody,,,,,
PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,0.8,computational_tool,Acumen eX3 laser-scanning fluorescence microplate cytometer,Computational Tool,,,,,
PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,0.85,computational_tool,GraphPad Prism 6.0,Computational Tool,,,,,
PMID:15255999,10.1186/1476-4598-3-20,"Molecular profiling of malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1, based on large-scale real-time RT-PCR.",,0.85,computational_tool,ABI Prism 7700 Sequence Detection System,Computational Tool,,,,,
PMID:15255999,10.1186/1476-4598-3-20,"Molecular profiling of malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1, based on large-scale real-time RT-PCR.",,0.8,computational_tool,PE Biosystems analysis software,Computational Tool,,,,,
PMID:15255999,10.1186/1476-4598-3-20,"Molecular profiling of malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1, based on large-scale real-time RT-PCR.",,0.85,computational_tool,Oligo 5.0 computer program,Computational Tool,,,,,
PMID:15255999,10.1186/1476-4598-3-20,"Molecular profiling of malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1, based on large-scale real-time RT-PCR.",,0.9,genetic_reagent,TaqMan PCR Core REAGENTS Kit,Genetic Reagent,,,,,
PMID:15255999,10.1186/1476-4598-3-20,"Molecular profiling of malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1, based on large-scale real-time RT-PCR.",,0.9,genetic_reagent,SYBR Green PCR Core Reagents kit,Genetic Reagent,,,,,
PMID:15255999,10.1186/1476-4598-3-20,"Molecular profiling of malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1, based on large-scale real-time RT-PCR.",,0.85,genetic_reagent,RNasin RNase inhibitor,Genetic Reagent,,,,,
PMID:15255999,10.1186/1476-4598-3-20,"Molecular profiling of malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1, based on large-scale real-time RT-PCR.",,0.9,genetic_reagent,Superscript II RNase H-reverse transcriptase,Genetic Reagent,,,,,
PMID:15255999,10.1186/1476-4598-3-20,"Molecular profiling of malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1, based on large-scale real-time RT-PCR.",,0.85,antibody,S100 antibody,Antibody,,,,,
PMID:40737523,10.2196/71728,Clinician Perspectives of a Magnetic Resonance Imaging-Based 3D Volumetric Analysis Tool for Neurofibromatosis Type 2-Related Schwannomatosis: Qualitative Pilot Study.,,0.85,clinical_assessment_tool,Likert scale questionnaire,Clinical Assessment Tool,,,,,
PMID:40737523,10.2196/71728,Clinician Perspectives of a Magnetic Resonance Imaging-Based 3D Volumetric Analysis Tool for Neurofibromatosis Type 2-Related Schwannomatosis: Qualitative Pilot Study.,,0.8,computational_tool,Qualtrics,Computational Tool,,,,,
PMID:40737523,10.2196/71728,Clinician Perspectives of a Magnetic Resonance Imaging-Based 3D Volumetric Analysis Tool for Neurofibromatosis Type 2-Related Schwannomatosis: Qualitative Pilot Study.,,0.75,computational_tool,Zoom's transcription feature,Computational Tool,,,,,
PMID:40737523,10.2196/71728,Clinician Perspectives of a Magnetic Resonance Imaging-Based 3D Volumetric Analysis Tool for Neurofibromatosis Type 2-Related Schwannomatosis: Qualitative Pilot Study.,,0.85,computational_tool,Dedoose,Computational Tool,,,,,
PMID:35723774,10.1007/s10072-022-06203-8,A randomized controlled trial of remote microphone listening devices to treat auditory deficits in children with neurofibromatosis type 1.,,0.85,clinical_assessment_tool,CNC-word test,Clinical Assessment Tool,,,,,
PMID:35723774,10.1007/s10072-022-06203-8,A randomized controlled trial of remote microphone listening devices to treat auditory deficits in children with neurofibromatosis type 1.,,0.9,clinical_assessment_tool,LIFE-R Questionnaire,Clinical Assessment Tool,,,,,
PMID:40529476,10.1016/j.xjidi.2025.100380,Using Durometers to Quantify Stiffness as an Outcome Measure for Cutaneous Neurofibroma in Neurofibromatosis Type 1.,,0.9,clinical_assessment_tool,Rex Gauge durometer,Clinical Assessment Tool,,,,,
PMID:40529476,10.1016/j.xjidi.2025.100380,Using Durometers to Quantify Stiffness as an Outcome Measure for Cutaneous Neurofibroma in Neurofibromatosis Type 1.,,0.9,clinical_assessment_tool,Delfin SkinFibroMeter,Clinical Assessment Tool,,,,,
PMID:40529476,10.1016/j.xjidi.2025.100380,Using Durometers to Quantify Stiffness as an Outcome Measure for Cutaneous Neurofibroma in Neurofibromatosis Type 1.,,0.8,computational_tool,R 4.4.2 software,Computational Tool,,,,,
PMID:28166733,10.1186/s12864-017-3519-7,A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma.,,0.95,cell_line,U87-MG,Cell Line,,,,,
PMID:28166733,10.1186/s12864-017-3519-7,A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma.,,0.85,cell_line,HEK293T,Cell Line,,,,,
PMID:28166733,10.1186/s12864-017-3519-7,A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma.,,0.95,antibody,anti-NF1 D7R7D #14624,Antibody,,,,,
PMID:28166733,10.1186/s12864-017-3519-7,A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma.,,0.9,antibody,anti-tubulin B-1-2-5,Antibody,,,,,
PMID:28166733,10.1186/s12864-017-3519-7,A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma.,,0.9,antibody,anti-EGFR D38B1 #4267,Antibody,,,,,
PMID:28166733,10.1186/s12864-017-3519-7,A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma.,,0.9,antibody,p-ERK ½ (p44/42 MAPK) #9101,Antibody,,,,,
PMID:28166733,10.1186/s12864-017-3519-7,A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma.,,0.9,antibody,SUZ12 D39F6 #3737,Antibody,,,,,
PMID:28166733,10.1186/s12864-017-3519-7,A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma.,,0.85,antibody,goat anti-rabbit HRP,Antibody,,,,,
PMID:28166733,10.1186/s12864-017-3519-7,A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma.,,0.85,antibody,goat anti-mouse HRP,Antibody,,,,,
PMID:28166733,10.1186/s12864-017-3519-7,A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma.,,0.9,computational_tool,Sci-kit Learn,Computational Tool,,,,,
PMID:28166733,10.1186/s12864-017-3519-7,A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma.,,0.85,computational_tool,python 3.5.1,Computational Tool,,,,,
PMID:28166733,10.1186/s12864-017-3519-7,A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma.,,0.9,computational_tool,Li-COR Image Studio Lite 5.0,Computational Tool,,,,,
PMID:28166733,10.1186/s12864-017-3519-7,A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma.,,0.85,computational_tool,R version 3.2.3,Computational Tool,,,,,
PMID:28166733,10.1186/s12864-017-3519-7,A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma.,,0.9,computational_tool,WGCNA,Computational Tool,,,,,
PMID:28166733,10.1186/s12864-017-3519-7,A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma.,,0.85,computational_tool,Docker,Computational Tool,,,,,
PMID:28166733,10.1186/s12864-017-3519-7,A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma.,,0.95,computational_tool,nf1_inactivation GitHub repository,Computational Tool,,,,,
PMID:28166733,10.1186/s12864-017-3519-7,A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma.,,0.9,computational_tool,GeneChip Human Transcriptome Array 2.0,Computational Tool,,,,,
PMID:25026211,10.1016/j.ccr.2014.05.001,Merlin/NF2 loss-driven tumorigenesis linked to CRL4(DCAF1)-mediated inhibition of the hippo pathway kinases Lats1 and 2 in the nucleus.,,0.85,genetic_reagent,NE-PER Nuclear and Cytoplasmic Extraction Reagents,Genetic Reagent,,,,,
PMID:25026211,10.1016/j.ccr.2014.05.001,Merlin/NF2 loss-driven tumorigenesis linked to CRL4(DCAF1)-mediated inhibition of the hippo pathway kinases Lats1 and 2 in the nucleus.,,0.9,cell_line,Meso-33,Cell Line,,,,,
PMID:25026211,10.1016/j.ccr.2014.05.001,Merlin/NF2 loss-driven tumorigenesis linked to CRL4(DCAF1)-mediated inhibition of the hippo pathway kinases Lats1 and 2 in the nucleus.,,0.9,cell_line,FC-1801,Cell Line,,,,,
PMID:25026211,10.1016/j.ccr.2014.05.001,Merlin/NF2 loss-driven tumorigenesis linked to CRL4(DCAF1)-mediated inhibition of the hippo pathway kinases Lats1 and 2 in the nucleus.,,0.85,cell_line,293T,Cell Line,,,,,
PMID:25026211,10.1016/j.ccr.2014.05.001,Merlin/NF2 loss-driven tumorigenesis linked to CRL4(DCAF1)-mediated inhibition of the hippo pathway kinases Lats1 and 2 in the nucleus.,,0.8,animal_model,nude mice,Animal Model,,,,,
PMID:25026211,10.1016/j.ccr.2014.05.001,Merlin/NF2 loss-driven tumorigenesis linked to CRL4(DCAF1)-mediated inhibition of the hippo pathway kinases Lats1 and 2 in the nucleus.,,0.75,genetic_reagent,Ultra Low Cluster Plates,Genetic Reagent,,,,,
PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,0.9,cell_line,NIH-3T3,Cell Line,,,,,
PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,0.85,cell_line,φNX packaging cell line,Cell Line,,,,,
PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,0.9,genetic_reagent,pBMN-I-GFP,Genetic Reagent,,,,,
PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,0.9,genetic_reagent,GST-PID,Genetic Reagent,,,,,
PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,0.9,genetic_reagent,Gst-PID L107F,Genetic Reagent,,,,,
PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,0.95,animal_model,BALB/c nu/nu,Animal Model,,,,,
PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,0.9,antibody,Pak1 antibody,Antibody,,,,,
PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,0.9,antibody,Pak2 antibody,Antibody,,,,,
PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,0.9,antibody,Mek1/2 antibody,Antibody,,,,,
PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,0.95,antibody,phospho-MEK1 (Ser298) antibody,Antibody,,,,,
PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,0.9,antibody,Erk1/2 antibody,Antibody,,,,,
PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,0.95,antibody,phospho-Erk1/2 (Thr202/Tyr204) antibody,Antibody,,,,,
PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,0.9,antibody,Akt antibody,Antibody,,,,,
PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,0.95,antibody,phospho-Akt (Thr308) antibody,Antibody,,,,,
PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,0.95,antibody,Merlin antibody,Antibody,,,,,
PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,0.95,antibody,phospho-Pak1–3 (Ser141) antibody,Antibody,,,,,
PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,0.9,antibody,GST antibody,Antibody,,,,,
PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,0.9,antibody,β-actin antibody,Antibody,,,,,
PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,0.85,computational_tool,CELLQuest™ software,Computational Tool,,,,,
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,0.85,cell_line,H1838,Cell Line,,,,,
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,0.85,cell_line,WM3918,Cell Line,,,,,
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,0.85,cell_line,M308,Cell Line,,,,,
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,0.85,cell_line,STS26T,Cell Line,,,,,
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,0.85,cell_line,ST8814,Cell Line,,,,,
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,0.85,cell_line,NF90.8,Cell Line,,,,,
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,0.85,cell_line,NF94.3,Cell Line,,,,,
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,0.85,cell_line,NF96.2,Cell Line,,,,,
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,0.85,cell_line,NF10.1,Cell Line,,,,,
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,0.85,cell_line,NF11.1,Cell Line,,,,,
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,0.9,patient_derived_model,JH-2–002,Patient-Derived Model,,,,,
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,0.9,patient_derived_model,JH-2–009,Patient-Derived Model,,,,,
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,0.9,patient_derived_model,JH-2–031,Patient-Derived Model,,,,,
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,0.9,patient_derived_model,JH-2–055,Patient-Derived Model,,,,,
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,0.9,patient_derived_model,JH-2–060,Patient-Derived Model,,,,,
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,0.9,patient_derived_model,JH-2–074,Patient-Derived Model,,,,,
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,0.9,patient_derived_model,JH-2–077,Patient-Derived Model,,,,,
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,0.9,antibody,DUSP6 antibody (ab76310),Antibody,,,,,
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,0.9,antibody,cyclin D1 antibody (sc-718),Antibody,,,,,
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,0.9,antibody,cyclin D1 antibody (sc-8396),Antibody,,,,,
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,0.9,antibody,Ki-67 antibody (Ab16667),Antibody,,,,,
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,0.85,computational_tool,PamChip peptide arrays,Computational Tool,,,,,
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,0.9,computational_tool,BioNavigator software V.6.3,Computational Tool,,,,,
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,0.85,animal_model,athymic nude mice (#002019),Animal Model,,,,,
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,0.85,animal_model,"NOD scid gamma mice (NSG, #005557)",Animal Model,,,,,
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,0.9,patient_derived_model,PDX JH-2–002,Patient-Derived Model,,,,,
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,0.85,genetic_reagent,ON-TARGETplus Non-targeting Pool (#D-001810–10-05),Genetic Reagent,,,,,
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,0.9,genetic_reagent,SMARTPool ON-TARGETplus Human PTPN11 siRNA (#L-003947–00-0005),Genetic Reagent,,,,,
PMID:39225289,10.1111/srt.70020,Comparing 3D imaging devices for the measurement of cutaneous neurofibromas in patients with Neurofibromatosis Type 1.,,0.9,clinical_assessment_tool,Vectra H1,Clinical Assessment Tool,,,,,
PMID:39225289,10.1111/srt.70020,Comparing 3D imaging devices for the measurement of cutaneous neurofibromas in patients with Neurofibromatosis Type 1.,,0.9,clinical_assessment_tool,LifeViz Micro,Clinical Assessment Tool,,,,,
PMID:39225289,10.1111/srt.70020,Comparing 3D imaging devices for the measurement of cutaneous neurofibromas in patients with Neurofibromatosis Type 1.,,0.9,clinical_assessment_tool,Cherry Imaging,Clinical Assessment Tool,,,,,
PMID:39225289,10.1111/srt.70020,Comparing 3D imaging devices for the measurement of cutaneous neurofibromas in patients with Neurofibromatosis Type 1.,,0.8,computational_tool,IBM SPSS Statistics,Computational Tool,,,,,
PMID:39225289,10.1111/srt.70020,Comparing 3D imaging devices for the measurement of cutaneous neurofibromas in patients with Neurofibromatosis Type 1.,,0.85,computational_tool,Vectra software,Computational Tool,,,,,
PMID:39225289,10.1111/srt.70020,Comparing 3D imaging devices for the measurement of cutaneous neurofibromas in patients with Neurofibromatosis Type 1.,,0.85,computational_tool,LifeViz App software,Computational Tool,,,,,
PMID:39225289,10.1111/srt.70020,Comparing 3D imaging devices for the measurement of cutaneous neurofibromas in patients with Neurofibromatosis Type 1.,,0.85,computational_tool,Cherry Imaging Trace software,Computational Tool,,,,,
PMID:41411243,10.1371/journal.pgen.1011976,PERADIGM: Phenotype embedding similarity-based rare disease gene mapping.,,0.95,computational_tool,PERADIGM,Computational Tool,,,,,
PMID:41411243,10.1371/journal.pgen.1011976,PERADIGM: Phenotype embedding similarity-based rare disease gene mapping.,,0.85,computational_tool,UK Biobank 200K dataset,Computational Tool,,,,,
PMID:41411243,10.1371/journal.pgen.1011976,PERADIGM: Phenotype embedding similarity-based rare disease gene mapping.,,0.9,computational_tool,PLINK,Computational Tool,,,,,
PMID:41411243,10.1371/journal.pgen.1011976,PERADIGM: Phenotype embedding similarity-based rare disease gene mapping.,,0.9,computational_tool,Word2Vec,Computational Tool,,,,,
PMID:41411243,10.1371/journal.pgen.1011976,PERADIGM: Phenotype embedding similarity-based rare disease gene mapping.,,0.85,computational_tool,CBOW,Computational Tool,,,,,
PMID:24465906,10.1371/journal.pone.0086115,"Multiscale, converging defects of macro-porosity, microstructure and matrix mineralization impact long bone fragility in NF1.",,0.95,animal_model,Nf1Prx1,Animal Model,,,,,
PMID:24465906,10.1371/journal.pone.0086115,"Multiscale, converging defects of macro-porosity, microstructure and matrix mineralization impact long bone fragility in NF1.",,0.95,animal_model,Nf1Col1,Animal Model,,,,,
PMID:24465906,10.1371/journal.pone.0086115,"Multiscale, converging defects of macro-porosity, microstructure and matrix mineralization impact long bone fragility in NF1.",,0.9,antibody,panendothelial cell antigen,Antibody,,,,,
PMID:24465906,10.1371/journal.pone.0086115,"Multiscale, converging defects of macro-porosity, microstructure and matrix mineralization impact long bone fragility in NF1.",,0.85,antibody,anti-ratAlexa555,Antibody,,,,,
PMID:24465906,10.1371/journal.pone.0086115,"Multiscale, converging defects of macro-porosity, microstructure and matrix mineralization impact long bone fragility in NF1.",,0.9,computational_tool,skyscan 1172,Computational Tool,,,,,
PMID:24465906,10.1371/journal.pone.0086115,"Multiscale, converging defects of macro-porosity, microstructure and matrix mineralization impact long bone fragility in NF1.",,0.85,computational_tool,NRecon,Computational Tool,,,,,
PMID:24465906,10.1371/journal.pone.0086115,"Multiscale, converging defects of macro-porosity, microstructure and matrix mineralization impact long bone fragility in NF1.",,0.85,computational_tool,CTan,Computational Tool,,,,,
PMID:24465906,10.1371/journal.pone.0086115,"Multiscale, converging defects of macro-porosity, microstructure and matrix mineralization impact long bone fragility in NF1.",,0.85,computational_tool,AxioVision Software,Computational Tool,,,,,
PMID:24465906,10.1371/journal.pone.0086115,"Multiscale, converging defects of macro-porosity, microstructure and matrix mineralization impact long bone fragility in NF1.",,0.9,computational_tool,ImageJ,Computational Tool,,,,,
PMID:24465906,10.1371/journal.pone.0086115,"Multiscale, converging defects of macro-porosity, microstructure and matrix mineralization impact long bone fragility in NF1.",,0.85,computational_tool,Labview 7.0,Computational Tool,,,,,
PMID:28051113,10.1038/srep39348,"A comprehensive custom panel design for routine hereditary cancer testing: preserving control, improving diagnostics and revealing a complex variation landscape.",,0.9,genetic_reagent,I2HCP panel,Genetic Reagent,,,,,
PMID:28051113,10.1038/srep39348,"A comprehensive custom panel design for routine hereditary cancer testing: preserving control, improving diagnostics and revealing a complex variation landscape.",,0.85,genetic_reagent,SureSelect bait library V1,Genetic Reagent,,,,,
PMID:28051113,10.1038/srep39348,"A comprehensive custom panel design for routine hereditary cancer testing: preserving control, improving diagnostics and revealing a complex variation landscape.",,0.85,genetic_reagent,SureSelect bait library V2,Genetic Reagent,,,,,
PMID:28051113,10.1038/srep39348,"A comprehensive custom panel design for routine hereditary cancer testing: preserving control, improving diagnostics and revealing a complex variation landscape.",,0.8,computational_tool,Covaris S2,Computational Tool,,,,,
PMID:28051113,10.1038/srep39348,"A comprehensive custom panel design for routine hereditary cancer testing: preserving control, improving diagnostics and revealing a complex variation landscape.",,0.9,computational_tool,BWA mem,Computational Tool,,,,,
PMID:28051113,10.1038/srep39348,"A comprehensive custom panel design for routine hereditary cancer testing: preserving control, improving diagnostics and revealing a complex variation landscape.",,0.9,computational_tool,samtools,Computational Tool,,,,,
PMID:28051113,10.1038/srep39348,"A comprehensive custom panel design for routine hereditary cancer testing: preserving control, improving diagnostics and revealing a complex variation landscape.",,0.9,computational_tool,bedtools,Computational Tool,,,,,
PMID:28051113,10.1038/srep39348,"A comprehensive custom panel design for routine hereditary cancer testing: preserving control, improving diagnostics and revealing a complex variation landscape.",,0.9,computational_tool,VarScan2,Computational Tool,,,,,
PMID:28051113,10.1038/srep39348,"A comprehensive custom panel design for routine hereditary cancer testing: preserving control, improving diagnostics and revealing a complex variation landscape.",,0.9,computational_tool,annovar,Computational Tool,,,,,
PMID:28051113,10.1038/srep39348,"A comprehensive custom panel design for routine hereditary cancer testing: preserving control, improving diagnostics and revealing a complex variation landscape.",,0.9,computational_tool,bam-readcount,Computational Tool,,,,,
PMID:28051113,10.1038/srep39348,"A comprehensive custom panel design for routine hereditary cancer testing: preserving control, improving diagnostics and revealing a complex variation landscape.",,0.9,computational_tool,regioneR,Computational Tool,,,,,
PMID:28051113,10.1038/srep39348,"A comprehensive custom panel design for routine hereditary cancer testing: preserving control, improving diagnostics and revealing a complex variation landscape.",,0.9,computational_tool,CLC Genomics Workbench v6,Computational Tool,,,,,
PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,0.9,animal_model,Nf1(fl/fl);DhhCre,Animal Model,,,,,
PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,0.9,animal_model,Stat3(fl/fl);Nf1(fl/fl);DhhCre,Animal Model,,,,,
PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,0.85,animal_model,athymic female nude mice,Animal Model,,,,,
PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,0.9,antibody,anti-S100β,Antibody,,,,,
PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,0.9,antibody,Ki67,Antibody,,,,,
PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,0.9,antibody,anti-P-Stat3 (Y705),Antibody,,,,,
PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,0.9,antibody,anti-cleaved caspase 3,Antibody,,,,,
PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,0.9,antibody,β-catenin antibody,Antibody,,,,,
PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,0.9,antibody,P-Jak2 antibody,Antibody,,,,,
PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,0.9,antibody,Jak2 antibody,Antibody,,,,,
PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,0.9,antibody,P-Stat3 antibody,Antibody,,,,,
PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,0.9,antibody,Stat3 antibody,Antibody,,,,,
PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,0.9,antibody,P-β-catenin antibody,Antibody,,,,,
PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,0.9,antibody,P-GSK3β antibody,Antibody,,,,,
PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,0.9,antibody,GSK3β antibody,Antibody,,,,,
PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,0.9,antibody,β-actin antibody,Antibody,,,,,
PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,0.85,genetic_reagent,shRNAs,Genetic Reagent,,,,,
PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,0.9,genetic_reagent,β-catenin overexpression lentivirus ΔN90,Genetic Reagent,,,,,
PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,0.85,computational_tool,Genemania algorithm,Computational Tool,,,,,
PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,0.8,computational_tool,GS20 Flex pyrosequencing machine,Computational Tool,,,,,
PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,0.9,advanced_cellular_model,neurofibroma spheres,Advanced Cellular Model,,,,,
PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,0.85,advanced_cellular_model,embryonic mouse spheres,Advanced Cellular Model,,,,,
PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,0.8,computational_tool,SAS mixed procedure,Computational Tool,,,,,
PMID:18974932,10.1007/s11060-008-9721-3,A role for the p53 pathway in the pathology of meningiomas with NF2 loss.,,0.85,genetic_reagent,D22S193,Genetic Reagent,,,,,
PMID:18974932,10.1007/s11060-008-9721-3,A role for the p53 pathway in the pathology of meningiomas with NF2 loss.,,0.85,genetic_reagent,NF2 TET,Genetic Reagent,,,,,
PMID:18974932,10.1007/s11060-008-9721-3,A role for the p53 pathway in the pathology of meningiomas with NF2 loss.,,0.85,genetic_reagent,D22S929,Genetic Reagent,,,,,
PMID:18974932,10.1007/s11060-008-9721-3,A role for the p53 pathway in the pathology of meningiomas with NF2 loss.,,0.85,genetic_reagent,D22S268,Genetic Reagent,,,,,
PMID:18974932,10.1007/s11060-008-9721-3,A role for the p53 pathway in the pathology of meningiomas with NF2 loss.,,0.85,genetic_reagent,D22S430,Genetic Reagent,,,,,
PMID:18974932,10.1007/s11060-008-9721-3,A role for the p53 pathway in the pathology of meningiomas with NF2 loss.,,0.9,genetic_reagent,BstUI,Genetic Reagent,,,,,
PMID:18974932,10.1007/s11060-008-9721-3,A role for the p53 pathway in the pathology of meningiomas with NF2 loss.,,0.9,genetic_reagent,"Taq polymerase (Qiagen, Valencia, CA)",Genetic Reagent,,,,,
PMID:18974932,10.1007/s11060-008-9721-3,A role for the p53 pathway in the pathology of meningiomas with NF2 loss.,,0.8,computational_tool,Research Patient Database Registry,Computational Tool,,,,,
PMID:34010628,10.1016/j.stem.2021.04.029,Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.,,0.9,animal_model,Nf1f/f;Trp53f/f;Nes-TK,Animal Model,,,,,
PMID:34010628,10.1016/j.stem.2021.04.029,Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.,,0.9,animal_model,Nf1f/f;Trp53f/f;CGD,Animal Model,,,,,
PMID:34010628,10.1016/j.stem.2021.04.029,Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.,,0.85,animal_model,cisNP,Animal Model,,,,,
PMID:34010628,10.1016/j.stem.2021.04.029,Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.,,0.9,antibody,TruStain FcX™ (anti-mouse CD16/32) antibody,Antibody,,,,,
PMID:34010628,10.1016/j.stem.2021.04.029,Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.,,0.9,antibody,PE-conjugated CD31 antibody,Antibody,,,,,
PMID:34010628,10.1016/j.stem.2021.04.029,Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.,,0.9,antibody,PE-conjugated Ter119 antibody,Antibody,,,,,
PMID:34010628,10.1016/j.stem.2021.04.029,Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.,,0.9,antibody,PE-conjugated CD45 antibody,Antibody,,,,,
PMID:34010628,10.1016/j.stem.2021.04.029,Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.,,0.8,genetic_reagent,Click-iT™ EdU Cell Proliferation Kit for Imaging,Genetic Reagent,,,,,
PMID:34010628,10.1016/j.stem.2021.04.029,Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.,,0.9,computational_tool,Seurat V3.0,Computational Tool,,,,,
PMID:34010628,10.1016/j.stem.2021.04.029,Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.,,0.9,computational_tool,STAR 2.4.2.8,Computational Tool,,,,,
PMID:34010628,10.1016/j.stem.2021.04.029,Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.,,0.9,computational_tool,DeSeq2,Computational Tool,,,,,
PMID:34010628,10.1016/j.stem.2021.04.029,Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.,,0.9,computational_tool,GSVA package,Computational Tool,,,,,
PMID:34010628,10.1016/j.stem.2021.04.029,Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.,,0.9,computational_tool,Limma package,Computational Tool,,,,,
PMID:34010628,10.1016/j.stem.2021.04.029,Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.,,0.8,computational_tool,gentleMACS Octo Dissociator,Computational Tool,,,,,
PMID:34010628,10.1016/j.stem.2021.04.029,Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.,,0.8,computational_tool,S3e sorter,Computational Tool,,,,,
PMID:34010628,10.1016/j.stem.2021.04.029,Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.,,0.8,computational_tool,IVIS Spectrum scanner,Computational Tool,,,,,
PMID:18242513,10.1016/j.ccr.2008.01.003,The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells.,,0.9,animal_model,Nf1-/- mice,Animal Model,,,,,
PMID:18242513,10.1016/j.ccr.2008.01.003,The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells.,,0.9,animal_model,Nf1fl mice,Animal Model,,,,,
PMID:18242513,10.1016/j.ccr.2008.01.003,The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells.,,0.9,animal_model,Nf1/p53-/- cis mutant mice,Animal Model,,,,,
PMID:18242513,10.1016/j.ccr.2008.01.003,The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells.,,0.9,animal_model,Wnt-1-Cre+ mice,Animal Model,,,,,
PMID:18242513,10.1016/j.ccr.2008.01.003,The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells.,,0.9,animal_model,3.9Periostin-Cre+ mice,Animal Model,,,,,
PMID:18242513,10.1016/j.ccr.2008.01.003,The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells.,,0.9,animal_model,P0a-Cre+ mice,Animal Model,,,,,
PMID:18242513,10.1016/j.ccr.2008.01.003,The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells.,,0.9,animal_model,Ink4a-/- mice,Animal Model,,,,,
PMID:18242513,10.1016/j.ccr.2008.01.003,The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells.,,0.9,animal_model,Ink4aArf-/- mice,Animal Model,,,,,
PMID:18242513,10.1016/j.ccr.2008.01.003,The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells.,,0.95,antibody,p75 antibody (Ab 1554; Chemicon),Antibody,,,,,
PMID:18242513,10.1016/j.ccr.2008.01.003,The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells.,,0.9,antibody,α4 integrin antibody (Becton-Dickinson),Antibody,,,,,
PMID:18242513,10.1016/j.ccr.2008.01.003,The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells.,,0.9,antibody,BrdU flow-cytometry kit (BD Pharmingen; cat#559619),Antibody,,,,,
PMID:18242513,10.1016/j.ccr.2008.01.003,The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells.,,0.85,computational_tool,FACSVantage SE-dual laser flow-cytometer,Computational Tool,,,,,
PMID:24386979,10.1186/1471-2407-14-6,"Modulation of Ras signaling alters the toxicity of hydroquinone, a benzene metabolite and component of cigarette smoke.",,0.95,animal_model,"Mx1-Cre, Nf1 flox/flox mice (129SV × C57BL/6 J)",Animal Model,,,,,
PMID:24386979,10.1186/1471-2407-14-6,"Modulation of Ras signaling alters the toxicity of hydroquinone, a benzene metabolite and component of cigarette smoke.",,0.85,cell_line,BY4743 background diploid yeast deletion strains,Cell Line,,,,,
PMID:24386979,10.1186/1471-2407-14-6,"Modulation of Ras signaling alters the toxicity of hydroquinone, a benzene metabolite and component of cigarette smoke.",,0.85,cell_line,Y258 background haploid yeast MORF strain,Cell Line,,,,,
PMID:24386979,10.1186/1471-2407-14-6,"Modulation of Ras signaling alters the toxicity of hydroquinone, a benzene metabolite and component of cigarette smoke.",,0.9,antibody,biotin-conjugated α-Lin Abs,Antibody,,,,,
PMID:24386979,10.1186/1471-2407-14-6,"Modulation of Ras signaling alters the toxicity of hydroquinone, a benzene metabolite and component of cigarette smoke.",,0.8,cell_line,MethoCult® M3434,Cell Line,,,,,
PMID:24386979,10.1186/1471-2407-14-6,"Modulation of Ras signaling alters the toxicity of hydroquinone, a benzene metabolite and component of cigarette smoke.",,0.75,genetic_reagent,StemSep negative selection column,Genetic Reagent,,,,,
PMID:24386979,10.1186/1471-2407-14-6,"Modulation of Ras signaling alters the toxicity of hydroquinone, a benzene metabolite and component of cigarette smoke.",,0.8,computational_tool,Axioplan 2 microscope,Computational Tool,,,,,
PMID:24386979,10.1186/1471-2407-14-6,"Modulation of Ras signaling alters the toxicity of hydroquinone, a benzene metabolite and component of cigarette smoke.",,0.85,computational_tool,GraphPad Prism version 5.01,Computational Tool,,,,,
PMID:24386979,10.1186/1471-2407-14-6,"Modulation of Ras signaling alters the toxicity of hydroquinone, a benzene metabolite and component of cigarette smoke.",,0.85,computational_tool,STATA 11,Computational Tool,,,,,
PMID:33369425,10.1021/acs.jpcb.0c09742,Machine Learning of Allosteric Effects: The Analysis of Ligand-Induced Dynamics to Predict Functional Effects in TRAP1.,,0.85,computational_tool,Schrödinger software suite release 2017–1,Computational Tool,,,,,
PMID:33369425,10.1021/acs.jpcb.0c09742,Machine Learning of Allosteric Effects: The Analysis of Ligand-Induced Dynamics to Predict Functional Effects in TRAP1.,,0.8,computational_tool,Glide,Computational Tool,,,,,
PMID:33369425,10.1021/acs.jpcb.0c09742,Machine Learning of Allosteric Effects: The Analysis of Ligand-Induced Dynamics to Predict Functional Effects in TRAP1.,,0.9,computational_tool,AMBER16,Computational Tool,,,,,
PMID:33369425,10.1021/acs.jpcb.0c09742,Machine Learning of Allosteric Effects: The Analysis of Ligand-Induced Dynamics to Predict Functional Effects in TRAP1.,,0.9,computational_tool,VMD (version 1.9.3),Computational Tool,,,,,
PMID:33369425,10.1021/acs.jpcb.0c09742,Machine Learning of Allosteric Effects: The Analysis of Ligand-Induced Dynamics to Predict Functional Effects in TRAP1.,,0.9,computational_tool,gromacs (version 4.6),Computational Tool,,,,,
PMID:33369425,10.1021/acs.jpcb.0c09742,Machine Learning of Allosteric Effects: The Analysis of Ligand-Induced Dynamics to Predict Functional Effects in TRAP1.,,0.85,computational_tool,MATLAB version 2019b,Computational Tool,,,,,
PMID:33369425,10.1021/acs.jpcb.0c09742,Machine Learning of Allosteric Effects: The Analysis of Ligand-Induced Dynamics to Predict Functional Effects in TRAP1.,,0.8,computational_tool,Classification Learner app,Computational Tool,,,,,
PMID:33369425,10.1021/acs.jpcb.0c09742,Machine Learning of Allosteric Effects: The Analysis of Ligand-Induced Dynamics to Predict Functional Effects in TRAP1.,,0.8,computational_tool,Curve Fitting tool of MATLAB,Computational Tool,,,,,
PMID:39373898,10.1007/s12031-024-02271-x,Identification of Pathogenic Missense Mutations of NF1 Using Computational Approaches.,,0.9,computational_tool,PredictSNP2,Computational Tool,,,,,
PMID:39373898,10.1007/s12031-024-02271-x,Identification of Pathogenic Missense Mutations of NF1 Using Computational Approaches.,,0.9,computational_tool,iStable,Computational Tool,,,,,
PMID:39373898,10.1007/s12031-024-02271-x,Identification of Pathogenic Missense Mutations of NF1 Using Computational Approaches.,,0.9,computational_tool,Align GVGD,Computational Tool,,,,,
PMID:39373898,10.1007/s12031-024-02271-x,Identification of Pathogenic Missense Mutations of NF1 Using Computational Approaches.,,0.9,computational_tool,AlphaFold3,Computational Tool,,,,,
PMID:39373898,10.1007/s12031-024-02271-x,Identification of Pathogenic Missense Mutations of NF1 Using Computational Approaches.,,0.85,computational_tool,SNPeffect 4.0,Computational Tool,,,,,
PMID:39373898,10.1007/s12031-024-02271-x,Identification of Pathogenic Missense Mutations of NF1 Using Computational Approaches.,,0.85,computational_tool,iMutant 2.0,Computational Tool,,,,,
PMID:39373898,10.1007/s12031-024-02271-x,Identification of Pathogenic Missense Mutations of NF1 Using Computational Approaches.,,0.85,computational_tool,MUpro,Computational Tool,,,,,
PMID:25012216,10.1186/s40478-014-0082-1,A neuronal function of the tumor suppressor protein merlin.,,0.85,clinical_assessment_tool,compound motor action potential (CMAP),Clinical Assessment Tool,,,,,
PMID:25012216,10.1186/s40478-014-0082-1,A neuronal function of the tumor suppressor protein merlin.,,0.8,clinical_assessment_tool,nerve conduction velocity,Clinical Assessment Tool,,,,,
PMID:25012216,10.1186/s40478-014-0082-1,A neuronal function of the tumor suppressor protein merlin.,,0.75,clinical_assessment_tool,electrophysiological measurements,Clinical Assessment Tool,,,,,
PMID:21216928,10.1158/1535-7163.MCT-10-0654,Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes.,,0.95,animal_model,Nf1 GFAP CKO mice (Nf1 flox/flox; GFAP-Cre),Animal Model,,,,,
PMID:21216928,10.1158/1535-7163.MCT-10-0654,Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes.,,0.9,cell_line,K4622 grade II glioma cell line,Cell Line,,,,,
PMID:21216928,10.1158/1535-7163.MCT-10-0654,Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes.,,0.85,antibody,Ki67 antibody (BD PharMingen),Antibody,,,,,
PMID:21216928,10.1158/1535-7163.MCT-10-0654,Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes.,,0.85,antibody,phospho-histone-H3 (Ser 10) antibody (Abcam),Antibody,,,,,
PMID:21216928,10.1158/1535-7163.MCT-10-0654,Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes.,,0.8,antibody,Cell Signaling Technology antibodies,Antibody,,,,,
PMID:21216928,10.1158/1535-7163.MCT-10-0654,Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes.,,0.85,antibody,α-tubulin antibody (Sigma),Antibody,,,,,
PMID:21216928,10.1158/1535-7163.MCT-10-0654,Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes.,,0.75,genetic_reagent,"Rapamycin (LC Laboratories, catalog number R-5000)",Genetic Reagent,,,,,
PMID:21216928,10.1158/1535-7163.MCT-10-0654,Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes.,,0.75,genetic_reagent,"NVP-BEZ235 (LC Laboratories, catalog number 915019-65-7)",Genetic Reagent,,,,,
PMID:21216928,10.1158/1535-7163.MCT-10-0654,Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes.,,0.75,genetic_reagent,LY294002 (Calbiochem),Genetic Reagent,,,,,
PMID:21216928,10.1158/1535-7163.MCT-10-0654,Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes.,,0.85,computational_tool,Gel-Pro Analyzer 4.0 software,Computational Tool,,,,,
PMID:21216928,10.1158/1535-7163.MCT-10-0654,Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes.,,0.8,computational_tool,R statistical package,Computational Tool,,,,,
PMID:25917366,10.1038/mp.2015.48,HCN channels are a novel therapeutic target for cognitive dysfunction in Neurofibromatosis type 1.,,0.9,animal_model,Nf1 9a−/9a− mice,Animal Model,,,,,
PMID:25917366,10.1038/mp.2015.48,HCN channels are a novel therapeutic target for cognitive dysfunction in Neurofibromatosis type 1.,,0.9,animal_model,Nf1 9a−/9a+ mice,Animal Model,,,,,
PMID:25917366,10.1038/mp.2015.48,HCN channels are a novel therapeutic target for cognitive dysfunction in Neurofibromatosis type 1.,,0.85,animal_model,C57BL/6JOlaHsd mice,Animal Model,,,,,
PMID:25917366,10.1038/mp.2015.48,HCN channels are a novel therapeutic target for cognitive dysfunction in Neurofibromatosis type 1.,,0.85,animal_model,129T2/SvEmsJ mice,Animal Model,,,,,
PMID:25917366,10.1038/mp.2015.48,HCN channels are a novel therapeutic target for cognitive dysfunction in Neurofibromatosis type 1.,,0.9,animal_model,G12V H-Ras mice,Animal Model,,,,,
PMID:25917366,10.1038/mp.2015.48,HCN channels are a novel therapeutic target for cognitive dysfunction in Neurofibromatosis type 1.,,0.8,genetic_reagent,lamotrigine,Genetic Reagent,,,,,
PMID:25917366,10.1038/mp.2015.48,HCN channels are a novel therapeutic target for cognitive dysfunction in Neurofibromatosis type 1.,,0.9,clinical_assessment_tool,Morris water maze,Clinical Assessment Tool,,,,,
PMID:25917366,10.1038/mp.2015.48,HCN channels are a novel therapeutic target for cognitive dysfunction in Neurofibromatosis type 1.,,0.9,clinical_assessment_tool,Rotarod,Clinical Assessment Tool,,,,,
PMID:25917366,10.1038/mp.2015.48,HCN channels are a novel therapeutic target for cognitive dysfunction in Neurofibromatosis type 1.,,0.8,computational_tool,Mini Analysis,Computational Tool,,,,,
PMID:25917366,10.1038/mp.2015.48,HCN channels are a novel therapeutic target for cognitive dysfunction in Neurofibromatosis type 1.,,0.8,computational_tool,Prism,Computational Tool,,,,,
PMID:25917366,10.1038/mp.2015.48,HCN channels are a novel therapeutic target for cognitive dysfunction in Neurofibromatosis type 1.,,0.8,computational_tool,SPSS,Computational Tool,,,,,
PMID:25917366,10.1038/mp.2015.48,HCN channels are a novel therapeutic target for cognitive dysfunction in Neurofibromatosis type 1.,,0.75,genetic_reagent,biocytin,Genetic Reagent,,,,,
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,0.9,cell_line,HSR-GBM1,Cell Line,,,,,
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,0.9,cell_line,JHH-520,Cell Line,,,,,
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,0.9,cell_line,JHU-0879,Cell Line,,,,,
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,0.9,cell_line,JHU-1016B,Cell Line,,,,,
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,0.9,cell_line,JHH-136,Cell Line,,,,,
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,0.85,cell_line,B76,Cell Line,,,,,
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,0.85,cell_line,NGT-41,Cell Line,,,,,
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,0.85,cell_line,NMCG-1,Cell Line,,,,,
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,0.85,cell_line,DBTRG,Cell Line,,,,,
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,0.8,cell_line,LN229,Cell Line,,,,,
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,0.8,cell_line,T98G,Cell Line,,,,,
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,0.9,animal_model,NSG mice,Animal Model,,,,,
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,0.95,genetic_reagent,mirdametinib,Genetic Reagent,,,,,
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,0.85,genetic_reagent,NucLight red lentivirus,Genetic Reagent,,,,,
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,0.9,antibody,total ERK antibody,Antibody,,,,,
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,0.9,antibody,phospho-ERKthr202/tyr204 antibody,Antibody,,,,,
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,0.9,antibody,phospho-MEKser217/221 antibody,Antibody,,,,,
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,0.9,antibody,cleaved PARP antibody,Antibody,,,,,
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,0.9,antibody,RAD51 antibody,Antibody,,,,,
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,0.9,antibody,BRCA2 antibody,Antibody,,,,,
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,0.9,antibody,GAPDH antibody,Antibody,,,,,
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,0.95,antibody,NF1 antibody (A300-140A),Antibody,,,,,
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,0.95,antibody,MGMT antibody (sc-166528),Antibody,,,,,
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,0.95,antibody,RAD51 antibody (ab133534),Antibody,,,,,
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,0.95,antibody,yH2AX antibody (05-636),Antibody,,,,,
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,0.85,computational_tool,SynergyFinder,Computational Tool,,,,,
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,0.8,computational_tool,ImageJ,Computational Tool,,,,,
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,0.8,computational_tool,FlowJo,Computational Tool,,,,,
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,0.8,computational_tool,Qupath,Computational Tool,,,,,
PMID:32419643,10.1177/1533033820919759,Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.,,0.85,cell_line,M059J,Cell Line,,,,,
PMID:32419643,10.1177/1533033820919759,Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.,,0.9,cell_line,U87,Cell Line,,,,,
PMID:32419643,10.1177/1533033820919759,Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.,,0.9,cell_line,U118,Cell Line,,,,,
PMID:32419643,10.1177/1533033820919759,Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.,,0.9,cell_line,U251,Cell Line,,,,,
PMID:32419643,10.1177/1533033820919759,Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.,,0.9,cell_line,A172,Cell Line,,,,,
PMID:32419643,10.1177/1533033820919759,Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.,,0.8,genetic_reagent,pcDNA vector,Genetic Reagent,,,,,
PMID:32419643,10.1177/1533033820919759,Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.,,0.75,genetic_reagent,TRIzol reagent,Genetic Reagent,,,,,
PMID:32419643,10.1177/1533033820919759,Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.,,0.8,genetic_reagent,Transcriptor First strand cDNA synthesis kit,Genetic Reagent,,,,,
PMID:32419643,10.1177/1533033820919759,Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.,,0.85,antibody,p-AKT antibody,Antibody,,,,,
PMID:32419643,10.1177/1533033820919759,Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.,,0.85,antibody,total AKT antibody,Antibody,,,,,
PMID:32419643,10.1177/1533033820919759,Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.,,0.85,antibody,β-Actin antibody,Antibody,,,,,
PMID:32419643,10.1177/1533033820919759,Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.,,0.85,antibody,Ago2 antibody,Antibody,,,,,
PMID:32419643,10.1177/1533033820919759,Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.,,0.8,genetic_reagent,pmirGLO vector,Genetic Reagent,,,,,
PMID:32419643,10.1177/1533033820919759,Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma.,,0.8,computational_tool,SPSS version 19.0,Computational Tool,,,,,
PMID:34049498,10.1186/s11689-021-09364-3,Early differences in auditory processing relate to Autism Spectrum Disorder traits in infants with Neurofibromatosis Type I.,,0.85,clinical_assessment_tool,EGI 128-electrode Hydrocel Sensor Net,Clinical Assessment Tool,,,,,
PMID:34049498,10.1186/s11689-021-09364-3,Early differences in auditory processing relate to Autism Spectrum Disorder traits in infants with Neurofibromatosis Type I.,,0.95,clinical_assessment_tool,Mullen Scales of Early Learning (MSEL),Clinical Assessment Tool,,,,,
PMID:34049498,10.1186/s11689-021-09364-3,Early differences in auditory processing relate to Autism Spectrum Disorder traits in infants with Neurofibromatosis Type I.,,0.95,clinical_assessment_tool,Autism Observation Score for Infants (AOSI),Clinical Assessment Tool,,,,,
PMID:34049498,10.1186/s11689-021-09364-3,Early differences in auditory processing relate to Autism Spectrum Disorder traits in infants with Neurofibromatosis Type I.,,0.9,clinical_assessment_tool,Infant Behaviour Questionnaire-Revised (IBQ-R),Clinical Assessment Tool,,,,,
PMID:34049498,10.1186/s11689-021-09364-3,Early differences in auditory processing relate to Autism Spectrum Disorder traits in infants with Neurofibromatosis Type I.,,0.9,clinical_assessment_tool,MacArthur Bates Communicative Development Inventory (CDI),Clinical Assessment Tool,,,,,
PMID:34049498,10.1186/s11689-021-09364-3,Early differences in auditory processing relate to Autism Spectrum Disorder traits in infants with Neurofibromatosis Type I.,,0.85,clinical_assessment_tool,NIH consensus criteria,Clinical Assessment Tool,,,,,
PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,0.85,animal_model,Tg(4xhre-tata:eGFP)ia,Animal Model,,,,,
PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,0.85,animal_model,Tg(ptf1a:Gal4)/UAS:eGFPKRAS G12D,Animal Model,,,,,
PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,0.9,cell_line,U87,Cell Line,,,,,
PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,0.9,cell_line,U251,Cell Line,,,,,
PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,0.9,cell_line,MiaPaCa-2,Cell Line,,,,,
PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,0.9,cell_line,PANC1,Cell Line,,,,,
PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,0.9,cell_line,BxPc3,Cell Line,,,,,
PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,0.95,cell_line,ipNF95.6,Cell Line,,,,,
PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,0.85,cell_line,HEK 293T,Cell Line,,,,,
PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,0.9,genetic_reagent,psPAX,Genetic Reagent,,,,,
PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,0.9,genetic_reagent,pMD2.G,Genetic Reagent,,,,,
PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,0.9,genetic_reagent,Tol2(UAS:eGFP-KRAS G12D),Genetic Reagent,,,,,
PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,0.9,computational_tool,CHOPCHOP,Computational Tool,,,,,
PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,0.85,computational_tool,DanioVision tracking system,Computational Tool,,,,,
PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,0.9,computational_tool,Ethovision 11,Computational Tool,,,,,
PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,0.85,computational_tool,ImageJ,Computational Tool,,,,,
PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,0.9,antibody,anti-rodent TRAP1,Antibody,,,,,
PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,0.9,antibody,anti-human TRAP1,Antibody,,,,,
PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,0.9,antibody,anti-β actin,Antibody,,,,,
PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,0.9,antibody,anti-citrate synthetase,Antibody,,,,,
PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,0.9,antibody,anti-HIF1α (Novus),Antibody,,,,,
PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,0.9,antibody,anti-HIF1α (GeneTex),Antibody,,,,,
PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,0.9,antibody,anti-phospho-ERK1/2,Antibody,,,,,
PMID:33934112,10.1038/s41419-021-03716-6,HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,0.9,antibody,anti-glucose transporter GLUT1,Antibody,,,,,
PMID:25340526,10.1371/journal.pone.0107760,Nilotinib is more potent than imatinib for treating plexiform neurofibroma in vitro and in vivo.,,0.9,animal_model,"athymic nude mice (female, nu/nu Balb/c)",Animal Model,,,,,
PMID:25340526,10.1371/journal.pone.0107760,Nilotinib is more potent than imatinib for treating plexiform neurofibroma in vitro and in vivo.,,0.85,cell_line,PNF-derived Schwann cells,Cell Line,,,,,
PMID:25340526,10.1371/journal.pone.0107760,Nilotinib is more potent than imatinib for treating plexiform neurofibroma in vitro and in vivo.,,0.9,computational_tool,Vevo 2100 micro-imaging system,Computational Tool,,,,,
PMID:25340526,10.1371/journal.pone.0107760,Nilotinib is more potent than imatinib for treating plexiform neurofibroma in vitro and in vivo.,,0.9,computational_tool,Vevo software version 5.0.0,Computational Tool,,,,,
PMID:25340526,10.1371/journal.pone.0107760,Nilotinib is more potent than imatinib for treating plexiform neurofibroma in vitro and in vivo.,,0.8,computational_tool,Galaxy server,Computational Tool,,,,,
PMID:25340526,10.1371/journal.pone.0107760,Nilotinib is more potent than imatinib for treating plexiform neurofibroma in vitro and in vivo.,,0.85,computational_tool,Chipster software,Computational Tool,,,,,
PMID:25340526,10.1371/journal.pone.0107760,Nilotinib is more potent than imatinib for treating plexiform neurofibroma in vitro and in vivo.,,0.8,computational_tool,R bioconductor,Computational Tool,,,,,
PMID:25340526,10.1371/journal.pone.0107760,Nilotinib is more potent than imatinib for treating plexiform neurofibroma in vitro and in vivo.,,0.8,genetic_reagent,CytoTox 96 Non-Radioactive Cytotoxicity assay,Genetic Reagent,,,,,
PMID:25340526,10.1371/journal.pone.0107760,Nilotinib is more potent than imatinib for treating plexiform neurofibroma in vitro and in vivo.,,0.8,genetic_reagent,TruSeq Stranded Total RNA Sample Preparation kit,Genetic Reagent,,,,,
PMID:25340526,10.1371/journal.pone.0107760,Nilotinib is more potent than imatinib for treating plexiform neurofibroma in vitro and in vivo.,,0.8,genetic_reagent,SuperScript III First-Strand Synthesis System,Genetic Reagent,,,,,
PMID:25340526,10.1371/journal.pone.0107760,Nilotinib is more potent than imatinib for treating plexiform neurofibroma in vitro and in vivo.,,0.85,computational_tool,Genome Analyzer IIx,Computational Tool,,,,,
PMID:29787563,10.1371/journal.pone.0190001,Graph complexity analysis identifies an ETV5 tumor-specific network in human and murine low-grade glioma.,,0.9,animal_model,Nf1flox/flox,Animal Model,,,,,
PMID:29787563,10.1371/journal.pone.0190001,Graph complexity analysis identifies an ETV5 tumor-specific network in human and murine low-grade glioma.,,0.9,animal_model,Nf1flox/null; GFAP-Cre (OPG-1),Animal Model,,,,,
PMID:29787563,10.1371/journal.pone.0190001,Graph complexity analysis identifies an ETV5 tumor-specific network in human and murine low-grade glioma.,,0.9,animal_model,Nf1flox/R681*; GFAP-Cre (OPG-2),Animal Model,,,,,
PMID:29787563,10.1371/journal.pone.0190001,Graph complexity analysis identifies an ETV5 tumor-specific network in human and murine low-grade glioma.,,0.9,animal_model,Nf1flox/null; Ptenflox/wt; GFAP-Cre (OPG-3),Animal Model,,,,,
PMID:29787563,10.1371/journal.pone.0190001,Graph complexity analysis identifies an ETV5 tumor-specific network in human and murine low-grade glioma.,,0.9,animal_model,Nf1flox/null; Olig2-Cre (OPG-4),Animal Model,,,,,
PMID:29787563,10.1371/journal.pone.0190001,Graph complexity analysis identifies an ETV5 tumor-specific network in human and murine low-grade glioma.,,0.9,antibody,Rabbit anti-Etv5 antibody (Novus Biologicals),Antibody,,,,,
PMID:29787563,10.1371/journal.pone.0190001,Graph complexity analysis identifies an ETV5 tumor-specific network in human and murine low-grade glioma.,,0.8,genetic_reagent,RNeasy Mini Kit (Qiagen),Genetic Reagent,,,,,
PMID:29787563,10.1371/journal.pone.0190001,Graph complexity analysis identifies an ETV5 tumor-specific network in human and murine low-grade glioma.,,0.9,computational_tool,ARACNe-AP algorithm,Computational Tool,,,,,
PMID:29787563,10.1371/journal.pone.0190001,Graph complexity analysis identifies an ETV5 tumor-specific network in human and murine low-grade glioma.,,0.9,computational_tool,DESeq2 version 1.18.1,Computational Tool,,,,,
PMID:29787563,10.1371/journal.pone.0190001,Graph complexity analysis identifies an ETV5 tumor-specific network in human and murine low-grade glioma.,,0.8,computational_tool,igraph package in R,Computational Tool,,,,,
PMID:29787563,10.1371/journal.pone.0190001,Graph complexity analysis identifies an ETV5 tumor-specific network in human and murine low-grade glioma.,,0.8,cell_line,Wild-type and Nf1-/- primary astrocytes,Cell Line,,,,,
PMID:28398289,10.1038/sdata.2017.45,A high-throughput molecular data resource for cutaneous neurofibromas.,,0.85,genetic_reagent,DNeasy mini kit,Genetic Reagent,,,,,
PMID:28398289,10.1038/sdata.2017.45,A high-throughput molecular data resource for cutaneous neurofibromas.,,0.8,computational_tool,Qubit 2.0 Fluorometer,Computational Tool,,,,,
PMID:28398289,10.1038/sdata.2017.45,A high-throughput molecular data resource for cutaneous neurofibromas.,,0.8,computational_tool,Covaris LE220,Computational Tool,,,,,
PMID:28398289,10.1038/sdata.2017.45,A high-throughput molecular data resource for cutaneous neurofibromas.,,0.8,computational_tool,Caliper LabChip GX,Computational Tool,,,,,
PMID:28398289,10.1038/sdata.2017.45,A high-throughput molecular data resource for cutaneous neurofibromas.,,0.85,genetic_reagent,NEBNext DNA Library Prep Reagent Set for Illumina,Genetic Reagent,,,,,
PMID:28398289,10.1038/sdata.2017.45,A high-throughput molecular data resource for cutaneous neurofibromas.,,0.8,computational_tool,"Agilent 2,100 Bioanalyzer",Computational Tool,,,,,
PMID:28398289,10.1038/sdata.2017.45,A high-throughput molecular data resource for cutaneous neurofibromas.,,0.85,genetic_reagent,KAPA Biosystems Library Quantification Kit,Genetic Reagent,,,,,
PMID:28398289,10.1038/sdata.2017.45,A high-throughput molecular data resource for cutaneous neurofibromas.,,0.8,computational_tool,Illumina HiSeqX sequencer,Computational Tool,,,,,
PMID:28398289,10.1038/sdata.2017.45,A high-throughput molecular data resource for cutaneous neurofibromas.,,0.9,computational_tool,Dragen program,Computational Tool,,,,,
PMID:28398289,10.1038/sdata.2017.45,A high-throughput molecular data resource for cutaneous neurofibromas.,,0.9,computational_tool,GATK pipeline,Computational Tool,,,,,
PMID:28398289,10.1038/sdata.2017.45,A high-throughput molecular data resource for cutaneous neurofibromas.,,0.9,computational_tool,VarDict,Computational Tool,,,,,
PMID:28398289,10.1038/sdata.2017.45,A high-throughput molecular data resource for cutaneous neurofibromas.,,0.85,genetic_reagent,HumanOmni2.5-8,Genetic Reagent,,,,,
PMID:28398289,10.1038/sdata.2017.45,A high-throughput molecular data resource for cutaneous neurofibromas.,,0.85,computational_tool,GenomeStudio,Computational Tool,,,,,
PMID:28398289,10.1038/sdata.2017.45,A high-throughput molecular data resource for cutaneous neurofibromas.,,0.85,genetic_reagent,miRNeasy mini kit,Genetic Reagent,,,,,
PMID:28398289,10.1038/sdata.2017.45,A high-throughput molecular data resource for cutaneous neurofibromas.,,0.85,genetic_reagent,NEBNext Magnetic Oligo d(T)25 Beads,Genetic Reagent,,,,,
PMID:28398289,10.1038/sdata.2017.45,A high-throughput molecular data resource for cutaneous neurofibromas.,,0.85,genetic_reagent,NEBNext mRNA Library Prep Reagent Set for Illumina,Genetic Reagent,,,,,
PMID:28398289,10.1038/sdata.2017.45,A high-throughput molecular data resource for cutaneous neurofibromas.,,0.85,genetic_reagent,TruSeq SBS HS v4 Kit,Genetic Reagent,,,,,
PMID:28398289,10.1038/sdata.2017.45,A high-throughput molecular data resource for cutaneous neurofibromas.,,0.8,computational_tool,Illumina HiSeq2500 sequencer,Computational Tool,,,,,
PMID:28398289,10.1038/sdata.2017.45,A high-throughput molecular data resource for cutaneous neurofibromas.,,0.9,computational_tool,HudsonAlpha RNA-seq data analysis pipeline,Computational Tool,,,,,
PMID:28398289,10.1038/sdata.2017.45,A high-throughput molecular data resource for cutaneous neurofibromas.,,0.85,computational_tool,TopHat v2.0,Computational Tool,,,,,
PMID:28398289,10.1038/sdata.2017.45,A high-throughput molecular data resource for cutaneous neurofibromas.,,0.85,computational_tool,Cufflinks v0.9.3,Computational Tool,,,,,
PMID:28398289,10.1038/sdata.2017.45,A high-throughput molecular data resource for cutaneous neurofibromas.,,0.8,computational_tool,FeatureCounts,Computational Tool,,,,,
PMID:28398289,10.1038/sdata.2017.45,A high-throughput molecular data resource for cutaneous neurofibromas.,,0.95,computational_tool,Cutaneous NF Github repository,Computational Tool,,,,,
PMID:39472976,10.1186/s40478-024-01875-z,NF1 expression profiling in IDH-wildtype glioblastoma: genomic associations and survival outcomes.,,0.95,antibody,"NFC antibody (Sigma-Aldrich, MABE1820)",Antibody,,,,,
PMID:39472976,10.1186/s40478-024-01875-z,NF1 expression profiling in IDH-wildtype glioblastoma: genomic associations and survival outcomes.,,0.95,antibody,iNF-07E antibody (iNFixion Bioscience),Antibody,,,,,
PMID:39472976,10.1186/s40478-024-01875-z,NF1 expression profiling in IDH-wildtype glioblastoma: genomic associations and survival outcomes.,,0.9,antibody,"podoplanin antibody (clone D2-40, Dako)",Antibody,,,,,
PMID:39472976,10.1186/s40478-024-01875-z,NF1 expression profiling in IDH-wildtype glioblastoma: genomic associations and survival outcomes.,,0.9,antibody,"phospho-ERK antibody (#9101, Cell Signaling)",Antibody,,,,,
PMID:39472976,10.1186/s40478-024-01875-z,NF1 expression profiling in IDH-wildtype glioblastoma: genomic associations and survival outcomes.,,0.95,cell_line,JHH-520 cell line,Cell Line,,,,,
PMID:39472976,10.1186/s40478-024-01875-z,NF1 expression profiling in IDH-wildtype glioblastoma: genomic associations and survival outcomes.,,0.9,cell_line,GBM1 cell line,Cell Line,,,,,
PMID:39472976,10.1186/s40478-024-01875-z,NF1 expression profiling in IDH-wildtype glioblastoma: genomic associations and survival outcomes.,,0.9,cell_line,JHH-0879 cell line,Cell Line,,,,,
PMID:39472976,10.1186/s40478-024-01875-z,NF1 expression profiling in IDH-wildtype glioblastoma: genomic associations and survival outcomes.,,0.95,computational_tool,QuPath (v0.4.3),Computational Tool,,,,,
PMID:39472976,10.1186/s40478-024-01875-z,NF1 expression profiling in IDH-wildtype glioblastoma: genomic associations and survival outcomes.,,0.85,computational_tool,R (version 4.3.1),Computational Tool,,,,,
PMID:39472976,10.1186/s40478-024-01875-z,NF1 expression profiling in IDH-wildtype glioblastoma: genomic associations and survival outcomes.,,0.9,computational_tool,cBioportal,Computational Tool,,,,,
PMID:39472976,10.1186/s40478-024-01875-z,NF1 expression profiling in IDH-wildtype glioblastoma: genomic associations and survival outcomes.,,0.85,computational_tool,REDCap,Computational Tool,,,,,
PMID:29670214,10.1038/s41598-018-24310-5,Restoring functional neurofibromin by protein transduction.,,0.85,cell_line,Sf21 insect cells,Cell Line,,,,,
PMID:29670214,10.1038/s41598-018-24310-5,Restoring functional neurofibromin by protein transduction.,,0.8,cell_line,E. coli DH10Multibac cells,Cell Line,,,,,
PMID:29670214,10.1038/s41598-018-24310-5,Restoring functional neurofibromin by protein transduction.,,0.85,genetic_reagent,pFastBacHta,Genetic Reagent,,,,,
PMID:29670214,10.1038/s41598-018-24310-5,Restoring functional neurofibromin by protein transduction.,,0.9,genetic_reagent,synNF1,Genetic Reagent,,,,,
PMID:29670214,10.1038/s41598-018-24310-5,Restoring functional neurofibromin by protein transduction.,,0.9,genetic_reagent,synNF1eGFP,Genetic Reagent,,,,,
PMID:29670214,10.1038/s41598-018-24310-5,Restoring functional neurofibromin by protein transduction.,,0.8,genetic_reagent,EndoPorter,Genetic Reagent,,,,,
PMID:29670214,10.1038/s41598-018-24310-5,Restoring functional neurofibromin by protein transduction.,,0.9,antibody,Anti-ERK1/2 (p44/42 MAPK (Erk1/2)),Antibody,,,,,
PMID:29670214,10.1038/s41598-018-24310-5,Restoring functional neurofibromin by protein transduction.,,0.9,antibody,anti-phopho ERK1/2 (Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204)),Antibody,,,,,
PMID:29670214,10.1038/s41598-018-24310-5,Restoring functional neurofibromin by protein transduction.,,0.85,antibody,anti-GAPDH,Antibody,,,,,
PMID:29670214,10.1038/s41598-018-24310-5,Restoring functional neurofibromin by protein transduction.,,0.85,antibody,anti-rabbit IgG HRP,Antibody,,,,,
PMID:29670214,10.1038/s41598-018-24310-5,Restoring functional neurofibromin by protein transduction.,,0.85,antibody,anti-mouse IgG HRP,Antibody,,,,,
PMID:29670214,10.1038/s41598-018-24310-5,Restoring functional neurofibromin by protein transduction.,,0.85,computational_tool,ImageJ,Computational Tool,,,,,
PMID:29670214,10.1038/s41598-018-24310-5,Restoring functional neurofibromin by protein transduction.,,0.85,genetic_reagent,FlexiTube siRNAs,Genetic Reagent,,,,,
PMID:29670214,10.1038/s41598-018-24310-5,Restoring functional neurofibromin by protein transduction.,,0.8,genetic_reagent,Allstar Negative Control siRNA,Genetic Reagent,,,,,
PMID:29670214,10.1038/s41598-018-24310-5,Restoring functional neurofibromin by protein transduction.,,0.8,genetic_reagent,Lipofectamine RNAiMAX,Genetic Reagent,,,,,
PMID:36565307,10.1016/j.gim.2022.10.007,"COVID-19 in people with neurofibromatosis 1, neurofibromatosis 2, or schwannomatosis.",,0.85,computational_tool,National COVID Cohort Collaborative (N3C),Computational Tool,,,,,
PMID:36565307,10.1016/j.gim.2022.10.007,"COVID-19 in people with neurofibromatosis 1, neurofibromatosis 2, or schwannomatosis.",,0.8,computational_tool,N3C Data Enclave,Computational Tool,,,,,
PMID:36565307,10.1016/j.gim.2022.10.007,"COVID-19 in people with neurofibromatosis 1, neurofibromatosis 2, or schwannomatosis.",,0.9,clinical_assessment_tool,"International Classification of Diseases, 10th Revision (ICD-10)",Clinical Assessment Tool,,,,,
PMID:36565307,10.1016/j.gim.2022.10.007,"COVID-19 in people with neurofibromatosis 1, neurofibromatosis 2, or schwannomatosis.",,0.9,clinical_assessment_tool,Systematized Nomenclature of Medicine (SNOMED),Clinical Assessment Tool,,,,,
PMID:36565307,10.1016/j.gim.2022.10.007,"COVID-19 in people with neurofibromatosis 1, neurofibromatosis 2, or schwannomatosis.",,0.85,clinical_assessment_tool,Logical Observation Identifiers Names and Codes (LOINC),Clinical Assessment Tool,,,,,
PMID:36565307,10.1016/j.gim.2022.10.007,"COVID-19 in people with neurofibromatosis 1, neurofibromatosis 2, or schwannomatosis.",,0.8,clinical_assessment_tool,Nebraska Lexicon,Clinical Assessment Tool,,,,,
PMID:36565307,10.1016/j.gim.2022.10.007,"COVID-19 in people with neurofibromatosis 1, neurofibromatosis 2, or schwannomatosis.",,0.85,computational_tool,Shapiro-Wilk test,Computational Tool,,,,,
PMID:36565307,10.1016/j.gim.2022.10.007,"COVID-19 in people with neurofibromatosis 1, neurofibromatosis 2, or schwannomatosis.",,0.9,computational_tool,R v3.6.3,Computational Tool,,,,,
PMID:36565307,10.1016/j.gim.2022.10.007,"COVID-19 in people with neurofibromatosis 1, neurofibromatosis 2, or schwannomatosis.",,0.85,computational_tool,BSDA v1.2.0,Computational Tool,,,,,
PMID:36565307,10.1016/j.gim.2022.10.007,"COVID-19 in people with neurofibromatosis 1, neurofibromatosis 2, or schwannomatosis.",,0.85,computational_tool,gdata v2.18.0,Computational Tool,,,,,
PMID:36565307,10.1016/j.gim.2022.10.007,"COVID-19 in people with neurofibromatosis 1, neurofibromatosis 2, or schwannomatosis.",,0.85,computational_tool,ggplot2 v3.3.2,Computational Tool,,,,,
PMID:36565307,10.1016/j.gim.2022.10.007,"COVID-19 in people with neurofibromatosis 1, neurofibromatosis 2, or schwannomatosis.",,0.85,computational_tool,Wilcoxon rank-sum test,Computational Tool,,,,,
PMID:36565307,10.1016/j.gim.2022.10.007,"COVID-19 in people with neurofibromatosis 1, neurofibromatosis 2, or schwannomatosis.",,0.85,computational_tool,Benjamini-Hochberg (BH) method,Computational Tool,,,,,
PMID:24619350,10.1007/s00415-014-7303-1,Longitudinal evaluation of quality of life in 288 patients with neurofibromatosis 2.,,0.95,clinical_assessment_tool,NFTI-QOL,Clinical Assessment Tool,,,,,
PMID:28256556,10.1038/srep43315,An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system.,,0.95,animal_model,Nf1fl/fl;DhhCre,Animal Model,,,,,
PMID:28256556,10.1038/srep43315,An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system.,,0.9,antibody,"anti-mouse monoclonal antibodies against CD11b (8G12/HPCA-2, Becton–Dickinson)",Antibody,,,,,
PMID:28256556,10.1038/srep43315,An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system.,,0.9,antibody,"anti-p75/NGFR (C40-1457, Becton–Dickinson)",Antibody,,,,,
PMID:28256556,10.1038/srep43315,An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system.,,0.85,antibody,anti-F4/80,Antibody,,,,,
PMID:28256556,10.1038/srep43315,An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system.,,0.9,antibody,Anti-CSF1 (R&D Systems MAB4161),Antibody,,,,,
PMID:28256556,10.1038/srep43315,An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system.,,0.8,computational_tool,FACSCanto (Becton–Dickinson),Computational Tool,,,,,
PMID:28256556,10.1038/srep43315,An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system.,,0.8,genetic_reagent,RNeasy mini kit (QIAGEN),Genetic Reagent,,,,,
PMID:28256556,10.1038/srep43315,An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system.,,0.9,computational_tool,Affymetrix Mouse Gene 2.0 ST array,Computational Tool,,,,,
PMID:28256556,10.1038/srep43315,An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system.,,0.85,computational_tool,ComBat method,Computational Tool,,,,,
PMID:28256556,10.1038/srep43315,An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system.,,0.9,computational_tool,limma package,Computational Tool,,,,,
PMID:28256556,10.1038/srep43315,An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system.,,0.9,computational_tool,WebGestalt webserver,Computational Tool,,,,,
PMID:28256556,10.1038/srep43315,An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system.,,0.85,computational_tool,NetWalk algorithm,Computational Tool,,,,,
PMID:28256556,10.1038/srep43315,An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system.,,0.8,genetic_reagent,PEGylated interferon alpha-2b,Genetic Reagent,,,,,
PMID:28256556,10.1038/srep43315,An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system.,,0.8,clinical_assessment_tool,"mouse cytokine array (panel A, R&D system)",Clinical Assessment Tool,,,,,
PMID:28589254,10.1007/s00259-017-3733-1,Characterisation of malignant peripheral nerve sheath tumours in neurofibromatosis-1 using heterogeneity analysis of ,,0.8,computational_tool,Discovery VCT,Computational Tool,,,,,
PMID:28589254,10.1007/s00259-017-3733-1,Characterisation of malignant peripheral nerve sheath tumours in neurofibromatosis-1 using heterogeneity analysis of ,,0.8,computational_tool,DST,Computational Tool,,,,,
PMID:28589254,10.1007/s00259-017-3733-1,Characterisation of malignant peripheral nerve sheath tumours in neurofibromatosis-1 using heterogeneity analysis of ,,0.9,computational_tool,MATLAB,Computational Tool,,,,,
PMID:28589254,10.1007/s00259-017-3733-1,Characterisation of malignant peripheral nerve sheath tumours in neurofibromatosis-1 using heterogeneity analysis of ,,0.85,computational_tool,SPSS,Computational Tool,,,,,
PMID:28589254,10.1007/s00259-017-3733-1,Characterisation of malignant peripheral nerve sheath tumours in neurofibromatosis-1 using heterogeneity analysis of ,,0.85,computational_tool,MedCalc,Computational Tool,,,,,
PMID:37174087,10.3390/cancers15092621,Vinblastine/Methotrexate for Debilitating and Progressive Plexiform Neurofibroma in Children and Young Adults with Neurofibromatosis Type 1: A Phase 2 Study.,,0.85,clinical_assessment_tool,NIH Consensus Conference criteria,Clinical Assessment Tool,,,,,
PMID:37174087,10.3390/cancers15092621,Vinblastine/Methotrexate for Debilitating and Progressive Plexiform Neurofibroma in Children and Young Adults with Neurofibromatosis Type 1: A Phase 2 Study.,,0.9,clinical_assessment_tool,Lansky performance status,Clinical Assessment Tool,,,,,
PMID:37174087,10.3390/cancers15092621,Vinblastine/Methotrexate for Debilitating and Progressive Plexiform Neurofibroma in Children and Young Adults with Neurofibromatosis Type 1: A Phase 2 Study.,,0.9,clinical_assessment_tool,Karnofsky performance status,Clinical Assessment Tool,,,,,
PMID:37174087,10.3390/cancers15092621,Vinblastine/Methotrexate for Debilitating and Progressive Plexiform Neurofibroma in Children and Young Adults with Neurofibromatosis Type 1: A Phase 2 Study.,,0.95,clinical_assessment_tool,National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0,Clinical Assessment Tool,,,,,
PMID:37174087,10.3390/cancers15092621,Vinblastine/Methotrexate for Debilitating and Progressive Plexiform Neurofibroma in Children and Young Adults with Neurofibromatosis Type 1: A Phase 2 Study.,,0.95,clinical_assessment_tool,Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS),Clinical Assessment Tool,,,,,
PMID:37174087,10.3390/cancers15092621,Vinblastine/Methotrexate for Debilitating and Progressive Plexiform Neurofibroma in Children and Young Adults with Neurofibromatosis Type 1: A Phase 2 Study.,,0.8,computational_tool,Stata 15,Computational Tool,,,,,
PMID:39093127,10.1158/1078-0432.CCR-24-0797,Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell-Free DNA Fragmentomics.,,0.85,genetic_reagent,QIAamp Circulating Nucleic Acid kit,Genetic Reagent,,,,,
PMID:39093127,10.1158/1078-0432.CCR-24-0797,Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell-Free DNA Fragmentomics.,,0.85,genetic_reagent,Qubit dsDNA High-Sensitivity Assay kit,Genetic Reagent,,,,,
PMID:39093127,10.1158/1078-0432.CCR-24-0797,Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell-Free DNA Fragmentomics.,,0.85,genetic_reagent,KAPA HyperPrep kit,Genetic Reagent,,,,,
PMID:39093127,10.1158/1078-0432.CCR-24-0797,Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell-Free DNA Fragmentomics.,,0.85,genetic_reagent,xGen UDI-UMI Adapters,Genetic Reagent,,,,,
PMID:39093127,10.1158/1078-0432.CCR-24-0797,Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell-Free DNA Fragmentomics.,,0.9,computational_tool,ichorCNA,Computational Tool,,,,,
PMID:39093127,10.1158/1078-0432.CCR-24-0797,Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell-Free DNA Fragmentomics.,,0.85,genetic_reagent,TruSight Oncology 500,Genetic Reagent,,,,,
PMID:39093127,10.1158/1078-0432.CCR-24-0797,Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell-Free DNA Fragmentomics.,,0.8,computational_tool,samtools,Computational Tool,,,,,
PMID:39093127,10.1158/1078-0432.CCR-24-0797,Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell-Free DNA Fragmentomics.,,0.8,computational_tool,Picard,Computational Tool,,,,,
PMID:39093127,10.1158/1078-0432.CCR-24-0797,Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell-Free DNA Fragmentomics.,,0.85,computational_tool,Python sklearn,Computational Tool,,,,,
PMID:39093127,10.1158/1078-0432.CCR-24-0797,Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell-Free DNA Fragmentomics.,,0.85,computational_tool,ComplexHeatmap,Computational Tool,,,,,
PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,0.9,animal_model,Prss56Cre/Cre,Animal Model,,,,,
PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,0.9,animal_model,R26tdTom/tdTom,Animal Model,,,,,
PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,0.95,animal_model,Nf1flox/flox,Animal Model,,,,,
PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,0.95,animal_model,Nf1+/−,Animal Model,,,,,
PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,0.9,animal_model,B6D2F1,Animal Model,,,,,
PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,0.9,antibody,rat anti-tomato,Antibody,,,,,
PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,0.9,antibody,rabbit anti-RFP,Antibody,,,,,
PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,0.9,antibody,goat anti-CD45,Antibody,,,,,
PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,0.9,antibody,goat anti-PDGFRα,Antibody,,,,,
PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,0.9,antibody,rabbit anti-Ki67,Antibody,,,,,
PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,0.9,antibody,rabbit anti-P-ERK,Antibody,,,,,
PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,0.9,antibody,goat anti-cKIT,Antibody,,,,,
PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,0.9,antibody,rat anti-F4/80,Antibody,,,,,
PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,0.9,antibody,rat anti-MBP,Antibody,,,,,
PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,0.9,antibody,goat anti-POSTN,Antibody,,,,,
PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,0.9,antibody,rabbit anti-TNC,Antibody,,,,,
PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,0.9,antibody,rabbit anti-PGP9.5,Antibody,,,,,
PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,0.9,antibody,rabbit anti-nestin,Antibody,,,,,
PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,0.9,antibody,mouse A488-anti-Aqp1,Antibody,,,,,
PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,0.9,antibody,mouse anti-S100β,Antibody,,,,,
PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,0.85,genetic_reagent,Click-IT Plus EdU Alexa Fluor 488 Imaging Kit,Genetic Reagent,,,,,
PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,0.8,computational_tool,Zeiss LSM 900 confocal microscope,Computational Tool,,,,,
PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,0.8,computational_tool,Image J software,Computational Tool,,,,,
PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,0.8,computational_tool,GraphPad Prism 10,Computational Tool,,,,,
PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,0.9,computational_tool,10x Genomics Cell Ranger 7.0.1,Computational Tool,,,,,
PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,0.85,computational_tool,Nextflow,Computational Tool,,,,,
PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,0.85,computational_tool,Singularity,Computational Tool,,,,,
PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,0.9,computational_tool,Seurat V3 package,Computational Tool,,,,,
PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,0.85,computational_tool,scDblFinder,Computational Tool,,,,,
PMID:40684195,10.1186/s40478-025-02075-z,Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1.,,0.85,computational_tool,harmony package,Computational Tool,,,,,
PMID:31053133,10.1186/s13023-019-1067-8,Burden of adult neurofibromatosis 1: development and validation of a burden assessment tool.,,0.95,clinical_assessment_tool,BoN (Burden of NF1) questionnaire,Clinical Assessment Tool,,,,,
PMID:31053133,10.1186/s13023-019-1067-8,Burden of adult neurofibromatosis 1: development and validation of a burden assessment tool.,,0.9,clinical_assessment_tool,Dermatology Life Quality Index (DLQI),Clinical Assessment Tool,,,,,
PMID:31053133,10.1186/s13023-019-1067-8,Burden of adult neurofibromatosis 1: development and validation of a burden assessment tool.,,0.9,clinical_assessment_tool,Perceived Stress Scale (PSS),Clinical Assessment Tool,,,,,
PMID:31053133,10.1186/s13023-019-1067-8,Burden of adult neurofibromatosis 1: development and validation of a burden assessment tool.,,0.9,clinical_assessment_tool,SF12,Clinical Assessment Tool,,,,,
PMID:31053133,10.1186/s13023-019-1067-8,Burden of adult neurofibromatosis 1: development and validation of a burden assessment tool.,,0.85,computational_tool,SAS software Version 9.4,Computational Tool,,,,,
PMID:31053133,10.1186/s13023-019-1067-8,Burden of adult neurofibromatosis 1: development and validation of a burden assessment tool.,,0.8,computational_tool,PROC CALIS procedure,Computational Tool,,,,,
PMID:33519543,10.3389/fpsyt.2020.585700,Autism Spectrum Disorder Symptom Profile Across the RASopathies.,,0.95,clinical_assessment_tool,Autism Diagnostic Interview Revised (ADI-R),Clinical Assessment Tool,,,,,
PMID:33519543,10.3389/fpsyt.2020.585700,Autism Spectrum Disorder Symptom Profile Across the RASopathies.,,0.95,clinical_assessment_tool,Autism Diagnostic Observation Schedule-2 (ADOS-2),Clinical Assessment Tool,,,,,
PMID:33519543,10.3389/fpsyt.2020.585700,Autism Spectrum Disorder Symptom Profile Across the RASopathies.,,0.9,clinical_assessment_tool,Wechsler Abbreviated Scale of Intelligence-II (WASI-II),Clinical Assessment Tool,,,,,
PMID:33519543,10.3389/fpsyt.2020.585700,Autism Spectrum Disorder Symptom Profile Across the RASopathies.,,0.9,clinical_assessment_tool,"Conners Parent Rating Scale (3rd edition, short form)",Clinical Assessment Tool,,,,,
PMID:33519543,10.3389/fpsyt.2020.585700,Autism Spectrum Disorder Symptom Profile Across the RASopathies.,,0.85,computational_tool,SPSS version 25,Computational Tool,,,,,
PMID:33082502,10.1038/s41598-020-74920-1,Image segmentation of plexiform neurofibromas from a deep neural network using multiple b-value diffusion data.,,0.85,clinical_assessment_tool,Magnetom Avanto,Clinical Assessment Tool,,,,,
PMID:33082502,10.1038/s41598-020-74920-1,Image segmentation of plexiform neurofibromas from a deep neural network using multiple b-value diffusion data.,,0.9,computational_tool,Analyze 12.0,Computational Tool,,,,,
PMID:33082502,10.1038/s41598-020-74920-1,Image segmentation of plexiform neurofibromas from a deep neural network using multiple b-value diffusion data.,,0.9,computational_tool,MIM Encore 6.9.3,Computational Tool,,,,,
PMID:33082502,10.1038/s41598-020-74920-1,Image segmentation of plexiform neurofibromas from a deep neural network using multiple b-value diffusion data.,,0.85,computational_tool,eLucidate,Computational Tool,,,,,
PMID:33082502,10.1038/s41598-020-74920-1,Image segmentation of plexiform neurofibromas from a deep neural network using multiple b-value diffusion data.,,0.8,computational_tool,multispectral neural network (MSNN),Computational Tool,,,,,
PMID:33082502,10.1038/s41598-020-74920-1,Image segmentation of plexiform neurofibromas from a deep neural network using multiple b-value diffusion data.,,0.75,computational_tool,Clinical Trials Processor,Computational Tool,,,,,
PMID:20049725,10.1002/emmm.200900027,Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene.,,0.85,antibody,S-100β antibody,Antibody,,,,,
PMID:20049725,10.1002/emmm.200900027,Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene.,,0.9,cell_line,ST88-14,Cell Line,,,,,
PMID:20049725,10.1002/emmm.200900027,Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene.,,0.9,cell_line,STS26T,Cell Line,,,,,
PMID:20049725,10.1002/emmm.200900027,Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene.,,0.9,cell_line,S520,Cell Line,,,,,
PMID:20049725,10.1002/emmm.200900027,Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene.,,0.9,cell_line,S462,Cell Line,,,,,
PMID:20049725,10.1002/emmm.200900027,Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene.,,0.9,cell_line,88-3,Cell Line,,,,,
PMID:20049725,10.1002/emmm.200900027,Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene.,,0.9,cell_line,90-8,Cell Line,,,,,
PMID:20049725,10.1002/emmm.200900027,Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene.,,0.9,cell_line,YST1,Cell Line,,,,,
PMID:20049725,10.1002/emmm.200900027,Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene.,,0.8,genetic_reagent,RNeasy kit (Qiagen),Genetic Reagent,,,,,
PMID:20049725,10.1002/emmm.200900027,Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene.,,0.85,computational_tool,Affymetrix GeneChip HU133 Plus 2.0,Computational Tool,,,,,
PMID:20049725,10.1002/emmm.200900027,Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene.,,0.9,antibody,anti-SOX9 (Santa Cruz Biotechnology),Antibody,,,,,
PMID:20049725,10.1002/emmm.200900027,Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene.,,0.9,antibody,"anti-β-actin (Cell Signaling Technology, Inc. #4967)",Antibody,,,,,
PMID:20049725,10.1002/emmm.200900027,Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene.,,0.9,antibody,polyclonal anti-SOX9 antibody (Abcam),Antibody,,,,,
PMID:20049725,10.1002/emmm.200900027,Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene.,,0.9,genetic_reagent,shRNAs targeting SOX9 (Open Biosystems; TRC library),Genetic Reagent,,,,,
PMID:20049725,10.1002/emmm.200900027,Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene.,,0.85,genetic_reagent,GFP (Addgene),Genetic Reagent,,,,,
PMID:20049725,10.1002/emmm.200900027,Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene.,,0.85,computational_tool,Genome TraFac 3,Computational Tool,,,,,
PMID:20049725,10.1002/emmm.200900027,Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene.,,0.8,genetic_reagent,CellTiter 96® Aqueous One Solution Cell Proliferation Assay (Promega),Genetic Reagent,,,,,
PMID:20049725,10.1002/emmm.200900027,Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene.,,0.8,genetic_reagent,DeadEnd Fluorometric TUNEL System (Promega),Genetic Reagent,,,,,
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,0.85,genetic_reagent,pTYcPPT,Genetic Reagent,,,,,
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,0.9,genetic_reagent,hTERT,Genetic Reagent,,,,,
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,0.9,genetic_reagent,mCdk4,Genetic Reagent,,,,,
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,0.95,cell_line,icNF97.2a,Cell Line,,,,,
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,0.95,cell_line,icNF97.2b,Cell Line,,,,,
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,0.95,cell_line,icNF98.4c,Cell Line,,,,,
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,0.95,cell_line,icNF98.4d,Cell Line,,,,,
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,0.95,cell_line,icNF00.10a,Cell Line,,,,,
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,0.95,cell_line,icNF04.9a,Cell Line,,,,,
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,0.95,cell_line,i28cNF,Cell Line,,,,,
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,0.95,cell_line,i18cNF,Cell Line,,,,,
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,0.95,cell_line,i21cNF,Cell Line,,,,,
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,0.95,antibody,N-Terminal NF1 antibody (Cell Signaling cat# D7R7D),Antibody,,,,,
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,0.95,antibody,beta-actin antibody (Cell Signaling cat# 3700),Antibody,,,,,
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,0.95,antibody,p-ERK antibody (Cell Signaling cat# 9101),Antibody,,,,,
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,0.95,antibody,total ERK antibody (Cell Signaling cat# 9102),Antibody,,,,,
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,0.85,computational_tool,ImageJ,Computational Tool,,,,,
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,0.9,computational_tool,Genome Analysis Toolkit (GATK),Computational Tool,,,,,
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,0.9,computational_tool,MuTect,Computational Tool,,,,,
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,0.85,computational_tool,AutoGVP,Computational Tool,,,,,
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,0.85,computational_tool,cBioPortal,Computational Tool,,,,,
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,0.95,computational_tool,nf-core sarek pipeline (v2.7.1),Computational Tool,,,,,
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,0.9,computational_tool,DeepVariant,Computational Tool,,,,,
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,0.85,computational_tool,FreeBayes,Computational Tool,,,,,
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,0.85,computational_tool,Strelka2,Computational Tool,,,,,
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,0.85,computational_tool,Control-FREEC,Computational Tool,,,,,
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,0.85,computational_tool,maftools R package,Computational Tool,,,,,
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,0.95,computational_tool,nf-core rnaseq pipeline (v3.5),Computational Tool,,,,,
PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,,0.9,cell_line,Nf1−/− MEFs,Cell Line,,,,,
PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,,0.9,cell_line,sMPNST cells,Cell Line,,,,,
PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,,0.9,cell_line,cisMPNST cells,Cell Line,,,,,
PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,,0.9,cell_line,ipNF 04.4 cells,Cell Line,,,,,
PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,,0.9,animal_model,cis Nf1+/−;P53+/− mice,Animal Model,,,,,
PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,,0.9,genetic_reagent,lentiCRISPRv2,Genetic Reagent,,,,,
PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,,0.9,genetic_reagent,pMSCV-GRD vector,Genetic Reagent,,,,,
PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,,0.9,genetic_reagent,pBABE vectors,Genetic Reagent,,,,,
PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,,0.9,computational_tool,XF24 Extracellular Flux Analyzer,Computational Tool,,,,,
PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,,0.8,genetic_reagent,NAD+/NADH colorimetric assay kit,Genetic Reagent,,,,,
PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,,0.9,computational_tool,LC-MS/MS (Quattro Premier),Computational Tool,,,,,
PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,,0.8,genetic_reagent,SuperScript III First-Strand Synthesis System,Genetic Reagent,,,,,
PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,,0.8,genetic_reagent,MitoSOX,Genetic Reagent,,,,,
PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,,0.9,computational_tool,FACSCanto II flow cytometer,Computational Tool,,,,,
PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,,0.9,computational_tool,FACSDiva software,Computational Tool,,,,,
PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,,0.9,computational_tool,ImageJ software,Computational Tool,,,,,
PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,,0.9,animal_model,nude female mice,Animal Model,,,,,
PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,,0.9,antibody,anti HIF1α antibody,Antibody,,,,,
PMID:35393510,10.1038/s41418-022-00991-4,Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,,0.9,computational_tool,Origin® 8,Computational Tool,,,,,
PMID:38603731,10.1371/journal.pone.0302017,Raman difference spectroscopy and U-Net convolutional neural network for molecular analysis of cutaneous neurofibroma.,,0.85,computational_tool,U-Net convolutional neural network,Computational Tool,,,,,
PMID:38603731,10.1371/journal.pone.0302017,Raman difference spectroscopy and U-Net convolutional neural network for molecular analysis of cutaneous neurofibroma.,,0.8,computational_tool,Shifted-Excitation Raman Spectroscopy,Computational Tool,,,,,
PMID:38603731,10.1371/journal.pone.0302017,Raman difference spectroscopy and U-Net convolutional neural network for molecular analysis of cutaneous neurofibroma.,,0.9,computational_tool,Ventana-785-Raman spectrometer,Computational Tool,,,,,
PMID:38603731,10.1371/journal.pone.0302017,Raman difference spectroscopy and U-Net convolutional neural network for molecular analysis of cutaneous neurofibroma.,,0.75,computational_tool,Principal component analysis (PCA),Computational Tool,,,,,
PMID:38603731,10.1371/journal.pone.0302017,Raman difference spectroscopy and U-Net convolutional neural network for molecular analysis of cutaneous neurofibroma.,,0.75,computational_tool,linear discriminant analysis (LDA),Computational Tool,,,,,
PMID:38603731,10.1371/journal.pone.0302017,Raman difference spectroscopy and U-Net convolutional neural network for molecular analysis of cutaneous neurofibroma.,,0.8,computational_tool,SERDS,Computational Tool,,,,,
PMID:38603731,10.1371/journal.pone.0302017,Raman difference spectroscopy and U-Net convolutional neural network for molecular analysis of cutaneous neurofibroma.,,0.85,genetic_reagent,Hematoxylin & Eosin,Genetic Reagent,,,,,
PMID:28725547,10.1016/j.nicl.2017.06.032,Spatial working memory in neurofibromatosis 1: Altered neural activity and functional connectivity.,,0.9,clinical_assessment_tool,Wechsler Abbreviated Scale of Intelligence (WASI),Clinical Assessment Tool,,,,,
PMID:28725547,10.1016/j.nicl.2017.06.032,Spatial working memory in neurofibromatosis 1: Altered neural activity and functional connectivity.,,0.9,clinical_assessment_tool,"Wechsler Adult Intelligence Scale, Version 4 (WAIS-IV)",Clinical Assessment Tool,,,,,
PMID:28725547,10.1016/j.nicl.2017.06.032,Spatial working memory in neurofibromatosis 1: Altered neural activity and functional connectivity.,,0.85,clinical_assessment_tool,University of Maryland Letter–Number Sequencing (LNS) task,Clinical Assessment Tool,,,,,
PMID:28725547,10.1016/j.nicl.2017.06.032,Spatial working memory in neurofibromatosis 1: Altered neural activity and functional connectivity.,,0.9,clinical_assessment_tool,Spatial capacity working memory (SCAP) task,Clinical Assessment Tool,,,,,
PMID:28725547,10.1016/j.nicl.2017.06.032,Spatial working memory in neurofibromatosis 1: Altered neural activity and functional connectivity.,,0.9,computational_tool,FMRIB software library (FSL),Computational Tool,,,,,
PMID:28725547,10.1016/j.nicl.2017.06.032,Spatial working memory in neurofibromatosis 1: Altered neural activity and functional connectivity.,,0.8,computational_tool,SPSS software v. 21,Computational Tool,,,,,
PMID:28725547,10.1016/j.nicl.2017.06.032,Spatial working memory in neurofibromatosis 1: Altered neural activity and functional connectivity.,,0.85,computational_tool,FMRIB's Local Analysis of Mixed Effects (FLAME),Computational Tool,,,,,
PMID:28725547,10.1016/j.nicl.2017.06.032,Spatial working memory in neurofibromatosis 1: Altered neural activity and functional connectivity.,,0.8,computational_tool,generalized psychophysiological interaction (gPPI) method,Computational Tool,,,,,
PMID:28725547,10.1016/j.nicl.2017.06.032,Spatial working memory in neurofibromatosis 1: Altered neural activity and functional connectivity.,,0.8,computational_tool,FSL motion outlier tool,Computational Tool,,,,,
PMID:28725547,10.1016/j.nicl.2017.06.032,Spatial working memory in neurofibromatosis 1: Altered neural activity and functional connectivity.,,0.85,computational_tool,Harvard-Oxford cortical and subcortical probabilistic atlases,Computational Tool,,,,,
PMID:32642733,10.1093/noajnl/vdz061,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors.,,0.9,cell_line,S462,Cell Line,,,,,
PMID:32642733,10.1093/noajnl/vdz061,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors.,,0.9,cell_line,ST88-14,Cell Line,,,,,
PMID:32642733,10.1093/noajnl/vdz061,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors.,,0.9,cell_line,sNF96.2,Cell Line,,,,,
PMID:32642733,10.1093/noajnl/vdz061,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors.,,0.9,cell_line,90-8,Cell Line,,,,,
PMID:32642733,10.1093/noajnl/vdz061,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors.,,0.9,cell_line,STS-26T,Cell Line,,,,,
PMID:32642733,10.1093/noajnl/vdz061,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors.,,0.9,cell_line,HS-Sch-2,Cell Line,,,,,
PMID:32642733,10.1093/noajnl/vdz061,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors.,,0.9,cell_line,CCD-1112Sk,Cell Line,,,,,
PMID:32642733,10.1093/noajnl/vdz061,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors.,,0.9,antibody,anti-KIF11 antibody (Proteintech),Antibody,,,,,
PMID:32642733,10.1093/noajnl/vdz061,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors.,,0.9,antibody,anti-KIF15 antibody (Proteintech),Antibody,,,,,
PMID:32642733,10.1093/noajnl/vdz061,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors.,,0.9,antibody,Ki67 (Ventana Medical Systems),Antibody,,,,,
PMID:32642733,10.1093/noajnl/vdz061,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors.,,0.9,antibody,anti-α-tubulin (Sigma-Aldrich),Antibody,,,,,
PMID:32642733,10.1093/noajnl/vdz061,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors.,,0.9,antibody,anti-α-tubulin-Alexa488 antibody (Life Technologies),Antibody,,,,,
PMID:32642733,10.1093/noajnl/vdz061,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors.,,0.9,genetic_reagent,siGENOME SMARTpool (Dharmacon),Genetic Reagent,,,,,
PMID:32642733,10.1093/noajnl/vdz061,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors.,,0.9,genetic_reagent,pX330-U6-Chimeric_BB-CBh-HSpCas0 (Addgene),Genetic Reagent,,,,,
PMID:32642733,10.1093/noajnl/vdz061,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors.,,0.9,genetic_reagent,pRGS2 surrogate reporter (Labomics),Genetic Reagent,,,,,
PMID:32642733,10.1093/noajnl/vdz061,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors.,,0.8,genetic_reagent,ispinesib (Selleckchem),Genetic Reagent,,,,,
PMID:32642733,10.1093/noajnl/vdz061,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors.,,0.8,genetic_reagent,ARRY-520 (MedChemExpress),Genetic Reagent,,,,,
PMID:32642733,10.1093/noajnl/vdz061,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors.,,0.8,computational_tool,Light-Cycler 480 Real-Time PCR System,Computational Tool,,,,,
PMID:32642733,10.1093/noajnl/vdz061,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors.,,0.8,computational_tool,Odyssey Imaging System (LI-COR),Computational Tool,,,,,
PMID:32642733,10.1093/noajnl/vdz061,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors.,,0.8,computational_tool,BD FACSAria II,Computational Tool,,,,,
PMID:32642733,10.1093/noajnl/vdz061,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors.,,0.8,computational_tool,Countess Automated Cell Counter (Life Technologies),Computational Tool,,,,,
PMID:32642733,10.1093/noajnl/vdz061,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors.,,0.8,computational_tool,BD LSRFortessa SORP cytometer,Computational Tool,,,,,
PMID:39881370,10.1186/s13065-024-01353-6,"Spectrophotometric and computational characterization of charge transfer complex of selumetinib with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone and its utilization in developing an innovative green and high throughput microwell assay for analysis of bulk form and pharmaceutical formulation.",,0.85,computational_tool,Spectramax M5,Computational Tool,,,,,
PMID:39881370,10.1186/s13065-024-01353-6,"Spectrophotometric and computational characterization of charge transfer complex of selumetinib with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone and its utilization in developing an innovative green and high throughput microwell assay for analysis of bulk form and pharmaceutical formulation.",,0.8,computational_tool,SoftMax Pro Enterprise software,Computational Tool,,,,,
PMID:39881370,10.1186/s13065-024-01353-6,"Spectrophotometric and computational characterization of charge transfer complex of selumetinib with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone and its utilization in developing an innovative green and high throughput microwell assay for analysis of bulk form and pharmaceutical formulation.",,0.9,computational_tool,GAMESS software,Computational Tool,,,,,
PMID:39881370,10.1186/s13065-024-01353-6,"Spectrophotometric and computational characterization of charge transfer complex of selumetinib with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone and its utilization in developing an innovative green and high throughput microwell assay for analysis of bulk form and pharmaceutical formulation.",,0.85,computational_tool,Mutiwfn 3.7,Computational Tool,,,,,
PMID:39881370,10.1186/s13065-024-01353-6,"Spectrophotometric and computational characterization of charge transfer complex of selumetinib with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone and its utilization in developing an innovative green and high throughput microwell assay for analysis of bulk form and pharmaceutical formulation.",,0.8,computational_tool,VMD,Computational Tool,,,,,
PMID:24882693,10.1016/j.jmb.2014.05.011,Molecular conformation of the full-length tumor suppressor NF2/Merlin--a small-angle neutron scattering study.,,0.85,genetic_reagent,pET32a vector,Genetic Reagent,,,,,
PMID:24882693,10.1016/j.jmb.2014.05.011,Molecular conformation of the full-length tumor suppressor NF2/Merlin--a small-angle neutron scattering study.,,0.8,genetic_reagent,QuikChange II site-directed mutagenesis kit,Genetic Reagent,,,,,
PMID:24882693,10.1016/j.jmb.2014.05.011,Molecular conformation of the full-length tumor suppressor NF2/Merlin--a small-angle neutron scattering study.,,0.85,cell_line,Rosetta2(DE3) competent cells,Cell Line,,,,,
PMID:24882693,10.1016/j.jmb.2014.05.011,Molecular conformation of the full-length tumor suppressor NF2/Merlin--a small-angle neutron scattering study.,,0.75,genetic_reagent,HiTrap Chelating Sepharose™ High Performance,Genetic Reagent,,,,,
PMID:24882693,10.1016/j.jmb.2014.05.011,Molecular conformation of the full-length tumor suppressor NF2/Merlin--a small-angle neutron scattering study.,,0.75,genetic_reagent,Superdex 200 10/300 GL column,Genetic Reagent,,,,,
PMID:24882693,10.1016/j.jmb.2014.05.011,Molecular conformation of the full-length tumor suppressor NF2/Merlin--a small-angle neutron scattering study.,,0.8,computational_tool,DynaPro NanoStar,Computational Tool,,,,,
PMID:24882693,10.1016/j.jmb.2014.05.011,Molecular conformation of the full-length tumor suppressor NF2/Merlin--a small-angle neutron scattering study.,,0.85,computational_tool,DYNAMIC software,Computational Tool,,,,,
PMID:24882693,10.1016/j.jmb.2014.05.011,Molecular conformation of the full-length tumor suppressor NF2/Merlin--a small-angle neutron scattering study.,,0.75,computational_tool,J-180 JASCO circular dichroism spectropolarimeter,Computational Tool,,,,,
PMID:24882693,10.1016/j.jmb.2014.05.011,Molecular conformation of the full-length tumor suppressor NF2/Merlin--a small-angle neutron scattering study.,,0.8,computational_tool,Spectra Manager,Computational Tool,,,,,
PMID:24882693,10.1016/j.jmb.2014.05.011,Molecular conformation of the full-length tumor suppressor NF2/Merlin--a small-angle neutron scattering study.,,0.85,computational_tool,DichroWeb,Computational Tool,,,,,
PMID:24882693,10.1016/j.jmb.2014.05.011,Molecular conformation of the full-length tumor suppressor NF2/Merlin--a small-angle neutron scattering study.,,0.8,computational_tool,Biacore X100,Computational Tool,,,,,
PMID:24882693,10.1016/j.jmb.2014.05.011,Molecular conformation of the full-length tumor suppressor NF2/Merlin--a small-angle neutron scattering study.,,0.8,computational_tool,MicroCal™ Auto-iTC 200,Computational Tool,,,,,
PMID:24882693,10.1016/j.jmb.2014.05.011,Molecular conformation of the full-length tumor suppressor NF2/Merlin--a small-angle neutron scattering study.,,0.85,computational_tool,Bindworks,Computational Tool,,,,,
PMID:24882693,10.1016/j.jmb.2014.05.011,Molecular conformation of the full-length tumor suppressor NF2/Merlin--a small-angle neutron scattering study.,,0.85,computational_tool,MantidPlot,Computational Tool,,,,,
PMID:24882693,10.1016/j.jmb.2014.05.011,Molecular conformation of the full-length tumor suppressor NF2/Merlin--a small-angle neutron scattering study.,,0.85,computational_tool,GNOM,Computational Tool,,,,,
PMID:24882693,10.1016/j.jmb.2014.05.011,Molecular conformation of the full-length tumor suppressor NF2/Merlin--a small-angle neutron scattering study.,,0.85,computational_tool,DAMMIN,Computational Tool,,,,,
PMID:24882693,10.1016/j.jmb.2014.05.011,Molecular conformation of the full-length tumor suppressor NF2/Merlin--a small-angle neutron scattering study.,,0.85,computational_tool,DAMAVER,Computational Tool,,,,,
PMID:24882693,10.1016/j.jmb.2014.05.011,Molecular conformation of the full-length tumor suppressor NF2/Merlin--a small-angle neutron scattering study.,,0.85,computational_tool,DAMFILT,Computational Tool,,,,,
PMID:24882693,10.1016/j.jmb.2014.05.011,Molecular conformation of the full-length tumor suppressor NF2/Merlin--a small-angle neutron scattering study.,,0.85,computational_tool,Situs,Computational Tool,,,,,
PMID:24882693,10.1016/j.jmb.2014.05.011,Molecular conformation of the full-length tumor suppressor NF2/Merlin--a small-angle neutron scattering study.,,0.85,computational_tool,UCS Chimera,Computational Tool,,,,,
PMID:17924978,10.1111/j.1750-3639.2007.00105.x,Natural history of meningioma development in mice reveals: a synergy of Nf2 and p16(Ink4a) mutations.,,0.9,animal_model,Nf2 flox2/flox2 mice,Animal Model,,,,,
PMID:17924978,10.1111/j.1750-3639.2007.00105.x,Natural history of meningioma development in mice reveals: a synergy of Nf2 and p16(Ink4a) mutations.,,0.9,animal_model,p16 Ink4a*/* mice,Animal Model,,,,,
PMID:17924978,10.1111/j.1750-3639.2007.00105.x,Natural history of meningioma development in mice reveals: a synergy of Nf2 and p16(Ink4a) mutations.,,0.95,animal_model,Nf2 flox2/flox2 ;p16 Ink4a*/* mice,Animal Model,,,,,
PMID:17924978,10.1111/j.1750-3639.2007.00105.x,Natural history of meningioma development in mice reveals: a synergy of Nf2 and p16(Ink4a) mutations.,,0.85,genetic_reagent,adCre,Genetic Reagent,,,,,
PMID:17924978,10.1111/j.1750-3639.2007.00105.x,Natural history of meningioma development in mice reveals: a synergy of Nf2 and p16(Ink4a) mutations.,,0.9,antibody,PGDS antibody (Santa Cruz sc-14825),Antibody,,,,,
PMID:17924978,10.1111/j.1750-3639.2007.00105.x,Natural history of meningioma development in mice reveals: a synergy of Nf2 and p16(Ink4a) mutations.,,0.8,computational_tool,Biospec 4.7 Tesla microimaging system,Computational Tool,,,,,
PMID:17924978,10.1111/j.1750-3639.2007.00105.x,Natural history of meningioma development in mice reveals: a synergy of Nf2 and p16(Ink4a) mutations.,,0.75,genetic_reagent,Gd-DTPA (Magnevist),Genetic Reagent,,,,,
PMID:17924978,10.1111/j.1750-3639.2007.00105.x,Natural history of meningioma development in mice reveals: a synergy of Nf2 and p16(Ink4a) mutations.,,0.7,computational_tool,LKB8801 ultramicrotome,Computational Tool,,,,,
PMID:17924978,10.1111/j.1750-3639.2007.00105.x,Natural history of meningioma development in mice reveals: a synergy of Nf2 and p16(Ink4a) mutations.,,0.7,computational_tool,Phillips 301 transmission electron microscope,Computational Tool,,,,,
PMID:37608248,10.1186/s11689-023-09492-y,Aberrant oscillatory activity in neurofibromatosis type 1: an EEG study of resting state and working memory.,,0.85,computational_tool,"ActiveTwo system (BioSemi, Amsterdam, Netherlands)",Computational Tool,,,,,
PMID:37608248,10.1186/s11689-023-09492-y,Aberrant oscillatory activity in neurofibromatosis type 1: an EEG study of resting state and working memory.,,0.9,computational_tool,MATLAB (2019a),Computational Tool,,,,,
PMID:37608248,10.1186/s11689-023-09492-y,Aberrant oscillatory activity in neurofibromatosis type 1: an EEG study of resting state and working memory.,,0.9,computational_tool,SPM12 (version 7771),Computational Tool,,,,,
PMID:37608248,10.1186/s11689-023-09492-y,Aberrant oscillatory activity in neurofibromatosis type 1: an EEG study of resting state and working memory.,,0.9,computational_tool,EEGLAB (version 13.6.5b),Computational Tool,,,,,
PMID:37608248,10.1186/s11689-023-09492-y,Aberrant oscillatory activity in neurofibromatosis type 1: an EEG study of resting state and working memory.,,0.85,computational_tool,FieldTrip,Computational Tool,,,,,
PMID:37608248,10.1186/s11689-023-09492-y,Aberrant oscillatory activity in neurofibromatosis type 1: an EEG study of resting state and working memory.,,0.85,computational_tool,G*Power,Computational Tool,,,,,
PMID:37608248,10.1186/s11689-023-09492-y,Aberrant oscillatory activity in neurofibromatosis type 1: an EEG study of resting state and working memory.,,0.95,clinical_assessment_tool,Vineland Adaptive Behaviour Scale (VABS-III),Clinical Assessment Tool,,,,,
PMID:37608248,10.1186/s11689-023-09492-y,Aberrant oscillatory activity in neurofibromatosis type 1: an EEG study of resting state and working memory.,,0.8,clinical_assessment_tool,adaptive auditory n-back task,Clinical Assessment Tool,,,,,
PMID:37608248,10.1186/s11689-023-09492-y,Aberrant oscillatory activity in neurofibromatosis type 1: an EEG study of resting state and working memory.,,0.8,clinical_assessment_tool,non-adaptive visual n-back task,Clinical Assessment Tool,,,,,
PMID:37608248,10.1186/s11689-023-09492-y,Aberrant oscillatory activity in neurofibromatosis type 1: an EEG study of resting state and working memory.,,0.75,computational_tool,laplacian_perrinX function,Computational Tool,,,,,
PMID:37608248,10.1186/s11689-023-09492-y,Aberrant oscillatory activity in neurofibromatosis type 1: an EEG study of resting state and working memory.,,0.85,computational_tool,SPSS (Version 25),Computational Tool,,,,,
PMID:41602242,10.7759/cureus.100193,Perspectives of Patients and Providers on Chronic Pain Assessment in Neurofibromatosis Type 1 (NF1): A Qualitative Study.,,0.95,clinical_assessment_tool,Brief Pain Inventory Short Form (BPI-SF),Clinical Assessment Tool,,,,,
PMID:41602242,10.7759/cureus.100193,Perspectives of Patients and Providers on Chronic Pain Assessment in Neurofibromatosis Type 1 (NF1): A Qualitative Study.,,0.9,clinical_assessment_tool,Patient Health Questionnaire (PHQ),Clinical Assessment Tool,,,,,
PMID:41602242,10.7759/cureus.100193,Perspectives of Patients and Providers on Chronic Pain Assessment in Neurofibromatosis Type 1 (NF1): A Qualitative Study.,,0.95,clinical_assessment_tool,Structured Clinical Interview for DSM Self Report version (SCID-SR),Clinical Assessment Tool,,,,,
PMID:41602242,10.7759/cureus.100193,Perspectives of Patients and Providers on Chronic Pain Assessment in Neurofibromatosis Type 1 (NF1): A Qualitative Study.,,0.95,clinical_assessment_tool,Generalized Anxiety Disorder 7 Item version (GAD-7),Clinical Assessment Tool,,,,,
PMID:41602242,10.7759/cureus.100193,Perspectives of Patients and Providers on Chronic Pain Assessment in Neurofibromatosis Type 1 (NF1): A Qualitative Study.,,0.9,clinical_assessment_tool,PHQ-9,Clinical Assessment Tool,,,,,
PMID:41602242,10.7759/cureus.100193,Perspectives of Patients and Providers on Chronic Pain Assessment in Neurofibromatosis Type 1 (NF1): A Qualitative Study.,,0.85,computational_tool,Qualtrics,Computational Tool,,,,,
PMID:41602242,10.7759/cureus.100193,Perspectives of Patients and Providers on Chronic Pain Assessment in Neurofibromatosis Type 1 (NF1): A Qualitative Study.,,0.95,computational_tool,ATLAS.ti (Version 9),Computational Tool,,,,,
PMID:25003081,10.3389/fonc.2014.00147,An integrative analysis of meningioma tumors reveals the determinant genes and pathways of malignant transformation.,,0.85,computational_tool,Weighted Gene Co-expression Network Analysis (WGCNA),Computational Tool,,,,,
PMID:25003081,10.3389/fonc.2014.00147,An integrative analysis of meningioma tumors reveals the determinant genes and pathways of malignant transformation.,,0.8,genetic_reagent,Human Mapping 100K Set,Genetic Reagent,,,,,
PMID:25003081,10.3389/fonc.2014.00147,An integrative analysis of meningioma tumors reveals the determinant genes and pathways of malignant transformation.,,0.8,genetic_reagent,GeneChip Human Genome U133 Plus 2.0 Arrays,Genetic Reagent,,,,,
PMID:25003081,10.3389/fonc.2014.00147,An integrative analysis of meningioma tumors reveals the determinant genes and pathways of malignant transformation.,,0.85,computational_tool,Affymetrix Genotyping Console,Computational Tool,,,,,
PMID:25003081,10.3389/fonc.2014.00147,An integrative analysis of meningioma tumors reveals the determinant genes and pathways of malignant transformation.,,0.75,computational_tool,R,Computational Tool,,,,,
PMID:25003081,10.3389/fonc.2014.00147,An integrative analysis of meningioma tumors reveals the determinant genes and pathways of malignant transformation.,,0.85,computational_tool,affy package,Computational Tool,,,,,
PMID:25003081,10.3389/fonc.2014.00147,An integrative analysis of meningioma tumors reveals the determinant genes and pathways of malignant transformation.,,0.85,computational_tool,arrayQualityMetrics package,Computational Tool,,,,,
PMID:25003081,10.3389/fonc.2014.00147,An integrative analysis of meningioma tumors reveals the determinant genes and pathways of malignant transformation.,,0.9,computational_tool,Cytoscape,Computational Tool,,,,,
PMID:25003081,10.3389/fonc.2014.00147,An integrative analysis of meningioma tumors reveals the determinant genes and pathways of malignant transformation.,,0.85,computational_tool,CentiScape plug-in,Computational Tool,,,,,
PMID:25003081,10.3389/fonc.2014.00147,An integrative analysis of meningioma tumors reveals the determinant genes and pathways of malignant transformation.,,0.85,computational_tool,ClueGO plug-in,Computational Tool,,,,,
PMID:25003081,10.3389/fonc.2014.00147,An integrative analysis of meningioma tumors reveals the determinant genes and pathways of malignant transformation.,,0.85,computational_tool,DAVID web tool,Computational Tool,,,,,
PMID:25003081,10.3389/fonc.2014.00147,An integrative analysis of meningioma tumors reveals the determinant genes and pathways of malignant transformation.,,0.85,computational_tool,snpStats package,Computational Tool,,,,,
PMID:25003081,10.3389/fonc.2014.00147,An integrative analysis of meningioma tumors reveals the determinant genes and pathways of malignant transformation.,,0.85,computational_tool,HaploReg v2,Computational Tool,,,,,
PMID:25003081,10.3389/fonc.2014.00147,An integrative analysis of meningioma tumors reveals the determinant genes and pathways of malignant transformation.,,0.85,computational_tool,oPPOSUM Single Site Analysis tool,Computational Tool,,,,,
PMID:25003081,10.3389/fonc.2014.00147,An integrative analysis of meningioma tumors reveals the determinant genes and pathways of malignant transformation.,,0.85,computational_tool,STRING,Computational Tool,,,,,
PMID:25003081,10.3389/fonc.2014.00147,An integrative analysis of meningioma tumors reveals the determinant genes and pathways of malignant transformation.,,0.8,computational_tool,ComBat function,Computational Tool,,,,,
PMID:25003081,10.3389/fonc.2014.00147,An integrative analysis of meningioma tumors reveals the determinant genes and pathways of malignant transformation.,,0.85,computational_tool,limma package,Computational Tool,,,,,
PMID:25003081,10.3389/fonc.2014.00147,An integrative analysis of meningioma tumors reveals the determinant genes and pathways of malignant transformation.,,0.8,computational_tool,GenABEL package,Computational Tool,,,,,
PMID:25003081,10.3389/fonc.2014.00147,An integrative analysis of meningioma tumors reveals the determinant genes and pathways of malignant transformation.,,0.8,computational_tool,matrixStats package,Computational Tool,,,,,
PMID:25003081,10.3389/fonc.2014.00147,An integrative analysis of meningioma tumors reveals the determinant genes and pathways of malignant transformation.,,0.8,computational_tool,fmsb package,Computational Tool,,,,,
PMID:25003081,10.3389/fonc.2014.00147,An integrative analysis of meningioma tumors reveals the determinant genes and pathways of malignant transformation.,,0.8,computational_tool,impute package,Computational Tool,,,,,
PMID:18483311,10.1158/1535-7163.MCT-07-2335,Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,0.9,cell_line,STS26T,Cell Line,,,,,
PMID:18483311,10.1158/1535-7163.MCT-07-2335,Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,0.9,cell_line,ST8814,Cell Line,,,,,
PMID:18483311,10.1158/1535-7163.MCT-07-2335,Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,0.9,cell_line,ST88-3,Cell Line,,,,,
PMID:18483311,10.1158/1535-7163.MCT-07-2335,Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,0.9,cell_line,S462,Cell Line,,,,,
PMID:18483311,10.1158/1535-7163.MCT-07-2335,Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,0.9,cell_line,T265p21,Cell Line,,,,,
PMID:18483311,10.1158/1535-7163.MCT-07-2335,Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,0.9,cell_line,S520,Cell Line,,,,,
PMID:18483311,10.1158/1535-7163.MCT-07-2335,Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,0.9,cell_line,90-8,Cell Line,,,,,
PMID:18483311,10.1158/1535-7163.MCT-07-2335,Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,0.9,cell_line,YST1,Cell Line,,,,,
PMID:18483311,10.1158/1535-7163.MCT-07-2335,Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,0.85,animal_model,athymic nu/nu mice,Animal Model,,,,,
PMID:18483311,10.1158/1535-7163.MCT-07-2335,Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,0.9,cell_line,DS-red STS26T cell line,Cell Line,,,,,
PMID:18483311,10.1158/1535-7163.MCT-07-2335,Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,0.9,antibody,phospho-AKT (S473) antibody,Antibody,,,,,
PMID:18483311,10.1158/1535-7163.MCT-07-2335,Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,0.9,antibody,total AKT antibody,Antibody,,,,,
PMID:18483311,10.1158/1535-7163.MCT-07-2335,Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,0.9,antibody,monoclonal rabbit anti-phospho-S6K (T389) antibody,Antibody,,,,,
PMID:18483311,10.1158/1535-7163.MCT-07-2335,Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,0.9,antibody,total S6K1 antibody,Antibody,,,,,
PMID:18483311,10.1158/1535-7163.MCT-07-2335,Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,0.9,antibody,rat anti-CD31 antibodies,Antibody,,,,,
PMID:18483311,10.1158/1535-7163.MCT-07-2335,Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,0.9,antibody,Mib1 antibody,Antibody,,,,,
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.95,clinical_assessment_tool,Social Responsiveness Scale 2nd Edition,Clinical Assessment Tool,,,,,
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.95,clinical_assessment_tool,Autism Diagnostic Observation Scale 2nd Edition,Clinical Assessment Tool,,,,,
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.95,clinical_assessment_tool,Autism Diagnostic Interview-Revised,Clinical Assessment Tool,,,,,
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.9,clinical_assessment_tool,WPPSI-IV,Clinical Assessment Tool,,,,,
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.9,clinical_assessment_tool,WISC-V,Clinical Assessment Tool,,,,,
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,clinical_assessment_tool,TEA-Ch Sky Search,Clinical Assessment Tool,,,,,
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,clinical_assessment_tool,TEA-Ch Score!,Clinical Assessment Tool,,,,,
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,clinical_assessment_tool,Shape School,Clinical Assessment Tool,,,,,
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,clinical_assessment_tool,NEPSY-II Inhibition,Clinical Assessment Tool,,,,,
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,clinical_assessment_tool,Tower of Hanoi,Clinical Assessment Tool,,,,,
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,clinical_assessment_tool,TEA-Ch Creature Counting,Clinical Assessment Tool,,,,,
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,clinical_assessment_tool,WIAT-II Abbreviated,Clinical Assessment Tool,,,,,
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,clinical_assessment_tool,NEPSY-II Affect Recognition,Clinical Assessment Tool,,,,,
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,clinical_assessment_tool,Benton Facial Recognition Test,Clinical Assessment Tool,,,,,
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,clinical_assessment_tool,NEPSY-II ToM,Clinical Assessment Tool,,,,,
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,clinical_assessment_tool,Reading the Mind in the Eyes Test-Child,Clinical Assessment Tool,,,,,
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,clinical_assessment_tool,Faux Pas Task,Clinical Assessment Tool,,,,,
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,clinical_assessment_tool,Strange Stories,Clinical Assessment Tool,,,,,
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,clinical_assessment_tool,CELF-Preschool-2,Clinical Assessment Tool,,,,,
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,clinical_assessment_tool,CELF-4 Formulated Sentences,Clinical Assessment Tool,,,,,
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,clinical_assessment_tool,NEPSY-II Comprehension of Instructions,Clinical Assessment Tool,,,,,
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.9,clinical_assessment_tool,SRS-2,Clinical Assessment Tool,,,,,
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,clinical_assessment_tool,CADS,Clinical Assessment Tool,,,,,
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,clinical_assessment_tool,Conners 3,Clinical Assessment Tool,,,,,
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,clinical_assessment_tool,BRIEF-Preschool,Clinical Assessment Tool,,,,,
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,clinical_assessment_tool,BRIEF,Clinical Assessment Tool,,,,,
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,clinical_assessment_tool,ABAS-3: 0–5 years,Clinical Assessment Tool,,,,,
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,clinical_assessment_tool,ABAS-3: 5–21 years,Clinical Assessment Tool,,,,,
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,clinical_assessment_tool,SSIS Rating Scale,Clinical Assessment Tool,,,,,
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,clinical_assessment_tool,Sensory Profile 2,Clinical Assessment Tool,,,,,
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,clinical_assessment_tool,CBCL: 1.5–5 years,Clinical Assessment Tool,,,,,
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,clinical_assessment_tool,CBCL: 6–18 years,Clinical Assessment Tool,,,,,
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.85,clinical_assessment_tool,CCC-2,Clinical Assessment Tool,,,,,
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.8,clinical_assessment_tool,3-Tesla Siemens MAGNETOM Prisma MRI scanner,Clinical Assessment Tool,,,,,
PMID:31558455,10.1136/bmjopen-2019-030601,Understanding autism spectrum disorder and social functioning in children with neurofibromatosis type 1: protocol for a cross-sectional multimodal study.,,0.8,clinical_assessment_tool,MEGA-PRESS,Clinical Assessment Tool,,,,,
PMID:35673329,10.1093/texcom/tgac021,Neuroanatomical correlates of working memory performance in Neurofibromatosis 1.,,0.85,clinical_assessment_tool,n-back task,Clinical Assessment Tool,,,,,
PMID:35673329,10.1093/texcom/tgac021,Neuroanatomical correlates of working memory performance in Neurofibromatosis 1.,,0.8,computational_tool,E-Prime software,Computational Tool,,,,,
PMID:35673329,10.1093/texcom/tgac021,Neuroanatomical correlates of working memory performance in Neurofibromatosis 1.,,0.85,computational_tool,Psychology Experiment Building Language (PEBL),Computational Tool,,,,,
PMID:35673329,10.1093/texcom/tgac021,Neuroanatomical correlates of working memory performance in Neurofibromatosis 1.,,0.85,clinical_assessment_tool,Corsi block task,Clinical Assessment Tool,,,,,
PMID:35673329,10.1093/texcom/tgac021,Neuroanatomical correlates of working memory performance in Neurofibromatosis 1.,,0.9,clinical_assessment_tool,Wechslers Intelligence Scale for Children-Fourth edition (WISC-IV),Clinical Assessment Tool,,,,,
PMID:35673329,10.1093/texcom/tgac021,Neuroanatomical correlates of working memory performance in Neurofibromatosis 1.,,0.9,clinical_assessment_tool,Vineland Adaptive Behavior Scale—third edition,Clinical Assessment Tool,,,,,
PMID:35673329,10.1093/texcom/tgac021,Neuroanatomical correlates of working memory performance in Neurofibromatosis 1.,,0.9,clinical_assessment_tool,Conners 3 rating scale,Clinical Assessment Tool,,,,,
PMID:35673329,10.1093/texcom/tgac021,Neuroanatomical correlates of working memory performance in Neurofibromatosis 1.,,0.85,computational_tool,SPM12 v7771,Computational Tool,,,,,
PMID:35673329,10.1093/texcom/tgac021,Neuroanatomical correlates of working memory performance in Neurofibromatosis 1.,,0.8,computational_tool,MATLAB vR2020b,Computational Tool,,,,,
PMID:35673329,10.1093/texcom/tgac021,Neuroanatomical correlates of working memory performance in Neurofibromatosis 1.,,0.85,computational_tool,MRIcroGL,Computational Tool,,,,,
PMID:35673329,10.1093/texcom/tgac021,Neuroanatomical correlates of working memory performance in Neurofibromatosis 1.,,0.8,computational_tool,marsbar,Computational Tool,,,,,
PMID:37140985,10.1172/JCI168227,Basement membrane proteins in extracellular matrix characterize NF1 neurofibroma development and response to MEK inhibitor.,,0.9,animal_model,H7;Nf1mut mice,Animal Model,,,,,
PMID:37140985,10.1172/JCI168227,Basement membrane proteins in extracellular matrix characterize NF1 neurofibroma development and response to MEK inhibitor.,,0.95,cell_line,hTERT ipNF05.5,Cell Line,,,,,
PMID:37140985,10.1172/JCI168227,Basement membrane proteins in extracellular matrix characterize NF1 neurofibroma development and response to MEK inhibitor.,,0.9,cell_line,hTERT ipn02.3 2λ,Cell Line,,,,,
PMID:37140985,10.1172/JCI168227,Basement membrane proteins in extracellular matrix characterize NF1 neurofibroma development and response to MEK inhibitor.,,0.85,genetic_reagent,PD0325901,Genetic Reagent,,,,,
PMID:37140985,10.1172/JCI168227,Basement membrane proteins in extracellular matrix characterize NF1 neurofibroma development and response to MEK inhibitor.,,0.9,genetic_reagent,NF1 siRNA,Genetic Reagent,,,,,
PMID:37140985,10.1172/JCI168227,Basement membrane proteins in extracellular matrix characterize NF1 neurofibroma development and response to MEK inhibitor.,,0.9,computational_tool,Cell Ranger 5.0.1,Computational Tool,,,,,
PMID:37140985,10.1172/JCI168227,Basement membrane proteins in extracellular matrix characterize NF1 neurofibroma development and response to MEK inhibitor.,,0.9,computational_tool,Seurat R package,Computational Tool,,,,,
PMID:37140985,10.1172/JCI168227,Basement membrane proteins in extracellular matrix characterize NF1 neurofibroma development and response to MEK inhibitor.,,0.9,computational_tool,Proteome Discoverer 2.4,Computational Tool,,,,,
PMID:37140985,10.1172/JCI168227,Basement membrane proteins in extracellular matrix characterize NF1 neurofibroma development and response to MEK inhibitor.,,0.8,genetic_reagent,CNMCS Compartmental Protein Extraction Kit,Genetic Reagent,,,,,
PMID:37140985,10.1172/JCI168227,Basement membrane proteins in extracellular matrix characterize NF1 neurofibroma development and response to MEK inhibitor.,,0.85,computational_tool,Chromium Single Cell Gene Expression,Computational Tool,,,,,
PMID:37140985,10.1172/JCI168227,Basement membrane proteins in extracellular matrix characterize NF1 neurofibroma development and response to MEK inhibitor.,,0.8,cell_line,E13.5 DRG neurosphere cells,Cell Line,,,,,
PMID:38499890,10.1186/s41687-024-00714-y,"The PlexiQoL, a patient-reported outcome measure on quality of life in neurofibromatosis type 1-associated plexiform neurofibroma: translation, cultural adaptation and validation into the Dutch language for the Netherlands.",,0.95,clinical_assessment_tool,PlexiQoL,Clinical Assessment Tool,,,,,
PMID:38499890,10.1186/s41687-024-00714-y,"The PlexiQoL, a patient-reported outcome measure on quality of life in neurofibromatosis type 1-associated plexiform neurofibroma: translation, cultural adaptation and validation into the Dutch language for the Netherlands.",,0.9,clinical_assessment_tool,Nottingham Health Profile (NHP),Clinical Assessment Tool,,,,,
PMID:38499890,10.1186/s41687-024-00714-y,"The PlexiQoL, a patient-reported outcome measure on quality of life in neurofibromatosis type 1-associated plexiform neurofibroma: translation, cultural adaptation and validation into the Dutch language for the Netherlands.",,0.85,computational_tool,SPSS version 28.0,Computational Tool,,,,,
PMID:20551058,10.1158/0008-5472.CAN-09-3769,Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,0.9,animal_model,Nf1^flox/flox;GFAP-Cre,Animal Model,,,,,
PMID:20551058,10.1158/0008-5472.CAN-09-3769,Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,0.9,animal_model,Nf1^flox/mut;GFAP-Cre,Animal Model,,,,,
PMID:20551058,10.1158/0008-5472.CAN-09-3769,Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,0.85,cell_line,Daoy,Cell Line,,,,,
PMID:20551058,10.1158/0008-5472.CAN-09-3769,Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,0.8,antibody,CXCL12 antibody,Antibody,,,,,
PMID:20551058,10.1158/0008-5472.CAN-09-3769,Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,0.8,antibody,mCherry antibody,Antibody,,,,,
PMID:20551058,10.1158/0008-5472.CAN-09-3769,Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,0.8,antibody,GFAP antibody,Antibody,,,,,
PMID:20551058,10.1158/0008-5472.CAN-09-3769,Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,0.8,antibody,PDE4A antibody,Antibody,,,,,
PMID:20551058,10.1158/0008-5472.CAN-09-3769,Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,0.8,antibody,LCA antibody,Antibody,,,,,
PMID:20551058,10.1158/0008-5472.CAN-09-3769,Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,0.8,antibody,IBA-1 antibody,Antibody,,,,,
PMID:20551058,10.1158/0008-5472.CAN-09-3769,Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,0.8,antibody,phosphorylated protein kinase A substrate antibody,Antibody,,,,,
PMID:20551058,10.1158/0008-5472.CAN-09-3769,Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,0.8,antibody,CNPase antibody,Antibody,,,,,
PMID:20551058,10.1158/0008-5472.CAN-09-3769,Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,0.8,antibody,phosphorylated CXCR4 antibody,Antibody,,,,,
PMID:20551058,10.1158/0008-5472.CAN-09-3769,Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,0.85,antibody,Olig2 antibody (DF-308),Antibody,,,,,
PMID:20551058,10.1158/0008-5472.CAN-09-3769,Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,0.9,genetic_reagent,PDE4A1-mCherry lentiviral construct,Genetic Reagent,,,,,
PMID:20551058,10.1158/0008-5472.CAN-09-3769,Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,0.9,genetic_reagent,PDE4A1-H229Q-mCherry lentiviral construct,Genetic Reagent,,,,,
PMID:20551058,10.1158/0008-5472.CAN-09-3769,Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,0.85,genetic_reagent,FUW-FLG lentiviral vector,Genetic Reagent,,,,,
PMID:35118381,10.1093/noajnl/vdab184,Neutrophil depletion enhanced the ,,0.85,cell_line,GL261,Cell Line,,,,,
PMID:35118381,10.1093/noajnl/vdab184,Neutrophil depletion enhanced the ,,0.8,cell_line,GL261-luc,Cell Line,,,,,
PMID:35118381,10.1093/noajnl/vdab184,Neutrophil depletion enhanced the ,,0.9,antibody,anti-Ly6G antibody,Antibody,,,,,
PMID:35118381,10.1093/noajnl/vdab184,Neutrophil depletion enhanced the ,,0.75,genetic_reagent,lentivirus carrying luciferase,Genetic Reagent,,,,,
PMID:41023593,10.1186/s10020-025-01353-9,Selective inhibition of BRAF and CRAF sensitizes NF1-deficient malignant peripheral nerve sheath tumors to MEK inhibitors.,,0.95,animal_model,"NSG (NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ, strain #:005557)",Animal Model,,,,,
PMID:41023593,10.1186/s10020-025-01353-9,Selective inhibition of BRAF and CRAF sensitizes NF1-deficient malignant peripheral nerve sheath tumors to MEK inhibitors.,,0.9,animal_model,SCID (C.B-17/IcrHsd-Prkdc scid),Animal Model,,,,,
PMID:41023593,10.1186/s10020-025-01353-9,Selective inhibition of BRAF and CRAF sensitizes NF1-deficient malignant peripheral nerve sheath tumors to MEK inhibitors.,,0.85,computational_tool,randomizr package,Computational Tool,,,,,
PMID:41023593,10.1186/s10020-025-01353-9,Selective inhibition of BRAF and CRAF sensitizes NF1-deficient malignant peripheral nerve sheath tumors to MEK inhibitors.,,0.8,patient_derived_model,patient-derived xenograft models,Patient-Derived Model,,,,,
PMID:41023593,10.1186/s10020-025-01353-9,Selective inhibition of BRAF and CRAF sensitizes NF1-deficient malignant peripheral nerve sheath tumors to MEK inhibitors.,,0.85,genetic_reagent,CRISPR-CAS9,Genetic Reagent,,,,,
PMID:41023593,10.1186/s10020-025-01353-9,Selective inhibition of BRAF and CRAF sensitizes NF1-deficient malignant peripheral nerve sheath tumors to MEK inhibitors.,,0.85,genetic_reagent,shRNA,Genetic Reagent,,,,,
PMID:38175707,10.1172/jci.insight.168826,Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas.,,0.85,cell_line,NF1-/- iPSC-derived neural crest cells,Cell Line,,,,,
PMID:38175707,10.1172/jci.insight.168826,Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas.,,0.9,advanced_cellular_model,neurofibromasphere model,Advanced Cellular Model,,,,,
PMID:38175707,10.1172/jci.insight.168826,Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas.,,0.95,antibody,"p75 antibody (Ab3125, Abcam)",Antibody,,,,,
PMID:38175707,10.1172/jci.insight.168826,Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas.,,0.95,antibody,"S100B antibody (Z0311, Dako)",Antibody,,,,,
PMID:38175707,10.1172/jci.insight.168826,Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas.,,0.95,antibody,"MPZ antibody (Ab183868, Abcam)",Antibody,,,,,
PMID:38175707,10.1172/jci.insight.168826,Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas.,,0.8,computational_tool,I2HCP NGS custom panel,Computational Tool,,,,,
PMID:38175707,10.1172/jci.insight.168826,Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas.,,0.85,computational_tool,bwa mem,Computational Tool,,,,,
PMID:38175707,10.1172/jci.insight.168826,Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas.,,0.85,computational_tool,strelka2,Computational Tool,,,,,
PMID:38175707,10.1172/jci.insight.168826,Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas.,,0.85,computational_tool,annovar,Computational Tool,,,,,
PMID:38175707,10.1172/jci.insight.168826,Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas.,,0.9,computational_tool,Salmon v1.8.0,Computational Tool,,,,,
PMID:38175707,10.1172/jci.insight.168826,Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas.,,0.85,computational_tool,tximport,Computational Tool,,,,,
PMID:38175707,10.1172/jci.insight.168826,Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas.,,0.85,computational_tool,DESeq2,Computational Tool,,,,,
PMID:38175707,10.1172/jci.insight.168826,Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas.,,0.85,computational_tool,clusterProfiler,Computational Tool,,,,,
PMID:38175707,10.1172/jci.insight.168826,Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas.,,0.9,genetic_reagent,"selumetinib (Tocris, catalog 6815)",Genetic Reagent,,,,,
PMID:38175707,10.1172/jci.insight.168826,Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas.,,0.9,genetic_reagent,"ogerin (Tocris, catalog 5722)",Genetic Reagent,,,,,
PMID:38175707,10.1172/jci.insight.168826,Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas.,,0.9,genetic_reagent,"GANT61 (Tocris, catalog 3191)",Genetic Reagent,,,,,
PMID:38175707,10.1172/jci.insight.168826,Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas.,,0.9,genetic_reagent,"LGK-974 (Selleckchem, catalog S7143)",Genetic Reagent,,,,,
PMID:38175707,10.1172/jci.insight.168826,Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas.,,0.9,genetic_reagent,"PAM71 (MedChemExpress, catalog HY-134494)",Genetic Reagent,,,,,
PMID:38175707,10.1172/jci.insight.168826,Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas.,,0.9,genetic_reagent,"8CPT cAMP (Abcam, catalog ab120424)",Genetic Reagent,,,,,
PMID:38175707,10.1172/jci.insight.168826,Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas.,,0.9,genetic_reagent,"Forskolin (MilliporeSigma, catalog F6886)",Genetic Reagent,,,,,
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,0.85,animal_model,DhhCre mice,Animal Model,,,,,
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,0.85,animal_model,Nf1flox/flox;PostnCre+ mice,Animal Model,,,,,
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,0.85,animal_model,Nf1flox/flox;Arf flox/flox;PostnCre+ mice,Animal Model,,,,,
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,0.9,antibody,"CD31 antibody (3528S, Cell Signaling)",Antibody,,,,,
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,0.9,antibody,"Survivin antibody (MA5-15077, Invitrogen)",Antibody,,,,,
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,0.9,antibody,"CENPF antibody (PA5-84637, Invitrogen)",Antibody,,,,,
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,0.9,antibody,"H3K27me3 antibody (9733S, Cell Signaling)",Antibody,,,,,
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,0.9,antibody,"CENPF antibody (ab223847, Abcam)",Antibody,,,,,
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,0.9,antibody,"Vinculin antibody (ab219649, Abcam)",Antibody,,,,,
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,0.9,cell_line,JH-2-002 cell line,Cell Line,,,,,
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,0.9,cell_line,JH-2-103 cell line,Cell Line,,,,,
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,0.9,cell_line,ST-8814 cell line,Cell Line,,,,,
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,0.9,cell_line,S462 cell line,Cell Line,,,,,
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,0.85,cell_line,hTERT ipn02.3 2λ cell line,Cell Line,,,,,
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,0.85,cell_line,hTERT NF1 ipNF95.6 cell line,Cell Line,,,,,
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,0.85,genetic_reagent,Ad5CMVCre-GFP adenovirus,Genetic Reagent,,,,,
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,0.9,computational_tool,nCounter Sprint Profiler,Computational Tool,,,,,
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,0.9,computational_tool,nSolver Advanced Analysis Software version 4.0,Computational Tool,,,,,
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,0.9,computational_tool,Omics Playground v2.7.18,Computational Tool,,,,,
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,0.9,computational_tool,UCSC Xena browser,Computational Tool,,,,,
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,0.9,computational_tool,IDEP.92,Computational Tool,,,,,
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,0.85,computational_tool,Morpheus,Computational Tool,,,,,
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,0.9,computational_tool,ComplexHeatmap R/Bioconductor package,Computational Tool,,,,,
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,0.9,computational_tool,Scanpy,Computational Tool,,,,,
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,0.85,computational_tool,scVI model,Computational Tool,,,,,
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,0.85,computational_tool,decoupler package,Computational Tool,,,,,
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,0.85,computational_tool,infercnvpy package,Computational Tool,,,,,
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,0.9,computational_tool,HALO Image Analysis software version 2.0.5,Computational Tool,,,,,
PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.85,genetic_reagent,Qiagen DNeasy Extraction kit,Genetic Reagent,,,,,
PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.85,genetic_reagent,Qiagen EpiTect plus,Genetic Reagent,,,,,
PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.9,computational_tool,Illumina Infinium HumanMethylationEPIC (EPIC) array,Computational Tool,,,,,
PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.95,computational_tool,minfi,Computational Tool,,,,,
PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.9,computational_tool,ConsensusClusterPlus,Computational Tool,,,,,
PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.9,computational_tool,limma,Computational Tool,,,,,
PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.9,computational_tool,Rtsne,Computational Tool,,,,,
PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.9,computational_tool,conumee,Computational Tool,,,,,
PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.85,genetic_reagent,Agilent SureSelect Human All Exon V5 + UTRs kit,Genetic Reagent,,,,,
PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.9,computational_tool,Haplotype Caller,Computational Tool,,,,,
PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.95,computational_tool,MuTect1,Computational Tool,,,,,
PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.95,computational_tool,Strelka,Computational Tool,,,,,
PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.95,computational_tool,Variant Effect Predictor,Computational Tool,,,,,
PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.95,computational_tool,Sequenza,Computational Tool,,,,,
PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.85,genetic_reagent,Illumina TruSeq PCR-free DNA library preparation kit,Genetic Reagent,,,,,
PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.95,computational_tool,BwaMem,Computational Tool,,,,,
PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.95,computational_tool,Delly,Computational Tool,,,,,
PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.95,computational_tool,MAVIS,Computational Tool,,,,,
PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.85,genetic_reagent,Illumina TruSeq mStranded Total RNA,Genetic Reagent,,,,,
PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.85,genetic_reagent,Ribo-Zero Gold,Genetic Reagent,,,,,
PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.9,computational_tool,FusionCatcher,Computational Tool,,,,,
PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.85,genetic_reagent,SuperScript VILO kit,Genetic Reagent,,,,,
PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.85,genetic_reagent,Qiagen MinElute PCR purification kit,Genetic Reagent,,,,,
PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.9,computational_tool,FastQC,Computational Tool,,,,,
PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.95,computational_tool,STAR aligner,Computational Tool,,,,,
PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.95,computational_tool,HtSeq,Computational Tool,,,,,
PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.95,computational_tool,DESeq2,Computational Tool,,,,,
PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.95,computational_tool,edgeR,Computational Tool,,,,,
PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.95,computational_tool,GSEA,Computational Tool,,,,,
PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.9,computational_tool,AutoAnnotate,Computational Tool,,,,,
PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.95,computational_tool,Cytoscape,Computational Tool,,,,,
PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.9,computational_tool,Enrichment Map,Computational Tool,,,,,
PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.9,computational_tool,CIBERSORT,Computational Tool,,,,,
PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.85,genetic_reagent,HaloPlex PCR target enrichment system,Genetic Reagent,,,,,
PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.85,computational_tool,SureDesign,Computational Tool,,,,,
PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.85,genetic_reagent,MiSeq reagent kit version 2,Genetic Reagent,,,,,
PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.9,computational_tool,BWA MEM,Computational Tool,,,,,
PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.85,genetic_reagent,ABI PRISM Linkage Mapping set version 2.5,Genetic Reagent,,,,,
PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.85,genetic_reagent,SMARCB1 MLPA test kit P044_B1,Genetic Reagent,,,,,
PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.85,genetic_reagent,NF2 MLPA test kit P258_C1,Genetic Reagent,,,,,
PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.85,genetic_reagent,22q11 MLPA test kit P324_A2,Genetic Reagent,,,,,
PMID:33025139,10.1007/s00401-020-02230-x,"Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.",,0.9,computational_tool,GeneMapper software,Computational Tool,,,,,
PMID:28525381,10.18632/oncotarget.17589,The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.,,0.9,animal_model,Nf1+/− mice,Animal Model,,,,,
PMID:28525381,10.18632/oncotarget.17589,The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.,,0.9,animal_model,Nf1flox/wt mice,Animal Model,,,,,
PMID:28525381,10.18632/oncotarget.17589,The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.,,0.9,animal_model,Nf1flox/mut mice,Animal Model,,,,,
PMID:28525381,10.18632/oncotarget.17589,The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.,,0.9,animal_model,Nf1flox/flox; Olig2-Cre mice,Animal Model,,,,,
PMID:28525381,10.18632/oncotarget.17589,The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.,,0.9,animal_model,Nf1flox/mut; Olig2-Cre (FMOC) mice,Animal Model,,,,,
PMID:28525381,10.18632/oncotarget.17589,The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.,,0.9,animal_model,Nf1flox/mut; GFAP-Cre (FMC) mice,Animal Model,,,,,
PMID:28525381,10.18632/oncotarget.17589,The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.,,0.9,animal_model,Nf1flox/flox mice,Animal Model,,,,,
PMID:28525381,10.18632/oncotarget.17589,The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.,,0.9,animal_model,Nf1flox/flox; Prom1-CreER mice,Animal Model,,,,,
PMID:28525381,10.18632/oncotarget.17589,The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.,,0.9,animal_model,Nf1flox/mut; Prom1-CreER (FMPrC) mice,Animal Model,,,,,
PMID:28525381,10.18632/oncotarget.17589,The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.,,0.95,animal_model,"B6-Olig2tm2(TVA,cre)Rth/J",Animal Model,,,,,
PMID:28525381,10.18632/oncotarget.17589,The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.,,0.9,animal_model,GFAP-Cre mice,Animal Model,,,,,
PMID:28525381,10.18632/oncotarget.17589,The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.,,0.95,animal_model,B6.Cg-Gt(ROSA)26Sortm(CAGZsGreen1)Hze+/J,Animal Model,,,,,
PMID:28525381,10.18632/oncotarget.17589,The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.,,0.8,genetic_reagent,tamoxifen,Genetic Reagent,,,,,
PMID:28525381,10.18632/oncotarget.17589,The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.,,0.8,genetic_reagent,progesterone,Genetic Reagent,,,,,
PMID:28525381,10.18632/oncotarget.17589,The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.,,0.8,antibody,Alexa-Fluor-tagged secondary antibodies,Antibody,,,,,
PMID:28525381,10.18632/oncotarget.17589,The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.,,0.8,genetic_reagent,DAPI,Genetic Reagent,,,,,
PMID:28525381,10.18632/oncotarget.17589,The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.,,0.8,antibody,biotinylated secondary antibodies,Antibody,,,,,
PMID:28525381,10.18632/oncotarget.17589,The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.,,0.8,genetic_reagent,Vectastain Elite ABC,Genetic Reagent,,,,,
PMID:31527226,10.1158/1535-7163.MCT-19-0123,"Ketotifen Modulates Mast Cell Chemotaxis to Kit-Ligand, but Does Not Impact Mast Cell Numbers, Degranulation, or Tumor Behavior in Neurofibromas of ",,0.95,animal_model,Nf1flox/flox;PostnCre+ mice,Animal Model,,,,,
PMID:31527226,10.1158/1535-7163.MCT-19-0123,"Ketotifen Modulates Mast Cell Chemotaxis to Kit-Ligand, but Does Not Impact Mast Cell Numbers, Degranulation, or Tumor Behavior in Neurofibromas of ",,0.85,genetic_reagent,Ketotifen fumarate,Genetic Reagent,,,,,
PMID:31527226,10.1158/1535-7163.MCT-19-0123,"Ketotifen Modulates Mast Cell Chemotaxis to Kit-Ligand, but Does Not Impact Mast Cell Numbers, Degranulation, or Tumor Behavior in Neurofibromas of ",,0.8,genetic_reagent,Kit Ligand,Genetic Reagent,,,,,
PMID:31527226,10.1158/1535-7163.MCT-19-0123,"Ketotifen Modulates Mast Cell Chemotaxis to Kit-Ligand, but Does Not Impact Mast Cell Numbers, Degranulation, or Tumor Behavior in Neurofibromas of ",,0.9,computational_tool,Agilent 1200 HPLC,Computational Tool,,,,,
PMID:31527226,10.1158/1535-7163.MCT-19-0123,"Ketotifen Modulates Mast Cell Chemotaxis to Kit-Ligand, but Does Not Impact Mast Cell Numbers, Degranulation, or Tumor Behavior in Neurofibromas of ",,0.9,computational_tool,ABI 3200 MS/MS,Computational Tool,,,,,
PMID:31527226,10.1158/1535-7163.MCT-19-0123,"Ketotifen Modulates Mast Cell Chemotaxis to Kit-Ligand, but Does Not Impact Mast Cell Numbers, Degranulation, or Tumor Behavior in Neurofibromas of ",,0.85,computational_tool,GraphPad Prism 5.0,Computational Tool,,,,,
PMID:31527226,10.1158/1535-7163.MCT-19-0123,"Ketotifen Modulates Mast Cell Chemotaxis to Kit-Ligand, but Does Not Impact Mast Cell Numbers, Degranulation, or Tumor Behavior in Neurofibromas of ",,0.85,computational_tool,GraphPad Prism 6.0,Computational Tool,,,,,
PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.95,cell_line,"M14 (ST88-14, RRID:CVCL_8916)",Cell Line,,,,,
PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.95,cell_line,M10 (MPNST1),Cell Line,,,,,
PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.9,cell_line,M1,Cell Line,,,,,
PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.9,cell_line,M3,Cell Line,,,,,
PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.9,cell_line,M4,Cell Line,,,,,
PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.9,cell_line,M6,Cell Line,,,,,
PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.85,animal_model,Eed f/f mice,Animal Model,,,,,
PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.9,animal_model,PLP-CreERT:: Nf1 f/f ; Cdkn2a f/f,Animal Model,,,,,
PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.95,animal_model,"CB-17 SCID mice (Taconic, RRID:IMSR_TAC:cb17sc)",Animal Model,,,,,
PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.95,cell_line,"HEK-293T cells (ATCC; cat. #CRL-3216, RRID:CVCL_0063)",Cell Line,,,,,
PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.95,genetic_reagent,"psPAX2 (gift from Didier Trono, Addgene Plasmid #12260, RRID:Addgene_12260)",Genetic Reagent,,,,,
PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.95,genetic_reagent,"pCMV-VSV-G (gift from Bob Weinberg, Addgene Plasmid #8454, RRID:Addgene_8454)",Genetic Reagent,,,,,
PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.85,genetic_reagent,LT3GEPIR mir-E backbone,Genetic Reagent,,,,,
PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.8,computational_tool,FastQC (RRID:SCR_014583),Computational Tool,,,,,
PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.8,computational_tool,Cutadapt (RRID:SCR_011841),Computational Tool,,,,,
PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.8,computational_tool,bowtie2 (RRID:SCR_016368),Computational Tool,,,,,
PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.8,computational_tool,edgeR (RRID:SCR_012802),Computational Tool,,,,,
PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.8,computational_tool,HiTSelect,Computational Tool,,,,,
PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.8,computational_tool,"GraphPad (Prism, RRID:SCR_002798)",Computational Tool,,,,,
PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.9,patient_derived_model,MPNST PDX-1,Patient-Derived Model,,,,,
PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.95,genetic_reagent,"LT3GEPIR (gift from Johannes Zuber, RRID:Addgene_111177)",Genetic Reagent,,,,,
PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.85,genetic_reagent,pL-CRISPR.EFS.Blast,Genetic Reagent,,,,,
PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.95,genetic_reagent,"pLV-EF1α-IRES-Puro (gift from Tobias Meyer, RRID:Addgene_85132)",Genetic Reagent,,,,,
PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.8,computational_tool,TrimGalore (RRID:SCR_011847),Computational Tool,,,,,
PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.8,computational_tool,STAR v2.6 (RRID:SCR_004463),Computational Tool,,,,,
PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.8,computational_tool,TPMCalculator,Computational Tool,,,,,
PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.8,computational_tool,HTSeq v0.9.1 (RRID:SCR_005514),Computational Tool,,,,,
PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.8,computational_tool,DESeq2 (RRID:SCR_000154),Computational Tool,,,,,
PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.8,computational_tool,deepTools v3.1 (RRID:SCR_016366),Computational Tool,,,,,
PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.8,computational_tool,Homer v4.5 (RRID:SCR_010881),Computational Tool,,,,,
PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.8,computational_tool,RepeatMasker (RRID:SCR_012954),Computational Tool,,,,,
PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.8,computational_tool,"featureCounts (v1.5.0-p1, RRID:SCR_012919)",Computational Tool,,,,,
PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.8,computational_tool,"pheatmap (v.1.0.12, RRID:SCR_016418)",Computational Tool,,,,,
PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.8,computational_tool,methylKit (RRID:SCR_005177),Computational Tool,,,,,
PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.8,computational_tool,annotatr,Computational Tool,,,,,
PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.8,computational_tool,BEDTools suite (RRID:SCR_006646),Computational Tool,,,,,
PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.8,computational_tool,Genomation (RRID:SCR_003435),Computational Tool,,,,,
PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.8,computational_tool,ggplot2 (RRID:SCR_014601),Computational Tool,,,,,
PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.8,computational_tool,"Partek Genomics Suite (v 7.0, RRID:SCR_011860)",Computational Tool,,,,,
PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.8,computational_tool,Integrative Genomics Viewer,Computational Tool,,,,,
PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.8,computational_tool,"FCS Express 7 Research Edition (De Novo Software, Inc.; RRID:SCR_016431)",Computational Tool,,,,,
PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.8,computational_tool,"GIMP (GNU Image Manipulation Program, RRID:SCR_003182)",Computational Tool,,,,,
PMID:35789380,10.1158/2159-8290.CD-21-1671,PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,0.8,computational_tool,MSK-IMPACT,Computational Tool,,,,,
PMID:38136356,10.3390/cancers15245811,Drug Responses in Plexiform Neurofibroma Type I (PNF1) Cell Lines Using High-Throughput Data and Combined Effectiveness and Potency.,,0.9,cell_line,ipnNF95.11C,Cell Line,,,,,
PMID:38136356,10.3390/cancers15245811,Drug Responses in Plexiform Neurofibroma Type I (PNF1) Cell Lines Using High-Throughput Data and Combined Effectiveness and Potency.,,0.9,cell_line,ipNF05.5-MX,Cell Line,,,,,
PMID:38136356,10.3390/cancers15245811,Drug Responses in Plexiform Neurofibroma Type I (PNF1) Cell Lines Using High-Throughput Data and Combined Effectiveness and Potency.,,0.9,cell_line,ipNF06.2A,Cell Line,,,,,
PMID:38136356,10.3390/cancers15245811,Drug Responses in Plexiform Neurofibroma Type I (PNF1) Cell Lines Using High-Throughput Data and Combined Effectiveness and Potency.,,0.9,cell_line,ipNF95.11b C/T,Cell Line,,,,,
PMID:38136356,10.3390/cancers15245811,Drug Responses in Plexiform Neurofibroma Type I (PNF1) Cell Lines Using High-Throughput Data and Combined Effectiveness and Potency.,,0.9,cell_line,ipNF95.6,Cell Line,,,,,
PMID:38136356,10.3390/cancers15245811,Drug Responses in Plexiform Neurofibroma Type I (PNF1) Cell Lines Using High-Throughput Data and Combined Effectiveness and Potency.,,0.85,cell_line,ipNF02.3 2λ,Cell Line,,,,,
PMID:38136356,10.3390/cancers15245811,Drug Responses in Plexiform Neurofibroma Type I (PNF1) Cell Lines Using High-Throughput Data and Combined Effectiveness and Potency.,,0.85,cell_line,ipNF02.8,Cell Line,,,,,
PMID:38136356,10.3390/cancers15245811,Drug Responses in Plexiform Neurofibroma Type I (PNF1) Cell Lines Using High-Throughput Data and Combined Effectiveness and Potency.,,0.8,genetic_reagent,MIPE 4.0 library,Genetic Reagent,,,,,
PMID:38136356,10.3390/cancers15245811,Drug Responses in Plexiform Neurofibroma Type I (PNF1) Cell Lines Using High-Throughput Data and Combined Effectiveness and Potency.,,0.8,computational_tool,SigmaPlot,Computational Tool,,,,,
PMID:38136356,10.3390/cancers15245811,Drug Responses in Plexiform Neurofibroma Type I (PNF1) Cell Lines Using High-Throughput Data and Combined Effectiveness and Potency.,,0.85,computational_tool,DREA web tool,Computational Tool,,,,,
PMID:38136356,10.3390/cancers15245811,Drug Responses in Plexiform Neurofibroma Type I (PNF1) Cell Lines Using High-Throughput Data and Combined Effectiveness and Potency.,,0.8,computational_tool,Synapse,Computational Tool,,,,,
PMID:40887659,10.1186/s40246-025-00803-z,RENOVO-NF1 accurately predicts NF1 missense variant pathogenicity.,,0.95,computational_tool,RENOVO-NF1,Computational Tool,,,,,
PMID:40887659,10.1186/s40246-025-00803-z,RENOVO-NF1 accurately predicts NF1 missense variant pathogenicity.,,0.9,computational_tool,ClinVar,Computational Tool,,,,,
PMID:40887659,10.1186/s40246-025-00803-z,RENOVO-NF1 accurately predicts NF1 missense variant pathogenicity.,,0.85,computational_tool,Ion Torrent,Computational Tool,,,,,
PMID:40887659,10.1186/s40246-025-00803-z,RENOVO-NF1 accurately predicts NF1 missense variant pathogenicity.,,0.8,computational_tool,MLPA,Computational Tool,,,,,
PMID:40887659,10.1186/s40246-025-00803-z,RENOVO-NF1 accurately predicts NF1 missense variant pathogenicity.,,0.9,computational_tool,Mutation Taster,Computational Tool,,,,,
PMID:40887659,10.1186/s40246-025-00803-z,RENOVO-NF1 accurately predicts NF1 missense variant pathogenicity.,,0.9,computational_tool,HGMD,Computational Tool,,,,,
PMID:40887659,10.1186/s40246-025-00803-z,RENOVO-NF1 accurately predicts NF1 missense variant pathogenicity.,,0.9,computational_tool,LOVD,Computational Tool,,,,,
PMID:40887659,10.1186/s40246-025-00803-z,RENOVO-NF1 accurately predicts NF1 missense variant pathogenicity.,,0.9,computational_tool,PolyPhen-2,Computational Tool,,,,,
PMID:40887659,10.1186/s40246-025-00803-z,RENOVO-NF1 accurately predicts NF1 missense variant pathogenicity.,,0.9,computational_tool,Human Splicing Finder,Computational Tool,,,,,
PMID:40887659,10.1186/s40246-025-00803-z,RENOVO-NF1 accurately predicts NF1 missense variant pathogenicity.,,0.9,computational_tool,ESE Finder,Computational Tool,,,,,
PMID:40887659,10.1186/s40246-025-00803-z,RENOVO-NF1 accurately predicts NF1 missense variant pathogenicity.,,0.9,computational_tool,ANNOVAR,Computational Tool,,,,,
PMID:40887659,10.1186/s40246-025-00803-z,RENOVO-NF1 accurately predicts NF1 missense variant pathogenicity.,,0.9,computational_tool,GnomAD,Computational Tool,,,,,
PMID:40887659,10.1186/s40246-025-00803-z,RENOVO-NF1 accurately predicts NF1 missense variant pathogenicity.,,0.9,computational_tool,1000 Genomes,Computational Tool,,,,,
PMID:40887659,10.1186/s40246-025-00803-z,RENOVO-NF1 accurately predicts NF1 missense variant pathogenicity.,,0.85,computational_tool,cutpointR,Computational Tool,,,,,
PMID:32839340,10.1073/pnas.2008391117,Brain-wide structural and functional disruption in mice with oligodendrocyte-specific ,,0.9,animal_model,Plp-Cre,Animal Model,,,,,
PMID:32839340,10.1073/pnas.2008391117,Brain-wide structural and functional disruption in mice with oligodendrocyte-specific ,,0.95,animal_model,Nf1 fl/+,Animal Model,,,,,
PMID:32839340,10.1073/pnas.2008391117,Brain-wide structural and functional disruption in mice with oligodendrocyte-specific ,,0.85,clinical_assessment_tool,Rotarod,Clinical Assessment Tool,,,,,
PMID:32839340,10.1073/pnas.2008391117,Brain-wide structural and functional disruption in mice with oligodendrocyte-specific ,,0.8,computational_tool,BioSpec 94/20 USR MRI,Computational Tool,,,,,
PMID:32839340,10.1073/pnas.2008391117,Brain-wide structural and functional disruption in mice with oligodendrocyte-specific ,,0.9,computational_tool,ExplorDTI,Computational Tool,,,,,
PMID:32839340,10.1073/pnas.2008391117,Brain-wide structural and functional disruption in mice with oligodendrocyte-specific ,,0.9,computational_tool,Advanced Normalization Tools (ANTs),Computational Tool,,,,,
PMID:32839340,10.1073/pnas.2008391117,Brain-wide structural and functional disruption in mice with oligodendrocyte-specific ,,0.85,computational_tool,Allen Brain Atlas,Computational Tool,,,,,
PMID:35735230,10.1093/database/baac045,Centralizing neurofibromatosis experimental tool knowledge with the NF Research Tools Database.,,0.95,computational_tool,NF Research Tools Database,Computational Tool,,,,,
PMID:35735230,10.1093/database/baac045,Centralizing neurofibromatosis experimental tool knowledge with the NF Research Tools Database.,,0.85,computational_tool,schematic Python library,Computational Tool,,,,,
PMID:35735230,10.1093/database/baac045,Centralizing neurofibromatosis experimental tool knowledge with the NF Research Tools Database.,,0.8,computational_tool,React JavaScript library,Computational Tool,,,,,
PMID:35735230,10.1093/database/baac045,Centralizing neurofibromatosis experimental tool knowledge with the NF Research Tools Database.,,0.85,computational_tool,Synapse React Client,Computational Tool,,,,,
PMID:35735230,10.1093/database/baac045,Centralizing neurofibromatosis experimental tool knowledge with the NF Research Tools Database.,,0.8,computational_tool,MySQL database,Computational Tool,,,,,
PMID:35735230,10.1093/database/baac045,Centralizing neurofibromatosis experimental tool knowledge with the NF Research Tools Database.,,0.85,computational_tool,JSON-LD schema,Computational Tool,,,,,
PMID:35735230,10.1093/database/baac045,Centralizing neurofibromatosis experimental tool knowledge with the NF Research Tools Database.,,0.9,computational_tool,Synapse collaborative science platform,Computational Tool,,,,,
PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,0.9,antibody,CD34 antibody,Antibody,,,,,
PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,0.9,antibody,CD56 antibody,Antibody,,,,,
PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,0.9,antibody,CD117/c-kit antibody,Antibody,,,,,
PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,0.9,antibody,NGFR antibody,Antibody,,,,,
PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,0.9,antibody,PanCytokeratin antibody,Antibody,,,,,
PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,0.9,antibody,SOX2 antibody,Antibody,,,,,
PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,0.9,antibody,SOX10 antibody,Antibody,,,,,
PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,0.9,antibody,S100 antibody,Antibody,,,,,
PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,0.9,antibody,APC Anti-c-Kit antibody [YB5.B8],Antibody,,,,,
PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,0.9,antibody,Recombinant PE Anti-S100A11 antibody [EPR11172],Antibody,,,,,
PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,0.9,antibody,FITC Anti-CD34 antibody [4H11[APG]],Antibody,,,,,
PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,0.95,advanced_cellular_model,cNF organoids,Advanced Cellular Model,,,,,
PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,0.9,patient_derived_model,Cutaneous neurofibroma samples,Patient-Derived Model,,,,,
PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,0.8,genetic_reagent,CellTiter-Glo 3D Reagent,Genetic Reagent,,,,,
PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,0.9,computational_tool,Salmon v1.4,Computational Tool,,,,,
PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,0.9,computational_tool,BWA-MEM2 v2.1,Computational Tool,,,,,
PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,0.9,computational_tool,GATK v4.1.9.0,Computational Tool,,,,,
PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,0.9,computational_tool,MCP-Counter,Computational Tool,,,,,
PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,0.9,computational_tool,BSBolt,Computational Tool,,,,,
PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,0.9,computational_tool,metilene v0.2-8,Computational Tool,,,,,
PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,0.9,computational_tool,DELLY v1.1.3,Computational Tool,,,,,
PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,0.9,computational_tool,InterVar,Computational Tool,,,,,
PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,0.85,computational_tool,rare disease workflows,Computational Tool,,,,,
PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,0.9,computational_tool,cNFOrganoidAnalysis,Computational Tool,,,,,
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.85,genetic_reagent,"All-Prep Universal Kit (#80224, QIAGEN)",Genetic Reagent,,,,,
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.8,computational_tool,TissueLyser II (QIAGEN),Computational Tool,,,,,
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.8,computational_tool,BioAnalyzer 2100,Computational Tool,,,,,
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.9,genetic_reagent,"Illumina Methylation EPIC Beadchip (#WG-317-1003, Illumina)",Genetic Reagent,,,,,
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.85,computational_tool,minfi,Computational Tool,,,,,
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.85,computational_tool,ConsensusClusterPlus,Computational Tool,,,,,
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.85,genetic_reagent,"Kapa Hyper Prep Kit (#07962312001, Roche)",Genetic Reagent,,,,,
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.85,genetic_reagent,Nimblegen SeqCap EZ Human Exome Kit v3.0 (Roche),Genetic Reagent,,,,,
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.85,computational_tool,Bowtie2,Computational Tool,,,,,
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.85,computational_tool,Genome Analysis Toolkit (GATK),Computational Tool,,,,,
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.85,computational_tool,Mutect2,Computational Tool,,,,,
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.85,computational_tool,Snpeff,Computational Tool,,,,,
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.85,genetic_reagent,"TruSeq RNA Library Prep Kit v2 (#RS-122-2001, Illumina)",Genetic Reagent,,,,,
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.85,computational_tool,HISAT2,Computational Tool,,,,,
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.85,computational_tool,DESeq2,Computational Tool,,,,,
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.9,antibody,"H3K27me3 (Cell Signaling Technology, #9733, clone C36B11)",Antibody,,,,,
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.9,antibody,"SOX10 (Cell Marque, #383R-1, clone EP268)",Antibody,,,,,
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.9,antibody,"S100B (Ventana, #760-2523)",Antibody,,,,,
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.85,genetic_reagent,Chromium Single Cell 3′ Library & Gel Bead Kit v3.1,Genetic Reagent,,,,,
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.85,computational_tool,CellRanger,Computational Tool,,,,,
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.85,computational_tool,Seurat,Computational Tool,,,,,
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.85,computational_tool,Harmony,Computational Tool,,,,,
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.85,computational_tool,Clustree,Computational Tool,,,,,
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.85,computational_tool,InferCNV,Computational Tool,,,,,
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.9,cell_line,NF95.11b,Cell Line,,,,,
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.9,cell_line,NF95.6,Cell Line,,,,,
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.9,cell_line,SNF02.2,Cell Line,,,,,
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.9,cell_line,SNF94.3,Cell Line,,,,,
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.9,cell_line,SNF96.2,Cell Line,,,,,
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.9,cell_line,ST88-14,Cell Line,,,,,
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.85,genetic_reagent,"CellTiter 96 Non-Radioactive Cell Proliferation Assay (#G410, Promega)",Genetic Reagent,,,,,
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.9,antibody,"pERK (Cell Signaling Technologies, #4370)",Antibody,,,,,
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.9,antibody,"total ERK (Cell Signaling Technologies, #4695)",Antibody,,,,,
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.9,antibody,"beta tubulin (Developmental Hybridoma Studies Bank, #E7)",Antibody,,,,,
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.9,antibody,"pAKT (Cell Signaling Technologies, #4060)",Antibody,,,,,
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.9,antibody,"total AKT (Cell Signaling Technologies, # 4685)",Antibody,,,,,
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.9,antibody,"pMEK (Cell Signaling Technologies, #9121)",Antibody,,,,,
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.9,antibody,"total MEK (Cell Signaling Technologies, #8727)",Antibody,,,,,
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.9,antibody,"pPAK (Cell Signaling Technologies, #2601)",Antibody,,,,,
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.9,antibody,"Caspase-3 (Cell Signaling Technologies, #9662)",Antibody,,,,,
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.9,antibody,"Caspase-7 (Cell Signaling Technologies, #9492)",Antibody,,,,,
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.9,antibody,"NF2/Merlin (Abcam, #ab88957, clone AF1G4)",Antibody,,,,,
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.85,genetic_reagent,"RNeasy Mini Kit (#74106, QIAGEN)",Genetic Reagent,,,,,
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.85,genetic_reagent,"iScript cDNA Synthesis kit (#1708891, Bio-Rad)",Genetic Reagent,,,,,
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.85,genetic_reagent,"PowerUp SYBR Green Master Mix (#A25918, Thermo Fisher Scientific)",Genetic Reagent,,,,,
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.9,genetic_reagent,"pMH0001 (UCOE-SFFV-dCas9-BFP-KRAB, #85969, Addgene)",Genetic Reagent,,,,,
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.9,genetic_reagent,"pCRISPRia-v2 vector (#84832, Addgene)",Genetic Reagent,,,,,
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.9,animal_model,NU/NU mice (Harlan Sprague Dawley),Animal Model,,,,,
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.85,cell_line,JW18.2,Cell Line,,,,,
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,0.85,cell_line,JW23.3,Cell Line,,,,,
PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,0.9,animal_model,Periostin-CRE;NF2 fl/fl,Animal Model,,,,,
PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,0.9,animal_model,NF2 fl/fl YAP fl/fl -CRE+,Animal Model,,,,,
PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,0.9,animal_model,NF2 fl/fl TAZ fl/fl -CRE+,Animal Model,,,,,
PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,0.85,animal_model,P0-CRE,Animal Model,,,,,
PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,0.9,cell_line,BenMen-1,Cell Line,,,,,
PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,0.9,cell_line,KT21-MG1,Cell Line,,,,,
PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,0.85,cell_line,293FT,Cell Line,,,,,
PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,0.9,genetic_reagent,ALDH1A1 shRNA (TRCN0000026415),Genetic Reagent,,,,,
PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,0.9,genetic_reagent,TAZ shRNA (TRCN0000307197),Genetic Reagent,,,,,
PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,0.9,genetic_reagent,YAP shRNA (TRCN0000107266),Genetic Reagent,,,,,
PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,0.9,genetic_reagent,Scramble shRNA (SHC002),Genetic Reagent,,,,,
PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,0.9,antibody,ALDH1A1 antibody (ab52492),Antibody,,,,,
PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,0.9,antibody,YAP antibody (#14074),Antibody,,,,,
PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,0.9,antibody,TAZ antibody (sc-48805),Antibody,,,,,
PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,0.9,antibody,Ki67 antibody (ab15580),Antibody,,,,,
PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,0.9,antibody,Neurofilament antibody (ab4680),Antibody,,,,,
PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,0.9,antibody,S100 antibody (GA504),Antibody,,,,,
PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,0.9,antibody,Pan-TEAD antibody (#13295),Antibody,,,,,
PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,0.9,antibody,GAPDH antibody (AB2302),Antibody,,,,,
PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,0.9,antibody,CTGF antibody (ab6992),Antibody,,,,,
PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,0.8,computational_tool,GraphPad Prism 8,Computational Tool,,,,,
PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,0.8,computational_tool,ImageJ,Computational Tool,,,,,
PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,,0.95,clinical_assessment_tool,WAIS-III,Clinical Assessment Tool,,,,,
PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,,0.95,clinical_assessment_tool,WISC-III,Clinical Assessment Tool,,,,,
PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,,0.9,clinical_assessment_tool,Nine-Hole Peg Test,Clinical Assessment Tool,,,,,
PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,,0.9,clinical_assessment_tool,Rey-Osterrieth Complex Figure Test,Clinical Assessment Tool,,,,,
PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,,0.9,clinical_assessment_tool,Rey Auditory-Verbal Learning Test (RAVLT),Clinical Assessment Tool,,,,,
PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,,0.85,clinical_assessment_tool,Category Fluency Test,Clinical Assessment Tool,,,,,
PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,,0.85,clinical_assessment_tool,Lexical Fluency Test,Clinical Assessment Tool,,,,,
PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,,0.9,clinical_assessment_tool,Five Digits Test (FDT),Clinical Assessment Tool,,,,,
PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,,0.85,clinical_assessment_tool,Corsi block-tapping task,Clinical Assessment Tool,,,,,
PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,,0.85,clinical_assessment_tool,Tower of London Test,Clinical Assessment Tool,,,,,
PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,,0.95,computational_tool,Statistical Parametric Mapping toolbox (SPM8),Computational Tool,,,,,
PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,,0.9,computational_tool,Matlab 7.12.0,Computational Tool,,,,,
PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,,0.9,computational_tool,kernlab R library,Computational Tool,,,,,
PMID:30192842,10.1371/journal.pone.0203520,Use of machine learning to predict cognitive performance based on brain metabolism in Neurofibromatosis type 1.,,0.85,clinical_assessment_tool,GE Discovery 690,Clinical Assessment Tool,,,,,
PMID:32098059,10.3390/genes11020226,Integrative Analysis Identifies Candidate Tumor Microenvironment and Intracellular Signaling Pathways that Define Tumor Heterogeneity in NF1.,,0.85,computational_tool,tidyverse,Computational Tool,,,,,
PMID:32098059,10.3390/genes11020226,Integrative Analysis Identifies Candidate Tumor Microenvironment and Intracellular Signaling Pathways that Define Tumor Heterogeneity in NF1.,,0.9,computational_tool,PLIER,Computational Tool,,,,,
PMID:32098059,10.3390/genes11020226,Integrative Analysis Identifies Candidate Tumor Microenvironment and Intracellular Signaling Pathways that Define Tumor Heterogeneity in NF1.,,0.85,computational_tool,synapser,Computational Tool,,,,,
PMID:32098059,10.3390/genes11020226,Integrative Analysis Identifies Candidate Tumor Microenvironment and Intracellular Signaling Pathways that Define Tumor Heterogeneity in NF1.,,0.85,computational_tool,tximport,Computational Tool,,,,,
PMID:32098059,10.3390/genes11020226,Integrative Analysis Identifies Candidate Tumor Microenvironment and Intracellular Signaling Pathways that Define Tumor Heterogeneity in NF1.,,0.85,computational_tool,immunedeconv,Computational Tool,,,,,
PMID:32098059,10.3390/genes11020226,Integrative Analysis Identifies Candidate Tumor Microenvironment and Intracellular Signaling Pathways that Define Tumor Heterogeneity in NF1.,,0.85,computational_tool,viper,Computational Tool,,,,,
PMID:32098059,10.3390/genes11020226,Integrative Analysis Identifies Candidate Tumor Microenvironment and Intracellular Signaling Pathways that Define Tumor Heterogeneity in NF1.,,0.9,computational_tool,Salmon,Computational Tool,,,,,
PMID:32098059,10.3390/genes11020226,Integrative Analysis Identifies Candidate Tumor Microenvironment and Intracellular Signaling Pathways that Define Tumor Heterogeneity in NF1.,,0.85,computational_tool,vcf2maf,Computational Tool,,,,,
PMID:32098059,10.3390/genes11020226,Integrative Analysis Identifies Candidate Tumor Microenvironment and Intracellular Signaling Pathways that Define Tumor Heterogeneity in NF1.,,0.85,computational_tool,org.Hs.eg.db,Computational Tool,,,,,
PMID:32098059,10.3390/genes11020226,Integrative Analysis Identifies Candidate Tumor Microenvironment and Intracellular Signaling Pathways that Define Tumor Heterogeneity in NF1.,,0.9,computational_tool,MultiPLIER,Computational Tool,,,,,
PMID:32098059,10.3390/genes11020226,Integrative Analysis Identifies Candidate Tumor Microenvironment and Intracellular Signaling Pathways that Define Tumor Heterogeneity in NF1.,,0.85,computational_tool,caret,Computational Tool,,,,,
PMID:32098059,10.3390/genes11020226,Integrative Analysis Identifies Candidate Tumor Microenvironment and Intracellular Signaling Pathways that Define Tumor Heterogeneity in NF1.,,0.85,computational_tool,randomforest,Computational Tool,,,,,
PMID:32098059,10.3390/genes11020226,Integrative Analysis Identifies Candidate Tumor Microenvironment and Intracellular Signaling Pathways that Define Tumor Heterogeneity in NF1.,,0.9,computational_tool,CIBERSORT,Computational Tool,,,,,
PMID:32098059,10.3390/genes11020226,Integrative Analysis Identifies Candidate Tumor Microenvironment and Intracellular Signaling Pathways that Define Tumor Heterogeneity in NF1.,,0.9,computational_tool,MCP-counter,Computational Tool,,,,,
PMID:32098059,10.3390/genes11020226,Integrative Analysis Identifies Candidate Tumor Microenvironment and Intracellular Signaling Pathways that Define Tumor Heterogeneity in NF1.,,0.9,computational_tool,metaVIPER,Computational Tool,,,,,
PMID:32098059,10.3390/genes11020226,Integrative Analysis Identifies Candidate Tumor Microenvironment and Intracellular Signaling Pathways that Define Tumor Heterogeneity in NF1.,,0.85,computational_tool,pheatmap,Computational Tool,,,,,
PMID:32098059,10.3390/genes11020226,Integrative Analysis Identifies Candidate Tumor Microenvironment and Intracellular Signaling Pathways that Define Tumor Heterogeneity in NF1.,,0.85,computational_tool,clusterProfiler,Computational Tool,,,,,
PMID:32098059,10.3390/genes11020226,Integrative Analysis Identifies Candidate Tumor Microenvironment and Intracellular Signaling Pathways that Define Tumor Heterogeneity in NF1.,,0.85,computational_tool,ggplot,Computational Tool,,,,,
PMID:32098059,10.3390/genes11020226,Integrative Analysis Identifies Candidate Tumor Microenvironment and Intracellular Signaling Pathways that Define Tumor Heterogeneity in NF1.,,0.85,computational_tool,enrichplot,Computational Tool,,,,,
PMID:32098059,10.3390/genes11020226,Integrative Analysis Identifies Candidate Tumor Microenvironment and Intracellular Signaling Pathways that Define Tumor Heterogeneity in NF1.,,0.9,computational_tool,NF Data Portal,Computational Tool,,,,,
PMID:32098059,10.3390/genes11020226,Integrative Analysis Identifies Candidate Tumor Microenvironment and Intracellular Signaling Pathways that Define Tumor Heterogeneity in NF1.,,0.85,computational_tool,Drug Target Explorer database,Computational Tool,,,,,
PMID:38115252,10.1097/MD.0000000000036696,Identification of hub genes and drug candidates for NF2-related vestibular schwannoma by bioinformatics tools.,,0.85,computational_tool,GSE108524,Computational Tool,,,,,
PMID:38115252,10.1097/MD.0000000000036696,Identification of hub genes and drug candidates for NF2-related vestibular schwannoma by bioinformatics tools.,,0.85,computational_tool,GSE141801,Computational Tool,,,,,
PMID:38115252,10.1097/MD.0000000000036696,Identification of hub genes and drug candidates for NF2-related vestibular schwannoma by bioinformatics tools.,,0.9,computational_tool,R 4.0.3,Computational Tool,,,,,
PMID:38115252,10.1097/MD.0000000000036696,Identification of hub genes and drug candidates for NF2-related vestibular schwannoma by bioinformatics tools.,,0.95,computational_tool,WGCNA,Computational Tool,,,,,
PMID:38115252,10.1097/MD.0000000000036696,Identification of hub genes and drug candidates for NF2-related vestibular schwannoma by bioinformatics tools.,,0.8,computational_tool,pickSoftThreshold,Computational Tool,,,,,
PMID:38115252,10.1097/MD.0000000000036696,Identification of hub genes and drug candidates for NF2-related vestibular schwannoma by bioinformatics tools.,,0.9,computational_tool,clusterProfiler,Computational Tool,,,,,
PMID:38115252,10.1097/MD.0000000000036696,Identification of hub genes and drug candidates for NF2-related vestibular schwannoma by bioinformatics tools.,,0.95,computational_tool,STRING,Computational Tool,,,,,
PMID:38115252,10.1097/MD.0000000000036696,Identification of hub genes and drug candidates for NF2-related vestibular schwannoma by bioinformatics tools.,,0.95,computational_tool,Cytoscape,Computational Tool,,,,,
PMID:38115252,10.1097/MD.0000000000036696,Identification of hub genes and drug candidates for NF2-related vestibular schwannoma by bioinformatics tools.,,0.9,computational_tool,miRTarBase,Computational Tool,,,,,
PMID:38115252,10.1097/MD.0000000000036696,Identification of hub genes and drug candidates for NF2-related vestibular schwannoma by bioinformatics tools.,,0.9,computational_tool,limma,Computational Tool,,,,,
PMID:38115252,10.1097/MD.0000000000036696,Identification of hub genes and drug candidates for NF2-related vestibular schwannoma by bioinformatics tools.,,0.9,computational_tool,connectivity map (CMap),Computational Tool,,,,,
PMID:28848060,10.1136/jmedgenet-2017-104519,Genetic Severity Score predicts clinical phenotype in NF2.,,0.95,clinical_assessment_tool,UK NF2 Genetic Severity Score,Clinical Assessment Tool,,,,,
PMID:28848060,10.1136/jmedgenet-2017-104519,Genetic Severity Score predicts clinical phenotype in NF2.,,0.9,clinical_assessment_tool,8-item NF2 disease-specific quality of life score,Clinical Assessment Tool,,,,,
PMID:28848060,10.1136/jmedgenet-2017-104519,Genetic Severity Score predicts clinical phenotype in NF2.,,0.85,clinical_assessment_tool,hearing grade score,Clinical Assessment Tool,,,,,
PMID:28848060,10.1136/jmedgenet-2017-104519,Genetic Severity Score predicts clinical phenotype in NF2.,,0.8,computational_tool,SPSS V.23,Computational Tool,,,,,
PMID:28848060,10.1136/jmedgenet-2017-104519,Genetic Severity Score predicts clinical phenotype in NF2.,,0.85,clinical_assessment_tool,Manchester NF2 diagnostic criteria,Clinical Assessment Tool,,,,,
PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,0.9,cell_line,U251,Cell Line,,,,,
PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,0.85,genetic_reagent,siRNA SMARTpool (Thermo Scientific),Genetic Reagent,,,,,
PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,0.9,genetic_reagent,pXJ40-HA-Merlin,Genetic Reagent,,,,,
PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,0.9,genetic_reagent,S518A pXJ40-HA-Merlin,Genetic Reagent,,,,,
PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,0.9,antibody,rabbit anti-EGFR (Cell Signaling),Antibody,,,,,
PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,0.9,antibody,rabbit anti-Notch1 (Cell Signaling),Antibody,,,,,
PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,0.9,antibody,rabbit anti S518-Merlin (Abcam),Antibody,,,,,
PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,0.9,antibody,rabbit anti S518-Merlin (Cell Signaling),Antibody,,,,,
PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,0.8,genetic_reagent,IPA-3 (Sigma-Aldrich),Genetic Reagent,,,,,
PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,0.8,genetic_reagent,Q-proteome cell compartment kit (Qiagen),Genetic Reagent,,,,,
PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,0.85,antibody,"rabbit anti-Na+,K+-ATPase (Cell Signaling)",Antibody,,,,,
PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,0.85,antibody,GAPDH antibody (Cell Signaling),Antibody,,,,,
PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,0.85,antibody,PARP antibody (Cell Signaling),Antibody,,,,,
PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,0.8,genetic_reagent,Co-IP kit (Thermo Scientific),Genetic Reagent,,,,,
PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,0.8,genetic_reagent,Rneasy Mini Kit (Qiagen),Genetic Reagent,,,,,
PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,0.8,genetic_reagent,SuperScript™ III first-strand synthesis system (Life Technologies),Genetic Reagent,,,,,
PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,0.8,genetic_reagent,Power SYBR Green PCR master mix (Life Technologies),Genetic Reagent,,,,,
PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,0.8,genetic_reagent,Vybrant® MTT cell proliferation assay kit (Life Technologies),Genetic Reagent,,,,,
PMID:36420221,10.1016/j.omtn.2022.10.026,Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype ,,0.85,genetic_reagent,I2HCP panel,Genetic Reagent,,,,,
PMID:36420221,10.1016/j.omtn.2022.10.026,Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype ,,0.9,computational_tool,CLC-workbench,Computational Tool,,,,,
PMID:36420221,10.1016/j.omtn.2022.10.026,Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype ,,0.95,computational_tool,PredictProtein,Computational Tool,,,,,
PMID:36420221,10.1016/j.omtn.2022.10.026,Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype ,,0.9,genetic_reagent,25-mer-specific PMOs,Genetic Reagent,,,,,
PMID:36420221,10.1016/j.omtn.2022.10.026,Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype ,,0.85,genetic_reagent,Endo-Porter,Genetic Reagent,,,,,
PMID:36420221,10.1016/j.omtn.2022.10.026,Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype ,,0.9,antibody,Phalloidin,Antibody,,,,,
PMID:36420221,10.1016/j.omtn.2022.10.026,Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype ,,0.85,genetic_reagent,Click-iT EdU Alexa Fluor 488 Flow Cytometry Assay Kit,Genetic Reagent,,,,,
PMID:36420221,10.1016/j.omtn.2022.10.026,Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype ,,0.85,genetic_reagent,RealTime-Glo MT Cell Viability Assay,Genetic Reagent,,,,,
PMID:36420221,10.1016/j.omtn.2022.10.026,Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype ,,0.9,genetic_reagent,Gateway Gene Cloning system,Genetic Reagent,,,,,
PMID:36420221,10.1016/j.omtn.2022.10.026,Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype ,,0.9,genetic_reagent,FLAG Tag Expression Vector,Genetic Reagent,,,,,
PMID:36420221,10.1016/j.omtn.2022.10.026,Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype ,,0.95,cell_line,HeLa cells,Cell Line,,,,,
PMID:36420221,10.1016/j.omtn.2022.10.026,Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype ,,0.85,genetic_reagent,Lipofectamine LTX with Plus Reagent,Genetic Reagent,,,,,
PMID:36420221,10.1016/j.omtn.2022.10.026,Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype ,,0.95,antibody,Monoclonal ANTI-FLAG M2 antibody,Antibody,,,,,
PMID:36420221,10.1016/j.omtn.2022.10.026,Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype ,,0.9,computational_tool,GraphPad Prism software v7,Computational Tool,,,,,
PMID:36420221,10.1016/j.omtn.2022.10.026,Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype ,,0.9,cell_line,NF2 primary fibroblasts,Cell Line,,,,,
PMID:32438526,10.1002/lary.28671,Effects of Neurod1 Expression on Mouse and Human Schwannoma Cells.,,0.9,animal_model,Postn-cre,Animal Model,,,,,
PMID:32438526,10.1002/lary.28671,Effects of Neurod1 Expression on Mouse and Human Schwannoma Cells.,,0.95,animal_model,Postn-cre;Nf2f/f,Animal Model,,,,,
PMID:32438526,10.1002/lary.28671,Effects of Neurod1 Expression on Mouse and Human Schwannoma Cells.,,0.9,animal_model,Rosa26 LSL-Neurod1 (R26ND1),Animal Model,,,,,
PMID:32438526,10.1002/lary.28671,Effects of Neurod1 Expression on Mouse and Human Schwannoma Cells.,,0.85,animal_model,tg(Atoh1-cre)8,Animal Model,,,,,
PMID:32438526,10.1002/lary.28671,Effects of Neurod1 Expression on Mouse and Human Schwannoma Cells.,,0.85,animal_model,tg(Neurod1-cre)29,Animal Model,,,,,
PMID:32438526,10.1002/lary.28671,Effects of Neurod1 Expression on Mouse and Human Schwannoma Cells.,,0.8,animal_model,R26LacZ,Animal Model,,,,,
PMID:32438526,10.1002/lary.28671,Effects of Neurod1 Expression on Mouse and Human Schwannoma Cells.,,0.9,genetic_reagent,AdCMVNeuroD1,Genetic Reagent,,,,,
PMID:32438526,10.1002/lary.28671,Effects of Neurod1 Expression on Mouse and Human Schwannoma Cells.,,0.85,genetic_reagent,AdCMVempty vector,Genetic Reagent,,,,,
PMID:32438526,10.1002/lary.28671,Effects of Neurod1 Expression on Mouse and Human Schwannoma Cells.,,0.95,antibody,"anti-NeuroD1 (Abcam, ab109224)",Antibody,,,,,
PMID:32438526,10.1002/lary.28671,Effects of Neurod1 Expression on Mouse and Human Schwannoma Cells.,,0.95,antibody,"anti-β-actin (Sigma, A5316)",Antibody,,,,,
PMID:32438526,10.1002/lary.28671,Effects of Neurod1 Expression on Mouse and Human Schwannoma Cells.,,0.8,genetic_reagent,Click-It EdU kit (Life Technologies),Genetic Reagent,,,,,
PMID:32438526,10.1002/lary.28671,Effects of Neurod1 Expression on Mouse and Human Schwannoma Cells.,,0.85,genetic_reagent,Click-it EdU Alexa Fluor 633 Image Kit (ThermoFisher C10340),Genetic Reagent,,,,,
PMID:32438526,10.1002/lary.28671,Effects of Neurod1 Expression on Mouse and Human Schwannoma Cells.,,0.8,computational_tool,SP5 Leica confocal microscope,Computational Tool,,,,,
PMID:32438526,10.1002/lary.28671,Effects of Neurod1 Expression on Mouse and Human Schwannoma Cells.,,0.85,computational_tool,Amira software,Computational Tool,,,,,
PMID:32438526,10.1002/lary.28671,Effects of Neurod1 Expression on Mouse and Human Schwannoma Cells.,,0.85,computational_tool,MetaMorph software package,Computational Tool,,,,,
PMID:32438526,10.1002/lary.28671,Effects of Neurod1 Expression on Mouse and Human Schwannoma Cells.,,0.9,clinical_assessment_tool,Noldus Cat-Walk XT system,Clinical Assessment Tool,,,,,
PMID:32438526,10.1002/lary.28671,Effects of Neurod1 Expression on Mouse and Human Schwannoma Cells.,,0.9,cell_line,Primary human vestibular schwannoma (VS) cell cultures,Cell Line,,,,,
PMID:18367665,10.1124/jpet.107.135830,Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin.,,0.95,cell_line,NF90-8,Cell Line,,,,,
PMID:18367665,10.1124/jpet.107.135830,Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin.,,0.95,cell_line,ST88-14,Cell Line,,,,,
PMID:18367665,10.1124/jpet.107.135830,Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin.,,0.85,cell_line,Primary normal rat Schwann cells,Cell Line,,,,,
PMID:18367665,10.1124/jpet.107.135830,Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin.,,0.85,cell_line,iSC,Cell Line,,,,,
PMID:18367665,10.1124/jpet.107.135830,Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin.,,0.9,antibody,anti-pan Ras monoclonal antibody,Antibody,,,,,
PMID:18367665,10.1124/jpet.107.135830,Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin.,,0.9,antibody,anti-Caspase-3 polycolonal antibody,Antibody,,,,,
PMID:18367665,10.1124/jpet.107.135830,Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin.,,0.9,antibody,anti-Phospho-Rb Ser 780 polyclonal antibody,Antibody,,,,,
PMID:18367665,10.1124/jpet.107.135830,Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin.,,0.9,antibody,E7 monoclonal antibody,Antibody,,,,,
PMID:18367665,10.1124/jpet.107.135830,Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin.,,0.85,computational_tool,FACScalibur instrument,Computational Tool,,,,,
PMID:18367665,10.1124/jpet.107.135830,Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin.,,0.85,computational_tool,MODFIT,Computational Tool,,,,,
PMID:18367665,10.1124/jpet.107.135830,Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin.,,0.8,computational_tool,Axiovert 200M fluorescence microscope,Computational Tool,,,,,
PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,0.9,animal_model,1016 tuba1a:GFP,Animal Model,,,,,
PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,0.9,animal_model,gfap:GFP,Animal Model,,,,,
PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,0.9,animal_model,tp1:mCherry,Animal Model,,,,,
PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,0.9,animal_model,zop:nsfb-EGFP,Animal Model,,,,,
PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,0.9,animal_model,hsp70:ca-Alk5,Animal Model,,,,,
PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,0.9,animal_model,hsp70:tgfb1b,Animal Model,,,,,
PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,0.9,animal_model,hsp70:tgfb3,Animal Model,,,,,
PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,0.9,genetic_reagent,Tgfb3-MO,Genetic Reagent,,,,,
PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,0.9,genetic_reagent,Tgfb1b-MO,Genetic Reagent,,,,,
PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,0.9,genetic_reagent,pCS2+ tgfb3-EGFP,Genetic Reagent,,,,,
PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,0.9,genetic_reagent,pCS2-nCas9n-nanos3'UTR,Genetic Reagent,,,,,
PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,0.9,antibody,anti-pSmad3,Antibody,,,,,
PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,0.9,antibody,Zpr-1,Antibody,,,,,
PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,0.9,antibody,Zn-5,Antibody,,,,,
PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,0.9,antibody,anti-HuC/D,Antibody,,,,,
PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,0.9,antibody,anti-PKC β1,Antibody,,,,,
PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,0.9,antibody,anti-glutamine synthetase (GS),Antibody,,,,,
PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,0.9,antibody,anti-SOX9,Antibody,,,,,
PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,0.9,antibody,anti-BrdU (rat),Antibody,,,,,
PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,0.9,antibody,anti-BrdU (mouse),Antibody,,,,,
PMID:32396062,10.7554/eLife.55137,Tgfb3 collaborates with PP2A and notch signaling pathways to inhibit retina regeneration.,,0.9,computational_tool,CRISPRscan,Computational Tool,,,,,
PMID:24559228,10.1186/1866-1955-6-4,Abnormal late visual responses and alpha oscillations in neurofibromatosis type 1: a link to visual and attention deficits.,,0.85,computational_tool,"MATLAB (R2008a, MathWorks, Natick, MA, USA)",Computational Tool,,,,,
PMID:24559228,10.1186/1866-1955-6-4,Abnormal late visual responses and alpha oscillations in neurofibromatosis type 1: a link to visual and attention deficits.,,0.9,computational_tool,"STIM 2 (Neuroscan, Charlotte, NC, USA)",Computational Tool,,,,,
PMID:24559228,10.1186/1866-1955-6-4,Abnormal late visual responses and alpha oscillations in neurofibromatosis type 1: a link to visual and attention deficits.,,0.8,clinical_assessment_tool,64-channel Neuroscan system,Clinical Assessment Tool,,,,,
PMID:24559228,10.1186/1866-1955-6-4,Abnormal late visual responses and alpha oscillations in neurofibromatosis type 1: a link to visual and attention deficits.,,0.9,computational_tool,Scan 4.5 (Neuroscan),Computational Tool,,,,,
PMID:24559228,10.1186/1866-1955-6-4,Abnormal late visual responses and alpha oscillations in neurofibromatosis type 1: a link to visual and attention deficits.,,0.95,clinical_assessment_tool,Wechsler Intelligence Scale for Children (WISC-III),Clinical Assessment Tool,,,,,
PMID:24559228,10.1186/1866-1955-6-4,Abnormal late visual responses and alpha oscillations in neurofibromatosis type 1: a link to visual and attention deficits.,,0.85,computational_tool,"IBM SPSS Statistics, version 19",Computational Tool,,,,,
PMID:24559228,10.1186/1866-1955-6-4,Abnormal late visual responses and alpha oscillations in neurofibromatosis type 1: a link to visual and attention deficits.,,0.75,clinical_assessment_tool,Diamond Digital color monitor (Mitsubishi Electric Australia),Clinical Assessment Tool,,,,,
PMID:33356508,10.1177/0963689720964383,C6 Cell Injection into the Optic Nerve of Long-Evans Rats: A Short-Term Model of Optic Pathway Gliomas.,,0.9,cell_line,C6 cells,Cell Line,,,,,
PMID:33356508,10.1177/0963689720964383,C6 Cell Injection into the Optic Nerve of Long-Evans Rats: A Short-Term Model of Optic Pathway Gliomas.,,0.95,animal_model,Long-Evans rats,Animal Model,,,,,
PMID:33356508,10.1177/0963689720964383,C6 Cell Injection into the Optic Nerve of Long-Evans Rats: A Short-Term Model of Optic Pathway Gliomas.,,0.9,antibody,S100-FITC antibody,Antibody,,,,,
PMID:33356508,10.1177/0963689720964383,C6 Cell Injection into the Optic Nerve of Long-Evans Rats: A Short-Term Model of Optic Pathway Gliomas.,,0.9,antibody,β-tubulin III-FITC antibody,Antibody,,,,,
PMID:33356508,10.1177/0963689720964383,C6 Cell Injection into the Optic Nerve of Long-Evans Rats: A Short-Term Model of Optic Pathway Gliomas.,,0.9,antibody,Ki67-FITC antibody,Antibody,,,,,
PMID:33356508,10.1177/0963689720964383,C6 Cell Injection into the Optic Nerve of Long-Evans Rats: A Short-Term Model of Optic Pathway Gliomas.,,0.9,antibody,Vimentin-APC antibody,Antibody,,,,,
PMID:33356508,10.1177/0963689720964383,C6 Cell Injection into the Optic Nerve of Long-Evans Rats: A Short-Term Model of Optic Pathway Gliomas.,,0.9,antibody,Foxp3-APC antibody,Antibody,,,,,
PMID:33356508,10.1177/0963689720964383,C6 Cell Injection into the Optic Nerve of Long-Evans Rats: A Short-Term Model of Optic Pathway Gliomas.,,0.9,antibody,CD45 antibody,Antibody,,,,,
PMID:33356508,10.1177/0963689720964383,C6 Cell Injection into the Optic Nerve of Long-Evans Rats: A Short-Term Model of Optic Pathway Gliomas.,,0.9,antibody,GFAP-APC antibody,Antibody,,,,,
PMID:33356508,10.1177/0963689720964383,C6 Cell Injection into the Optic Nerve of Long-Evans Rats: A Short-Term Model of Optic Pathway Gliomas.,,0.85,computational_tool,MACSQuant flow cytometer,Computational Tool,,,,,
PMID:33356508,10.1177/0963689720964383,C6 Cell Injection into the Optic Nerve of Long-Evans Rats: A Short-Term Model of Optic Pathway Gliomas.,,0.85,computational_tool,MACSQuantify software,Computational Tool,,,,,
PMID:33356508,10.1177/0963689720964383,C6 Cell Injection into the Optic Nerve of Long-Evans Rats: A Short-Term Model of Optic Pathway Gliomas.,,0.8,computational_tool,MATLAB software,Computational Tool,,,,,
PMID:33356508,10.1177/0963689720964383,C6 Cell Injection into the Optic Nerve of Long-Evans Rats: A Short-Term Model of Optic Pathway Gliomas.,,0.75,computational_tool,GraphPad software,Computational Tool,,,,,
PMID:40723243,10.3390/cancers17142359,The Combination of HSP90 Inhibitors and Selumetinib Reinforces the Inhibitory Effects on Plexiform Neurofibromas.,,0.85,computational_tool,WGCNA package v1.69,Computational Tool,,,,,
PMID:40723243,10.3390/cancers17142359,The Combination of HSP90 Inhibitors and Selumetinib Reinforces the Inhibitory Effects on Plexiform Neurofibromas.,,0.8,computational_tool,IDACombo package,Computational Tool,,,,,
PMID:40723243,10.3390/cancers17142359,The Combination of HSP90 Inhibitors and Selumetinib Reinforces the Inhibitory Effects on Plexiform Neurofibromas.,,0.9,cell_line,ipNF95.11bC,Cell Line,,,,,
PMID:40723243,10.3390/cancers17142359,The Combination of HSP90 Inhibitors and Selumetinib Reinforces the Inhibitory Effects on Plexiform Neurofibromas.,,0.9,cell_line,ipnNF95.11c,Cell Line,,,,,
PMID:40723243,10.3390/cancers17142359,The Combination of HSP90 Inhibitors and Selumetinib Reinforces the Inhibitory Effects on Plexiform Neurofibromas.,,0.9,cell_line,ipNF05.5 Single Clone,Cell Line,,,,,
PMID:40723243,10.3390/cancers17142359,The Combination of HSP90 Inhibitors and Selumetinib Reinforces the Inhibitory Effects on Plexiform Neurofibromas.,,0.9,cell_line,ipNF05.5 Mixed Clones,Cell Line,,,,,
PMID:40723243,10.3390/cancers17142359,The Combination of HSP90 Inhibitors and Selumetinib Reinforces the Inhibitory Effects on Plexiform Neurofibromas.,,0.85,animal_model,DhhCre;Nf1f/f;Luciferase,Animal Model,,,,,
PMID:40723243,10.3390/cancers17142359,The Combination of HSP90 Inhibitors and Selumetinib Reinforces the Inhibitory Effects on Plexiform Neurofibromas.,,0.8,genetic_reagent,CellTiter-Glo Luminescent Cell Viability Assay,Genetic Reagent,,,,,
PMID:40723243,10.3390/cancers17142359,The Combination of HSP90 Inhibitors and Selumetinib Reinforces the Inhibitory Effects on Plexiform Neurofibromas.,,0.85,computational_tool,SynergyFinder,Computational Tool,,,,,
PMID:34647023,10.1093/noajnl/vdab129,A genetic mouse model with postnatal ,,0.9,animal_model,NPcis (Stock #008191),Animal Model,,,,,
PMID:34647023,10.1093/noajnl/vdab129,A genetic mouse model with postnatal ,,0.9,animal_model,Nf1 (#017640),Animal Model,,,,,
PMID:34647023,10.1093/noajnl/vdab129,A genetic mouse model with postnatal ,,0.9,animal_model,fl Trp53 (#008462),Animal Model,,,,,
PMID:34647023,10.1093/noajnl/vdab129,A genetic mouse model with postnatal ,,0.9,animal_model,fl Plp-CreER (#005975),Animal Model,,,,,
PMID:34647023,10.1093/noajnl/vdab129,A genetic mouse model with postnatal ,,0.9,animal_model,T Nestin-Cre (#003771),Animal Model,,,,,
PMID:34647023,10.1093/noajnl/vdab129,A genetic mouse model with postnatal ,,0.8,genetic_reagent,Direct-zol RNA Miniprep Kit (Zymo),Genetic Reagent,,,,,
PMID:34647023,10.1093/noajnl/vdab129,A genetic mouse model with postnatal ,,0.8,genetic_reagent,TruSeq Stranded Total RNA Library Prep Kit (Illumina),Genetic Reagent,,,,,
PMID:34647023,10.1093/noajnl/vdab129,A genetic mouse model with postnatal ,,0.85,computational_tool,STAR aligner,Computational Tool,,,,,
PMID:34647023,10.1093/noajnl/vdab129,A genetic mouse model with postnatal ,,0.85,computational_tool,RSEM,Computational Tool,,,,,
PMID:34647023,10.1093/noajnl/vdab129,A genetic mouse model with postnatal ,,0.85,computational_tool,limma R package,Computational Tool,,,,,
PMID:34647023,10.1093/noajnl/vdab129,A genetic mouse model with postnatal ,,0.8,computational_tool,ComBat,Computational Tool,,,,,
PMID:34647023,10.1093/noajnl/vdab129,A genetic mouse model with postnatal ,,0.8,computational_tool,UMAP,Computational Tool,,,,,
PMID:35332608,10.1002/humu.24370,Re-evaluation of missense variant classifications in NF2.,,0.85,computational_tool,Leiden Open Variation Database (LOVD),Computational Tool,,,,,
PMID:35332608,10.1002/humu.24370,Re-evaluation of missense variant classifications in NF2.,,0.85,computational_tool,ClinVar NCBI,Computational Tool,,,,,
PMID:35332608,10.1002/humu.24370,Re-evaluation of missense variant classifications in NF2.,,0.85,computational_tool,Human Gene Mutation Database (HGMD),Computational Tool,,,,,
PMID:35332608,10.1002/humu.24370,Re-evaluation of missense variant classifications in NF2.,,0.85,computational_tool,Clinical Interpretation of Variants in Cancer (CIViC),Computational Tool,,,,,
PMID:35332608,10.1002/humu.24370,Re-evaluation of missense variant classifications in NF2.,,0.85,computational_tool,Mastermind Genomic Search Engine,Computational Tool,,,,,
PMID:35332608,10.1002/humu.24370,Re-evaluation of missense variant classifications in NF2.,,0.85,computational_tool,LitVar,Computational Tool,,,,,
PMID:35332608,10.1002/humu.24370,Re-evaluation of missense variant classifications in NF2.,,0.9,computational_tool,Alamut Visual version 2.15,Computational Tool,,,,,
PMID:35332608,10.1002/humu.24370,Re-evaluation of missense variant classifications in NF2.,,0.85,computational_tool,Align-GVGD,Computational Tool,,,,,
PMID:35332608,10.1002/humu.24370,Re-evaluation of missense variant classifications in NF2.,,0.85,computational_tool,SIFT,Computational Tool,,,,,
PMID:35332608,10.1002/humu.24370,Re-evaluation of missense variant classifications in NF2.,,0.85,computational_tool,PolyPhen-2,Computational Tool,,,,,
PMID:35332608,10.1002/humu.24370,Re-evaluation of missense variant classifications in NF2.,,0.85,computational_tool,MutationTaster2,Computational Tool,,,,,
PMID:35332608,10.1002/humu.24370,Re-evaluation of missense variant classifications in NF2.,,0.85,computational_tool,SpliceSiteFinder-like tool,Computational Tool,,,,,
PMID:35332608,10.1002/humu.24370,Re-evaluation of missense variant classifications in NF2.,,0.85,computational_tool,MaxEntScan,Computational Tool,,,,,
PMID:35332608,10.1002/humu.24370,Re-evaluation of missense variant classifications in NF2.,,0.9,computational_tool,gnomAD v2.1.1,Computational Tool,,,,,
PMID:35332608,10.1002/humu.24370,Re-evaluation of missense variant classifications in NF2.,,0.85,computational_tool,UCSC LiftOver tool,Computational Tool,,,,,
PMID:35332608,10.1002/humu.24370,Re-evaluation of missense variant classifications in NF2.,,0.85,computational_tool,alleleFrequencyApp,Computational Tool,,,,,
PMID:35332608,10.1002/humu.24370,Re-evaluation of missense variant classifications in NF2.,,0.85,computational_tool,DECIPHER database,Computational Tool,,,,,
PMID:35332608,10.1002/humu.24370,Re-evaluation of missense variant classifications in NF2.,,0.85,computational_tool,REVEL (Rare Exome Variant Ensemble Learner),Computational Tool,,,,,
PMID:35332608,10.1002/humu.24370,Re-evaluation of missense variant classifications in NF2.,,0.85,computational_tool,ClinPred,Computational Tool,,,,,
PMID:35332608,10.1002/humu.24370,Re-evaluation of missense variant classifications in NF2.,,0.85,computational_tool,COSMIC,Computational Tool,,,,,
PMID:35332608,10.1002/humu.24370,Re-evaluation of missense variant classifications in NF2.,,0.85,computational_tool,CanVar-UK cancer predisposition gene variant database,Computational Tool,,,,,
PMID:35332608,10.1002/humu.24370,Re-evaluation of missense variant classifications in NF2.,,0.9,clinical_assessment_tool,Manchester Criteria,Clinical Assessment Tool,,,,,
PMID:15240917,10.1155/S1110724304308107,Survival of Human Neurofibroma in Immunodeficient Mice and Initial Results of Therapy With Pirfenidone.,,0.9,animal_model,SCID mice,Animal Model,,,,,
PMID:15240917,10.1155/S1110724304308107,Survival of Human Neurofibroma in Immunodeficient Mice and Initial Results of Therapy With Pirfenidone.,,0.85,antibody,rabbit anti-S-100 antibodies,Antibody,,,,,
PMID:15240917,10.1155/S1110724304308107,Survival of Human Neurofibroma in Immunodeficient Mice and Initial Results of Therapy With Pirfenidone.,,0.8,antibody,biotinylated F(ab')2 swine anti-rabbit IgG,Antibody,,,,,
PMID:15240917,10.1155/S1110724304308107,Survival of Human Neurofibroma in Immunodeficient Mice and Initial Results of Therapy With Pirfenidone.,,0.8,antibody,horseradish peroxidase-conjugated streptavidin,Antibody,,,,,
PMID:15240917,10.1155/S1110724304308107,Survival of Human Neurofibroma in Immunodeficient Mice and Initial Results of Therapy With Pirfenidone.,,0.85,antibody,Fluorescein-conjugated IB4,Antibody,,,,,
PMID:15240917,10.1155/S1110724304308107,Survival of Human Neurofibroma in Immunodeficient Mice and Initial Results of Therapy With Pirfenidone.,,0.9,patient_derived_model,human neurofibroma xenografts,Patient-Derived Model,,,,,
PMID:21963652,10.1016/j.expneurol.2011.09.005,PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice.,,0.95,animal_model,Nf1+/− GFAP CKO mice,Animal Model,,,,,
PMID:21963652,10.1016/j.expneurol.2011.09.005,PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice.,,0.9,animal_model,Nf1 flox/flox mice,Animal Model,,,,,
PMID:21963652,10.1016/j.expneurol.2011.09.005,PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice.,,0.85,genetic_reagent,[3H]-SCH23390,Genetic Reagent,,,,,
PMID:21963652,10.1016/j.expneurol.2011.09.005,PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice.,,0.85,genetic_reagent,[3H]-raclopride,Genetic Reagent,,,,,
PMID:21963652,10.1016/j.expneurol.2011.09.005,PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice.,,0.85,genetic_reagent,[3H]-Win 35428,Genetic Reagent,,,,,
PMID:21963652,10.1016/j.expneurol.2011.09.005,PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice.,,0.85,genetic_reagent,[3H]-WC-10,Genetic Reagent,,,,,
PMID:21963652,10.1016/j.expneurol.2011.09.005,PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice.,,0.85,genetic_reagent,[3H]-DTBZ,Genetic Reagent,,,,,
PMID:21963652,10.1016/j.expneurol.2011.09.005,PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice.,,0.85,genetic_reagent,[11C]-raclopride,Genetic Reagent,,,,,
PMID:21963652,10.1016/j.expneurol.2011.09.005,PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice.,,0.9,computational_tool,Beta Imager 2000Z Digital Beta Imaging System,Computational Tool,,,,,
PMID:21963652,10.1016/j.expneurol.2011.09.005,PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice.,,0.85,computational_tool,Beta-Vision Plus program,Computational Tool,,,,,
PMID:21963652,10.1016/j.expneurol.2011.09.005,PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice.,,0.9,computational_tool,Siemens Focus F220,Computational Tool,,,,,
PMID:21963652,10.1016/j.expneurol.2011.09.005,PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice.,,0.85,computational_tool,ASIPro VM,Computational Tool,,,,,
PMID:21963652,10.1016/j.expneurol.2011.09.005,PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice.,,0.9,antibody,DARPP32 antibody,Antibody,,,,,
PMID:21963652,10.1016/j.expneurol.2011.09.005,PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice.,,0.9,antibody,p-MAPK antibody,Antibody,,,,,
PMID:21963652,10.1016/j.expneurol.2011.09.005,PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice.,,0.9,antibody,total MAPK antibody,Antibody,,,,,
PMID:21963652,10.1016/j.expneurol.2011.09.005,PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice.,,0.9,antibody,p-DARPP32 antibody,Antibody,,,,,
PMID:34155781,10.1002/ajmg.a.62392,L-carnitine supplementation for muscle weakness and fatigue in children with neurofibromatosis type 1: A Phase 2a clinical trial.,,0.85,clinical_assessment_tool,MC-780MA Tanita Tokyo body composition analyzer,Clinical Assessment Tool,,,,,
PMID:34155781,10.1002/ajmg.a.62392,L-carnitine supplementation for muscle weakness and fatigue in children with neurofibromatosis type 1: A Phase 2a clinical trial.,,0.8,clinical_assessment_tool,Citec hand-held dynamometer,Clinical Assessment Tool,,,,,
PMID:34155781,10.1002/ajmg.a.62392,L-carnitine supplementation for muscle weakness and fatigue in children with neurofibromatosis type 1: A Phase 2a clinical trial.,,0.9,clinical_assessment_tool,Handwriting Speed Test,Clinical Assessment Tool,,,,,
PMID:34155781,10.1002/ajmg.a.62392,L-carnitine supplementation for muscle weakness and fatigue in children with neurofibromatosis type 1: A Phase 2a clinical trial.,,0.95,clinical_assessment_tool,6-minute-walk test,Clinical Assessment Tool,,,,,
PMID:34155781,10.1002/ajmg.a.62392,L-carnitine supplementation for muscle weakness and fatigue in children with neurofibromatosis type 1: A Phase 2a clinical trial.,,0.95,clinical_assessment_tool,PedsQL Generic 4.0,Clinical Assessment Tool,,,,,
PMID:34155781,10.1002/ajmg.a.62392,L-carnitine supplementation for muscle weakness and fatigue in children with neurofibromatosis type 1: A Phase 2a clinical trial.,,0.95,clinical_assessment_tool,PedsQL Neuromuscular 3.0,Clinical Assessment Tool,,,,,
PMID:34155781,10.1002/ajmg.a.62392,L-carnitine supplementation for muscle weakness and fatigue in children with neurofibromatosis type 1: A Phase 2a clinical trial.,,0.95,clinical_assessment_tool,CBCL/6-18,Clinical Assessment Tool,,,,,
PMID:31462295,10.1186/s40478-019-0792-5,Telomere alterations in neurofibromatosis type 1-associated solid tumors.,,0.85,genetic_reagent,Cy3-labeled peptide nucleic acid (PNA) probe complementary to the mammalian telomere repeat sequence,Genetic Reagent,,,,,
PMID:31462295,10.1186/s40478-019-0792-5,Telomere alterations in neurofibromatosis type 1-associated solid tumors.,,0.85,genetic_reagent,Alexa Fluor-488–labeled PNA probe specific to human centromeric DNA repeats,Genetic Reagent,,,,,
PMID:31462295,10.1186/s40478-019-0792-5,Telomere alterations in neurofibromatosis type 1-associated solid tumors.,,0.9,antibody,"monoclonal anti-Cy3/Cy5 antibody (ab52060, Abcam, 1:2500)",Antibody,,,,,
PMID:31462295,10.1186/s40478-019-0792-5,Telomere alterations in neurofibromatosis type 1-associated solid tumors.,,0.95,antibody,"ATRX antibody (Rabbit polyclonal, 1:200 dilution, catalog# HPA001906 Sigma-Aldrich)",Antibody,,,,,
PMID:31462295,10.1186/s40478-019-0792-5,Telomere alterations in neurofibromatosis type 1-associated solid tumors.,,0.95,antibody,"DAXX (Rabbit polyclonal, 1:100 dilution, catalog# HPA008736, Atlas Antibodies)",Antibody,,,,,
PMID:31462295,10.1186/s40478-019-0792-5,Telomere alterations in neurofibromatosis type 1-associated solid tumors.,,0.95,antibody,"H3K27me3 mouse monoclonal antibody (Abcam, Cat# ab6002)",Antibody,,,,,
PMID:31462295,10.1186/s40478-019-0792-5,Telomere alterations in neurofibromatosis type 1-associated solid tumors.,,0.8,genetic_reagent,Agilent SureSelect-XT reagents,Genetic Reagent,,,,,
PMID:31462295,10.1186/s40478-019-0792-5,Telomere alterations in neurofibromatosis type 1-associated solid tumors.,,0.85,genetic_reagent,Agilent custom-designed bait set covering the full coding regions of 644 cancer associated genes,Genetic Reagent,,,,,
PMID:31462295,10.1186/s40478-019-0792-5,Telomere alterations in neurofibromatosis type 1-associated solid tumors.,,0.85,computational_tool,Illumina HiSeq 2500 platform,Computational Tool,,,,,
PMID:31462295,10.1186/s40478-019-0792-5,Telomere alterations in neurofibromatosis type 1-associated solid tumors.,,0.9,computational_tool,Illumina bcl2fastq v1.8.4 software,Computational Tool,,,,,
PMID:31462295,10.1186/s40478-019-0792-5,Telomere alterations in neurofibromatosis type 1-associated solid tumors.,,0.9,computational_tool,Burrows-Wheeler Aligner v0.7.10,Computational Tool,,,,,
PMID:31462295,10.1186/s40478-019-0792-5,Telomere alterations in neurofibromatosis type 1-associated solid tumors.,,0.9,computational_tool,Picard Tools v1.119,Computational Tool,,,,,
PMID:31462295,10.1186/s40478-019-0792-5,Telomere alterations in neurofibromatosis type 1-associated solid tumors.,,0.9,computational_tool,MDLVC v5.0,Computational Tool,,,,,
PMID:31462295,10.1186/s40478-019-0792-5,Telomere alterations in neurofibromatosis type 1-associated solid tumors.,,0.9,computational_tool,HaplotypeCaller (Genome Analysis Tool Kit 3.3),Computational Tool,,,,,
PMID:31462295,10.1186/s40478-019-0792-5,Telomere alterations in neurofibromatosis type 1-associated solid tumors.,,0.9,computational_tool,Integrated Genomics Viewer v2.3.4 (IGV),Computational Tool,,,,,
PMID:31462295,10.1186/s40478-019-0792-5,Telomere alterations in neurofibromatosis type 1-associated solid tumors.,,0.85,computational_tool,GraphPad Prism version 8.0,Computational Tool,,,,,
PMID:31462295,10.1186/s40478-019-0792-5,Telomere alterations in neurofibromatosis type 1-associated solid tumors.,,0.85,computational_tool,SAS version 9.4,Computational Tool,,,,,
PMID:31462295,10.1186/s40478-019-0792-5,Telomere alterations in neurofibromatosis type 1-associated solid tumors.,,0.85,computational_tool,R version 3.3.2,Computational Tool,,,,,
PMID:35087195,10.1038/s41380-021-01422-5,Altered canonical and striatal-frontal resting state functional connectivity in children with pathogenic variants in the Ras/mitogen-activated protein kinase pathway.,,0.85,clinical_assessment_tool,Wechsler Intelligence Scale,Clinical Assessment Tool,,,,,
PMID:35087195,10.1038/s41380-021-01422-5,Altered canonical and striatal-frontal resting state functional connectivity in children with pathogenic variants in the Ras/mitogen-activated protein kinase pathway.,,0.9,clinical_assessment_tool,A Developmental NEuroPSYchological Assessment (NEPSY-II),Clinical Assessment Tool,,,,,
PMID:35087195,10.1038/s41380-021-01422-5,Altered canonical and striatal-frontal resting state functional connectivity in children with pathogenic variants in the Ras/mitogen-activated protein kinase pathway.,,0.85,computational_tool,FMRIPrep,Computational Tool,,,,,
PMID:35087195,10.1038/s41380-021-01422-5,Altered canonical and striatal-frontal resting state functional connectivity in children with pathogenic variants in the Ras/mitogen-activated protein kinase pathway.,,0.9,computational_tool,melodic v3.15,Computational Tool,,,,,
PMID:35087195,10.1038/s41380-021-01422-5,Altered canonical and striatal-frontal resting state functional connectivity in children with pathogenic variants in the Ras/mitogen-activated protein kinase pathway.,,0.85,computational_tool,FSLCC,Computational Tool,,,,,
PMID:35087195,10.1038/s41380-021-01422-5,Altered canonical and striatal-frontal resting state functional connectivity in children with pathogenic variants in the Ras/mitogen-activated protein kinase pathway.,,0.85,computational_tool,randomise,Computational Tool,,,,,
PMID:35087195,10.1038/s41380-021-01422-5,Altered canonical and striatal-frontal resting state functional connectivity in children with pathogenic variants in the Ras/mitogen-activated protein kinase pathway.,,0.85,computational_tool,FSLeyes,Computational Tool,,,,,
PMID:35087195,10.1038/s41380-021-01422-5,Altered canonical and striatal-frontal resting state functional connectivity in children with pathogenic variants in the Ras/mitogen-activated protein kinase pathway.,,0.9,computational_tool,fMRI Expert Analysis Tool (FEAT),Computational Tool,,,,,
PMID:35087195,10.1038/s41380-021-01422-5,Altered canonical and striatal-frontal resting state functional connectivity in children with pathogenic variants in the Ras/mitogen-activated protein kinase pathway.,,0.8,computational_tool,prcomp,Computational Tool,,,,,
PMID:35087195,10.1038/s41380-021-01422-5,Altered canonical and striatal-frontal resting state functional connectivity in children with pathogenic variants in the Ras/mitogen-activated protein kinase pathway.,,0.9,computational_tool,Multiple Imputation by Chained Equations (MICE),Computational Tool,,,,,
PMID:35087195,10.1038/s41380-021-01422-5,Altered canonical and striatal-frontal resting state functional connectivity in children with pathogenic variants in the Ras/mitogen-activated protein kinase pathway.,,0.85,clinical_assessment_tool,Tanner staging,Clinical Assessment Tool,,,,,
PMID:24932921,10.1002/jbmr.2298,Neurofibromin deficiency-associated transcriptional dysregulation suggests a novel therapy for tibial pseudoarthrosis in NF1.,,0.85,genetic_reagent,SeqCap EZ Human Exome Library,Genetic Reagent,,,,,
PMID:24932921,10.1002/jbmr.2298,Neurofibromin deficiency-associated transcriptional dysregulation suggests a novel therapy for tibial pseudoarthrosis in NF1.,,0.85,genetic_reagent,TruSeq Exome kit,Genetic Reagent,,,,,
PMID:24932921,10.1002/jbmr.2298,Neurofibromin deficiency-associated transcriptional dysregulation suggests a novel therapy for tibial pseudoarthrosis in NF1.,,0.8,computational_tool,Burrow-Wheeler aligner,Computational Tool,,,,,
PMID:24932921,10.1002/jbmr.2298,Neurofibromin deficiency-associated transcriptional dysregulation suggests a novel therapy for tibial pseudoarthrosis in NF1.,,0.8,computational_tool,Genome Analysis Toolkit,Computational Tool,,,,,
PMID:24932921,10.1002/jbmr.2298,Neurofibromin deficiency-associated transcriptional dysregulation suggests a novel therapy for tibial pseudoarthrosis in NF1.,,0.8,computational_tool,Samtools,Computational Tool,,,,,
PMID:24932921,10.1002/jbmr.2298,Neurofibromin deficiency-associated transcriptional dysregulation suggests a novel therapy for tibial pseudoarthrosis in NF1.,,0.8,computational_tool,Picard,Computational Tool,,,,,
PMID:24932921,10.1002/jbmr.2298,Neurofibromin deficiency-associated transcriptional dysregulation suggests a novel therapy for tibial pseudoarthrosis in NF1.,,0.9,genetic_reagent,pcDNA3.1 vector,Genetic Reagent,,,,,
PMID:24932921,10.1002/jbmr.2298,Neurofibromin deficiency-associated transcriptional dysregulation suggests a novel therapy for tibial pseudoarthrosis in NF1.,,0.8,computational_tool,TopHat,Computational Tool,,,,,
PMID:24932921,10.1002/jbmr.2298,Neurofibromin deficiency-associated transcriptional dysregulation suggests a novel therapy for tibial pseudoarthrosis in NF1.,,0.8,computational_tool,BEDtools software,Computational Tool,,,,,
PMID:24932921,10.1002/jbmr.2298,Neurofibromin deficiency-associated transcriptional dysregulation suggests a novel therapy for tibial pseudoarthrosis in NF1.,,0.85,computational_tool,EdgeR software,Computational Tool,,,,,
PMID:24932921,10.1002/jbmr.2298,Neurofibromin deficiency-associated transcriptional dysregulation suggests a novel therapy for tibial pseudoarthrosis in NF1.,,0.85,computational_tool,Partek Genomics Suite software,Computational Tool,,,,,
PMID:24932921,10.1002/jbmr.2298,Neurofibromin deficiency-associated transcriptional dysregulation suggests a novel therapy for tibial pseudoarthrosis in NF1.,,0.75,genetic_reagent,Minimum Essential Medium (MEM) Alpha,Genetic Reagent,,,,,
PMID:24932921,10.1002/jbmr.2298,Neurofibromin deficiency-associated transcriptional dysregulation suggests a novel therapy for tibial pseudoarthrosis in NF1.,,0.95,antibody,Alexa Fluor 647-conjugated anti-phospho-ERK1/2 primary antibody,Antibody,,,,,
PMID:24932921,10.1002/jbmr.2298,Neurofibromin deficiency-associated transcriptional dysregulation suggests a novel therapy for tibial pseudoarthrosis in NF1.,,0.85,computational_tool,INFLUX cell sorter,Computational Tool,,,,,
PMID:40304934,10.1186/s41687-025-00877-2,Development of patient reported outcome measures assessing tumor pain intensity and tumor pain interference for individuals with neurofibromatosis type 1 and plexiform neurofibromas: qualitative findings.,,0.85,computational_tool,NVivo software,Computational Tool,,,,,
PMID:40304934,10.1186/s41687-025-00877-2,Development of patient reported outcome measures assessing tumor pain intensity and tumor pain interference for individuals with neurofibromatosis type 1 and plexiform neurofibromas: qualitative findings.,,0.9,clinical_assessment_tool,Numeric Rating Scale-11,Clinical Assessment Tool,,,,,
PMID:40304934,10.1186/s41687-025-00877-2,Development of patient reported outcome measures assessing tumor pain intensity and tumor pain interference for individuals with neurofibromatosis type 1 and plexiform neurofibromas: qualitative findings.,,0.9,clinical_assessment_tool,Pain Interference Index,Clinical Assessment Tool,,,,,
PMID:40304934,10.1186/s41687-025-00877-2,Development of patient reported outcome measures assessing tumor pain intensity and tumor pain interference for individuals with neurofibromatosis type 1 and plexiform neurofibromas: qualitative findings.,,0.85,clinical_assessment_tool,NRS-11,Clinical Assessment Tool,,,,,
PMID:40304934,10.1186/s41687-025-00877-2,Development of patient reported outcome measures assessing tumor pain intensity and tumor pain interference for individuals with neurofibromatosis type 1 and plexiform neurofibromas: qualitative findings.,,0.85,clinical_assessment_tool,PII,Clinical Assessment Tool,,,,,
PMID:40304934,10.1186/s41687-025-00877-2,Development of patient reported outcome measures assessing tumor pain intensity and tumor pain interference for individuals with neurofibromatosis type 1 and plexiform neurofibromas: qualitative findings.,,0.95,clinical_assessment_tool,PAin INtensity Scale for plexiform neurofibromas (PAINS-pNF),Clinical Assessment Tool,,,,,
PMID:40304934,10.1186/s41687-025-00877-2,Development of patient reported outcome measures assessing tumor pain intensity and tumor pain interference for individuals with neurofibromatosis type 1 and plexiform neurofibromas: qualitative findings.,,0.95,clinical_assessment_tool,Pain Interference Index for plexiform neurofibromas (PII-pNF),Clinical Assessment Tool,,,,,
PMID:22961690,10.1002/pbc.24281,Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas.,,0.95,clinical_assessment_tool,PedsQL 4.0 Generic Core Scales,Clinical Assessment Tool,,,,,
PMID:22961690,10.1002/pbc.24281,Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas.,,0.85,clinical_assessment_tool,Quantikine™ human VEGF immunoassay kit,Clinical Assessment Tool,,,,,
PMID:22961690,10.1002/pbc.24281,Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas.,,0.85,clinical_assessment_tool,Quantikine™ human sVEGFR2 immunoassay kit,Clinical Assessment Tool,,,,,
PMID:22961690,10.1002/pbc.24281,Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas.,,0.8,computational_tool,CADvue software,Computational Tool,,,,,
PMID:22961690,10.1002/pbc.24281,Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas.,,0.75,clinical_assessment_tool,HPLC/MS/MS method,Clinical Assessment Tool,,,,,
PMID:39415595,10.1242/dmm.050862,Generation of a zebrafish neurofibromatosis model via inducible knockout of nf2a/b.,,0.9,animal_model,Tg(HOTCre:Cas9),Animal Model,,,,,
PMID:39415595,10.1242/dmm.050862,Generation of a zebrafish neurofibromatosis model via inducible knockout of nf2a/b.,,0.9,animal_model,Tg(-7.2kb-sox10:mRFP),Animal Model,,,,,
PMID:39415595,10.1242/dmm.050862,Generation of a zebrafish neurofibromatosis model via inducible knockout of nf2a/b.,,0.95,animal_model,Tg(U6x:nf2a/b-4sgRNA),Animal Model,,,,,
PMID:39415595,10.1242/dmm.050862,Generation of a zebrafish neurofibromatosis model via inducible knockout of nf2a/b.,,0.85,animal_model,ABWT,Animal Model,,,,,
PMID:39415595,10.1242/dmm.050862,Generation of a zebrafish neurofibromatosis model via inducible knockout of nf2a/b.,,0.8,antibody,anti-pH3 antibody,Antibody,,,,,
PMID:39415595,10.1242/dmm.050862,Generation of a zebrafish neurofibromatosis model via inducible knockout of nf2a/b.,,0.85,antibody,A21202,Antibody,,,,,
PMID:39415595,10.1242/dmm.050862,Generation of a zebrafish neurofibromatosis model via inducible knockout of nf2a/b.,,0.9,antibody,anti-merlin antibody,Antibody,,,,,
PMID:39415595,10.1242/dmm.050862,Generation of a zebrafish neurofibromatosis model via inducible knockout of nf2a/b.,,0.85,antibody,Anti-Sox10 antibody,Antibody,,,,,
PMID:39415595,10.1242/dmm.050862,Generation of a zebrafish neurofibromatosis model via inducible knockout of nf2a/b.,,0.8,genetic_reagent,pU6(x):sgRNA#(x) vectors,Genetic Reagent,,,,,
PMID:39415595,10.1242/dmm.050862,Generation of a zebrafish neurofibromatosis model via inducible knockout of nf2a/b.,,0.85,genetic_reagent,pGGDestTol2LC-4sgRNA,Genetic Reagent,,,,,
PMID:39415595,10.1242/dmm.050862,Generation of a zebrafish neurofibromatosis model via inducible knockout of nf2a/b.,,0.9,computational_tool,CHOP-CHOP,Computational Tool,,,,,
PMID:39415595,10.1242/dmm.050862,Generation of a zebrafish neurofibromatosis model via inducible knockout of nf2a/b.,,0.9,computational_tool,CRISPResso2,Computational Tool,,,,,
PMID:39415595,10.1242/dmm.050862,Generation of a zebrafish neurofibromatosis model via inducible knockout of nf2a/b.,,0.85,computational_tool,ImageJ,Computational Tool,,,,,
PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,0.9,animal_model,NOD-Rag1 null IL2rg (NRG) mice,Animal Model,,,,,
PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,0.95,cell_line,ST88-14,Cell Line,,,,,
PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,0.9,antibody,"anti-human HLA-A,B,C (311405)",Antibody,,,,,
PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,0.9,antibody,anti-mouse H-2 (125505),Antibody,,,,,
PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,0.9,antibody,"human nuclei (ab254080, Abcam)",Antibody,,,,,
PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,0.9,antibody,"Ki-67 (RM9106S1, Fisher Scientific)",Antibody,,,,,
PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,0.9,antibody,"S-100 b (sc-393919, Santa Cruz Biotechnology)",Antibody,,,,,
PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,0.9,antibody,"H3K27me3 (9733, Cell Signaling Technologies)",Antibody,,,,,
PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,0.9,antibody,"pERK (4370, Cell Signaling Technologies)",Antibody,,,,,
PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,0.85,computational_tool,Zeiss Axio Observer,Computational Tool,,,,,
PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,0.9,computational_tool,Cellpose,Computational Tool,,,,,
PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,0.85,computational_tool,ImageJ,Computational Tool,,,,,
PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,0.9,computational_tool,Trimmomatic v 0.39,Computational Tool,,,,,
PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,0.85,computational_tool,BWA-MEM,Computational Tool,,,,,
PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,0.9,computational_tool,GATK V4.2,Computational Tool,,,,,
PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,0.9,computational_tool,Xenosplit,Computational Tool,,,,,
PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,0.85,computational_tool,VarScan2,Computational Tool,,,,,
PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,0.85,computational_tool,Strelka2,Computational Tool,,,,,
PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,0.85,computational_tool,MuTect2,Computational Tool,,,,,
PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,0.85,computational_tool,Pindel,Computational Tool,,,,,
PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,0.9,computational_tool,Variant Effect Predictor (VEP),Computational Tool,,,,,
PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,0.9,computational_tool,maftools v2.10.0,Computational Tool,,,,,
PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,0.9,computational_tool,CNVkit V2.0,Computational Tool,,,,,
PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,0.85,computational_tool,Salmon algorithm,Computational Tool,,,,,
PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,0.9,computational_tool,DESeq2 package,Computational Tool,,,,,
PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,0.95,advanced_cellular_model,3D microtissues,Advanced Cellular Model,,,,,
PMID:37246765,10.1093/neuonc/noad097,Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.,,0.95,patient_derived_model,NF1-associated MPNST-PDX,Patient-Derived Model,,,,,
PMID:41591566,10.1007/s00401-026-02979-7,FAP expression as a marker of malignant transformation enabling in vivo characterization in peripheral nerve sheath tumors: a multimodal and translational study.,,0.9,antibody,ab207178,Antibody,,,,,
PMID:41591566,10.1007/s00401-026-02979-7,FAP expression as a marker of malignant transformation enabling in vivo characterization in peripheral nerve sheath tumors: a multimodal and translational study.,,0.8,computational_tool,Ventana BenchMark ULTRA,Computational Tool,,,,,
PMID:41591566,10.1007/s00401-026-02979-7,FAP expression as a marker of malignant transformation enabling in vivo characterization in peripheral nerve sheath tumors: a multimodal and translational study.,,0.8,computational_tool,iVIEW DAB detection system,Computational Tool,,,,,
PMID:41591566,10.1007/s00401-026-02979-7,FAP expression as a marker of malignant transformation enabling in vivo characterization in peripheral nerve sheath tumors: a multimodal and translational study.,,0.85,computational_tool,TruSight RNA Pan-Cancer Panel,Computational Tool,,,,,
PMID:41591566,10.1007/s00401-026-02979-7,FAP expression as a marker of malignant transformation enabling in vivo characterization in peripheral nerve sheath tumors: a multimodal and translational study.,,0.85,computational_tool,Illumina EPIC DNA methylation profiling,Computational Tool,,,,,
PMID:41591566,10.1007/s00401-026-02979-7,FAP expression as a marker of malignant transformation enabling in vivo characterization in peripheral nerve sheath tumors: a multimodal and translational study.,,0.85,computational_tool,Heidelberg sarcoma classifier,Computational Tool,,,,,
PMID:41591566,10.1007/s00401-026-02979-7,FAP expression as a marker of malignant transformation enabling in vivo characterization in peripheral nerve sheath tumors: a multimodal and translational study.,,0.9,computational_tool,GEOquery,Computational Tool,,,,,
PMID:41591566,10.1007/s00401-026-02979-7,FAP expression as a marker of malignant transformation enabling in vivo characterization in peripheral nerve sheath tumors: a multimodal and translational study.,,0.9,computational_tool,Biobase,Computational Tool,,,,,
PMID:41591566,10.1007/s00401-026-02979-7,FAP expression as a marker of malignant transformation enabling in vivo characterization in peripheral nerve sheath tumors: a multimodal and translational study.,,0.95,computational_tool,Seurat,Computational Tool,,,,,
PMID:41591566,10.1007/s00401-026-02979-7,FAP expression as a marker of malignant transformation enabling in vivo characterization in peripheral nerve sheath tumors: a multimodal and translational study.,,0.9,computational_tool,Slingshot,Computational Tool,,,,,
PMID:41591566,10.1007/s00401-026-02979-7,FAP expression as a marker of malignant transformation enabling in vivo characterization in peripheral nerve sheath tumors: a multimodal and translational study.,,0.85,computational_tool,Read10X,Computational Tool,,,,,
PMID:41591566,10.1007/s00401-026-02979-7,FAP expression as a marker of malignant transformation enabling in vivo characterization in peripheral nerve sheath tumors: a multimodal and translational study.,,0.8,computational_tool,Biograph mCT 40,Computational Tool,,,,,
PMID:41591566,10.1007/s00401-026-02979-7,FAP expression as a marker of malignant transformation enabling in vivo characterization in peripheral nerve sheath tumors: a multimodal and translational study.,,0.85,genetic_reagent,[68Ga]Ga-LNTH-1363S,Genetic Reagent,,,,,
PMID:41591566,10.1007/s00401-026-02979-7,FAP expression as a marker of malignant transformation enabling in vivo characterization in peripheral nerve sheath tumors: a multimodal and translational study.,,0.9,clinical_assessment_tool,H-score,Clinical Assessment Tool,,,,,
PMID:32642740,10.1093/noajnl/vdaa003,Quality of life in patients with neurofibromatosis type 1 and 2 in Canada.,,0.95,clinical_assessment_tool,SF-36,Clinical Assessment Tool,,,,,
PMID:32642740,10.1093/noajnl/vdaa003,Quality of life in patients with neurofibromatosis type 1 and 2 in Canada.,,0.95,clinical_assessment_tool,EQ-5D-5L,Clinical Assessment Tool,,,,,
PMID:32642740,10.1093/noajnl/vdaa003,Quality of life in patients with neurofibromatosis type 1 and 2 in Canada.,,0.95,clinical_assessment_tool,PROMIS pain interference short form 8a,Clinical Assessment Tool,,,,,
PMID:32642740,10.1093/noajnl/vdaa003,Quality of life in patients with neurofibromatosis type 1 and 2 in Canada.,,0.95,clinical_assessment_tool,PedsQL NF1 adult module,Clinical Assessment Tool,,,,,
PMID:32642740,10.1093/noajnl/vdaa003,Quality of life in patients with neurofibromatosis type 1 and 2 in Canada.,,0.95,clinical_assessment_tool,NFTI-QOL,Clinical Assessment Tool,,,,,
PMID:32642740,10.1093/noajnl/vdaa003,Quality of life in patients with neurofibromatosis type 1 and 2 in Canada.,,0.9,clinical_assessment_tool,Ablon visibility index,Clinical Assessment Tool,,,,,
PMID:32642740,10.1093/noajnl/vdaa003,Quality of life in patients with neurofibromatosis type 1 and 2 in Canada.,,0.9,clinical_assessment_tool,House and Brackmann facial nerve scale,Clinical Assessment Tool,,,,,
PMID:32642740,10.1093/noajnl/vdaa003,Quality of life in patients with neurofibromatosis type 1 and 2 in Canada.,,0.85,computational_tool,R statistical software version 3.5.1,Computational Tool,,,,,
PMID:37770931,10.1186/s40478-023-01639-1,"Integration of single-nuclei RNA-sequencing, spatial transcriptomics and histochemistry defines the complex microenvironment of NF1-associated plexiform neurofibromas.",,0.85,computational_tool,10x Genomics Chromium 3' gene expression,Computational Tool,,,,,
PMID:37770931,10.1186/s40478-023-01639-1,"Integration of single-nuclei RNA-sequencing, spatial transcriptomics and histochemistry defines the complex microenvironment of NF1-associated plexiform neurofibromas.",,0.9,computational_tool,CellRanger,Computational Tool,,,,,
PMID:37770931,10.1186/s40478-023-01639-1,"Integration of single-nuclei RNA-sequencing, spatial transcriptomics and histochemistry defines the complex microenvironment of NF1-associated plexiform neurofibromas.",,0.95,computational_tool,Seurat 3.1.0,Computational Tool,,,,,
PMID:37770931,10.1186/s40478-023-01639-1,"Integration of single-nuclei RNA-sequencing, spatial transcriptomics and histochemistry defines the complex microenvironment of NF1-associated plexiform neurofibromas.",,0.85,computational_tool,Harmony,Computational Tool,,,,,
PMID:37770931,10.1186/s40478-023-01639-1,"Integration of single-nuclei RNA-sequencing, spatial transcriptomics and histochemistry defines the complex microenvironment of NF1-associated plexiform neurofibromas.",,0.85,computational_tool,Presto,Computational Tool,,,,,
PMID:37770931,10.1186/s40478-023-01639-1,"Integration of single-nuclei RNA-sequencing, spatial transcriptomics and histochemistry defines the complex microenvironment of NF1-associated plexiform neurofibromas.",,0.9,computational_tool,CellChatDB,Computational Tool,,,,,
PMID:37770931,10.1186/s40478-023-01639-1,"Integration of single-nuclei RNA-sequencing, spatial transcriptomics and histochemistry defines the complex microenvironment of NF1-associated plexiform neurofibromas.",,0.9,computational_tool,Space Ranger,Computational Tool,,,,,
PMID:37770931,10.1186/s40478-023-01639-1,"Integration of single-nuclei RNA-sequencing, spatial transcriptomics and histochemistry defines the complex microenvironment of NF1-associated plexiform neurofibromas.",,0.95,computational_tool,Seurat v4.0.1,Computational Tool,,,,,
PMID:37770931,10.1186/s40478-023-01639-1,"Integration of single-nuclei RNA-sequencing, spatial transcriptomics and histochemistry defines the complex microenvironment of NF1-associated plexiform neurofibromas.",,0.85,computational_tool,Clustree,Computational Tool,,,,,
PMID:37770931,10.1186/s40478-023-01639-1,"Integration of single-nuclei RNA-sequencing, spatial transcriptomics and histochemistry defines the complex microenvironment of NF1-associated plexiform neurofibromas.",,0.9,computational_tool,DAVID,Computational Tool,,,,,
PMID:37770931,10.1186/s40478-023-01639-1,"Integration of single-nuclei RNA-sequencing, spatial transcriptomics and histochemistry defines the complex microenvironment of NF1-associated plexiform neurofibromas.",,0.85,computational_tool,Loupe Browser,Computational Tool,,,,,
PMID:37770931,10.1186/s40478-023-01639-1,"Integration of single-nuclei RNA-sequencing, spatial transcriptomics and histochemistry defines the complex microenvironment of NF1-associated plexiform neurofibromas.",,0.95,antibody,LAMA2 antibody,Antibody,,,,,
PMID:37770931,10.1186/s40478-023-01639-1,"Integration of single-nuclei RNA-sequencing, spatial transcriptomics and histochemistry defines the complex microenvironment of NF1-associated plexiform neurofibromas.",,0.95,antibody,SLC22A3 antibody,Antibody,,,,,
PMID:37770931,10.1186/s40478-023-01639-1,"Integration of single-nuclei RNA-sequencing, spatial transcriptomics and histochemistry defines the complex microenvironment of NF1-associated plexiform neurofibromas.",,0.95,antibody,PRRX1 antibody,Antibody,,,,,
PMID:37770931,10.1186/s40478-023-01639-1,"Integration of single-nuclei RNA-sequencing, spatial transcriptomics and histochemistry defines the complex microenvironment of NF1-associated plexiform neurofibromas.",,0.95,antibody,SOX10 antibody,Antibody,,,,,
PMID:37770931,10.1186/s40478-023-01639-1,"Integration of single-nuclei RNA-sequencing, spatial transcriptomics and histochemistry defines the complex microenvironment of NF1-associated plexiform neurofibromas.",,0.85,computational_tool,Visium spatial transcriptomics,Computational Tool,,,,,
PMID:33978635,10.1093/noajnl/vdab020,Selumetinib normalizes Ras/MAPK signaling in clinically relevant neurofibromatosis type 1 minipig tissues in vivo.,,0.95,animal_model,NF1 R1947X minipig model,Animal Model,,,,,
PMID:33978635,10.1093/noajnl/vdab020,Selumetinib normalizes Ras/MAPK signaling in clinically relevant neurofibromatosis type 1 minipig tissues in vivo.,,0.95,antibody,Phospho-p44/42 ERK1/2 antibody (Cell Signaling Technologies #4370S),Antibody,,,,,
PMID:33978635,10.1093/noajnl/vdab020,Selumetinib normalizes Ras/MAPK signaling in clinically relevant neurofibromatosis type 1 minipig tissues in vivo.,,0.95,antibody,p44/42 ERK1/2 antibody (Cell Signaling Technologies #4695S),Antibody,,,,,
PMID:33978635,10.1093/noajnl/vdab020,Selumetinib normalizes Ras/MAPK signaling in clinically relevant neurofibromatosis type 1 minipig tissues in vivo.,,0.95,antibody,phosphor-p44/p42 MAPK (ERK1/2) (Thr202/Tyr204) antibody (Cell Signaling Technology #4370),Antibody,,,,,
PMID:33978635,10.1093/noajnl/vdab020,Selumetinib normalizes Ras/MAPK signaling in clinically relevant neurofibromatosis type 1 minipig tissues in vivo.,,0.9,computational_tool,R Studio PKNCA package (version 0.9.3),Computational Tool,,,,,
PMID:33978635,10.1093/noajnl/vdab020,Selumetinib normalizes Ras/MAPK signaling in clinically relevant neurofibromatosis type 1 minipig tissues in vivo.,,0.85,computational_tool,Wes system (ProteinSimple 004–600),Computational Tool,,,,,
PMID:33978635,10.1093/noajnl/vdab020,Selumetinib normalizes Ras/MAPK signaling in clinically relevant neurofibromatosis type 1 minipig tissues in vivo.,,0.8,computational_tool,Fluidigm platform,Computational Tool,,,,,
PMID:33978635,10.1093/noajnl/vdab020,Selumetinib normalizes Ras/MAPK signaling in clinically relevant neurofibromatosis type 1 minipig tissues in vivo.,,0.9,genetic_reagent,DUSP6 TaqMan primer (Ss06941845_m1),Genetic Reagent,,,,,
PMID:33978635,10.1093/noajnl/vdab020,Selumetinib normalizes Ras/MAPK signaling in clinically relevant neurofibromatosis type 1 minipig tissues in vivo.,,0.9,genetic_reagent,FOS TaqMan primer (Ss03390402_m1),Genetic Reagent,,,,,
PMID:24375753,10.1002/ana.24093,Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.,,0.95,animal_model,"Nf1+/- GFAP CKO (Nf1flox/mut;GFAP-Cre, Nf1-CKO)",Animal Model,,,,,
PMID:24375753,10.1002/ana.24093,Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.,,0.9,animal_model,littermate control (Nf1flox/flox; CTL),Animal Model,,,,,
PMID:24375753,10.1002/ana.24093,Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.,,0.85,antibody,pDARPP32 antibody,Antibody,,,,,
PMID:24375753,10.1002/ana.24093,Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.,,0.85,antibody,DARPP32 antibody,Antibody,,,,,
PMID:24375753,10.1002/ana.24093,Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.,,0.85,antibody,pERK1/2 antibody,Antibody,,,,,
PMID:24375753,10.1002/ana.24093,Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.,,0.85,antibody,ERK1/2 antibody,Antibody,,,,,
PMID:24375753,10.1002/ana.24093,Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.,,0.8,clinical_assessment_tool,Ras activation assay (Millipore),Clinical Assessment Tool,,,,,
PMID:24375753,10.1002/ana.24093,Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.,,0.8,clinical_assessment_tool,cAMP assay (New East Biosciences),Clinical Assessment Tool,,,,,
PMID:24375753,10.1002/ana.24093,Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.,,0.8,clinical_assessment_tool,TUNEL assay (Roche Diagnostics),Clinical Assessment Tool,,,,,
PMID:24375753,10.1002/ana.24093,Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.,,0.8,clinical_assessment_tool,dopamine assay (Rocky Mountain Diagnostics),Clinical Assessment Tool,,,,,
PMID:24375753,10.1002/ana.24093,Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.,,0.9,clinical_assessment_tool,Morris Water Maze,Clinical Assessment Tool,,,,,
PMID:24375753,10.1002/ana.24093,Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.,,0.85,clinical_assessment_tool,virtual optokinetic system (VOS),Clinical Assessment Tool,,,,,
PMID:37681415,10.1172/jci.insight.168445,Structural and functional analyses of a germline KRAS T50I mutation provide insights into Raf activation.,,0.85,cell_line,MOLM-13,Cell Line,,,,,
PMID:37681415,10.1172/jci.insight.168445,Structural and functional analyses of a germline KRAS T50I mutation provide insights into Raf activation.,,0.9,genetic_reagent,pCW57.1,Genetic Reagent,,,,,
PMID:37681415,10.1172/jci.insight.168445,Structural and functional analyses of a germline KRAS T50I mutation provide insights into Raf activation.,,0.9,genetic_reagent,pDONR223 KRAS WT,Genetic Reagent,,,,,
PMID:37681415,10.1172/jci.insight.168445,Structural and functional analyses of a germline KRAS T50I mutation provide insights into Raf activation.,,0.9,genetic_reagent,pDONR223 KRAS G12D,Genetic Reagent,,,,,
PMID:37681415,10.1172/jci.insight.168445,Structural and functional analyses of a germline KRAS T50I mutation provide insights into Raf activation.,,0.85,cell_line,293T lenti-X cells,Cell Line,,,,,
PMID:37681415,10.1172/jci.insight.168445,Structural and functional analyses of a germline KRAS T50I mutation provide insights into Raf activation.,,0.9,antibody,"KRAS antibody (Sigma; WH0003845M1, clone 3B10-2F2)",Antibody,,,,,
PMID:37681415,10.1172/jci.insight.168445,Structural and functional analyses of a germline KRAS T50I mutation provide insights into Raf activation.,,0.9,antibody,"EGFP antibody (Thermo Fisher Scientific; 11575712, clone F56-6A1.2.3)",Antibody,,,,,
PMID:37681415,10.1172/jci.insight.168445,Structural and functional analyses of a germline KRAS T50I mutation provide insights into Raf activation.,,0.9,antibody,"p-ERK1/2 antibody (CST 4370, clone D13.14.4E)",Antibody,,,,,
PMID:37681415,10.1172/jci.insight.168445,Structural and functional analyses of a germline KRAS T50I mutation provide insights into Raf activation.,,0.9,antibody,"ERK1/2 antibody (CST 9107, clone 3A7)",Antibody,,,,,
PMID:37681415,10.1172/jci.insight.168445,Structural and functional analyses of a germline KRAS T50I mutation provide insights into Raf activation.,,0.85,genetic_reagent,Active RAS Pull-Down Kit,Genetic Reagent,,,,,
PMID:37681415,10.1172/jci.insight.168445,Structural and functional analyses of a germline KRAS T50I mutation provide insights into Raf activation.,,0.8,computational_tool,GraphPad Prism 8,Computational Tool,,,,,
PMID:37681415,10.1172/jci.insight.168445,Structural and functional analyses of a germline KRAS T50I mutation provide insights into Raf activation.,,0.85,computational_tool,MOSFLM,Computational Tool,,,,,
PMID:37681415,10.1172/jci.insight.168445,Structural and functional analyses of a germline KRAS T50I mutation provide insights into Raf activation.,,0.85,computational_tool,SCALA,Computational Tool,,,,,
PMID:37681415,10.1172/jci.insight.168445,Structural and functional analyses of a germline KRAS T50I mutation provide insights into Raf activation.,,0.85,computational_tool,CCP4 package,Computational Tool,,,,,
PMID:25043591,10.1002/jbmr.2316,Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -/- mice.,,0.9,animal_model,Nf1Osx-/- mice,Animal Model,,,,,
PMID:25043591,10.1002/jbmr.2316,Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -/- mice.,,0.85,animal_model,Osx-/- Nf1flox/flox mice,Animal Model,,,,,
PMID:25043591,10.1002/jbmr.2316,Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -/- mice.,,0.85,animal_model,"Osx-tTA,tetO-cre;Nf1flox/flox mice",Animal Model,,,,,
PMID:25043591,10.1002/jbmr.2316,Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -/- mice.,,0.8,cell_line,Nf1flox/flox bone marrow stromal cells,Cell Line,,,,,
PMID:25043591,10.1002/jbmr.2316,Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -/- mice.,,0.9,antibody,anti-Phospho-ERK1/2 antibody,Antibody,,,,,
PMID:25043591,10.1002/jbmr.2316,Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -/- mice.,,0.9,antibody,anti-ERK1/2 antibody,Antibody,,,,,
PMID:25043591,10.1002/jbmr.2316,Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -/- mice.,,0.85,genetic_reagent,Ad5-CMV-GFP,Genetic Reagent,,,,,
PMID:25043591,10.1002/jbmr.2316,Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -/- mice.,,0.85,genetic_reagent,Ad5-CMV-cre,Genetic Reagent,,,,,
PMID:25043591,10.1002/jbmr.2316,Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -/- mice.,,0.8,genetic_reagent,Trametinib,Genetic Reagent,,,,,
PMID:25043591,10.1002/jbmr.2316,Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -/- mice.,,0.8,computational_tool,GraphPad PRISM,Computational Tool,,,,,
PMID:25043591,10.1002/jbmr.2316,Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -/- mice.,,0.75,computational_tool,Matlab algorithms,Computational Tool,,,,,
PMID:34377779,10.1212/NXG.0000000000000616,Impact of MEK Inhibitor Therapy on Neurocognitive Functioning in NF1.,,0.9,clinical_assessment_tool,Cogstate,Clinical Assessment Tool,,,,,
PMID:34377779,10.1212/NXG.0000000000000616,Impact of MEK Inhibitor Therapy on Neurocognitive Functioning in NF1.,,0.9,clinical_assessment_tool,BRIEF,Clinical Assessment Tool,,,,,
PMID:34377779,10.1212/NXG.0000000000000616,Impact of MEK Inhibitor Therapy on Neurocognitive Functioning in NF1.,,0.85,clinical_assessment_tool,Behavior Rating Inventory of Executive Function,Clinical Assessment Tool,,,,,
PMID:34377779,10.1212/NXG.0000000000000616,Impact of MEK Inhibitor Therapy on Neurocognitive Functioning in NF1.,,0.8,computational_tool,Reliable Change Index,Computational Tool,,,,,
PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,0.9,animal_model,"p16/p19+/− Cdkn2a mice (01XB2, FVB/N.129-Cdkn2atm1Rdp)",Animal Model,,,,,
PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,0.85,animal_model,Nf2 mice,Animal Model,,,,,
PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,0.8,animal_model,SCID mice,Animal Model,,,,,
PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,0.9,antibody,c-met rabbit polyclonal antibody (Santa Cruz),Antibody,,,,,
PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,0.9,antibody,phosphorylated c-met rabbit polyclonal antibody (Invitrogen),Antibody,,,,,
PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,0.9,antibody,Ki67 rat monoclonal antibody (Dako),Antibody,,,,,
PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,0.85,antibody,pan-cytokeratin antibody (Sigma),Antibody,,,,,
PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,0.85,antibody,cytokeratin 8 antibody (Sigma),Antibody,,,,,
PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,0.85,antibody,mesothelin antibody (Santa Cruz),Antibody,,,,,
PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,0.8,antibody,Sox2 antibody,Antibody,,,,,
PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,0.8,antibody,Nanog antibody,Antibody,,,,,
PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,0.8,antibody,Oct 3/4 antibody,Antibody,,,,,
PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,0.8,antibody,beta-catenin antibody,Antibody,,,,,
PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,0.9,antibody,phospho P-Met antibody (Cell Signaling),Antibody,,,,,
PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,0.9,antibody,Akt antibody (Cell Signaling),Antibody,,,,,
PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,0.9,antibody,P-Akt antibody (Cell Signaling),Antibody,,,,,
PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,0.9,antibody,MAPK antibody (Cell Signaling),Antibody,,,,,
PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,0.9,antibody,c-Met antibody (Santa Cruz),Antibody,,,,,
PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,0.9,antibody,P-Erk antibody (Santa Cruz),Antibody,,,,,
PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,0.9,antibody,β-actin antibody (Santa Cruz),Antibody,,,,,
PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,0.9,antibody,"p53 antibody (NCL-p53-505, Novocastra)",Antibody,,,,,
PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,0.9,antibody,anti-CD24 FITC-labeled antibody (BD Biosciences),Antibody,,,,,
PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,0.85,genetic_reagent,SU-11274,Genetic Reagent,,,,,
PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,0.85,genetic_reagent,SGX2943 (Calbiochem),Genetic Reagent,,,,,
PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,0.9,genetic_reagent,siRNA against Tp53 (Dharmacon),Genetic Reagent,,,,,
PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,0.9,genetic_reagent,siRNA against miR34a (Dharmacon),Genetic Reagent,,,,,
PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,0.85,computational_tool,ABI Prism 7900 Sequence Detection System,Computational Tool,,,,,
PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,0.85,computational_tool,FlowJo analysis software,Computational Tool,,,,,
PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,0.8,advanced_cellular_model,BioCoat Matrigel invasion chambers (Becton Dickinson),Advanced Cellular Model,,,,,
PMID:34782607,10.1038/s41525-021-00258-w,Pathogenic neurofibromatosis type 1 (NF1) RNA splicing resolved by targeted RNAseq.,,0.8,genetic_reagent,ficoll (Sigma-Aldrich),Genetic Reagent,,,,,
PMID:34782607,10.1038/s41525-021-00258-w,Pathogenic neurofibromatosis type 1 (NF1) RNA splicing resolved by targeted RNAseq.,,0.75,genetic_reagent,RPMI 1640,Genetic Reagent,,,,,
PMID:34782607,10.1038/s41525-021-00258-w,Pathogenic neurofibromatosis type 1 (NF1) RNA splicing resolved by targeted RNAseq.,,0.8,genetic_reagent,PHA (Gibco),Genetic Reagent,,,,,
PMID:34782607,10.1038/s41525-021-00258-w,Pathogenic neurofibromatosis type 1 (NF1) RNA splicing resolved by targeted RNAseq.,,0.8,genetic_reagent,IL-2 (Roche),Genetic Reagent,,,,,
PMID:34782607,10.1038/s41525-021-00258-w,Pathogenic neurofibromatosis type 1 (NF1) RNA splicing resolved by targeted RNAseq.,,0.8,genetic_reagent,puromycin (Sigma-Aldrich),Genetic Reagent,,,,,
PMID:34782607,10.1038/s41525-021-00258-w,Pathogenic neurofibromatosis type 1 (NF1) RNA splicing resolved by targeted RNAseq.,,0.85,computational_tool,NuGEN SPET for RNA,Computational Tool,,,,,
PMID:34782607,10.1038/s41525-021-00258-w,Pathogenic neurofibromatosis type 1 (NF1) RNA splicing resolved by targeted RNAseq.,,0.85,computational_tool,Agilent SureSelect RNA Target Enrichment,Computational Tool,,,,,
PMID:34782607,10.1038/s41525-021-00258-w,Pathogenic neurofibromatosis type 1 (NF1) RNA splicing resolved by targeted RNAseq.,,0.8,genetic_reagent,RNeasy Plus micro columns (Qiagen),Genetic Reagent,,,,,
PMID:34782607,10.1038/s41525-021-00258-w,Pathogenic neurofibromatosis type 1 (NF1) RNA splicing resolved by targeted RNAseq.,,0.9,computational_tool,NextSeq500 instrument (Illumina),Computational Tool,,,,,
PMID:34782607,10.1038/s41525-021-00258-w,Pathogenic neurofibromatosis type 1 (NF1) RNA splicing resolved by targeted RNAseq.,,0.9,computational_tool,STAR mapper (Version 2.4.1d),Computational Tool,,,,,
PMID:34782607,10.1038/s41525-021-00258-w,Pathogenic neurofibromatosis type 1 (NF1) RNA splicing resolved by targeted RNAseq.,,0.85,computational_tool,Picard tools,Computational Tool,,,,,
PMID:34782607,10.1038/s41525-021-00258-w,Pathogenic neurofibromatosis type 1 (NF1) RNA splicing resolved by targeted RNAseq.,,0.95,computational_tool,QURNAs,Computational Tool,,,,,
PMID:34782607,10.1038/s41525-021-00258-w,Pathogenic neurofibromatosis type 1 (NF1) RNA splicing resolved by targeted RNAseq.,,0.9,computational_tool,Alamut v2.15 (Interactive Biosoftware),Computational Tool,,,,,
PMID:34782607,10.1038/s41525-021-00258-w,Pathogenic neurofibromatosis type 1 (NF1) RNA splicing resolved by targeted RNAseq.,,0.85,computational_tool,IGV,Computational Tool,,,,,
PMID:39669605,10.1016/j.gimo.2024.101816,Next-generation variant exon screening: Moving forward in routine genetic disease investigations.,,0.85,computational_tool,exome hidden Markov model (XHMM),Computational Tool,,,,,
PMID:39669605,10.1016/j.gimo.2024.101816,Next-generation variant exon screening: Moving forward in routine genetic disease investigations.,,0.8,genetic_reagent,IGT-T192V1 Plus panel,Genetic Reagent,,,,,
PMID:39669605,10.1016/j.gimo.2024.101816,Next-generation variant exon screening: Moving forward in routine genetic disease investigations.,,0.75,genetic_reagent,Qiagen DNA Blood Midi/Mini kit,Genetic Reagent,,,,,
PMID:39669605,10.1016/j.gimo.2024.101816,Next-generation variant exon screening: Moving forward in routine genetic disease investigations.,,0.75,genetic_reagent,Fast DNA Library Prep Set CW3045M,Genetic Reagent,,,,,
PMID:39669605,10.1016/j.gimo.2024.101816,Next-generation variant exon screening: Moving forward in routine genetic disease investigations.,,0.85,computational_tool,Burrows-Wheeler Aligner (bwa-0.7.15),Computational Tool,,,,,
PMID:39669605,10.1016/j.gimo.2024.101816,Next-generation variant exon screening: Moving forward in routine genetic disease investigations.,,0.85,computational_tool,Sambamba (v0.6.6),Computational Tool,,,,,
PMID:39669605,10.1016/j.gimo.2024.101816,Next-generation variant exon screening: Moving forward in routine genetic disease investigations.,,0.85,computational_tool,Genome Analysis Toolkit (GATK),Computational Tool,,,,,
PMID:39669605,10.1016/j.gimo.2024.101816,Next-generation variant exon screening: Moving forward in routine genetic disease investigations.,,0.8,computational_tool,CASAVA v1.82,Computational Tool,,,,,
PMID:30274822,10.1016/j.ebiom.2018.09.039,Exhaustive non-synonymous variants functionality prediction enables high resolution characterization of the neurofibromin architecture.,,0.85,computational_tool,Leiden Open Variation Database (LOVD),Computational Tool,,,,,
PMID:30274822,10.1016/j.ebiom.2018.09.039,Exhaustive non-synonymous variants functionality prediction enables high resolution characterization of the neurofibromin architecture.,,0.8,computational_tool,1000 Genomes Project,Computational Tool,,,,,
PMID:30274822,10.1016/j.ebiom.2018.09.039,Exhaustive non-synonymous variants functionality prediction enables high resolution characterization of the neurofibromin architecture.,,0.8,computational_tool,Exome Aggregation Consortium (ExAC),Computational Tool,,,,,
PMID:30274822,10.1016/j.ebiom.2018.09.039,Exhaustive non-synonymous variants functionality prediction enables high resolution characterization of the neurofibromin architecture.,,0.8,computational_tool,Genome Aggregation Database (gnomAD),Computational Tool,,,,,
PMID:30274822,10.1016/j.ebiom.2018.09.039,Exhaustive non-synonymous variants functionality prediction enables high resolution characterization of the neurofibromin architecture.,,0.9,computational_tool,SnpEff,Computational Tool,,,,,
PMID:30274822,10.1016/j.ebiom.2018.09.039,Exhaustive non-synonymous variants functionality prediction enables high resolution characterization of the neurofibromin architecture.,,0.85,computational_tool,dbNSFP,Computational Tool,,,,,
PMID:30274822,10.1016/j.ebiom.2018.09.039,Exhaustive non-synonymous variants functionality prediction enables high resolution characterization of the neurofibromin architecture.,,0.8,computational_tool,Interpro,Computational Tool,,,,,
PMID:30274822,10.1016/j.ebiom.2018.09.039,Exhaustive non-synonymous variants functionality prediction enables high resolution characterization of the neurofibromin architecture.,,0.8,computational_tool,Nextprot,Computational Tool,,,,,
PMID:30274822,10.1016/j.ebiom.2018.09.039,Exhaustive non-synonymous variants functionality prediction enables high resolution characterization of the neurofibromin architecture.,,0.85,computational_tool,H2O R package,Computational Tool,,,,,
PMID:30274822,10.1016/j.ebiom.2018.09.039,Exhaustive non-synonymous variants functionality prediction enables high resolution characterization of the neurofibromin architecture.,,0.8,computational_tool,shiny web application framework,Computational Tool,,,,,
PMID:30274822,10.1016/j.ebiom.2018.09.039,Exhaustive non-synonymous variants functionality prediction enables high resolution characterization of the neurofibromin architecture.,,0.75,computational_tool,shinyapps.io,Computational Tool,,,,,
PMID:32869517,10.1002/mgg3.1400,Genome-wide association study of café-au-lait macule number in neurofibromatosis type 1.,,0.85,computational_tool,Illumina Infinium HumanOmni-1Quad bead-chips,Computational Tool,,,,,
PMID:32869517,10.1002/mgg3.1400,Genome-wide association study of café-au-lait macule number in neurofibromatosis type 1.,,0.85,computational_tool,Illumina Infinium Omni2.5 bead-chips,Computational Tool,,,,,
PMID:32869517,10.1002/mgg3.1400,Genome-wide association study of café-au-lait macule number in neurofibromatosis type 1.,,0.9,computational_tool,PLINK,Computational Tool,,,,,
PMID:32869517,10.1002/mgg3.1400,Genome-wide association study of café-au-lait macule number in neurofibromatosis type 1.,,0.85,computational_tool,LitfOver,Computational Tool,,,,,
PMID:32869517,10.1002/mgg3.1400,Genome-wide association study of café-au-lait macule number in neurofibromatosis type 1.,,0.85,computational_tool,AmpliSeq/IonTorrent platform,Computational Tool,,,,,
PMID:32869517,10.1002/mgg3.1400,Genome-wide association study of café-au-lait macule number in neurofibromatosis type 1.,,0.95,computational_tool,SNP & Variation Suite v8.3.4,Computational Tool,,,,,
PMID:32869517,10.1002/mgg3.1400,Genome-wide association study of café-au-lait macule number in neurofibromatosis type 1.,,0.9,computational_tool,EMMAX,Computational Tool,,,,,
PMID:32869517,10.1002/mgg3.1400,Genome-wide association study of café-au-lait macule number in neurofibromatosis type 1.,,0.9,computational_tool,METAL,Computational Tool,,,,,
PMID:32869517,10.1002/mgg3.1400,Genome-wide association study of café-au-lait macule number in neurofibromatosis type 1.,,0.9,computational_tool,ComPaSS-GWAS,Computational Tool,,,,,
PMID:32869517,10.1002/mgg3.1400,Genome-wide association study of café-au-lait macule number in neurofibromatosis type 1.,,0.95,computational_tool,Haploview 4.2,Computational Tool,,,,,
PMID:32869517,10.1002/mgg3.1400,Genome-wide association study of café-au-lait macule number in neurofibromatosis type 1.,,0.85,computational_tool,UCSC Genome browser,Computational Tool,,,,,
PMID:32869517,10.1002/mgg3.1400,Genome-wide association study of café-au-lait macule number in neurofibromatosis type 1.,,0.85,computational_tool,HaploReg,Computational Tool,,,,,
PMID:32869517,10.1002/mgg3.1400,Genome-wide association study of café-au-lait macule number in neurofibromatosis type 1.,,0.85,computational_tool,RegulomeDB,Computational Tool,,,,,
PMID:32869517,10.1002/mgg3.1400,Genome-wide association study of café-au-lait macule number in neurofibromatosis type 1.,,0.85,computational_tool,GTEx,Computational Tool,,,,,
PMID:32869517,10.1002/mgg3.1400,Genome-wide association study of café-au-lait macule number in neurofibromatosis type 1.,,0.85,computational_tool,Metabolomics GWAS,Computational Tool,,,,,
PMID:32869517,10.1002/mgg3.1400,Genome-wide association study of café-au-lait macule number in neurofibromatosis type 1.,,0.8,clinical_assessment_tool,Wood's lamp,Clinical Assessment Tool,,,,,
PMID:19144871,10.3181/0809-RM-275,Identification of erythrocyte p55/MPP1 as a binding partner of NF2 tumor suppressor protein/Merlin.,,0.9,antibody,anti-p55 mouse monoclonal antibody (clone 2G4),Antibody,,,,,
PMID:19144871,10.3181/0809-RM-275,Identification of erythrocyte p55/MPP1 as a binding partner of NF2 tumor suppressor protein/Merlin.,,0.85,antibody,anti-merlin polyclonal antibody (A-19),Antibody,,,,,
PMID:19144871,10.3181/0809-RM-275,Identification of erythrocyte p55/MPP1 as a binding partner of NF2 tumor suppressor protein/Merlin.,,0.8,genetic_reagent,pMAL-c2X vector,Genetic Reagent,,,,,
PMID:19144871,10.3181/0809-RM-275,Identification of erythrocyte p55/MPP1 as a binding partner of NF2 tumor suppressor protein/Merlin.,,0.8,cell_line,DH5α bacteria,Cell Line,,,,,
PMID:19144871,10.3181/0809-RM-275,Identification of erythrocyte p55/MPP1 as a binding partner of NF2 tumor suppressor protein/Merlin.,,0.85,computational_tool,BIAcore 1000 system,Computational Tool,,,,,
PMID:19144871,10.3181/0809-RM-275,Identification of erythrocyte p55/MPP1 as a binding partner of NF2 tumor suppressor protein/Merlin.,,0.75,genetic_reagent,CM5 sensor chip,Genetic Reagent,,,,,
PMID:19144871,10.3181/0809-RM-275,Identification of erythrocyte p55/MPP1 as a binding partner of NF2 tumor suppressor protein/Merlin.,,0.8,antibody,mouse anti-S100 (SIGMA),Antibody,,,,,
PMID:19144871,10.3181/0809-RM-275,Identification of erythrocyte p55/MPP1 as a binding partner of NF2 tumor suppressor protein/Merlin.,,0.8,antibody,mouse anti-GFAP (Chemicon),Antibody,,,,,
PMID:19144871,10.3181/0809-RM-275,Identification of erythrocyte p55/MPP1 as a binding partner of NF2 tumor suppressor protein/Merlin.,,0.8,antibody,rabbit anti-GFAP (SIGMA),Antibody,,,,,
PMID:19144871,10.3181/0809-RM-275,Identification of erythrocyte p55/MPP1 as a binding partner of NF2 tumor suppressor protein/Merlin.,,0.8,antibody,rabbit anti-NF-H (Chemicon),Antibody,,,,,
PMID:19144871,10.3181/0809-RM-275,Identification of erythrocyte p55/MPP1 as a binding partner of NF2 tumor suppressor protein/Merlin.,,0.8,antibody,mouse anti-Caspr,Antibody,,,,,
PMID:19144871,10.3181/0809-RM-275,Identification of erythrocyte p55/MPP1 as a binding partner of NF2 tumor suppressor protein/Merlin.,,0.8,animal_model,BALB/c mice,Animal Model,,,,,
PMID:23071067,10.1158/0008-5472.CAN-12-1728,Genetically mediated Nf1 loss in mice promotes diverse radiation-induced tumors modeling second malignant neoplasms.,,0.95,animal_model,Nf1+/- mice,Animal Model,,,,,
PMID:23071067,10.1158/0008-5472.CAN-12-1728,Genetically mediated Nf1 loss in mice promotes diverse radiation-induced tumors modeling second malignant neoplasms.,,0.85,computational_tool,"cesium-137 source (J.L. Shepherd & Associates, San Fernando, CA) animal irradiator",Computational Tool,,,,,
PMID:23071067,10.1158/0008-5472.CAN-12-1728,Genetically mediated Nf1 loss in mice promotes diverse radiation-induced tumors modeling second malignant neoplasms.,,0.8,computational_tool,Olympus BX41 microscope,Computational Tool,,,,,
PMID:23071067,10.1158/0008-5472.CAN-12-1728,Genetically mediated Nf1 loss in mice promotes diverse radiation-induced tumors modeling second malignant neoplasms.,,0.8,computational_tool,Olympus DP72 camera,Computational Tool,,,,,
PMID:23071067,10.1158/0008-5472.CAN-12-1728,Genetically mediated Nf1 loss in mice promotes diverse radiation-induced tumors modeling second malignant neoplasms.,,0.85,computational_tool,Adobe Photoshop CS2,Computational Tool,,,,,
PMID:23071067,10.1158/0008-5472.CAN-12-1728,Genetically mediated Nf1 loss in mice promotes diverse radiation-induced tumors modeling second malignant neoplasms.,,0.85,computational_tool,Hemavet,Computational Tool,,,,,
PMID:23071067,10.1158/0008-5472.CAN-12-1728,Genetically mediated Nf1 loss in mice promotes diverse radiation-induced tumors modeling second malignant neoplasms.,,0.9,computational_tool,Peak Scanner software from Applied Biosystems,Computational Tool,,,,,
PMID:23071067,10.1158/0008-5472.CAN-12-1728,Genetically mediated Nf1 loss in mice promotes diverse radiation-induced tumors modeling second malignant neoplasms.,,0.85,genetic_reagent,REPLI-g FFPE kit (Qiagen),Genetic Reagent,,,,,
PMID:23071067,10.1158/0008-5472.CAN-12-1728,Genetically mediated Nf1 loss in mice promotes diverse radiation-induced tumors modeling second malignant neoplasms.,,0.85,computational_tool,"7900 HT Fast Real-Time PCR system (Applied Biosystems, USA)",Computational Tool,,,,,
PMID:23071067,10.1158/0008-5472.CAN-12-1728,Genetically mediated Nf1 loss in mice promotes diverse radiation-induced tumors modeling second malignant neoplasms.,,0.85,computational_tool,SDS3.0,Computational Tool,,,,,
PMID:23071067,10.1158/0008-5472.CAN-12-1728,Genetically mediated Nf1 loss in mice promotes diverse radiation-induced tumors modeling second malignant neoplasms.,,0.9,computational_tool,COSMIC Database,Computational Tool,,,,,
PMID:23071067,10.1158/0008-5472.CAN-12-1728,Genetically mediated Nf1 loss in mice promotes diverse radiation-induced tumors modeling second malignant neoplasms.,,0.85,computational_tool,Prizm v.4 (GraphPad),Computational Tool,,,,,
PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,0.9,antibody,CD3,Antibody,,,,,
PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,0.9,antibody,CD8,Antibody,,,,,
PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,0.9,antibody,CD11c,Antibody,,,,,
PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,0.9,antibody,CD19,Antibody,,,,,
PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,0.9,antibody,CD163,Antibody,,,,,
PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,0.9,antibody,CSF1R,Antibody,,,,,
PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,0.9,antibody,FOXP3,Antibody,,,,,
PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,0.9,antibody,PD-L1,Antibody,,,,,
PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,0.95,antibody,"H3K27me3 antibody (Cell Signaling Technology, #9733, clone C36B11)",Antibody,,,,,
PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,0.8,genetic_reagent,"Bond Polymer Refine Kit (DS9800, Leica Biosystems)",Genetic Reagent,,,,,
PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,0.8,genetic_reagent,"eBioscience FOXP3/Transcription Factor Fixation/Permeabilization kit (Thermo Fisher Scientific, #00552100)",Genetic Reagent,,,,,
PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,0.8,genetic_reagent,"KAPA RiboErase HMR (Roche, #07962274001)",Genetic Reagent,,,,,
PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,0.8,genetic_reagent,"TruSeq Stranded Total RNA Library Prep Gold kit (Illumina, #20020599)",Genetic Reagent,,,,,
PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,0.9,computational_tool,nf-core/rnaseq (v3.11.2),Computational Tool,,,,,
PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,0.9,computational_tool,salmon (v1.10.1),Computational Tool,,,,,
PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,0.9,computational_tool,sva R package (v3.42.0),Computational Tool,,,,,
PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,0.9,computational_tool,immunedeconv (v2.1.0),Computational Tool,,,,,
PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,0.85,computational_tool,quanTIseq algorithm,Computational Tool,,,,,
PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,0.9,computational_tool,ggplot2 (v3.4.4),Computational Tool,,,,,
PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,0.9,computational_tool,ggridges (v0.5.5),Computational Tool,,,,,
PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,0.9,computational_tool,HALO imaging analysis software,Computational Tool,,,,,
PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,0.85,computational_tool,BDdiva,Computational Tool,,,,,
PMID:39321200,10.1158/1078-0432.CCR-24-1454,Multidimensional Immunotyping of Human NF1-Associated Peripheral Nerve Sheath Tumors Uncovers Tumor-Associated Macrophages as Key Drivers of Immune Evasion in the Tumor Microenvironment.,,0.85,computational_tool,FCS Express Software,Computational Tool,,,,,
PMID:38621478,10.1016/j.bpsc.2024.04.003,Influences of RASopathies on Neuroanatomical Variation in Children.,,0.85,clinical_assessment_tool,Wechsler Intelligence Scales,Clinical Assessment Tool,,,,,
PMID:38621478,10.1016/j.bpsc.2024.04.003,Influences of RASopathies on Neuroanatomical Variation in Children.,,0.9,computational_tool,FreeSurfer,Computational Tool,,,,,
PMID:38621478,10.1016/j.bpsc.2024.04.003,Influences of RASopathies on Neuroanatomical Variation in Children.,,0.8,computational_tool,ComBat harmonization,Computational Tool,,,,,
PMID:38621478,10.1016/j.bpsc.2024.04.003,Influences of RASopathies on Neuroanatomical Variation in Children.,,0.85,computational_tool,mri_glmfit,Computational Tool,,,,,
PMID:38621478,10.1016/j.bpsc.2024.04.003,Influences of RASopathies on Neuroanatomical Variation in Children.,,0.85,computational_tool,mri_glmfit-sim,Computational Tool,,,,,
PMID:38621478,10.1016/j.bpsc.2024.04.003,Influences of RASopathies on Neuroanatomical Variation in Children.,,0.8,computational_tool,Desikan ROI parcellation,Computational Tool,,,,,
PMID:38621478,10.1016/j.bpsc.2024.04.003,Influences of RASopathies on Neuroanatomical Variation in Children.,,0.75,computational_tool,RStudio,Computational Tool,,,,,
PMID:28392281,10.1016/j.expneurol.2017.04.001,Human stem cell modeling in neurofibromatosis type 1 (NF1).,,0.8,genetic_reagent,gamma retroviruses,Genetic Reagent,,,,,
PMID:28392281,10.1016/j.expneurol.2017.04.001,Human stem cell modeling in neurofibromatosis type 1 (NF1).,,0.8,genetic_reagent,murine leukemia retroviruses,Genetic Reagent,,,,,
PMID:28392281,10.1016/j.expneurol.2017.04.001,Human stem cell modeling in neurofibromatosis type 1 (NF1).,,0.8,genetic_reagent,Lentiviral vectors,Genetic Reagent,,,,,
PMID:28392281,10.1016/j.expneurol.2017.04.001,Human stem cell modeling in neurofibromatosis type 1 (NF1).,,0.9,genetic_reagent,Cre/loxP,Genetic Reagent,,,,,
PMID:28392281,10.1016/j.expneurol.2017.04.001,Human stem cell modeling in neurofibromatosis type 1 (NF1).,,0.8,genetic_reagent,Adenoviral vectors,Genetic Reagent,,,,,
PMID:28392281,10.1016/j.expneurol.2017.04.001,Human stem cell modeling in neurofibromatosis type 1 (NF1).,,0.8,genetic_reagent,Sendai viral vectors,Genetic Reagent,,,,,
PMID:28392281,10.1016/j.expneurol.2017.04.001,Human stem cell modeling in neurofibromatosis type 1 (NF1).,,0.9,genetic_reagent,oriP/EBNA1 episomal vectors,Genetic Reagent,,,,,
PMID:28392281,10.1016/j.expneurol.2017.04.001,Human stem cell modeling in neurofibromatosis type 1 (NF1).,,0.9,cell_line,mouse embryonic fibroblasts (MEFs),Cell Line,,,,,
PMID:28392281,10.1016/j.expneurol.2017.04.001,Human stem cell modeling in neurofibromatosis type 1 (NF1).,,0.9,cell_line,tail-tip fibroblasts (TTFs),Cell Line,,,,,
PMID:28392281,10.1016/j.expneurol.2017.04.001,Human stem cell modeling in neurofibromatosis type 1 (NF1).,,0.95,advanced_cellular_model,NF1 patient-derived induced pluripotent stem cells (iPSCs),Advanced Cellular Model,,,,,
PMID:16835260,10.1093/hmg/ddl165,Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.,,0.9,animal_model,Nf1+/- mice,Animal Model,,,,,
PMID:16835260,10.1093/hmg/ddl165,Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.,,0.85,antibody,FITC-conjugated anti-ColIA monoclonal antibody,Antibody,,,,,
PMID:16835260,10.1093/hmg/ddl165,Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.,,0.85,antibody,PE-conjugated anti-ColIA antibody,Antibody,,,,,
PMID:16835260,10.1093/hmg/ddl165,Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.,,0.9,antibody,anti-Abl (K12; Santa Cruz Biotechnology Inc.),Antibody,,,,,
PMID:16835260,10.1093/hmg/ddl165,Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.,,0.85,antibody,anti-Flag (Sigma-Aldrich),Antibody,,,,,
PMID:16835260,10.1093/hmg/ddl165,Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.,,0.9,antibody,"c-abl antibody (Cat. no. 554148, BD Biosciences)",Antibody,,,,,
PMID:16835260,10.1093/hmg/ddl165,Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.,,0.9,antibody,"TGF-β neutralizing antibodies (Cat. no. AF-101-NA, R&D Systems)",Antibody,,,,,
PMID:16835260,10.1093/hmg/ddl165,Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.,,0.9,genetic_reagent,MSCV-NF1 GRD-pac,Genetic Reagent,,,,,
PMID:16835260,10.1093/hmg/ddl165,Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.,,0.9,genetic_reagent,MSCV-1276P NF1 GRD-pac,Genetic Reagent,,,,,
PMID:16835260,10.1093/hmg/ddl165,Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.,,0.85,genetic_reagent,MSCV-pac,Genetic Reagent,,,,,
PMID:16835260,10.1093/hmg/ddl165,Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.,,0.9,genetic_reagent,"c-abl siRNA oligonucleotides (Cat. no. sc-29844, Santa Cruz Biotechnology)",Genetic Reagent,,,,,
PMID:16835260,10.1093/hmg/ddl165,Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.,,0.85,genetic_reagent,"Scrambled oligonucleotides (Cat. no. sc-36869, Santa Cruz)",Genetic Reagent,,,,,
PMID:16835260,10.1093/hmg/ddl165,Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.,,0.8,genetic_reagent,p21 ras activation pulldown assay kit (Upstate Biotechnology),Genetic Reagent,,,,,
PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,0.85,animal_model,Sprague‒Dawley rats,Animal Model,,,,,
PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,0.9,genetic_reagent,LV-NF-1 sgRNA-CAS9 lentivirus,Genetic Reagent,,,,,
PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,0.9,genetic_reagent,LV-Rictor sgRNA-CAS9 lentivirus,Genetic Reagent,,,,,
PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,0.85,antibody,Anti-Nestin antibody,Antibody,,,,,
PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,0.85,antibody,Anti-SOX2 antibody,Antibody,,,,,
PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,0.85,antibody,Anti-MAP2 antibody,Antibody,,,,,
PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,0.85,antibody,Anti-β3-Tubulin antibody,Antibody,,,,,
PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,0.85,antibody,Anti-GFAP antibody,Antibody,,,,,
PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,0.85,antibody,Anti-NF-200 antibody,Antibody,,,,,
PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,0.85,antibody,Anti-NeuN antibody,Antibody,,,,,
PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,0.85,antibody,Anti-cleaved caspase-3 antibody,Antibody,,,,,
PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,0.9,antibody,Anti-neurofibromin antibody,Antibody,,,,,
PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,0.85,antibody,Anti-P-mTOR antibody,Antibody,,,,,
PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,0.85,antibody,Anti-Rictor antibody,Antibody,,,,,
PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,0.85,antibody,Anti-GAPDH antibody,Antibody,,,,,
PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,0.85,antibody,Anti-Bcl-2 antibody,Antibody,,,,,
PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,0.85,antibody,Anti-CNPase antibody,Antibody,,,,,
PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,0.85,antibody,Anti-myelin basic protein (MBP) antibody,Antibody,,,,,
PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,0.8,cell_line,Neural stem cells,Cell Line,,,,,
PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,0.9,clinical_assessment_tool,BBB open-field locomotor test,Clinical Assessment Tool,,,,,
PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,0.8,genetic_reagent,TUNEL kit,Genetic Reagent,,,,,
PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,0.85,computational_tool,GraphPad Prism 8,Computational Tool,,,,,
PMID:24817309,10.1371/journal.pone.0097320,Nf2/Merlin controls spinal cord neural progenitor function in a Rac1/ErbB2-dependent manner.,,0.9,animal_model,Nf2flox/flox mice,Animal Model,,,,,
PMID:24817309,10.1371/journal.pone.0097320,Nf2/Merlin controls spinal cord neural progenitor function in a Rac1/ErbB2-dependent manner.,,0.85,antibody,cleaved caspase-3 antibody,Antibody,,,,,
PMID:24817309,10.1371/journal.pone.0097320,Nf2/Merlin controls spinal cord neural progenitor function in a Rac1/ErbB2-dependent manner.,,0.8,genetic_reagent,NSC23766,Genetic Reagent,,,,,
PMID:24817309,10.1371/journal.pone.0097320,Nf2/Merlin controls spinal cord neural progenitor function in a Rac1/ErbB2-dependent manner.,,0.8,genetic_reagent,AG825,Genetic Reagent,,,,,
PMID:24817309,10.1371/journal.pone.0097320,Nf2/Merlin controls spinal cord neural progenitor function in a Rac1/ErbB2-dependent manner.,,0.85,genetic_reagent,MSCV,Genetic Reagent,,,,,
PMID:24817309,10.1371/journal.pone.0097320,Nf2/Merlin controls spinal cord neural progenitor function in a Rac1/ErbB2-dependent manner.,,0.85,genetic_reagent,Rac1 N17,Genetic Reagent,,,,,
PMID:24817309,10.1371/journal.pone.0097320,Nf2/Merlin controls spinal cord neural progenitor function in a Rac1/ErbB2-dependent manner.,,0.8,genetic_reagent,PLKO virus,Genetic Reagent,,,,,
PMID:24817309,10.1371/journal.pone.0097320,Nf2/Merlin controls spinal cord neural progenitor function in a Rac1/ErbB2-dependent manner.,,0.8,genetic_reagent,Rac1 activation Assay Kit,Genetic Reagent,,,,,
PMID:24817309,10.1371/journal.pone.0097320,Nf2/Merlin controls spinal cord neural progenitor function in a Rac1/ErbB2-dependent manner.,,0.85,antibody,pErbB2 antibody,Antibody,,,,,
PMID:24817309,10.1371/journal.pone.0097320,Nf2/Merlin controls spinal cord neural progenitor function in a Rac1/ErbB2-dependent manner.,,0.85,computational_tool,Metamorph analysis software,Computational Tool,,,,,
PMID:24817309,10.1371/journal.pone.0097320,Nf2/Merlin controls spinal cord neural progenitor function in a Rac1/ErbB2-dependent manner.,,0.8,computational_tool,GraphPad Prism 5.0,Computational Tool,,,,,
PMID:24817309,10.1371/journal.pone.0097320,Nf2/Merlin controls spinal cord neural progenitor function in a Rac1/ErbB2-dependent manner.,,0.9,cell_line,Nf2-deficient spinal cord neural progenitor cells,Cell Line,,,,,
PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,0.9,animal_model,hGFAP-cre transgenic mice,Animal Model,,,,,
PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,0.9,animal_model,Math1-cre transgenic mice,Animal Model,,,,,
PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,0.9,animal_model,L7-cre transgenic mice,Animal Model,,,,,
PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,0.9,animal_model,Nf1 flox/flox mice,Animal Model,,,,,
PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,0.9,animal_model,Nestin-creER transgenic mice,Animal Model,,,,,
PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,0.9,animal_model,R26 LacZR mice,Animal Model,,,,,
PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,0.85,genetic_reagent,PD0325901,Genetic Reagent,,,,,
PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,0.9,antibody,BLBP antibody,Antibody,,,,,
PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,0.9,antibody,Calbindin antibody,Antibody,,,,,
PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,0.9,antibody,GFAP antibody,Antibody,,,,,
PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,0.9,antibody,BrdU antibody,Antibody,,,,,
PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,0.9,antibody,NeuN antibody,Antibody,,,,,
PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,0.9,antibody,GABARα6 antibody,Antibody,,,,,
PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,0.9,antibody,Ki-67 antibody,Antibody,,,,,
PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,0.9,antibody,Tbr2 antibody,Antibody,,,,,
PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,0.9,antibody,Calretinin antibody,Antibody,,,,,
PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,0.9,antibody,MAP2 antibody,Antibody,,,,,
PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,0.9,antibody,P27 antibody,Antibody,,,,,
PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,0.9,antibody,β-gal antibody,Antibody,,,,,
PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,0.9,antibody,p-Erk antibody,Antibody,,,,,
PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,0.9,antibody,p-S6 antibody,Antibody,,,,,
PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,0.9,antibody,Nf1 antibody,Antibody,,,,,
PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,0.85,computational_tool,ImageJ,Computational Tool,,,,,
PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,0.8,clinical_assessment_tool,Rotarod apparatus,Clinical Assessment Tool,,,,,
PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,,0.85,genetic_reagent,pGEX 4T-1 expression plasmid,Genetic Reagent,,,,,
PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,,0.9,cell_line,BL21 (DE3) E.coli,Cell Line,,,,,
PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,,0.85,cell_line,H929,Cell Line,,,,,
PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,,0.85,cell_line,U266B1,Cell Line,,,,,
PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,,0.85,cell_line,U2932,Cell Line,,,,,
PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,,0.85,cell_line,MCF7,Cell Line,,,,,
PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,,0.85,cell_line,HT229,Cell Line,,,,,
PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,,0.85,cell_line,HCC1937,Cell Line,,,,,
PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,,0.9,genetic_reagent,pCMV-T7-(FZ) SpCas9-BPNLS(SV40)-3xFLAG-P2A-Puro-R plasmid,Genetic Reagent,,,,,
PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,,0.9,antibody,anti-human C-terminal BIM,Antibody,,,,,
PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,,0.9,antibody,anti-human N-terminal BIM (C34C5),Antibody,,,,,
PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,,0.9,antibody,anti-b-tubulin,Antibody,,,,,
PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,,0.85,computational_tool,FACSDiva v6.1,Computational Tool,,,,,
PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,,0.85,computational_tool,FlowJo software v10.0.8,Computational Tool,,,,,
PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,,0.85,computational_tool,GraphPad Prism v8.3,Computational Tool,,,,,
PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,,0.85,computational_tool,HALO image analysis software v3.2,Computational Tool,,,,,
PMID:40507334,10.3390/cancers17111852,Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,,0.85,computational_tool,ZEN imaging software v2.3,Computational Tool,,,,,
PMID:41001593,10.1080/23723556.2025.2561292,Loss of Schwann cell's normal rhythmic core clock gene expression and gain of rhythmic expression of oncogenic driver genes in malignant NF1-associated peripheral nerve sheath tumor.,,0.9,cell_line,T265,Cell Line,,,,,
PMID:41001593,10.1080/23723556.2025.2561292,Loss of Schwann cell's normal rhythmic core clock gene expression and gain of rhythmic expression of oncogenic driver genes in malignant NF1-associated peripheral nerve sheath tumor.,,0.9,cell_line,S462,Cell Line,,,,,
PMID:41001593,10.1080/23723556.2025.2561292,Loss of Schwann cell's normal rhythmic core clock gene expression and gain of rhythmic expression of oncogenic driver genes in malignant NF1-associated peripheral nerve sheath tumor.,,0.9,cell_line,NSF1,Cell Line,,,,,
PMID:41001593,10.1080/23723556.2025.2561292,Loss of Schwann cell's normal rhythmic core clock gene expression and gain of rhythmic expression of oncogenic driver genes in malignant NF1-associated peripheral nerve sheath tumor.,,0.8,cell_line,BRGN,Cell Line,,,,,
PMID:41001593,10.1080/23723556.2025.2561292,Loss of Schwann cell's normal rhythmic core clock gene expression and gain of rhythmic expression of oncogenic driver genes in malignant NF1-associated peripheral nerve sheath tumor.,,0.85,cell_line,primary human Schwann cells (HSC),Cell Line,,,,,
PMID:41001593,10.1080/23723556.2025.2561292,Loss of Schwann cell's normal rhythmic core clock gene expression and gain of rhythmic expression of oncogenic driver genes in malignant NF1-associated peripheral nerve sheath tumor.,,0.9,antibody,S100 mouse monoclonal primary antibody,Antibody,,,,,
PMID:41001593,10.1080/23723556.2025.2561292,Loss of Schwann cell's normal rhythmic core clock gene expression and gain of rhythmic expression of oncogenic driver genes in malignant NF1-associated peripheral nerve sheath tumor.,,0.9,antibody,"Anti-Mouse IgG (H+L), F(ab')2 Fragment Alexa Fluor 488 Conjugate",Antibody,,,,,
PMID:41001593,10.1080/23723556.2025.2561292,Loss of Schwann cell's normal rhythmic core clock gene expression and gain of rhythmic expression of oncogenic driver genes in malignant NF1-associated peripheral nerve sheath tumor.,,0.9,computational_tool,CLC Genomics Workbench 22,Computational Tool,,,,,
PMID:41001593,10.1080/23723556.2025.2561292,Loss of Schwann cell's normal rhythmic core clock gene expression and gain of rhythmic expression of oncogenic driver genes in malignant NF1-associated peripheral nerve sheath tumor.,,0.9,computational_tool,CosinorPy Python package,Computational Tool,,,,,
PMID:41001593,10.1080/23723556.2025.2561292,Loss of Schwann cell's normal rhythmic core clock gene expression and gain of rhythmic expression of oncogenic driver genes in malignant NF1-associated peripheral nerve sheath tumor.,,0.85,genetic_reagent,Illumina custom panel,Genetic Reagent,,,,,
PMID:26190969,10.3389/fncel.2015.00234,"In vivo synaptic transmission and morphology in mouse models of Tuberous sclerosis, Fragile X syndrome, Neurofibromatosis type 1, and Costello syndrome.",,0.85,animal_model,Fmr1 KO,Animal Model,,,,,
PMID:26190969,10.3389/fncel.2015.00234,"In vivo synaptic transmission and morphology in mouse models of Tuberous sclerosis, Fragile X syndrome, Neurofibromatosis type 1, and Costello syndrome.",,0.95,animal_model,Nf1 (+/-),Animal Model,,,,,
PMID:26190969,10.3389/fncel.2015.00234,"In vivo synaptic transmission and morphology in mouse models of Tuberous sclerosis, Fragile X syndrome, Neurofibromatosis type 1, and Costello syndrome.",,0.85,animal_model,H-ras G12V,Animal Model,,,,,
PMID:26190969,10.3389/fncel.2015.00234,"In vivo synaptic transmission and morphology in mouse models of Tuberous sclerosis, Fragile X syndrome, Neurofibromatosis type 1, and Costello syndrome.",,0.85,animal_model,Tsc1 (+/-),Animal Model,,,,,
PMID:26190969,10.3389/fncel.2015.00234,"In vivo synaptic transmission and morphology in mouse models of Tuberous sclerosis, Fragile X syndrome, Neurofibromatosis type 1, and Costello syndrome.",,0.8,animal_model,CAGG-Cre,Animal Model,,,,,
PMID:26190969,10.3389/fncel.2015.00234,"In vivo synaptic transmission and morphology in mouse models of Tuberous sclerosis, Fragile X syndrome, Neurofibromatosis type 1, and Costello syndrome.",,0.9,genetic_reagent,Alexa Fluor 594-labeled dextrans,Genetic Reagent,,,,,
PMID:26190969,10.3389/fncel.2015.00234,"In vivo synaptic transmission and morphology in mouse models of Tuberous sclerosis, Fragile X syndrome, Neurofibromatosis type 1, and Costello syndrome.",,0.85,computational_tool,MultiClamp 700B,Computational Tool,,,,,
PMID:26190969,10.3389/fncel.2015.00234,"In vivo synaptic transmission and morphology in mouse models of Tuberous sclerosis, Fragile X syndrome, Neurofibromatosis type 1, and Costello syndrome.",,0.9,computational_tool,pCLAMP 9.2,Computational Tool,,,,,
PMID:26190969,10.3389/fncel.2015.00234,"In vivo synaptic transmission and morphology in mouse models of Tuberous sclerosis, Fragile X syndrome, Neurofibromatosis type 1, and Costello syndrome.",,0.8,computational_tool,MATLAB,Computational Tool,,,,,
PMID:26190969,10.3389/fncel.2015.00234,"In vivo synaptic transmission and morphology in mouse models of Tuberous sclerosis, Fragile X syndrome, Neurofibromatosis type 1, and Costello syndrome.",,0.85,computational_tool,LSM 700,Computational Tool,,,,,
PMID:26190969,10.3389/fncel.2015.00234,"In vivo synaptic transmission and morphology in mouse models of Tuberous sclerosis, Fragile X syndrome, Neurofibromatosis type 1, and Costello syndrome.",,0.9,computational_tool,Volocity 4.2,Computational Tool,,,,,
PMID:26190969,10.3389/fncel.2015.00234,"In vivo synaptic transmission and morphology in mouse models of Tuberous sclerosis, Fragile X syndrome, Neurofibromatosis type 1, and Costello syndrome.",,0.9,computational_tool,ImageJ 1.46,Computational Tool,,,,,
PMID:26190969,10.3389/fncel.2015.00234,"In vivo synaptic transmission and morphology in mouse models of Tuberous sclerosis, Fragile X syndrome, Neurofibromatosis type 1, and Costello syndrome.",,0.85,computational_tool,Igor 6.22A,Computational Tool,,,,,
PMID:26190969,10.3389/fncel.2015.00234,"In vivo synaptic transmission and morphology in mouse models of Tuberous sclerosis, Fragile X syndrome, Neurofibromatosis type 1, and Costello syndrome.",,0.85,computational_tool,NeuroMatic,Computational Tool,,,,,
PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,,0.85,animal_model,NSG mice,Animal Model,,,,,
PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,,0.95,patient_derived_model,NF1-MPNST patient-derived xenografts,Patient-Derived Model,,,,,
PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,,0.9,antibody,S100 antibody,Antibody,,,,,
PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,,0.9,antibody,KI-67 antibody,Antibody,,,,,
PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,,0.9,antibody,COL4A antibody,Antibody,,,,,
PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,,0.9,antibody,anti-histone H3 (tri methyl K27) antibody,Antibody,,,,,
PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,,0.85,computational_tool,Trim Galore,Computational Tool,,,,,
PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,,0.85,computational_tool,BWA-MEM,Computational Tool,,,,,
PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,,0.9,computational_tool,Disambiguate v1.0,Computational Tool,,,,,
PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,,0.85,computational_tool,Manta,Computational Tool,,,,,
PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,,0.85,computational_tool,VarScan2,Computational Tool,,,,,
PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,,0.85,computational_tool,Strelka2,Computational Tool,,,,,
PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,,0.85,computational_tool,MuTect2,Computational Tool,,,,,
PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,,0.85,computational_tool,Pindel,Computational Tool,,,,,
PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,,0.9,computational_tool,Variant Effect Predictor (VEP),Computational Tool,,,,,
PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,,0.85,computational_tool,GenVisR,Computational Tool,,,,,
PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,,0.85,computational_tool,Xenosplit,Computational Tool,,,,,
PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,,0.85,computational_tool,PartekFlow,Computational Tool,,,,,
PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,,0.85,computational_tool,DESeq2,Computational Tool,,,,,
PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,,0.85,computational_tool,CNVkit,Computational Tool,,,,,
PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,,0.9,genetic_reagent,Vysis CEP 8 (D8Z2) SpectrumGreen,Genetic Reagent,,,,,
PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,,0.9,genetic_reagent,Vysis LSI MYC SpectrumOrange,Genetic Reagent,,,,,
PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,,0.9,computational_tool,Cell Ranger,Computational Tool,,,,,
PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,,0.9,computational_tool,Seurat,Computational Tool,,,,,
PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,,0.9,computational_tool,inferCNV,Computational Tool,,,,,
PMID:33591953,10.1172/jci.insight.146351,Chromosome 8 gain is associated with high-grade transformation in MPNST.,,0.9,computational_tool,UPhyloplot2,Computational Tool,,,,,
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,0.9,cell_line,S462TY,Cell Line,,,,,
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,0.9,cell_line,STS26T,Cell Line,,,,,
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,0.9,cell_line,T265,Cell Line,,,,,
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,0.9,cell_line,ST8814,Cell Line,,,,,
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,0.85,cell_line,Normal human Schwann cells (HSC),Cell Line,,,,,
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,0.9,antibody,anti-XBP1 antibodies,Antibody,,,,,
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,0.9,antibody,anti-GAPDH,Antibody,,,,,
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,0.9,antibody,anti-α-tubulin,Antibody,,,,,
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,0.9,antibody,anti-XBP1u,Antibody,,,,,
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,0.9,antibody,anti-XBP1s,Antibody,,,,,
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,0.9,antibody,anti-Parkin,Antibody,,,,,
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,0.9,antibody,anti-PINK1,Antibody,,,,,
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,0.9,antibody,anti-LC3B,Antibody,,,,,
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,0.9,antibody,anti-GLUT1,Antibody,,,,,
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,0.9,antibody,anti-ATP5H,Antibody,,,,,
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,0.9,antibody,anti-LC3 antibodies,Antibody,,,,,
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,0.9,computational_tool,HISAT2 version 2.2.1,Computational Tool,,,,,
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,0.9,computational_tool,StringTie version 2.2.1,Computational Tool,,,,,
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,0.9,computational_tool,DEGseq version 1.48.0,Computational Tool,,,,,
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,0.9,computational_tool,ClusterProfiler version 4.2.2,Computational Tool,,,,,
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,0.9,computational_tool,STRING version 11.5,Computational Tool,,,,,
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,0.9,computational_tool,FlowJo™ software v10.8,Computational Tool,,,,,
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,0.9,computational_tool,Seahorse Wave Pro software,Computational Tool,,,,,
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,0.9,computational_tool,GraphPad Prism version 9,Computational Tool,,,,,
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,0.8,computational_tool,FASTQC,Computational Tool,,,,,
PMID:39409151,10.3390/ijms251910822,Proof of Concept for Genome Profiling of the Neurofibroma/Sarcoma Sequence in Neurofibromatosis Type 1.,,0.85,genetic_reagent,Magcore DNA FFPE One-Step Kit (Code 405),Genetic Reagent,,,,,
PMID:39409151,10.3390/ijms251910822,Proof of Concept for Genome Profiling of the Neurofibroma/Sarcoma Sequence in Neurofibromatosis Type 1.,,0.9,computational_tool,Agilent Tapestation 4200,Computational Tool,,,,,
PMID:39409151,10.3390/ijms251910822,Proof of Concept for Genome Profiling of the Neurofibroma/Sarcoma Sequence in Neurofibromatosis Type 1.,,0.85,genetic_reagent,Qubit dsDNA High Sensitivity kit,Genetic Reagent,,,,,
PMID:39409151,10.3390/ijms251910822,Proof of Concept for Genome Profiling of the Neurofibroma/Sarcoma Sequence in Neurofibromatosis Type 1.,,0.9,genetic_reagent,Agilent Sure Select XT HS2 all exon v8 kit,Genetic Reagent,,,,,
PMID:39409151,10.3390/ijms251910822,Proof of Concept for Genome Profiling of the Neurofibroma/Sarcoma Sequence in Neurofibromatosis Type 1.,,0.9,computational_tool,Illumina NextSeq550Dx,Computational Tool,,,,,
PMID:39409151,10.3390/ijms251910822,Proof of Concept for Genome Profiling of the Neurofibroma/Sarcoma Sequence in Neurofibromatosis Type 1.,,0.95,computational_tool,Varsome Clinical Software v.12.3.2,Computational Tool,,,,,
PMID:39409151,10.3390/ijms251910822,Proof of Concept for Genome Profiling of the Neurofibroma/Sarcoma Sequence in Neurofibromatosis Type 1.,,0.85,computational_tool,Plotly v4.9.3,Computational Tool,,,,,
PMID:39409151,10.3390/ijms251910822,Proof of Concept for Genome Profiling of the Neurofibroma/Sarcoma Sequence in Neurofibromatosis Type 1.,,0.9,computational_tool,CNVKit version 0.9.11,Computational Tool,,,,,
PMID:39409151,10.3390/ijms251910822,Proof of Concept for Genome Profiling of the Neurofibroma/Sarcoma Sequence in Neurofibromatosis Type 1.,,0.85,computational_tool,ggplot2 v3.5.1,Computational Tool,,,,,
PMID:39409151,10.3390/ijms251910822,Proof of Concept for Genome Profiling of the Neurofibroma/Sarcoma Sequence in Neurofibromatosis Type 1.,,0.9,computational_tool,GEPIA,Computational Tool,,,,,
PMID:39409151,10.3390/ijms251910822,Proof of Concept for Genome Profiling of the Neurofibroma/Sarcoma Sequence in Neurofibromatosis Type 1.,,0.9,computational_tool,Cluster Profiler v.4.0,Computational Tool,,,,,
PMID:39409151,10.3390/ijms251910822,Proof of Concept for Genome Profiling of the Neurofibroma/Sarcoma Sequence in Neurofibromatosis Type 1.,,0.85,computational_tool,UpSetR Version 1.4.0,Computational Tool,,,,,
PMID:28735371,10.1007/s10897-017-0128-1,Identifying Symptoms of Distress in Youth Living with Neurofibromatosis Type 1 (NF1).,,0.95,clinical_assessment_tool,Distress Thermometer (DT),Clinical Assessment Tool,,,,,
PMID:28735371,10.1007/s10897-017-0128-1,Identifying Symptoms of Distress in Youth Living with Neurofibromatosis Type 1 (NF1).,,0.9,clinical_assessment_tool,Children's Depression Inventory (CDI-S),Clinical Assessment Tool,,,,,
PMID:28735371,10.1007/s10897-017-0128-1,Identifying Symptoms of Distress in Youth Living with Neurofibromatosis Type 1 (NF1).,,0.9,clinical_assessment_tool,Children's Depression Inventory Parent Version (CDI-P),Clinical Assessment Tool,,,,,
PMID:28735371,10.1007/s10897-017-0128-1,Identifying Symptoms of Distress in Youth Living with Neurofibromatosis Type 1 (NF1).,,0.9,clinical_assessment_tool,Brief Symptom Inventory 18 (BSI-18),Clinical Assessment Tool,,,,,
PMID:28735371,10.1007/s10897-017-0128-1,Identifying Symptoms of Distress in Youth Living with Neurofibromatosis Type 1 (NF1).,,0.85,clinical_assessment_tool,Lansky Score,Clinical Assessment Tool,,,,,
PMID:28735371,10.1007/s10897-017-0128-1,Identifying Symptoms of Distress in Youth Living with Neurofibromatosis Type 1 (NF1).,,0.85,clinical_assessment_tool,Karnofsky Score,Clinical Assessment Tool,,,,,
PMID:28735371,10.1007/s10897-017-0128-1,Identifying Symptoms of Distress in Youth Living with Neurofibromatosis Type 1 (NF1).,,0.8,clinical_assessment_tool,Distress Thermometer Acceptability and Feasibility Scales,Clinical Assessment Tool,,,,,
PMID:39845289,10.1093/jamiaopen/ooae157,Evaluating dimensionality reduction of comorbidities for predictive modeling in individuals with neurofibromatosis type 1.,,0.85,computational_tool,XGBoost,Computational Tool,,,,,
PMID:39845289,10.1093/jamiaopen/ooae157,Evaluating dimensionality reduction of comorbidities for predictive modeling in individuals with neurofibromatosis type 1.,,0.8,computational_tool,Yellowbrick,Computational Tool,,,,,
PMID:39845289,10.1093/jamiaopen/ooae157,Evaluating dimensionality reduction of comorbidities for predictive modeling in individuals with neurofibromatosis type 1.,,0.8,computational_tool,HoloViews,Computational Tool,,,,,
PMID:39845289,10.1093/jamiaopen/ooae157,Evaluating dimensionality reduction of comorbidities for predictive modeling in individuals with neurofibromatosis type 1.,,0.75,computational_tool,Clinical Classifications Software Refined,Computational Tool,,,,,
PMID:39845289,10.1093/jamiaopen/ooae157,Evaluating dimensionality reduction of comorbidities for predictive modeling in individuals with neurofibromatosis type 1.,,0.75,computational_tool,Phecode,Computational Tool,,,,,
PMID:32948135,10.1186/s12885-020-07397-w,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.,,0.9,cell_line,S462,Cell Line,,,,,
PMID:32948135,10.1186/s12885-020-07397-w,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.,,0.9,cell_line,T265,Cell Line,,,,,
PMID:32948135,10.1186/s12885-020-07397-w,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.,,0.9,cell_line,NSF1,Cell Line,,,,,
PMID:32948135,10.1186/s12885-020-07397-w,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.,,0.85,cell_line,B8 fibroblasts,Cell Line,,,,,
PMID:32948135,10.1186/s12885-020-07397-w,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.,,0.8,computational_tool,CellTiter-Blue® assay,Computational Tool,,,,,
PMID:32948135,10.1186/s12885-020-07397-w,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.,,0.95,antibody,"Ki67 antibody (clone MIB1, M7240, DAKO)",Antibody,,,,,
PMID:32948135,10.1186/s12885-020-07397-w,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.,,0.95,antibody,"p21 antibody (M7202, DAKO)",Antibody,,,,,
PMID:32948135,10.1186/s12885-020-07397-w,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.,,0.95,antibody,"p53 antibody (M7001, DAKO)",Antibody,,,,,
PMID:32948135,10.1186/s12885-020-07397-w,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.,,0.95,antibody,"bcl2 antibody (M887, DAKO)",Antibody,,,,,
PMID:32948135,10.1186/s12885-020-07397-w,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.,,0.95,antibody,"bcl6 antibody (M7211, DAKO)",Antibody,,,,,
PMID:32948135,10.1186/s12885-020-07397-w,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.,,0.95,antibody,"cyclin D1 antibody (M3642, DAKO)",Antibody,,,,,
PMID:32948135,10.1186/s12885-020-07397-w,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.,,0.85,genetic_reagent,pSG5 vector,Genetic Reagent,,,,,
PMID:32948135,10.1186/s12885-020-07397-w,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.,,0.8,computational_tool,MATLAB® version R2007a,Computational Tool,,,,,
PMID:32948135,10.1186/s12885-020-07397-w,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.,,0.8,computational_tool,pathoZoom®,Computational Tool,,,,,
PMID:32948135,10.1186/s12885-020-07397-w,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.,,0.75,computational_tool,DAKO Autostainer Link 48,Computational Tool,,,,,
PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,0.9,cell_line,STS26T,Cell Line,,,,,
PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,0.9,cell_line,S462,Cell Line,,,,,
PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,0.85,animal_model,C57BL/6N mice,Animal Model,,,,,
PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,0.85,animal_model,NOD scid gamma mice,Animal Model,,,,,
PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,0.85,animal_model,NRG mice,Animal Model,,,,,
PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,0.9,genetic_reagent,adenovirus containing Cas9 and sgRNAs targeting Nf1+Cdkn2a,Genetic Reagent,,,,,
PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,0.9,antibody,phospho-RB1 S807/811 antibody,Antibody,,,,,
PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,0.9,antibody,kappa light chain antibody,Antibody,,,,,
PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,0.9,antibody,B220 antibody,Antibody,,,,,
PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,0.9,antibody,CD3 antibody,Antibody,,,,,
PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,0.85,antibody,SIAH antibody,Antibody,,,,,
PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,0.85,antibody,RABL6A antibody,Antibody,,,,,
PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,0.9,antibody,anti-PDL1 antibody,Antibody,,,,,
PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,0.9,computational_tool,SynergyFinder,Computational Tool,,,,,
PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,0.9,computational_tool,ImageJ,Computational Tool,,,,,
PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,0.9,computational_tool,FlowJo v10,Computational Tool,,,,,
PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,0.85,computational_tool,salmon,Computational Tool,,,,,
PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,0.9,computational_tool,DESeq2,Computational Tool,,,,,
PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,0.9,computational_tool,CIBERSORT,Computational Tool,,,,,
PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,0.85,computational_tool,iPathwayGuide,Computational Tool,,,,,
PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,0.9,patient_derived_model,Patient-derived xenografts,Patient-Derived Model,,,,,
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,0.9,cell_line,ipNF05.5,Cell Line,,,,,
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,0.9,cell_line,95.6,Cell Line,,,,,
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,0.9,cell_line,ipn02.3,Cell Line,,,,,
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,0.95,cell_line,ST88-14,Cell Line,,,,,
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,0.95,cell_line,S462,Cell Line,,,,,
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,0.95,cell_line,NF90-8,Cell Line,,,,,
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,0.9,patient_derived_model,RHT-92,Patient-Derived Model,,,,,
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,0.9,animal_model,Nf1 flox/flox-;Postn-Cre,Animal Model,,,,,
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,0.9,animal_model,Nf1-Arf flox/flox ;Postn-Cre,Animal Model,,,,,
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,0.95,animal_model,NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ (NSG),Animal Model,,,,,
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,0.95,antibody,"Ref-1 antibody (13B8E5C2, Novus Biologicals)",Antibody,,,,,
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,0.95,antibody,"p-STAT3 (Y705) antibody (D3A7, Cell Signaling)",Antibody,,,,,
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,0.9,antibody,"HIF1-α antibody (GTX127309, GeneTex)",Antibody,,,,,
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,0.9,antibody,"STAT3 antibody (124H6, Cell Signaling)",Antibody,,,,,
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,0.9,antibody,"Cleaved PARP antibody (D64E10, Cell Signaling)",Antibody,,,,,
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,0.9,antibody,"total PARP antibody (#9542, Cell Signaling)",Antibody,,,,,
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,0.9,antibody,"Vinculin antibody (V284, Sigma)",Antibody,,,,,
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,0.9,antibody,"Actin antibody (ACTN05(C4), NeoMarkers)",Antibody,,,,,
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,0.85,genetic_reagent,APX3330,Genetic Reagent,,,,,
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,0.85,genetic_reagent,APX2009,Genetic Reagent,,,,,
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,0.85,genetic_reagent,APX2014,Genetic Reagent,,,,,
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,0.8,genetic_reagent,Napabucasin,Genetic Reagent,,,,,
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,0.8,genetic_reagent,Ruxolitinib,Genetic Reagent,,,,,
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,0.9,genetic_reagent,Ref-1 siRNA #1,Genetic Reagent,,,,,
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,0.9,genetic_reagent,"Ref-1 siRNA (s1447, Santa Cruz)",Genetic Reagent,,,,,
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,0.9,genetic_reagent,"STAT3 siRNA (sc-44275, sc-29493)",Genetic Reagent,,,,,
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,0.9,computational_tool,ImageJ (v1.48),Computational Tool,,,,,
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,0.9,computational_tool,HALO (Indica Labs),Computational Tool,,,,,
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,0.9,computational_tool,Aperio Image Analysis (Leica Biosystems),Computational Tool,,,,,
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,0.85,computational_tool,Incucyte system (Essen Bioscience),Computational Tool,,,,,
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,0.85,computational_tool,Studylog system software (Pacifica),Computational Tool,,,,,
PMID:33085177,10.1002/mgg3.1530,The development of the PlexiQoL: A patient-reported outcome measure for adults with neurofibromatosis type 1-associated plexiform neurofibromas.,,0.95,clinical_assessment_tool,PlexiQoL,Clinical Assessment Tool,,,,,
PMID:33085177,10.1002/mgg3.1530,The development of the PlexiQoL: A patient-reported outcome measure for adults with neurofibromatosis type 1-associated plexiform neurofibromas.,,0.9,clinical_assessment_tool,Nottingham Health Profile,Clinical Assessment Tool,,,,,
PMID:33085177,10.1002/mgg3.1530,The development of the PlexiQoL: A patient-reported outcome measure for adults with neurofibromatosis type 1-associated plexiform neurofibromas.,,0.9,clinical_assessment_tool,Short Form-36,Clinical Assessment Tool,,,,,
PMID:33085177,10.1002/mgg3.1530,The development of the PlexiQoL: A patient-reported outcome measure for adults with neurofibromatosis type 1-associated plexiform neurofibromas.,,0.85,computational_tool,RUMM2030,Computational Tool,,,,,
PMID:33085177,10.1002/mgg3.1530,The development of the PlexiQoL: A patient-reported outcome measure for adults with neurofibromatosis type 1-associated plexiform neurofibromas.,,0.8,computational_tool,Children's Tumor Foundation Patient Registry,Computational Tool,,,,,
PMID:38945076,10.1016/j.redox.2024.103249,Selective nitration of Hsp90 acts as a metabolic switch promoting tumor cell proliferation.,,0.9,cell_line,"normal human Schwann cells (Cat. No. 1700, ScienCell Research Laboratories)",Cell Line,,,,,
PMID:38945076,10.1016/j.redox.2024.103249,Selective nitration of Hsp90 acts as a metabolic switch promoting tumor cell proliferation.,,0.95,cell_line,Mouse merlin-null schwannoma cells,Cell Line,,,,,
PMID:38945076,10.1016/j.redox.2024.103249,Selective nitration of Hsp90 acts as a metabolic switch promoting tumor cell proliferation.,,0.9,animal_model,Nf2 flox2/flox2 mice,Animal Model,,,,,
PMID:38945076,10.1016/j.redox.2024.103249,Selective nitration of Hsp90 acts as a metabolic switch promoting tumor cell proliferation.,,0.85,genetic_reagent,LookOut Mycoplasma PCR detection kit (Sigma-Aldrich),Genetic Reagent,,,,,
PMID:38945076,10.1016/j.redox.2024.103249,Selective nitration of Hsp90 acts as a metabolic switch promoting tumor cell proliferation.,,0.9,antibody,"anti-merlin antibody (Cat. No. 12888, Cell Signaling Technology)",Antibody,,,,,
PMID:38945076,10.1016/j.redox.2024.103249,Selective nitration of Hsp90 acts as a metabolic switch promoting tumor cell proliferation.,,0.9,genetic_reagent,pBad/Myc-Hisx6 vector (Invitrogen),Genetic Reagent,,,,,
PMID:38945076,10.1016/j.redox.2024.103249,Selective nitration of Hsp90 acts as a metabolic switch promoting tumor cell proliferation.,,0.8,genetic_reagent,Ni-NTA purification system (Invitrogen),Genetic Reagent,,,,,
PMID:38945076,10.1016/j.redox.2024.103249,Selective nitration of Hsp90 acts as a metabolic switch promoting tumor cell proliferation.,,0.85,genetic_reagent,Chariot (Active Motif),Genetic Reagent,,,,,
PMID:38945076,10.1016/j.redox.2024.103249,Selective nitration of Hsp90 acts as a metabolic switch promoting tumor cell proliferation.,,0.9,computational_tool,XF96 Extracellular Flux Analyzer (Agilent Technologies),Computational Tool,,,,,
PMID:38945076,10.1016/j.redox.2024.103249,Selective nitration of Hsp90 acts as a metabolic switch promoting tumor cell proliferation.,,0.9,antibody,"anti-Ki-67 antibody (Cat. no. 9449, Cell Signaling)",Antibody,,,,,
PMID:38945076,10.1016/j.redox.2024.103249,Selective nitration of Hsp90 acts as a metabolic switch promoting tumor cell proliferation.,,0.95,antibody,in-house developed antibodies specific for Hsp90 nitrated at Tyr 33 or Tyr 56,Antibody,,,,,
PMID:38945076,10.1016/j.redox.2024.103249,Selective nitration of Hsp90 acts as a metabolic switch promoting tumor cell proliferation.,,0.85,computational_tool,LSM780 NLO confocal microscope (Carl Zeiss AG),Computational Tool,,,,,
PMID:38945076,10.1016/j.redox.2024.103249,Selective nitration of Hsp90 acts as a metabolic switch promoting tumor cell proliferation.,,0.85,computational_tool,"Cytation 5 instrument equipped with Gen5 software (Biotek, Agilent)",Computational Tool,,,,,
PMID:24753394,10.1002/pbc.25041,Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas.,,0.85,clinical_assessment_tool,NCI Common Terminology Criteria for Adverse Events (CTCAE) version 3,Clinical Assessment Tool,,,,,
PMID:24753394,10.1002/pbc.25041,Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas.,,0.9,clinical_assessment_tool,Impact of Pediatric Illness (IPI) Scale,Clinical Assessment Tool,,,,,
PMID:24753394,10.1002/pbc.25041,Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas.,,0.8,clinical_assessment_tool,STIR MRI,Clinical Assessment Tool,,,,,
